53793

ExxonMobil Chemical Company
13501 Katy Freeway
Houston, Texas 77079-1398
281 870 6149 Telephone
281 588 4606 Facsimile

David D. Sigman
Senior Counsel

RECEIVED
OPPT CBIC
2002 JAN -4 AM 11:24

8EHQ-0102-1324

ExxonMobil
Chemical

Ref. No. 8EHQ-0891-1324S
November 27, 2001
(Replaces letter dated November 19, 1991)

Document Processing Center (TS-790)
Attn: Section 8(e) Coordination
Office of Toxic Substances Control
U.S. Environmental Protection Agency
401M Street, SW
Washington, DC 20460

Contain NO CBI

Contain NO CBI

RECEIVED
OPPT NCIC
2002 JAN 23 AM 9:01

Re: Aliphatic Hydrocarbon Solvent

Dear Sir or Madam:

Pursuant to Section 8(e) of the TSCA, ExxonMobil Chemical Company, formerly Exxon Chemical Company, herewith furnishes a summary of findings concerning a 13-week toxicity study of an aliphatic hydrocarbon solvent CAS #64742-47-8, Light Hydrotreated Distillate (Petroleum).

Although we are reporting this information under TSCA 8(e), we do so because of the uncertainty created by EPA's response to the American Chemistry Council, formerly Chemical Manufacturers Association ("CMA") case studies concerning toxicity effects pursuant to the EPA Compliance Audit Program for TSCA 8(e). The effects being reported herewith, namely, failure to gain weight, increased organ weights, and reduction in specific blood values, appear to us to be due to the inability of the animal to ingest and retain food as a result of the irritation caused by the aliphatic hydrocarbon. Further, these effects appear to be reversible after cessation of exposure and after a period of recovery. These effects may be expected for aliphatic hydrocarbons at the high dose levels used in the study. In our view, this result may not suggest "newly discovered" "substantial risk" information. However, we feel compelled to report this information, given EPA's position suggested in its response to the CMA case studies. Enclosed is a version of this correspondence for public file.

The final report is attached. If you have any questions, please contact me at (281) 870-6149 or Allan K. Fleeger at (281) 870-6804.

Very truly yours,

David D. Sigman

8EHQ-91-1324

DDS/
Enclosures

cc: J. S. Catanach

89020000037

ExxonMobil Chemical Company
13501 Katy Freeway
Houston, Texas 77079-1398
281 870 6149 Telephone
281 588 4606 Facsimile

David D. Sigman
Senior Counsel

RECEIVED
OPPT CBIC

2002 JAN -4 AM 11:24

ExxonMobil
Chemical

November 27, 2001

Document Processing Center
Attn: Section 8(e) Coordination
Office of Toxic Substances Control
U.S. Environmental Protection Agency
401 M Street, S.W.
Washington D.C. 20460

Contain NO CBI

Re: TSCA 8(e) Submissions for
Aliphatic Hydrocarbon Solvent
And Aromatic Hydrocarbon Solvent

Dear Sir or Madam:

Enclosed are two revised 8(e) submissions previously made by Exxon Chemical Company, one on August 20, 1991 and the second on November 19, 1991. The November, 1991 revision to the original 8(e) submission was one where we elected to withdraw the confidential business information (CBI) for CAS numbers on the original 8(e) submissions and maintain the CBI for company name.

Upon further discussions with your office, ExxonMobil Chemical Company (previously Exxon Chemical Company) has elected to withdraw its CBI requirements for company name as well.

We've also included an additional copy of full report on this 8(e) submission for your records.

Your interest in this matter is sincerely appreciated.

Very truly yours,

David D Sigman

Enclosures

I/law\shared\d d sigman\2001\corr2001\exxsold60 9(3)update

SUMMARY OF METHODS AND RESULTS

13 WEEK GAVAGE STUDY IN RATS

USING AN ALIPHATIC HYDROCARBON SOLVENT

Material:

The aliphatic hydrocarbon tested is a member of the class of petroleum hydrocarbons described under CAS #64742-47-8. Distillates (Petroleum), hydrotreated light.

Methods:

The test material was administered orally, by gavage, to groups of 10 male and 10 female rats 7 days per week for 13 weeks followed by a 4 week recovery period.

The doses used were 0 (control), 500, 2500 or 5000 mg/kg/d. There were daily observations for mortality and signs of toxicity; weekly body weight and feed consumption measurements and complete necropsy observations at the conclusion of the study. Additional measurements included hematology and serum chemistry at the conclusion of the dosing interval and at the end of the recovery period. At necropsy the principal organs were removed and weighed. Histopathological observations were made of 40 tissues and organs from all animals in the control and high-dose group with target organs evaluated in the other test groups.

Principal Findings:

1. Clinical Observations

The majority of the animals in the control, low- and mid-dose groups displayed no observable abnormalities during the test period. In the high-dose group, there was a dramatic increase in the incidence of swollen anus, anogenital staining, emaciation, and alopecia. During the recovery period, the incidence of abnormal signs decreased over time with an increase in the number of animals exhibiting no observable abnormalities.

2. Mean Body Weight

Mean body weights of the high-dose male rats were significantly less than control ($p \leq 0.05$) at Day 42 and until study termination ($p \leq 0.01$). The mean body weights of the mid-dose male rats were also less ($p \leq 0.05$) on Day 77 until study termination.

The mean body weights of the female rats were significantly less than control ($p \leq 0.05$) at the mid-dose on Day 91 and at the high-dose on Days 77 and 91. Both the mid and high-dose female rats were significantly lighter ($p \leq 0.01$) at study termination.

Associated with these body weight changes were significant decreases in feed consumption at the mid- and high-dose for both male and female rats.

3. Hematologic Parameters

Platelet count was significantly elevated in the low-dose males (p. $\leq$ 0.05) and the mid- and high-dose males (p $\leq$ 0.01). Other hematologic parameters in males which differed from controls were found only in the mid-does: hematocrit (p $\leq$ 0.01), hemoglobin (p $\leq$ 0.01), mean corpuscular volume (p $\leq$ 0.05), and mean corpuscular hemoglobin (p $\leq$ 0.05).

In females, the only hematologic parameter which significantly differed from controls was the platelet count in the high-dose (p $\leq$ 0.01).

After the recovery period, there were no significant differences in the hematologic parameters in any of the dose groups as compared to the control group.

4. Serum Chemistry

In male rats, serum glucose was significantly decreased at all doses. At the mid- and high-doses, urea nitrogen, alanine aminotransferase and cholesterol were significantly increased, and at the high dose total bilirubin and gamma-glutamyl transferase were significantly elevated.

In female rats at the mid- and high-dose, serum glucose and chloride were significantly decreased and cholesterol was increased. After the recovery period, there were no differences between male and female test groups and the corresponding controls.

5. Organ Weight Data

The organ weight and organ/body weight ratio data are summarized in the following tabulation. Only statistically significant changes at p $\leq$ 0.05(*) or p $\leq$ 0.01 (**) are shown.

Organ	500	2500	5000 mg/kg/d
Kidney - male	Incr. **	Incr. **	Incr. **
Kidney ratio - male	Incr. **	Incr. **	Incr. **
Kidney ratio - female	Incr. **	Incr. **	Incr. **
Liver - male	Incr. *	Incr. **	---
Liver - female	Incr. *	Incr. **	Incr. **
Liver ratio - male	---	Incr. **	Incr. **
Liver ratio - female	---	Incr. **	Incr. **
Adrenal - male	---	---	Incr. **
Adrenal - female	---	Incr. **	Incr. **
Adrenal ratio - male	---	---	Incr. **
Adrenal ratio - female	---	Incr. **	Incr. **
Testes ratio - male	---	---	Incr. *

6. Histopathology

Treatment-related microscopic changes were observed in the kidneys of male rats at all dose levels of the aliphatic hydrocarbon, the liver of male and female at all dose levels, and the stomach and/or anus of males and females at 2500 and 5000 mg/kg.

Histopathologic examination of the kidneys of male rats showed changes typical of hyaline droplet nephropathy, with essentially no difference in the incidence and/or severity of the lesions among the exposed groups. These renal changes consisted of accumulation of hyaline droplets in the cytoplasm of the proximal convoluted tubules, dilatation and granular cast formations in the medullary tubules and increased basophilia of cortical tubules. These affected basophilic cortical tubules showed changes consistent with both degeneration and regeneration. By the end of the recovery period, there was no evidence of hyaline droplets in the cortical tubules, but there were dilated tubules with granular casts in the medulla of 4/8 male rats. There was no difference in the incidence of cortical basophilic tubules between the control and the treated groups. No significant histopathologic changes were observed in any of the female rats.

The treatment-related effect in the liver of both male and female rats consisted of hepatocellular hypertrophy, predominantly in the centrilobular areas. The incidence and intensity of this centrilobular hepatocellular hypertrophy generally occurred in a dose-related manner. This hepatocellular hypertrophy completely disappeared after the recovery period.

Histopathologic examination of the stomach showed a thickening of the nonglandular mucosa due to hyperplasia and hyperkeratosis of the squamous epithelium, the incidence and severity of which occurred in a dose-dependent manner. Other associated gastric changes seen at a low incidence in a few of the affected rats included edema and inflammatory cell infiltrations in the submucosa and focal necrosis of the superficial glandular mucosa. After the recovery period, the three female rats showed no residual changes, but 3/8 male rats still had a minimal to slight hyperplasia and hyperkeratosis of the mucosa of the nonglandular area of the stomach (the incidence and severity was decreased).

At necropsy, the anus of most of the male and female rats of the high-dose was described as being swollen. Microscopically, the skin and mucosa around the anus of these rats was thickened due to hyperplasia and hyperkeratosis. Also, there were areas of necrosis, neutrophilic inflammatory cell infiltrations and pustular formations in the superficial mucosa and epidermis of the anus and skin around the anus. These changes were not seen after the recovery period.

Conclusions:

The findings of importance are failure to gain weight and an associated decrease in feed consumption: reduction in certain blood values, changes in serum chemistry and increased organ weights. The histopathology was largely confirmatory of the other observations. Mechanistically, we believe there are two simultaneous events occurring. There is the well-known male rat nephropathy associated with aliphatic hydrocarbons. From the organ weight and pathology data, the effect is less severe than with other hydrocarbons.

The second effect appears to be the direct result of high-dose intubation of a locally irritating substance. We believe the aliphatic hydrocarbon at the doses employed produced irritation of the gastrointestinal tract. They led to decreased food consumption and resultant reduction in blood components, serum chemistry and enzyme changes and the reversible liver enlargement. The platelet changes and adrenal enlargement could also be a part of this picture. This type of study has not been done before and the high gavage doses (up to 5000 mg/kg body weight/day) are outside our prior experience.

53793

EXXON BIOMEDICAL SCIENCES, INC.

FINAL REPORT

STUDY TITLE

90-DAY SUBCHRONIC ORAL TOXICITY STUDY IN RATS WITH MRD-89-582

EXXSOL D60

Data Requirements
Guideline: 82-1

Author
Gary W. Trimmer, B.A.

Study Completed
October 24, 1991

Sponsor
EXXON CHEMICAL AMERICAS
Houston, Texas

Performing Laboratory
EXXON BIOMEDICAL SCIENCES, INC.
Toxicology Laboratory
Mettlers Road, CN 2350
East Millstone, New Jersey 08875-2350

Laboratory Project ID

158270

STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA Section 10(d)(1)(A), (B) or (C).

Company: Exxon Chemical Americas

Agent: Janet S. Catanach Date: 10/10-91

Title Environmental Coordinator Janet S. Catanach
Signature

CERTIFICATION OF GOOD LABORATORY PRACTICES

I hereby declare that to the best of my knowledge, the study contained herein was performed under my supervision in accordance with the Good Laboratory Practice Regulations (40 CFR Part 160), EPA regulatory guidelines for pesticide assesment (Subdivision F, section 82-1) with the following exceptions: 1) It is unknown whether the determination of the stability, identity, strength and composition or other characteristics which appropriately identifies the test material were performed in a GLP compliant manner. 2) The Technicon H-1 Hematology Analyzer was used during this study. At that time, there was no Laboratory Standard Operating Procedure in place for this instrument.

Gary W. Trimmer
G. W. Trimmer
Study Director

24 OCT 91
Date

This study was conducted in compliance with Good Laboratory Practice Standards, 40 CFR Part 160. This statement is based on the statement of the project director set forth above, the terms of the contract between the sponsor and the laboratory that conducted the study, other assurances given by the testing facility, and the absence of any knowledge to the contrary.

Janet S. Catanach
Janet S. Catanach
Exxon Chemical Americas
Sponsor Representative/Submitter

10-10-91
Date

TABLE OF CONTENTS

	Page
STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS	2
CERTIFICATION OF GOOD LABORATORY PRACTICES	3
APPROVAL SIGNATURES	5
QUALITY ASSURANCE STATEMENT	6
PERSONNEL	7
SUMMARY	8 - 9
MATERIALS AND METHODS	10 - 11
TEST SYSTEM AND HUSBANDRY	12 - 15
EXPERIMENTAL DESIGN AND STATISTICAL EVALUATION	16 - 21
RESULTS	22 - 27
DISCUSSION	28 - 30
TABLES	
TABLE 1 - SURVIVAL BAR GRAPH	31 - 33
TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS	35 - 77
TABLE 3 - MEAN BODY WEIGHTS (GRAMS)	79 - 80
TABLE 4 - MEAN WEEKLY FOOD CONSUMPTION (GRAMS)	81 - 82
TABLE 5 - MEAN QUANTITATIVE HEMATOLOGY (TERMINAL)	84
TABLE 6 - MEAN SERUM CHEMISTRY (TERMINAL)	86 - 87
TABLE 7 - MEAN ORGAN WEIGHTS	89
TABLE 8 - MEAN RELATIVE ORGAN WEIGHTS	90
TABLE 9 - MEAN QUANTITATIVE HEMATOLOGY SATELLITE (DAY 96/97 VS. 125)	91
TABLE 10 - MEAN SERUM CHEMISTRY SATELLITE (DAY 96/97 VS. DAY 125)	92 - 93
TABLE 11 - MEAN RELATIVE ORGAN WEIGHTS CONTROL VS. SATELLITE	94
TABLE 12 - NECROPSY OBSERVATIONS	95 - 106
KEYS	
KEY A - KEY TO INLIFE OBSERVATIONS ABBREVIATIONS	34
KEY B - KEY TO STATISTICAL ABBREVIATIONS	78
KEY C - KEY TO HEMATOLOGY ABBREVIATIONS AND UNITS	83
KEY D - KEY TO SERUM CHEMISTRY ABBREVIATIONS AND UNITS	85
KEY E - KEY TO ORGAN ABBREVIATIONS	88
APPENDICES	
APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS	107 - 174
APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS)	175 - 184
APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS)	185 - 194
APPENDIX D - INDIVIDUAL QUANTITATIVE HEMATOLOGY	195 - 200
APPENDIX E - INDIVIDUAL QUALITATIVE HEMATOLOGY	201 - 206
APPENDIX F - METHODOLOGY AND REFERENCES FOR HEMATOLOGY	207
APPENDIX G - INDIVIDUAL SERUM CHEMISTRY	208 - 219
APPENDIX H - METHODOLOGY AND REFERENCES FOR SERUM CHEMISTRY	220
APPENDIX I - INDIVIDUAL ORGAN WEIGHTS	221 - 225
APPENDIX J - INDIVIDUAL RELATIVE ORGAN WEIGHTS	226 - 230
APPENDIX K - TOTAL VOLUME OF INDIVIDUAL DOSES (ML)	231 - 235
APPENDIX L - DOSING TIMES IN RELATION TO PHOTOPERIOD	236
APPENDIX M - OPHTHALMOSCOPIC EXAMINATION SUMMARY	237 - 238
APPENDIX N - ANALYTICAL REPORT	239 - 243
APPENDIX O - NOTES AND PROTOCOL/ENVIRONMENTAL DEVIATIONS	244 - 245
APPENDIX P - HISTOPATHOLOGY REPORT	246 - 396

APPROVAL SIGNATURES

G. W. Trimmer, B.A.
Study Director

24/OCT/91
Date

R. D. Phillips, Ph.D.
Laboratory Director: Mammalian Toxicology

24-Oct-91
Date

J. P. Kovach, B.S., MT(ASCP)
Clinical Laboratory Supervisor

24-Oct-91
Date

D. J. Letinski, M.S.
Analytical Chemistry Supervisor

24 Oct 91
Date

QUALITY ASSURANCE STATEMENT

STUDY NUMBER: 158270

TEST SUBSTANCE/ARTICLE: MRD-89-582

STUDY SPONSOR: Exxon Chemical Americas

Listed below are the dates that this study was inspected by the Quality Assurance Unit of Exxon Biomedical Sciences, Inc., and the dates findings were reported to the Study Director and Management.

Date(s) of Inspection	Reported to Study Director	Reported to Management
15,16 Oct 90	16 Oct 90	17 Oct 90
20-22 Feb 91 25,27 Feb 91	29 Aug 91	03 Sep 91
18 Jul- 08 Aug 91	04 Sep 91	06,09 Sep 91
21 Aug 91	22 Aug 91	22,23 Aug 91
22 Aug 91	09 Sep 91	10 Sep 91

Robert T. Plutnick
Group Head, Quality Assurance

23-OCT-91
Date

PERSONNEL

Study Director:	G. W. Trimmer, B.A.
General Toxicology and Animal Care Supervisor:	R. C. Forgash, B.S.
Report Preparation Supervisor:	M. A. Elliott, B.S.
Histology and Clinical Chemistry Supervisor:	J. P. Kovach, B.S. MT(ASCP)
Necropsy Supervisor:	F. T. Whitman, B.A.
Veterinarian:	R. L. Harris, D.V.M.
Compound Preparation Supervisor:	T. M. Federici, B.S.
Analytical Chemistry Supervisor:	D. J. Letinski, M.S.
Quality Assurance Supervisor:	R. T. Plutnick, B.A.
Maintenance Supervisor:	J. L. McGrath, A.S.
Veterinary Pathologist:	W. R. Brown, D.V.M., Ph.D.
Veterinary Ophthalmologist:	J. M. Clinton, V.M.D.

SUMMARY

The objective of this study was to evaluate the toxicity of MRD-89-582 when administered via oral gavage, 7 days per week for 13 weeks. Group 1 was used as a control and received carrier only. Groups 2, 3 and 4 received 500, 2500 and 5000 mg/kg/day of MRD-89-582 respectively, at a dose volume of 10 ml/kg. Group 5 (satellite) received 5000 mg/kg/day for 13 weeks and then was observed for reversibility for 28 days post-treatment. Detailed clinical examinations were conducted daily. Body weights and food consumption were recorded weekly during the test period. Serum chemistry and hematology studies were performed on all animals at termination and at satellite termination for satellite animals. Ophthalmoscopic examinations were performed prior to study initiation and during the final week of the study. Necropsies were performed and selected organs and tissues were collected and weighed. Microscopic examinations were performed on a complete set of tissues from the high dose and control animals and on a limited set of tissues from the animals in the mid and low dose groups.

Fourteen animals died prior to study termination, with thirteen of these deaths attributed to dosing trauma or aspiration of the test material.

The majority of animals in the control, low and mid dose groups displayed no observable abnormalities during the test period. The abnormal clinical signs most frequently noted included swollen anus, ano-genital staining, emaciation, and alopecia.

The mean body weight values of the male animals in the mid and high dose groups were depressed relative to the controls while male food consumption values showed increases in food consumption for these two groups relative to controls during most of the treatment period. Food consumption values for high dose females also displayed an increase relative to controls however no significant body weight differences from controls were noted for the majority of the treatment period.

Hematology studies revealed most notably an increase in platelets compared to control values for both male and female animals. Serum chemistry studies revealed increases in alanine aminotransferase, glutamyl transferase and bilirubin in both male and female animals indicative of changes in the liver, which was confirmed upon microscopic examination.

The mean absolute and relative liver and kidney weights for male rats in the mid and high dose groups were increased relative to the controls. Female absolute and relative liver weights were also increased compared to the controls, but only

the relative kidney weights were increased compared to the control values. These trends in organ weight data correlate to signs of both liver and kidney effects observed at microscopic examination.

No findings indicative of treatment related effects were noted in the ophthalmology.

Microscopic examination of the required tissues from the terminal sacrifice revealed treatment related changes in the kidneys in the males of all treatment groups, treatment related changes in the liver of the males and females of all treatment groups and treatment related changes in the stomach and/or anus of the mid and high dose groups.

The treatment related changes seen in the male kidneys were consistent with "male rat hydrocarbon nephropathy syndrome" and consisted of hyaline droplets in the proximal convoluted tubules, dilatation and granular cast formations in the medullary tubules and increased basophilia of cortical tubules representing areas of degeneration and regeneration of cortical tubular epithelium. There were no differences in the incidence and/or severity of the lesions among the treated groups.

The treatment related effects seen in the liver consisted of a dose related increased incidence and/or intensity of centrilobular hepatocellular hypertrophy.

The treatment related effects seen in the stomach consisted of hyperplasia and hyperkeratosis of the squamous mucosa. The treatment related effects seen in the anus consisted of hyperplasia and hyperkeratosis of the epidermis, focal necrosis and neutrophilic infiltrations with pustule formation.

Microscopic examination of the required tissues from the satellite animals sacrifice after a 28-day recovery period revealed complete reversibility of the hepatic changes. Evidence of reversibility was also noted for the male kidney effects, however, dilatation and cast formation in the medullary tubules were still evident in half of the males. The incidence and intensity of the gastric changes were diminished after the recovery period and these effects were also reversible. Gross changes seen in the anus were not observed at the recovery sacrifice.

Based on the findings of this study, the no effect level for MRD-89-582 was below 500 mg/kg.

MATERIALS AND METHODS

Test Material

Material identification

MRD-89-582

Description

Sponsor Identification: Exxsol D60

Batch II

The test material was a colorless liquid which was assumed to be 100% pure for purposes of dosing.

Characterization of test material:

The documentation of the methods of synthesis, fabrication and/or derivation of the test material is documented by the sponsor and is maintained at Exxon Chemical Americas, Houston, Texas.

Analysis of test material:

The stability, identity, strength and composition or other characteristics which appropriately identifies the test substance was determined by the Sponsor and is maintained at Exxon Chemical Americas, Houston, Texas.

Analysis of mixtures:

The stability, uniformity and the concentration verification of the test substance mixtures were determined by the testing laboratory. Stability and uniformity analyses commenced prior to study initiation and concentration verification was performed monthly during the study.

Solubility of the test material

Soluble in the carrier at the concentrations used for this study.

Date received

August 10, 1990

Storage conditions

Room temperature

Sample retention

Two archival samples of neat MRD-89-582 were collected by the Compound Preparation Department and stored under the appropriate conditions.

Two 15 ml aliquots of the test material/carrier mixture were retained for all mixtures where concentration verification was not performed. One 15 ml aliquot was retained for all mixtures where concentration verification was performed. All samples are stored under the appropriate conditions.

Carrier

Corn oil

Supplier: Best Foods (CPC)

Batch/Lot Number: JUL1691A
AUG1691A
SEP2691A
JAN2892A

TEST SYSTEM AND HUSBANDRY

Test System

Test animal

Rat

Strain/stock

HSD:SD (CD) (Sprague Dawley)

Supplier

Harlan Sprague Dawley Inc., Indianapolis, Indiana

Number and sex

50 Males, 50 Females (nulliparous and non-pregnant)

Age at initiation of dosing

Approximately 8 weeks

Weight at initiation of dosing

Males: 238.1 to 294.6 grams
Females: 180.3 to 236.3 grams

Quarantine and acclimation period

16 Days

Date received

October 2, 1990
Purchase Order: XGD31406
Packing List: 377436

Room Number

526

Study Initiation (Protocol signature date)

October 17, 1990

Biophase test period

October 18, 1990 through February 20, 1991

Experimental termination

July 13, 1991

Animal identification

Monel ear tags and corresponding cage identification

Justification

Rats have historically been used in safety evaluation studies and are the species of choice for subchronic oral gavage studies.

Selection

More animals than required for the conduct of the study were purchased and acclimated. Animals determined to be unsuitable for inclusion on this study because of poor health, or other abnormalities were excluded from selection by R. L. Harris, D.V.M., Staff Veterinarian, on October 3, 1990 and J. M. Clinton, V.M.D., Veterinary Ophthalmologist on October 16, 1990. Study animals were selected from the remaining animals on October 17, 1990, using the computer generated, body weight sorting program "WTALOC".

Husbandry

Housing

Individual (except during the first week of acclimation)

Caging

Suspended stainless steel

Bedding

Indirect

Feed

Purina Certified Rodent Chow 5002 (mash), ad libitum.
Manufacturer: Ralston Purina Company, Checkerboard Square, St. Louis, Missouri, 63164
Analysis: As provided by Purina.
Contaminants: Purina Certified Rodent Chow has had extensive use and has not, to the best of our knowledge, adversely affected the outcome of studies of this nature.

Water

Automatic watering system, ad libitum.
Supplier: Elizabethtown Water Company, Elizabeth, New Jersey.
Analysis: As provided by Elizabethtown Water Company.
Contaminants: There are no known contaminants in the water believed to be present at levels that may have interfered with this study.

Temperature

Monitored twice daily Monday through Friday, and once daily Saturdays, Sundays and holidays; maintained range of 68 to 76 degrees Fahrenheit.

Humidity

Monitored once daily; maintained range of 40 to 70% relative humidity.

Lighting

Approximately 12 hours light and 12 hours dark by automatic timer

EXPERIMENTAL DESIGN AND STATISTICAL EVALUATION

Experimental Design

Preparation of animals

No special preparation of the study animals was required prior to dose initiation.

Preparation of test material

The test material was mixed with corn oil at the following concentrations to ensure a 10.0 ml/kg dose volume at all dose levels:

Group 2 (500 mg/kg)	5.0% (w/v)
Group 3 (2500 mg/kg)	25.0% (w/v)
Groups 4 and 5 (5000 mg/kg)	50.0% (w/v)

Experimental groups

DOSE GROUP	DOSE mg/kg*	TOTAL ANIMALS M	F
1 (Control)	0	10	10
2	500	10	10
3	2500	10	10
4	5000	10	14a
5 (Satellite)	5000	10	6a

* - mg of test material/kg of body weight
a - See Appendix O for note.

Administration of test material

The test material mixtures were administered by oral gavage at a dose volume of 10 ml/kg, 7 days per week for a period of at least 13 weeks. The control animals received carrier at a dose of 10 ml/kg. The satellite group was dosed at the high dose level seven days a week for approximately 13 weeks and was then observed for reversibility, persistence or delayed occurance of toxic effects for 28 days post-treatment. The amount of test material administered to each animal was recalculated weekly, based on the most recent body weight.

pituitary
prostate
rectum

(a) - Only one parathyroid may be present on the slide. A single parathyroid is sufficient for examination by the pathologist.

Histopathology

Preserved tissues from the control and high dose groups, as well as from all animals that were sacrificed moribund or succumbed during the study, were processed, sectioned, stained (hematoxylin and eosin) and examined microscopically. Gross lesions, tissue masses, and liver, stomach, lungs and kidney from the low and mid dose groups were also processed, sectioned, stained and examined microscopically.

The protocol, all raw data, and the final report are maintained on file in the archives of Exxon Biomedical Sciences Inc..

Statistical Evaluation

The following parameters were statistically analyzed for significant differences:

mean hematology parameters*
mean serum chemistry parameters
mean organ weights
mean organ to body weight ratios
mean body weights, by weighing period
mean food consumption

* excluding qualitative data

Comparisons were limited to within sex analysis. Statistical evaluation of equality of means was done by an appropriate one way analysis of variance and a test for ordered response in the dose groups. First, Bartlett's test was performed to determine if the dose groups have equal variance. If the variances were equal, the testing was done using parametric methods, otherwise nonparametric techniques were used.

For the parametric procedures, a standard one way ANOVA using the F distribution to assess significance was used. If significant differences among the means were indicated,

Dunnett's test was used to determine which treatment groups differ significantly from control. In addition to the ANOVA, a standard regression analysis for linear response in the dose groups and linear lack of fit were performed.

For the nonparametric procedures the test of equality of means was performed using the Kruskal-Wallis test. If significant differences among the means were indicated, Dunn's Summed Rank test was used to determine which treatment group differ significantly from control. In addition to the Kruskal-Wallis test, Jonckheere's test for monotonic trend in the dose response was performed.

The test for equal variance (Bartlett) was conducted at the 1% level of significance. All other tests were conducted at the 5% and 1% level of significance.

The statistical t-test was used to compare the satellite group's main study termination and recovery termination hematology and clinical chemistry values. In addition, the t-test was used to compare the satellite group's and the control groups relative organ weights. The t-test was also used to compare the high dose and satellite groups to ensure similar results in order to accurately evaluate the recovery effects. These statistical runs are maintained in the Archives of Exxon Biomedical Sciences.

References:

1) Snedecor G. and W. Cochran. Statistical Methods, 6th ed. Iowa State University Press, Ames, Iowa (1967): Bartlett's Test, p. 296-298; ANOVA, p. 277-279; Regression Analysis for Trend, p. 149-152; Regression analysis for Lack of Fit, p. 160-164.

2) Dunnett, C.W., J. Am. Sta. Assoc. 50: p. 1096-1121 (1955) and Dunnett, C.W., Biometrics 20: p.114-116 (1964): Dunnett's Test.

3) Hollander and Wolfe, Nonparametric Statistical Methods, John Wiley and Sons, New York (1973): Kruskal-Wallis, p. 114-116; Dunn's Summed Rank Test, p. 131; Jonckeere's Test, p. 120-123.

4) Dixon and Massey, Introduction to Statistical Analysis, 3rd ed. McGraw-Hill Inc., New York (1969): Smith-Satterthwaithe t-test, p. 114-116.

RESULTS

A survival bar graph is presented in Table 1. The following is a summary of this mortality data:

Group (MG/KG)	0		500		2500		5000		SATELLITE	
Sex	M	F	M	F	M	F	M	F	M	F
Survivors	8	9	10	10	10	8	10	10	8	3
Spontaneous deaths	2	1	0	0	0	2	0	4	2	3

With the exception of one 2500 mg/kg female all of the listed spontaneous deaths appear to be the result of dosing trauma and/or aspiration of test material based on postmortem and histopathological findings. This appeared to be related to the physical characteristics of the test material and the high dosage volume.

The incidence of clinical inlife observations is presented in Table 2 with individual inlife observations presented in Appendix A. The majority of animals in the control, low and mid dose groups displayed no observable abnormalities during the test period. Observations noted sporadically in these groups included but were not limited to scabs, maloccluded incisors, alopecia and staining of the fur. Very low incidences of emaciation, dry/wet rales, dyspnea, dried red nasal discharge, poor condition and hypoactivity were also noted. During the treatment period the type and incidence of abnormal clinical signs were similar between the high dose and satellite groups with a dramatic increase in incidence when compared to the mid dose group. The abnormal clinical signs most frequently noted included swollen anus, ano-genital staining, emaciation, and alopecia. Observations noted at a lower incidence included but were not limited to wet/dry rales, nasal and oral discharges, maloccluded incisors, scabs and sores. During the satellite recovery period the incidence of abnormal signs decreased over time with an increase in the number of animals exhibiting no observable abnormalities. Some animals in the mid, high and satellite dose groups exhibited clear oral discharge prior to dosing sporadically during the test period.

Mean body weights are presented in Table 3 with individual animal values presented in Appendix B. Terminal body weights of surviving animals are presented in the organ weight data (Table 7 and Appendix I). Statistically significant decreases from controls at the $p \leq 0.05$ level of significance were noted for mid dose males on days 77, 84, 91, and termination and for the high dose males on day 42. A statistically significant decrease ($p \leq 0.01$) was noted for the high dose group males on Day 49 and continued through the end of the treatment period.

Statistically significant decreases were noted for mid dose females ($p \leq 0.05$) on day 91 and for high dose females on days 77 and 91. At termination both mid and high dose females displayed a statistically significant decrease in body weight ($p \leq 0.01$).

Mean weekly food consumption was calculated and statistically analyzed. The results are presented in Table 4 with individual animal values presented in Appendix C. Statistically significant increases in food consumption which were linearly related to dose were noted for males on Days 28 through 56 and Day 70 through term. Significance levels of both $p \leq 0.05$ and $p \leq 0.01$ were noted for both the mid and high dose group males during these periods. These trends were also evident in the females where statistically significant increases in food consumption were noted on Days 21, 42, 49 and 63 through 95. The significance level for mid dose females was $p \leq 0.05$ and was noted Day 63, 84 and 95. High dose females displayed a $p \leq 0.05$ level of significance on Day 49 and a $p \leq 0.01$ level of significance at the rest of the above mentioned times.

Mean quantitative hematology values were calculated and statistically analyzed and the results presented in Table 5. Individual values are presented in Appendix D. Statistical analyses of the terminal hematology values revealed a statistically significant increase in platelets which was linearly related to dose in both the males and females. In males the low dose group showed a level of significance of $p \leq 0.05$, while the mid and high dose groups displayed a $p \leq 0.01$ level of significance. In the females a $p \leq 0.01$ level of significance was limited to the high dose group. In addition the male animals displayed a linear dose related increase in white blood cells. The mid dose male values were noted to differ significantly from those of controls for hematocrit and hemoglobin at the $p \leq 0.01$ level of significance and mean corpuscular volume and mean corpuscular hemoglobin at the $p \leq 0.05$ level of significance.

Inspection of qualitative hematology values revealed an increase in segmented neutrophils for animals of the high and satellite dose groups at termination (Appendix E).

Serum chemistry values are presented in Table 6 with individual animal values presented in Appendix G. Serum chemistry results revealed linearly dose related increases in males for urea nitrogen and gamma glutamyl transpeptidase with levels of significance of $p \leq 0.01$ for the high dose males and also the mid-dose males for urea nitrogen. An increase (related to dose) for cholesterol was noted for the mid and high dose groups of both sexes differing from the controls at a significance level of $p \leq 0.01$. An ordered response to dose (increase) was also noted for the female triglycerides but none of the groups were statistically significantly different

from the controls. An ordered response to dose (increase) for alanine aminotransferase was also noted for the mid and high dose males differing from the controls at a significance level of $p \leq 0.01$. Glucose values were significantly lower than the control values at the $p \leq 0.01$ level for both sexes in the mid and high dose and for the male low dose at the $p \leq 0.05$ level. Also noted was a statistically significant ($p \leq 0.05$) increase in bilirubin in the high dose of both sexes. Several other parameters (creatinine, chloride and triglycerides) also displayed statistically significant differences from the controls.

Mean organ weights and mean relative organ weights were calculated and statistically analyzed and are presented in Tables 7 and 8. Individual animal values are presented in Appendices I and J. Significant differences among the means (increases) were noted for livers in both males and females and for kidneys for male animals, in all cases showing an increase compared to control means. The low and mid-dose male liver weights were significantly different from the control means at the $p \leq 0.05$ and $p \leq 0.01$ levels respectively. All treated group female liver weights were significantly different from the control mean with a $p \leq 0.05$ level of significance for the low dose and the $p \leq 0.01$ level for the mid and high dose groups. All treated group male kidney weights were significantly different from the control at the $p \leq 0.01$ level of significance. Analyses of mean male organ weights revealed a statistically significant increase in both male and female adrenal weights with the high dose groups and mid dose females displaying a significance of $p \leq 0.01$.

Male relative organ weight analyses revealed ordered responses to dose (increases) for liver/body weight, adrenal/body weight and testes/body weight. The male mid and high dose groups values were significantly different from controls at the $p \leq 0.01$ level as was the high dose adrenal value. The high dose testes values were also significantly different from the controls, but at the $p \leq 0.05$ level. An ordered response to dose (increase) was also noted for female liver/body weight with the mid and high dose groups significantly different from controls at the $p \leq 0.01$ level of significance. A linearly dose related increase in adrenal/body weight was noted with the mid and high dose groups significantly different from the control mean at $p \leq 0.01$. Both the male and female relative kidney weights for all treated groups were significantly different from the control value at the $p \leq 0.01$ level.

Analysis of satellite recovery hematology values for evidence of recovery trends against those at main study termination (Table 9) revealed a lowering of white blood cell values toward those of control animals at main study termination for male animals. Serum chemistry analyses (Table 10) revealed recovery trends toward terminal control values in males for total bilirubin, gamma glutamyl transpeptidase, glucose,

alanine aminotransferase and cholesterol. Female analyses revealed recovery trends in chloride and alanine aminotransferase.

There were no treatment-related findings noted at the terminal ophthalmological examination (Appendix M).

Analytical results are presented in Appendix N. Stability was demonstrated for up to 8 days under conditions of both room temperature and refrigeration. Good uniformity was demonstrated at both the 5% and 50% dose levels.

The gross individual postmortem examination findings are listed in Table 11. The following is a list of the number of animals exhibiting no observable abnormalities and the most frequently noted abnormalities for survivors at the terminal sacrifice:

Group (MG/KG)	0		500		2500		5000		SATELLITE	
Sex	M	F	M	F	M	F	M	F	M	F
(N) per group	8	9	10	10	10	8	10	10	8	3
No observable abnormalities	5	5	8	4	0	4	0	0	4	1
Swollen anus	0	0	0	0	0	0	9	10	0	0
Small intestine abnormal contents	0	0	0	0	2	1	1	1	1	0
Small intestine distension	0	0	0	0	1	1	1	1	1	0
Large intestine abnormal contents	0	0	0	1	2	1	3	2	2	1
Large intestine distension	0	0	0	1	2	1	4	5	2	1
Cervical lymph nodes red	0	1	0	1	0	0	1	2	0	0
Staining of the fur	0	0	1	0	8	2	4	1	0	0
Emaciation	0	0	0	0	2	0	4	1	0	0

Also noted sporadically were lung discoloration, pale or tan area on the liver, eye damage from bleeding, maloccluded or broken incisors, alopecia, uterine distension, thickened stomach and cecum vascularization.

Single incidences of the following were also noted; reddened mesenteric lymph nodes, distension and abnormal contents of the stomach, larger than normal ovaries, ovarian foci, smaller than normal testes, anal scabs, pale adrenals, ocular discharge and an additional liver cleft.

In addition, one surviving male and 3 surviving female rats in Group 1 and one surviving female rat in Group 2 displayed postmortem findings at termination which can be associated with dosing trauma and/or aspiration of the test material. These included tan liquid, oily liquid or tan caseous material in the thoracic cavity, lung discoloration, and abnormalities of the heart/and or pericardium.

The following lists the frequently noted gross postmortem abnormalities for the animals which succumbed prior to study termination.

Group (MG/KG)	0		2500		5000		SATELLITE	
Sex	M	F	M	F	M	F	M	F
(N) per group	2	1	0	2	0	4	2	3
No observable abnormalities	0	0	0	0	0	0	0	0
Lung discoloration	2	1	0	2	0	2	2	2
Staining of the fur	1	1	0	0	0	1	2	2
Emaciated	0	1	0	0	0	1	0	1
Small intestine abnormal contents	0	0	0	1	0	2	1	1
Stomach distended	0	0	0	1	0	1	2	0
Stomach abnormal contents	1	0	0	1	0	3	1	0
Anus swollen	0	0	0	0	0	4	2	1

Also noted at a low incidence were large and small intestine distension, abnormal content in the large intestine, ocular discharge and reddened trachea.

Detailed postmortem findings for all animals are presented in Table 11.

All of the above deaths with the exception of one Group 3 female are felt to be the result of dosing trauma and/or aspiration of the test material. This determination is based on gross postmortem results and correlating pathology findings. These postmortem findings included but were not limited to abnormal thoracic cavity contents including red, oily, clear liquids and/or tan or white caseous material, holes in the esophagus, thoracic aorta and bronchi, lung tissue consolidation and discoloration.

The complete histopathology report is presented in Appendix P. Microscopic examination of livers revealed a dose-related occurence of hepatocellular hypertrophy in both male and female rats in all treatment groups. Satellite animals

sacrificed 28 days post-treatment did not display this change, indicating reversibility. Treatment-related changes in the kidneys of male rats included accumulations of hyaline droplets in the cytoplasm of the proximal convoluted tubules, dilatation and granular cast formations in the medullary tubules and increased basophilia of cortical tubules these kidney changes were essentially the same in incidence and severity throughout the treatment groups. Examination of the kidneys of male satellite group animals revealed only dilated tubules with granular casts in the medulla in four of the eight rats, indicative of reversibility of renal changes. A dose-related occurence of thickening of the non-glandular portion of the stomach related to hyperplasia and hyperkeratosis was observed. At recovery three of eight male animals displayed residual effects of stomach changes, however no changes were seen in any females or the remaining five males, again indicating reversibility. Gross lesions of the anus noted at postmortem examination in Group 4 animals were microscopically found to include hyperplasia and hyperkeratosis of the skin and mucosa. Necrosis, neutrophilic inflammatory cell infiltrations and pustule formation were also noted. At the satellite sacrifice these gross changes were no longer noted.

DISCUSSION

Administration of MRD-89-582 to rats produced several effects related to irritation from dosing and hepatic involvement. Minor effects in the kidney were also noted.

Fourteen animals died prior to termination of which thirteen can be attributed to dosing trauma and/or aspiration of the test material. The salivation noted prior to dosing appears to indicate that the test material was irritating to the animals. The physical characteristics of the test material as well as the high volume administered probably contributed to the high incidence of dosing trauma.

The most noted clinical sign during the study was "swollen anus" in the high dose and satellite groups. Microscopic examination of the skin around the anus revealed hyperplasia and hyperkeratosis of the skin and mucosa and necrosis, neutrophilic inflammatory cell infiltration and pustule formation. Other frequently noted clinical signs could not be directly related to the clinical chemistry results or the histopathology results.

A decrease in mean body weight was noted with increasing dose during the later stages of the study in both the male and the female mid- and high dose groups. This effect is probably related somewhat to the stomach lesions seen by the pathologist in these groups. It should be noted that the body weights, recovered slightly during the recovery period.

Also during the second half of the study an increase in food consumption was noted with increasing dose for both the males and females, primarily in the mid- and high dose groups. Also noted during the study was an increasing incidence of excessive spillage from the animals' feeders with increasing dose. These two trends appear to indicate that the animals were digging in their feeders. This is commonly seen after dosing with irritating materials.

Hematology values displayed a linear increase in the male white blood cells, however, none of the groups were statistically significantly different from the controls. This increase and an increase in the number of segmented neutrophils may have been related to infection of the lesions seen in the area of the anus. A decrease in the hematocrit, hemoglobin, mean corpuscular volume and mean corpuscular hemoglobin were noted for the mid-dose males. The cause of this decrease is unknown and since it occurred only in the mid-dose group it does not appear to have been treatment related. Finally, the increase in platelets for both sexes may have been related to the stomach irritation caused by the test material. With the exception of the increased platelets all of these effects appeared be reversed at the recovery

sacrifice.

Several clinical chemistry values were affected which were consistent with liver effects by the test material. This includes an increase in male gamma glutamyl transferase and alanine amino transferase. The alanine aminotransferase values for the females do not appear increased when compared to the control. However, the mean control value was high due to the values of two animals. If these values were excluded, the mean for the control females would be approximately 37.0 IU/L and the mid- and high dose would probably be statistically significantly different from the control. The control value would be similar to the value seen in the females after the recovery period. The male and female recovery values indicate reversibility of the effect. Also the cholesterol values were increased which may be related to a liver effect. The male mean low dose triglyceride value was noted as being statistically significantly different from the control. This difference was not considered to be test material related since it only occurred at the low dose level. The triglyceride values for the females displayed an ordered response (increase) to dose but none of the groups, primarily the high dose group, were noted as being statistically significantly different from the controls due to the large variation among the high dose data points. Finally, the increase seen in the bilirubin values is suggestive of a liver effect. After the recovery period, these values were essentially the same as the main study terminal control values representing the reversibility of the effect.

Minor differences were observed for creatinine and urea nitrogen. However, these changes were slight and not indicative of major functional changes in the kidneys. The cause of the depressed chloride values may be related to the kidney effects seen by the pathologist, however the decrease in the chloride values while statistically significant (females) was small. The values did show reversibility at the recovery sacrifice of the satellite animals with the values approximately the same as the main study terminal control values.

The reason for the decrease in glucose values is unknown however it may be attributed to the the general health of the animals since the body weights were somewhat depressed at the termination of the study. The glucose values at recovery for the satellite group were approximately the same as the main study terminal control values indicating reversibility of the condition which caused the depressed glucose values.

The absolute and relative male and female liver weights and the male absolute and relative kidney weights were consistent with the changes seen by the pathologist. However the reason for the increased relative kidney weights for the female is unknown. The increased absolute and relative adrenal weights

in both the males and females may be attributed to stress of the animals receiving an irritating test material. The increased relative testes weights were probably due the testes not losing weight as fast as the body as a whole. There was no evidence of testicular effects in the microscopic examination and the absolute weights appeared normal.

In conclusion a no-effect level was not determined in this study due to the changes seen in the liver and kidneys of the low dose group during the microscopic examination by the pathologist. These effects were also reflected in the organ weight effects seen in the low dose group.

TABLE 1 - SURVIVAL BAR GRAPH



TABLE 1 - SURVIVAL BAR GRAPH CONT.



TABLE 1 - SURVIVAL BAR GRAPH CONT.



NOTE:

T - TERMINAL
S - SPONTANEOUS DEATH
M - MORIBUND EUTHANASIA
= - 1.25 DAYS

KEY A - KEY TO INLIFE OBSERVATIONS ABBREVIATIONS

+ = Observation present

- = Observation not present at scheduled interval

CONDITION	LOCATIONS
Scabs:	Ventral cervical Posterior ventral Mouth Anus Head Snout Both forepaws
Alopecia:	Trunk Head Extremities Entire body

NOTE: This is a list of possible locations for observations listed in Table 2 (Incidence of Inlife Observations), for each animal's specific observations see Appendix A (Individual Inlife Observations).

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS

MALES

		DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
SURVIVORS	CONTROL	10	10	10	10	10	9	9	9	9	9	9	9	9	9	9	9	9
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	5000 MG/KG(SATELLITE)	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
GENERAL OBSERVATION WITHIN NORMAL LIMITS																		
	CONTROL	10	10	10	10	9	9	9	9	9	9	9	9	9	9	9	9	9
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	9	9	9	9	7	7
	5000 MG/KG	10	9	9	10	9	9	9	9	8	6	0	0	2	3	1	0	0
	5000 MG/KG(SATELLITE)	10	10	10	10	10	10	10	10	8	8	0	0	0	0	0	0	0
RESPIRATION DYSPNEA																		
	CONTROL	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLEAR ORAL DISCHARGE																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
APPEARANCE URINE STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANOGENITAL STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2
	5000 MG/KG	0	0	1	0	0	0	0	0	1	1	3	1	1	1	0	2	3
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	2	2	2	1	1	1	1	3	6

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
SOFT STOOL																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	10	10	7	6	9	10	10
SORES (ANUS/PALATE/HINDLEG)											10	10	10	10	10	10	10
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	2	1	2	2	2	2
PALE EXTREMITIES																	
CONTROL	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RED DISCHARGE ANUS																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RED MATERIAL SEEN MOUTH																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1
5000 MG/KG	0	0	0	0	0	1	1	1	1	2	2	2	2	2	2	2	2
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2	1
ACTIVITY																	
HYPOACTIVITY																	
CONTROL	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
SURVIVORS																	
CONTROL	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
GENERAL OBSERVATION WITHIN NORMAL LIMITS																	
CONTROL	9	9	9	9	9	8	8	8	8	8	8	8	8	8	8	8	8
500 MG/KG	10	10	10	10	9	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG	6	9	9	9	9	9	9	6	7	6	4	8	8	8	9	9	8
5000 MG/KG	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION WET RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	0	1	1	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED NASAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	1	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
CLEAR ORAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	1	0
APPEARANCE URINE STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ANOGENITAL STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	2	0	0	0	0	0	0	2	1	2	4	1	1	1	0	0	1
5000 MG/KG	3	3	1	1	1	0	1	0	0	0	0	0	1	1	0	1	3
5000 MG/KG(SATELLITE)	5	6	2	3	1	0	3	3	3	2	2	2	3	2	0	3	4
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	1	1	1	1	1	1	0	0	0	0	0	0	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0
5000 MG/KG	10	10	10	8	9	10	10	10	10	10	10	10	10	9	10	10	10
5000 MG/KG(SATELLITE)	10	10	10	10	10	10	10	9	10	10	10	10	10	10	10	10	10
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	1	1	1	1	2	3	2	2	1	1	1	1	0	0	0
5000 MG/KG(SATELLITE)	0	1	1	2	2	1	3	5	5	5	2	0	0	0	0	0	0
POOR CONDITION																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	1	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0
5000 MG/KG(SATELLITE)	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROTRUDING ANUSG																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
MALOCCLUDED INCISORS																	
CONTROL	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG	2	2	2	2	2	2	3	3	3	3	3	3	3	3	3	3	3
5000 MG/KG(SATELLITE)	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
SURVIVORS																	
CONTROL	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
GENERAL OBSERVATION WITHIN NORMAL LIMITS																	
CONTROL	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8
500 MG/KG	10	10	10	10	10	10	10	10	10	8	8	6	8	10	10	9	8
2500 MG/KG	8	7	8	8	8	9	9	6	7	5	7	6	5	6	6	6	6
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION WET RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	1	0	0	0	0	0	1	1	1	1	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLEAR ORAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0
APPEARANCE ANOGENITAL STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	2	2	4	2	0	0	1	2
2500 MG/KG	1	1	0	0	0	0	0	3	2	4	2	3	4	3	1	2	3
5000 MG/KG	1	2	1	2	2	4	3	3	1	2	1	1	5	2	0	2	4
5000 MG/KG(SATELLITE)	2	1	0	0	0	2	2	3	1	2	3	3	3	1	0	2	3
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	1	1	0	0	0	1	0	0	0	0	0	1	1	1	0	0
5000 MG/KG(SATELLITE)	0	1	1	1	0	0	0	0	0	1	2	2	1	1	1	1	2
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	2	2	0	0	0	0	1	1	1	1	2	0
5000 MG/KG(SATELLITE)	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0
RED MATERIAL SEEN MOUTH																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
MALOCCLUDED INCISORS																	
CONTROL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	1	2	2	2	2	1	1	1	1	1	2	2	2	2	2	2	1
5000 MG/KG	3	3	3	3	3	3	3	3	3	3	3	3	2	2	2	2	2
5000 MG/KG(SATELLITE)	2	3	3	2	2	2	1	1	1	1	1	2	3	3	3	3	1

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
SURVIVORS																	
CONTROL	9	9	9	9	9	9	9	9	9	9	8	8	8	8	8	8	8
500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	10	10	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
GENERAL OBSERVATION WITHIN NORMAL LIMITS																	
CONTROL	8	8	7	8	8	7	7	7	6	6	5	6	6	6	6	6	6
500 MG/KG	8	9	9	9	9	6	7	6	7	8	8	7	8	8	7	8	9
2500 MG/KG	6	6	8	8	8	4	6	4	1	0	3	2	8	8	7	8	8
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION DRY RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED NASAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLEAR ORAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0
APPEARANCE ANOGENITAL STAINING																	
CONTROL	0	0	0	0	0	1	0	0	1	0	1	0	0	0	0	0	0
500 MG/KG	1	0	0	0	0	3	2	4	3	2	2	3	2	2	3	1	0
2500 MG/KG	3	2	1	1	1	5	3	5	9	6	7	8	1	1	2	1	1
5000 MG/KG	2	3	1	1	1	3	0	3	7	8	8	7	4	1	1	0	0
5000 MG/KG(SATELLITE)	2	3	1	0	0	3	2	6	5	8	7	7	4	2	4	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	4	6	0	0	0	0	0	0	0
5000 MG/KG	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	1	0	0	0	0	0	0	2	1	2	0	0	0	0	0	0	0
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	1	0	1	1	1	1	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	10	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	2	1	3	2	1	2	1	1
5000 MG/KG(SATELLITE)	2	1	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1
TEETH CUT																	
CONTROL	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	2	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
BROKEN INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0
RED MATERIAL SEEN MOUTH																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUDED INCISORS																	
CONTROL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
500 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
2500 MG/KG	2	2	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG	2	2	2	3	3	2	2	2	2	2	2	2	2	2	5	5	7
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	1	2	2	2	2	2	2	3
OCULAR																	
DRIED RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
SURVIVORS																	
CONTROL	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8
500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
GENERAL OBSERVATION WITHIN NORMAL LIMITS																	
CONTROL	6	6	7	7	7	6	6	7	7	7	6	7	6	7	7	7	7
500 MG/KG	9	9	8	9	9	7	8	8	9	9	8	9	9	9	9	9	9
2500 MG/KG	8	8	6	7	8	8	5	8	8	8	0	6	6	5	5	5	6
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION WET RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRY RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED NASAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
APPEARANCE URINE STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	2
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ANOGENITAL STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
500 MG/KG	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
2500 MG/KG	1	1	3	2	1	1	4	1	1	1	9	2	2	4	4	3	4
5000 MG/KG	0	0	2	0	0	0	0	2	2	0	2	0	1	1	0	2	4
5000 MG/KG(SATELLITE)	0	0	0	1	0	1	0	1	1	0	3	1	1	1	2	4	4
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	2	1	1	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0
5000 MG/KG	1	1	2	2	1	1	1	1	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	1	1	2	2	0	1	0	0	0	0	1	0	0	0	0	0	0
TEETH CUT																	
CONTROL	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
BROKEN INCISOR(S)																	
CONTROL	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUDED INCISORS																	
CONTROL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
500 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	1	1	1	1	1	1	1	1	1	2	1	2	2	2	2	2	2
5000 MG/KG	7	7	6	7	6	7	7	5	6	5	5	2	2	2	2	2	2
5000 MG/KG(SATELLITE)	3	3	2	4	4	4	2	2	2	2	2	2	2	2	2	2	2
ANOGENITAL STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

		DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
SURVIVORS	CONTROL	8	8	8	8	8	8	8	8	8	8	8	8					
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10					
	2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10					
	5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10					
	5000 MG/KG(SATELLITE)	9	9	9	9	9	9	9	9	9	9	9	8	8	8	8	8	8
GENERAL OBSERVATION WITHIN NORMAL LIMITS																		
	CONTROL	7	7	7	7	6	7	7	7	7	7	7	7					
	500 MG/KG	9	9	8	9	8	8	8	8	9	8	9	8					
	2500 MG/KG	7	8	8	8	8	8	8	8	7	6	8	1					
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION DYSPNEA																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0
WET RALES																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
DRY RALES																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG	1	1	1	0	0	0	0	0	0	0	0	0					
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
DRIED RED NASAL DISCHARGE																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0
CLEAR ORAL DISCHARGE																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
APPEARANCE																	
URINE STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	1	1	1	1	0	0	0	1					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANOGENITAL STAINING																	
CONTROL	0	0	0	0	1	0	0	0	0	0	0	0					
500 MG/KG	0	0	1	0	1	1	1	1	0	1	0	0					
2500 MG/KG	2	1	1	1	1	1	1	2	2	3	2	8					
5000 MG/KG	0	1	0	0	0	1	1	4	0	0	0	3					
5000 MG/KG(SATELLITE)	1	1	0	0	0	0	0	1	0	2	0	5	6	1	0	0	0
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	1	0	0	0	0	0	1	1	1	0	0	1					
5000 MG/KG	0	0	0	0	0	0	0	0	1	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0
SOFT STOOL																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	1	1	1	0	1					
5000 MG/KG(SATELLITE)	1	1	1	1	0	1	1	1	1	0	0	0	0	1	1	1	1
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10					
5000 MG/KG(SATELLITE)	9	9	9	9	9	9	9	9	9	9	8	8	8	8	8	8	8

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	3					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	5					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	0	5	4	4	4	4	1
TEETH CUT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	1	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
POOR CONDITION																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0
RED MATERIAL SEEN MOUTH																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	1	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LITTLE SIGN OF STOOL																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
MALOCCLUDED INCISORS																	
CONTROL	1	1	1	1	1	1	1	1	1	1	1	1					
500 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	2	2	2	2	2	2	2	2	2	2	1	1					
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	0	1					
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
OCULAR																	
RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
DRIED RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0
ACTIVITY																	
HYPOACTIVITY																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0					
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0					
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 102	DAY 103	DAY 104	DAY 105	DAY 106	DAY 107	DAY 108	DAY 109	DAY 110	DAY 111	DAY 112	DAY 113	DAY 114	DAY 115	DAY 116	DAY 117	DAY 118
SURVIVORS																	
5000 MG/KG(SATELLITE)	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8
GENERAL OBSERVATION																	
WITHIN NORMAL LIMITS																	
5000 MG/KG(SATELLITE)	0	0	0	0	0	1	1	1	1	1	1	3	5	7	7	7	7
RESPIRATION																	
DRY RALES																	
5000 MG/KG(SATELLITE)	1	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0
APPEARANCE																	
SCABS (SEE KEY A FOR LOCATIONS)																	
5000 MG/KG(SATELLITE)	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
5000 MG/KG(SATELLITE)	8	8	8	8	8	6	6	6	6	6	6	3	1	1	0	0	0
EMACIATED																	
5000 MG/KG(SATELLITE)	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0
TEETH CUT																	
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
POOR CONDITION																	
5000 MG/KG(SATELLITE)	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUDED INCISORS																	
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	2	2	2	2	0	0	0	0
OCULAR																	
CLEAR OCULAR DISCHARGE																	
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
DRIED RED OCULAR DISCHARGE																	
5000 MG/KG(SATELLITE)	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	0	1

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

MALES

	DAY 119	DAY 120	DAY 121	DAY 122	DAY 123	DAY 124	DAY 125
SURVIVORS							
5000 MG/KG(SATELLITE)	8	8	8	8	8	8	8
GENERAL OBSERVATION							
WITHIN NORMAL LIMITS							
5000 MG/KG(SATELLITE)	7	7	7	7	7	7	6
RESPIRATION							
DRIED RED NASAL DISCHARGE							
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	1
OCULAR							
RED OCULAR DISCHARGE							
5000 MG/KG(SATELLITE)	1	0	1	0	0	0	1
DRIED RED OCULAR DISCHARGE							
5000 MG/KG(SATELLITE)	0	1	0	1	1	1	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

		DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
SURVIVORS	CONTROL	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	5000 MG/KG	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14
	5000 MG/KG(SATELLITE)	6	6	6	6	6	6	6	6	5	4	4	4	4	4	4	4	4
GENERAL OBSERVATION WITHIN NORMAL LIMITS																		
	CONTROL	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	2500 MG/KG	10	10	10	10	10	10	10	9	10	10	10	10	10	10	10	10	10
	5000 MG/KG	14	14	14	14	14	14	14	12	9	11	6	4	3	3	2	2	2
	5000 MG/KG(SATELLITE)	6	6	6	6	6	6	6	5	3	3	1	0	0	0	0	0	0
RESPIRATION DYSPNEA																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
CLEAR ORAL DISCHARGE																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
APPEARANCE URINE STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
ANOGENITAL STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	1	3	2	1	1	2	2	2	1	3
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	7	9	10	10	12	12	11
EMACIATED											3	4	4	4	4	4	4
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1
ACTIVITY																	
HYPOACTIVITY																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

		DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
SURVIVORS	CONTROL	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	5000 MG/KG	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14
	5000 MG/KG(SATELLITE)	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
GENERAL OBSERVATION WITHIN NORMAL LIMITS																		
	CONTROL	10	10	10	10	10	9	9	9	10	10	10	10	10	10	10	10	10
	500 MG/KG	10	10	10	10	10	10	10	10	9	10	10	10	10	10	10	10	10
	2500 MG/KG	10	10	10	10	10	10	8	8	9	9	9	9	8	8	8	9	9
	5000 MG/KG	1	1	0	0	0	0	0	2	1	1	1	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION DRY RALES																		
	CONTROL	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED NASAL DISCHARGE																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	2	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLEAR ORAL DISCHARGE																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	1	0
	5000 MG/KG(SATELLITE)	0	1	0	0	0	0	0	0	0	0	3	0	0	0	0	1	0
APPEARANCE ANOGENITAL STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0
	5000 MG/KG	2	1	1	1	1	0	2	1	2	2	3	3	3	1	0	4	2
	5000 MG/KG(SATELLITE)	2	1	1	1	2	1	0	1	0	0	0	0	0	0	0	0	2

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
5000 MG/KG	0	0	0	0	0	0	2	2	2	2	2	2	1	1	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	13	13	14	14	14	14	14	12	13	13	13	14	14	14	14	14	14
5000 MG/KG(SATELLITE)	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
EMACIATED																	
CONTROL	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	1	1	2	2	2	2	1	1	1	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TEETH CUT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	1	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
POOR CONDITION																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	0	0	1	1	2	1	1	1	1	0	1	1	1	0	0	0
5000 MG/KG(SATELLITE)	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
MALOCCLUDED INCISORS																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	1	0	0	1	1	1	1	1	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
MISSING INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OCULAR																	
DRIED RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	1	1	1	0	0	0	0	1	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
SURVIVORS																	
CONTROL	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14
5000 MG/KG(SATELLITE)	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
GENERAL OBSERVATION WITHIN NORMAL LIMITS																	
CONTROL	10	9	9	10	10	10	10	10	10	10	10	10	10	10	10	9	9
500 MG/KG	10	10	10	10	10	10	10	10	10	10	9	10	10	10	10	10	10
2500 MG/KG	9	9	8	9	9	9	8	9	9	9	9	9	9	9	9	8	8
5000 MG/KG	0	0	0	0	0	0	1	1	1	2	1	2	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0
RESPIRATION DYSPNEA																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRY RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED NASAL DISCHARGE																	
CONTROL	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLEAR ORAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	4	1	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
APPEARANCE																	
URINE STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANOGENITAL STAINING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
2500 MG/KG	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	1
5000 MG/KG	3	0	0	0	0	0	1	3	1	1	1	1	2	1	1	2	2
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	0	0	2	1	0	0	1
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOFT STOOL																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	14	14	14	14	14	14	13	13	13	12	13	12	14	14	14	14	13
5000 MG/KG(SATELLITE)	4	4	4	4	4	4	3	4	4	3	3	3	4	4	4	4	4

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	1	2	2	2	1	2	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TEETH CUT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
POOR CONDITION																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	1	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0
LITTLE SIGN OF STOOL																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG	1	1	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
MISSING INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OCULAR																	
CLEAR OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	1	1	1	0	1	1	1	0	0	1	2	2
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
SURVIVORS																	
CONTROL	10	10	10	10	10	10	9	9	9	9	9	9	9	9	9	9	9
500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	9	9	9	9	9	9
5000 MG/KG	13	13	13	13	12	11	11	11	11	11	11	11	11	11	11	11	11
5000 MG/KG(SATELLITE)	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
GENERAL OBSERVATION WITHIN NORMAL LIMITS																	
CONTROL	9	9	9	9	9	9	7	7	7	8	8	9	9	9	9	9	9
500 MG/KG	10	10	10	10	10	10	10	9	9	7	7	7	9	9	10	10	10
2500 MG/KG	8	7	9	9	9	9	9	7	6	3	4	6	8	8	8	8	8
5000 MG/KG	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION DYSPNEA																	
CONTROL	1	1	1	1	1	0	0	1	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
WET RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRY RALES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED NASAL DISCHARGE																	
CONTROL	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	0	1	0	0	0	1	1	0	1	1	1	1	1	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLEAR ORAL DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
APPEARANCE																	
URINE STAINING																	
CONTROL	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ANOGENITAL STAINING																	
CONTROL	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	3	2	2	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	3	6	4	2	0	0	0	0	0
5000 MG/KG	3	3	3	3	1	2	1	1	2	8	6	4	0	0	2	1	1
5000 MG/KG(SATELLITE)	0	1	0	0	0	0	0	0	0	1	0	2	0	0	1	0	0
UNTHRIFTY COAT																	
CONTROL	1	1	1	1	1	0	0	1	1	1	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0
2500 MG/KG	1	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0
5000 MG/KG	0	1	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOFT STOOL																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTHERMIA																	
CONTROL	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
5000 MG/KG	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	13	13	13	12	11	10	10	11	10	11	11	11	11	11	9	11	11
5000 MG/KG(SATELLITE)	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	3	3
EMACIATED																	
CONTROL	1	1	1	1	1	0	1	1	1	1	1	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	1	1	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0
5000 MG/KG	1	1	1	3	1	1	0	1	1	3	2	1	1	2	2	2	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
TEETH CUT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
POOR CONDITION																	
CONTROL	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
5000 MG/KG	1	1	3	2	1	1	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BROKEN INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
PALE EXTREMITIES																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RED MATERIAL SEEN MOUTH																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LITTLE SIGN OF STOOL																	
CONTROL	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LITTLE SIGN OF FOOD CONSUMPTIO N																	
CONTROL	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUDED INCISORS																	
CONTROL	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	2	3	3	3	4	4	4
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1	1

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
MISSING INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
OCULAR																	
RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLEAR OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	3	2	0	0	0	0	0	0	0	0	0	0	0	0	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRIED RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0
5000 MG/KG	2	2	1	1	1	1	1	1	1	1	1	0	0	1	1	1	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ACTIVITY																	
HYPOACTIVITY																	
CONTROL	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
5000 MG/KG	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

		DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
SURVIVORS	CONTROL	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	2500 MG/KG	9	9	9	9	9	9	9	9	9	9	8	8	8	8	8	8	8
	5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
	5000 MG/KG(SATELLITE)	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
GENERAL OBSERVATION WITHIN NORMAL LIMITS																		
	CONTROL	9	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9
	500 MG/KG	10	10	10	9	9	9	10	9	9	10	9	10	10	9	10	9	9
	2500 MG/KG	8	8	8	4	5	7	8	7	8	8	6	6	6	6	6	5	5
	5000 MG/KG	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION WET RALES																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DRY RALES																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
APPEARANCE URINE STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0
	2500 MG/KG	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
ANOGENITAL STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	500 MG/KG	0	0	0	1	0	0	0	1	1	0	1	0	0	1	0	1	1
	2500 MG/KG	0	0	0	2	1	0	0	0	0	0	0	1	1	0	0	1	1
	5000 MG/KG	1	1	1	0	0	0	1	0	1	0	3	1	0	0	0	0	2
	5000 MG/KG(SATELLITE)	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
UNTHRIFTY COAT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	1
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	10	10	10	10	9	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG(SATELLITE)	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	1	1	1	1	1	0	0	0	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TEETH CUT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	0	0	1	0	0	0	1	1	0	0	0	0	1	0	0	1	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SORES (ANUS/PALATE/HINDLEG)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	1	2	1	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
BROKEN INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG(SATELLITE)	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUDED INCISORS																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG	5	5	5	4	4	4	4	4	4	4	3	3	3	3	3	3	3
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	1
MISSING INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
5000 MG/KG(SATELLITE)	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OCULAR																	
DRIED RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5000 MG/KG	1	0	0	1	1	1	1	1	1	1	1	1	1	1	2	1	1
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

		DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
SURVIVORS	CONTROL	9	9	9	9	9	9	9	9	9	9	9	9	9				
	500 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10				
	2500 MG/KG	8	8	8	8	8	8	8	8	8	8	8	8	8				
	5000 MG/KG	10	10	10	10	10	10	10	10	10	10	10	10	10				
	5000 MG/KG(SATELLITE)	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
GENERAL OBSERVATION WITHIN NORMAL LIMITS																		
	CONTROL	8	8	8	8	8	8	8	9	9	9	9	9	9				
	500 MG/KG	10	10	10	10	9	9	9	6	7	8	8	8	7				
	2500 MG/KG	6	6	5	6	7	7	7	4	6	6	7	7	6				
	5000 MG/KG	0	0	0	1	0	0	0	0	0	0	0	1	0				
	5000 MG/KG(SATELLITE)	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATION WET RALES																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
	5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
	5000 MG/KG(SATELLITE)	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
DRY RALES																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
	2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
	5000 MG/KG	0	0	0	0	0	0	0	0	1	0	0	0	0				
	5000 MG/KG(SATELLITE)	1	0	0	0	0	0	0	0	1	1	0	1	1	1	0	0	1
APPEARANCE ANOGENITAL STAINING																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
	500 MG/KG	0	0	0	0	1	1	0	2	1	0	0	0	0				
	2500 MG/KG	0	0	1	0	0	0	0	3	1	1	0	0	2				
	5000 MG/KG	0	0	0	0	0	0	0	1	0	0	0	0	1				
	5000 MG/KG(SATELLITE)	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
UNTHRIFTY COAT																		
	CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
	500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	1				
	2500 MG/KG	1	1	1	1	0	0	0	0	0	0	0	0	0				
	5000 MG/KG	0	1	1	0	0	0	0	0	0	0	0	0	0				
	5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
SCABS (SEE KEY A FOR LOCATIONS)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	1	1	1	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0				
SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	10	10	10	9	10	10	10	10	10	10	10	9	10				
5000 MG/KG(SATELLITE)	3	3	3	2	3	3	3	3	3	3	3	3	3	3	3	3	3
EMACIATED																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	1	2	2	2	1	2	1	1	1	1	1	1	1				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
TEETH CUT																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	0	0	0	1	0	0	1	0	0	1	0	0	1				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BROKEN INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	1	1	1	1	1	1	1	1	1				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MALOCCLUDED INCISORS																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	0				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
CONTROL	1	1	1	1	1	1	1	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	1	1	1	1	1	1				
2500 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1				
5000 MG/KG	3	3	2	0	1	1	1	1	1	2	2	2	2				
5000 MG/KG(SATELLITE)	1	1	1	1	2	2	2	2	2	2	1	1	1	1	1	2	2
MISSING INCISOR(S)																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	1	1	1	1	1	1	1	1	1	1	1	1	1				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OCULAR																	
EYE DAMAGED FROM EYEBLEEDING																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1
DRIED RED OCULAR DISCHARGE																	
CONTROL	0	0	0	0	0	0	0	0	0	0	0	0	0				
500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
2500 MG/KG	0	0	0	0	0	0	0	0	0	0	0	0	0				
5000 MG/KG	1	0	0	0	0	0	0	1	1	1	1	1	1				
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 102	DAY 103	DAY 104	DAY 105	DAY 106	DAY 107	DAY 108	DAY 109	DAY 110	DAY 111	DAY 112	DAY 113	DAY 114	DAY 115	DAY 116	DAY 117	DAY 118
SURVIVORS																	
5000 MG/KG(SATELLITE)	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3
GENERAL OBSERVATION WITHIN NORMAL LIMITS																	
5000 MG/KG(SATELLITE)	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1
RESPIRATION DRY RALES																	
5000 MG/KG(SATELLITE)	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
APPEARANCE SWOLLEN (ANUS/ABDOMEN/TRUNK)																	
5000 MG/KG(SATELLITE)	3	3	3	3	3	3	3	2	2	1	1	1	1	0	0	0	0
ALOPECIA (SEE KEY A FOR LOCATIONS)																	
5000 MG/KG(SATELLITE)	2	2	2	2	2	2	2	2	2	1	1	1	1	1	1	1	1
OCULAR EYE DAMAGED FROM EYEBLEEDING																	
5000 MG/KG(SATELLITE)	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1

TABLE 2 - INCIDENCE OF INLIFE OBSERVATIONS CONT.

FEMALES

	DAY 119	DAY 120	DAY 121	DAY 122	DAY 123	DAY 124	DAY 125
SURVIVORS							
5000 MG/KG(SATELLITE)	3	3	3	3	3	3	3
GENERAL OBSERVATION							
WITHIN NORMAL LIMITS							
5000 MG/KG(SATELLITE)	1	1	1	1	1	2	2
RESPIRATION							
DRY RALES							
5000 MG/KG(SATELLITE)	1	1	1	1	1	1	1
APPEARANCE							
ALOPECIA (SEE KEY A FOR LOCATIONS)							
5000 MG/KG(SATELLITE)	1	1	1	1	1	0	0
OCULAR							
EYE DAMAGED FROM EYEBLEEDING							
5000 MG/KG(SATELLITE)	1	1	1	1	1	0	0

KEY B - KEY TO STATISTICAL ABBREVIATIONS

No difference	$p \leq 0.05$	$p \leq 0.01$	Statistical Statement
(PARAMETRIC)			
A-			No statistical difference among the means
	A	A+	Significant difference among the means
L-			No linear response to the dose levels
	L	L+	Response is linearly related to dose
	Q	Q+	Linear response shows lack of fit
	*	**	Mean significantly different from control mean
(NONPARAMETRIC)			
K-			No statistical difference among the means
	K	K+	Means differ significantly
J-			No ordered response to the dose levels
	J	J+	An ordered response to the dose levels
	*	**	Mean significantly different from control mean
(T-TEST)			
T-			No statistical difference among the means
	T	T+	Means differ significantly
NT			Data not tested

TABLE 3 - MEAN BODY WEIGHTS (GRAMS)
(SEE KEY B FOR STATISTICAL ABBREVIATIONS)

	PRETEST	DAY 0	DAY 7	DAY 14	DAY 21	DAY 28	DAY 35	DAY 42	DAY 49	DAY 56	DAY 63
MALE	A-L-	A-L-	A-L-	A-L	AL+	AL+	AL+	A+L+	A+L+	K+J+	A+L+
0 MG/KG											
MEAN	262.6	272.8	303.1	333.3	357.0	388.0	406.4	431.7	457.7	480.3	480.3
STD.DEV.	12.6	15.2	27.2	36.9	43.6	49.4	61.4	67.2	69.4	75.1	74.3
(N)	10	10	9	9	9	9	9	9	9	9	8
500 MG/KG											
MEAN	261.9	271.6	305.5	337.0	365.0	396.2	426.6	451.5	476.9	495.6	508.0
STD.DEV.	14.8	13.9	25.1	33.8	41.4	48.1	52.9	56.6	59.7	63.9	66.8
(N)	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG											
MEAN	262.1	272.5	298.4	318.4	336.2	361.9	381.4	395.2	405.8	415.6	420.3
STD.DEV.	13.0	13.8	20.0	17.6	20.9	24.4	31.4	32.4	31.9	30.9	34.9
(N)	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG											
MEAN	261.3	272.0	292.7	309.8	321.8	349.1	359.0	*	**	**	**
STD.DEV.	12.1	12.5	13.5	16.1	25.9	23.3	30.4	372.0	383.7	397.2	391.4
(N)	10	10	10	10	10	10	10	25.3	26.8	28.0	36.8
								10	10	10	10
FEMALE	A-L-	A-L-	A-L-	A-L-	A-L-	A-L-	A-L-	A-L-	A-L	A-L	A-L
0 MG/KG											
MEAN	201.8	209.9	219.5	234.9	244.7	258.6	269.2	275.0	283.0	292.9	291.9
STD.DEV.	10.6	11.2	12.1	12.4	14.9	14.6	19.7	21.5	26.6	22.8	21.5
(N)	10	10	10	10	10	10	10	10	10	9	9
500 MG/KG											
MEAN	201.9	208.2	220.0	236.0	246.5	255.9	264.2	271.2	279.7	286.9	287.2
STD.DEV.	11.7	11.5	13.6	14.8	16.6	17.5	19.1	20.3	18.5	17.2	19.3
(N)	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG											
MEAN	202.8	210.7	220.5	230.6	249.8	259.5	266.6	271.8	269.3	278.8	282.3
STD.DEV.	10.7	11.8	14.4	13.4	14.1	15.9	16.2	20.6	19.2	15.8	16.4
(N)	10	10	10	10	10	10	10	10	10	10	9
5000 MG/KG											
MEAN	201.5	206.5	218.8	233.2	241.6	252.3	262.8	264.8	263.5	273.6	273.7
STD.DEV.	10.7	14.5	12.6	14.0	18.0	14.3	15.0	16.7	22.8	22.8	21.8
(N)	14	14	14	14	14	14	14	14	14	11	11

RUN 3

TABLE 3 - MEAN BODY WEIGHTS (GRAMS) CONT.
(SEE KEY B FOR STATISTICAL ABBREVIATIONS)

	DAY 70	DAY 77	DAY 84	DAY 91	DAY 95
MALE	A+L+	A+L+	A+L+	A+L+	A+L+
0 MG/KG					
MEAN	496.5	510.9	528.3	537.2	542.5
STD.DEV.	74.7	78.0	79.1	86.1	87.3
(N)	8	8	8	8	8
500 MG/KG					
MEAN	527.1	536.1	560.5	570.6	575.3
STD.DEV.	68.3	72.4	76.8	77.7	77.7
(N)	10	10	10	10	10
2500 MG/KG		*	*	*	*
MEAN	434.2	437.1	452.6	461.8	460.0
STD.DEV.	34.2	32.5	38.6	40.3	38.1
(N)	10	10	10	10	10
5000 MG/KG	**	**	**	**	**
MEAN	408.2	419.5	434.6	428.8	432.4
STD.DEV.	36.0	31.3	34.3	37.9	33.7
(N)	10	10	10	10	10
FEMALE	A-L-	AL	A-L-	AL	A+L
0 MG/KG					
MEAN	300.6	303.7	308.9	316.9	316.0
STD.DEV.	22.5	21.6	25.4	25.5	27.8
(N)	9	9	9	9	9
500 MG/KG					
MEAN	289.6	292.3	295.6	300.0	299.0
STD.DEV.	19.4	17.6	19.1	20.1	19.6
(N)	10	10	10	10	10
2500 MG/KG				*	**
MEAN	283.9	282.4	285.3	283.6	281.3
STD.DEV.	16.5	12.8	18.0	15.8	15.8
(N)	9	9	8	8	8
5000 MG/KG		*		*	*
MEAN	285.5	280.1	288.1	290.0	287.9
STD.DEV.	28.0	22.1	18.7	18.9	18.5
(N)	10	10	10	10	10

RUN 3

TABLE 4 - MEAN WEEKLY FOOD CONSUMPTION (GRAMS)
(SEE KEY B FOR STATISTICAL ABBREVIATIONS)

	DAY 7	DAY 14	DAY 21	DAY 28	DAY 35	DAY 42	DAY 49	DAY 56	DAY 63	DAY 70	DAY 77
MALE	A-L-	A-L-	A-L-	A+L+	AL+	AL	A+L+	A+L+	A-L-	A+L+	A+L+
0 MG/KG											
MEAN	147.8	130.8	123.4	127.7	120.3	116.0	128.5	124.2	106.1	119.6	120.5
STD.DEV.	19.7	21.1	22.1	12.8	20.2	17.8	12.7	15.9	15.0	9.9	12.6
(N)	9	9	9	8	8	9	9	9	8	8	8
500 MG/KG											
MEAN	154.2	134.9	126.0	140.3	140.0	128.4	134.2	131.7	104.6	128.7	128.2
STD.DEV.	19.0	23.0	21.1	21.3	20.0	20.8	18.6	20.2	21.8	14.9	20.5
(N)	10	10	9	10	9	10	9	9	6	9	9
2500 MG/KG					*					**	*
MEAN	147.1	134.8	127.5	141.3	145.2	124.9	135.9	132.1	113.0	144.9	142.4
STD.DEV.	19.8	13.6	10.5	12.7	18.6	14.9	8.8	6.8	16.8	7.1	11.8
(N)	10	8	7	7	8	10	7	7	10	7	9
5000 MG/KG				**	*	*	**	**		**	**
MEAN	137.7	141.9	143.1	165.8	150.5	141.9	162.4	158.2	119.9	171.1	173.8
STD.DEV.	10.9	11.3	20.1	10.7	12.8	15.7	11.6	15.2	22.8	22.0	7.4
(N)	10	10	5	6	8	9	8	7	6	4	8
FEMALE	A-L	A-L	A+L+	A-L-	A-L-	K+J+	KJ+	K-J+	K+J+	A+L+	A+L+
0 MG/KG											
MEAN	111.3	103.9	97.6	112.5	101.0	92.2	96.8	100.9	75.5	96.0	96.4
STD.DEV.	13.2	11.5	10.1	12.6	14.7	14.6	12.8	16.8	20.3	15.9	10.5
(N)	7	8	6	8	9	10	9	8	9	9	8
500 MG/KG											
MEAN	110.5	102.2	96.0	102.5	100.6	90.7	96.2	102.3	79.9	103.7	89.3
STD.DEV.	10.3	8.7	7.7	6.2	9.3	7.4	6.4	3.2	6.5	17.3	6.7
(N)	10	10	7	6	9	9	8	6	8	10	9
2500 MG/KG									*		
MEAN	104.9	105.9	107.1	112.9	110.0	101.7	99.9	111.2	106.6	115.7	104.4
STD.DEV.	7.8	13.0	15.4	12.6	11.2	11.5	10.0	8.5	23.9	9.7	11.2
(N)	10	8	7	6	6	7	6	7	8	7	7
5000 MG/KG			**			**	*		**	**	**
MEAN	100.8	113.6	118.8	120.6	(+)	140.7	118.2	128.9	122.5	158.8	125.4
STD.DEV.	10.1	11.2	11.4	16.3		46.5	31.0	26.1	47.5	33.4	10.4
(N)	11	11	9	7		10	9	5	10	6	5

(+) - ALL ANIMALS NOTED WITH EXCESSIVE SPILLAGE

RUN 1

TABLE 4 - MEAN WEEKLY FOOD CONSUMPTION (GRAMS) CON'T
(SEE KEY B FOR STATISTICAL ABBREVIATIONS)

	DAY 84	DAY 91	DAY 95 (a)
MALE	A+L+	A+L+	A+L+
0 MG/KG			
MEAN	112.4	108.9	61.9
STD.DEV.	10.9	21.0	8.7
(N)	8	8	8
500 MG/KG			
MEAN	124.6	116.4	70.1
STD.DEV.	19.8	14.4	9.4
(N)	10	10	10
2500 MG/KG	*	**	**
MEAN	137.2	140.9	80.3
STD.DEV.	17.3	13.3	9.2
(N)	8	8	10
5000 MG/KG	**	**	**
MEAN	155.4	144.2	90.8
STD.DEV.	11.8	14.3	7.1
(N)	9	9	9
FEMALE	A+L+	A+L+	A+L+
0 MG/KG			
MEAN	87.7	91.5	53.2
STD.DEV.	13.2	14.4	7.9
(N)	9	9	9
500 MG/KG			
MEAN	93.8	94.3	53.3
STD.DEV.	15.5	5.1	5.4
(N)	9	7	9
2500 MG/KG	*		*
MEAN	106.0	105.8	62.5
STD.DEV.	8.4	9.2	4.1
(N)	7	8	8
5000 MG/KG	**	**	**
MEAN	127.8	129.5	76.4
STD.DEV.	14.4	17.2	6.4
(N)	7	6	9

(a) - FOUR DAY FOOD CONSUMPTION INTERVAL

RUN 1

KEY C - KEY TO HEMATOLOGY ABBREVIATIONS AND UNITS

Abbreviation	Parameter	Units of Measure
WBC	White Blood Cells (Total Leukocytes)	x10E3/mmE3
RBC	Red Blood Cells (Erythrocytes)	x10E6/mmE3
HGB	Hemoglobin	g/dL
HCT	Hematocrit	%
PLT	Platelet	x10E3/mmE3
MCV	Mean Corpuscular Volume	fL
MCH	Mean Corpuscular Hemoglobin	pg
MCHC	Mean Corpuscular Hemoglobin Concentration	g/dL
PT	Prothrombin Time	sec
APTT	Activated Partial Thromboplastin Time	sec
SEG	Mature (Segmented) Neutrophils	% of WBC
LYMPH	Lymphocytes	% of WBC
MONO	Monocytes	% of WBC
BAND	Band Cells	% of WBC
META	Metamyelocyte	% of WBC
MYELO	Myelocyte	% of WBC
EOSIN	Mature (Segmented) Eosinophil	% of WBC
BASO	Mature (Segmented) Basophil	% of WBC
ALYMPH	Atypical Lymphocyte	N (number of cells)
RETIC	Reticulocytes	% of RBC

Remarkable Erythrocyte or Leukocyte Morphology:

POLYCH	Polychromia	HYPO	Hypochromia
ANISO	Anisocytosis	HYPER	Hyperchromia
MICRO	Microcytosis	BASOST	Basophilic Stippling
POIK	Poikilocytosis	TARG	Target Cells
MACRO	Macrocytosis	TOXGR	WBC-Toxic Granulation
HJB	Howell-Jolly Body	HB	Heinz Bodies

[Range: 1=slight; 2=moderate; 3=marked]

NRBC Nucleated Erythrocyte; (N) - number of cells/high power field

TABLE 5 - MEAN QUANTITATIVE HEMATOLOGY (TERMINAL)
(SEE KEYS B AND C FOR ABBREVIATIONS AND UNITS)

	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS>>>>>	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
MALE	A-L-	A-L	A+L-Q+	A+L-Q+	A+L+Q+	AL-Q	AL-	A-L-
0 MG/KG								
MEAN	8.72	7.6	45.0	15.6	770.	52.	17.9	34.7
STD.DEV.	0.27	2.7	1.3	0.6	40.	2.	0.7	0.4
(N)	7	7	7	7	7	7	7	7
500 MG/KG					*			
MEAN	8.66	9.2	44.0	15.2	877.	51.	17.6	34.6
STD.DEV.	0.36	2.3	1.3	0.4	45.	2.	0.5	0.4
(N)	10	10	10	10	10	10	10	10
2500 MG/KG			**	**	**	*	*	
MEAN	8.53	10.4	41.9	14.6	1008.	49.	17.1	34.9
STD.DEV.	0.34	2.8	1.8	0.6	73.	1.	0.5	0.4
(N)	10	10	10	10	10	10	10	10
5000 MG/KG					**			
MEAN	8.78	10.8	44.0	15.2	984.	50.	17.4	34.6
STD.DEV.	0.21	2.3	1.7	0.5	115.	2.	0.6	0.4
(N)	10	10	10	10	10	10	10	10
FEMALE	A-L-	K+J	A-L-Q	A-L-Q	A+L+	A-L-	A-L-	A-L-
0 MG/KG								
MEAN	7.43	5.4	39.6	14.1	792.	53.	19.0	35.6
STD.DEV.	0.32	2.5	1.5	0.6	116.	1.	0.5	0.3
(N)	8	8	8	8	8	8	8	8
500 MG/KG								
MEAN	7.35	4.4	40.0	14.1	846.	54.	19.2	35.2
STD.DEV.	0.31	1.0	1.2	0.4	81.	1.	0.6	0.5
(N)	10	10	10	10	10	10	10	10
2500 MG/KG								
MEAN	7.21	4.2	38.0	13.5	892.	53.	18.7	35.5
STD.DEV.	0.57	0.8	3.4	1.2	89.	2.	0.7	0.3
(N)	8	8	8	8	8	8	8	8
5000 MG/KG					**			
MEAN	7.72	6.8	40.8	14.5	1023.	53.	18.8	35.6
STD.DEV.	0.44	1.6	1.9	0.7	110.	1.	0.4	0.4
(N)	10	10	10	10	10	10	10	10

RUN 1

KEY D - KEY TO SERUM CHEMISTRY ABBREVIATIONS AND UNITS

Abbreviation	Parameter	Units
GLU	Glucose	mg/dL
BUN	Blood Urea Nitrogen	mg/dL
CREA	Creatinine	mg/dL
AST	Aspartate Aminotransferase	IU/L
ALT	Alanine Aminotransferase	IU/L
ALKP	Alkaline Phosphatase	IU/L
CHOL	Cholesterol	mg/dL
TP	Total Protein	g/dL
ALB	Albumin	g/dL
GLOB	Globulin (calculated: TP - ALB)	g/dL
A/G	Albumin / Globulin Ratio	
TBIL	Total Bilirubin	mg/dL
K+	Potassium	mmol/L
Na+	Sodium	mmol/L
Cl-	Chloride	mmol/L
Ca	Calcium	mg/dL
PHOS	Inorganic Phosphorous	mg/dL
CO2	Carbon Dioxide	mEq/L
GGT	Gamma Glutamyl Transferase	IU/L
TRIG	Triglycerides	mg/dL
UA	Uric Acid	mg/dL
SOSM	Serum Osmolality	mOsm/kg

Note: This is an overall key, actual parameters evaluated for this study are listed under Experimental Evaluation.

TABLE 6 - MEAN SERUM CHEMISTRY (TERMINAL)
(SEE KEYS B AND D FOR ABBREVIATIONS AND UNITS)

	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST
UNITS>>>>>	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L
MALE	A-L-	K+J+	A+L+	A-L-	A+L+	A+L+Q+	A-L-	A-L	A-L-	A-L-	A-L-	A-L
0 MG/KG												
MEAN	4.2	0.49	9.8	0.5	1.88	128.6	10.8	7.2	148.0	5.26	110.0	94.8
STD.DEV.	0.1	0.04	1.5	0.1	0.83	11.3	0.5	0.6	1.8	0.42	2.2	18.4
(N)	8	8	8	8	8	8	8	8	8	8	8	8
500 MG/KG						*						
MEAN	4.2	0.48	10.4	0.6	1.60	113.8	11.2	7.3	148.1	5.26	108.4	88.0
STD.DEV.	0.1	0.06	1.3	0.1	0.97	10.5	0.3	0.4	0.7	0.34	1.4	15.2
(N)	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG			**			**						
MEAN	4.1	0.62	13.3	0.6	2.90	94.9	11.0	7.6	148.3	5.15	108.3	91.7
STD.DEV.	0.2	0.15	3.4	0.1	0.99	12.5	0.4	0.6	1.7	0.30	2.6	18.3
(N)	10	10	10	10	10	10	10	10	10	10	10	10
5000 MG/KG		*	**		**	**						
MEAN	4.1	0.61	14.5	0.6	4.90	93.8	11.0	7.7	148.8	5.29	107.8	106.0
STD.DEV.	0.1	0.12	2.4	0.1	1.91	12.6	0.4	0.7	1.4	0.41	2.6	10.0
(N)	10	10	10	10	10	10	10	10	10	10	10	10
FEMALE	A-L-	AL+	A-L-	AL-Q+	A-L	A+L+	A-L-	AL	A-L-	A-L-	AL+	KJ
0 MG/KG												
MEAN	4.6	0.54	12.8	0.6	1.00	107.2	11.2	5.5	146.6	4.68	109.9	113.9
STD.DEV.	0.3	0.07	2.6	0.1	0.87	6.4	0.3	0.5	2.2	0.42	2.9	49.0
(N)	9	9	9	9	9	9	9	9	9	9	9	9
500 MG/KG				*								
MEAN	4.8	0.58	12.2	0.7	0.60	104.0	11.2	5.0	147.0	4.83	107.9	93.6
STD.DEV.	0.3	0.08	1.9	0.1	0.70	13.6	0.4	0.5	3.1	0.37	2.8	38.3
(N)	10	10	10	10	10	10	10	10	10	10	10	10
2500 MG/KG						**					*	
MEAN	5.0	0.64	11.6	0.6	1.38	89.5	11.1	5.2	145.5	4.88	106.7	97.3
STD.DEV.	0.2	0.07	1.8	0.1	0.92	9.7	0.4	0.7	1.7	0.42	1.8	13.6
(N)	8	8	8	8	8	8	8	8	8	8	8	8
5000 MG/KG		*				**					*	
MEAN	4.8	0.68	13.2	0.7	1.90	81.4	11.1	5.9	145.3	4.98	106.5	115.9
STD.DEV.	0.4	0.15	1.9	0.1	1.60	6.8	0.5	0.8	2.0	0.23	1.9	13.9
(N)	10	10	10	10	10	10	10	10	10	10	10	10

TABLE 6 - MEAN SERUM CHEMISTRY (TERMINAL) CON'T
(SEE KEYS B AND D FOR ABBREVIATIONS AND UNITS)

	ALT	TP	CHOL	TRIG
UNITS>>>>>	IU/L	g/dL	mg/dL	mg/dL
MALE	K+J+	A-L-	K+J+	K+J-
0 MG/KG				
MEAN	37.5	7.2	39.3	103.
STD.DEV.	3.9	0.2	3.8	13.
(N)	8	8	8	8
500 MG/KG				*
MEAN	42.5	7.4	46.8	130.
STD.DEV.	8.0	0.2	8.8	16.
(N)	10	10	10	10
2500 MG/KG	**		**	
MEAN	75.0	7.1	65.0	130.
STD.DEV.	18.3	0.4	14.6	82.
(N)	10	10	10	10
5000 MG/KG	**		**	
MEAN	90.7	7.1	66.8	101.
STD.DEV.	26.0	0.3	15.0	18.
(N)	10	10	10	10
FEMALE	A-L-	K-J	A+L+Q+	KJ
0 MG/KG				
MEAN	60.7	7.7	48.3	93.
STD.DEV.	48.2	0.3	8.4	18.
(N)	9	9	9	9
500 MG/KG				
MEAN	38.0	8.0	63.6	83.
STD.DEV.	39.5	0.4	9.8	9.
(N)	10	10	10	10
2500 MG/KG			**	
MEAN	51.5	8.1	95.0	120.
STD.DEV.	22.4	0.2	18.2	39.
(N)	8	8	8	8
5000 MG/KG			**	
MEAN	69.3	8.1	81.9	162.
STD.DEV.	16.0	0.7	16.1	146.
(N)	10	10	10	10

KEY E - KEY TO ORGAN ABBREVIATIONS

Abbreviation	Organ Name
RT EP	Right Epididymis
LT EP	Left Epididymis
PROST	Prostate
SMNLV	Seminal Vesicles
PT+SV	Prostate and Seminal Vesicles
RT TS	Right Testis
LT TS	Left Testis
TS+EP	Testes and Epididymides
TESTS	Testes
EPIDY	Epididymides
OVAR	Ovaries
ADRNL	Adrenal Glands
SPLN	Spleen
KIDNY	Kidneys
BLDR	Urinary Bladder
L KID	Left Kidney
R KID	Right Kidney
THYRP	Thyroids and Parathyroids
TBW	Terminal Body Weight

Note: This is an overall key, actual parameters evaluated in this study are listed under Experimental Evaluation.

TABLE 7 - MEAN ORGAN WEIGHTS
(SEE KEYS B AND E FOR ABBREVIATIONS)

	TBW	LIVER	KIDNEY	ADRNL	TESTES	OVAR
UNITS>>>>>	(g)	(g)	(g)	(g)	(g)	(g)
MALE	A+L+	A+L-Q+	A+L-Q+	A+L+	A-L-	
0 MG/KG						
MEAN	530.5	14.69	3.32	0.048	3.8519	
STD.DEV.	87.1	2.93	0.46	0.008	0.3234	
(N)	8	8	8	7	8	
500 MG/KG		*	**			
MEAN	560.2	18.50	4.43	0.048	3.7200	
STD.DEV.	77.2	2.51	0.58	0.009	0.3770	
(N)	10	10	10	10	10	
2500 MG/KG	*	**	**			
MEAN	439.3	19.85	4.38	0.061	3.4232	
STD.DEV.	37.7	2.98	0.57	0.009	0.7249	
(N)	10	10	10	10	10	
5000 MG/KG	**		**	**		
MEAN	405.8	18.01	4.11	0.078	3.5136	
STD.DEV.	35.8	2.90	0.40	0.015	0.3797	
(N)	10	10	10	10	10	
FEMALE	A+L+Q	A+L+Q+	A-L-	A+L+		A-L-
0 MG/KG						
MEAN	304.8	8.57	2.18	0.067		0.081
STD.DEV.	28.3	1.12	0.28	0.019		0.020
(N)	9	9	9	9		8
500 MG/KG		*				
MEAN	285.7	10.33	2.40	0.074		0.082
STD.DEV.	18.2	0.89	0.17	0.010		0.033
(N)	10	10	10	10		10
2500 MG/KG	**	**		**		
MEAN	262.5	14.71	2.34	0.094		0.067
STD.DEV.	13.1	1.51	0.18	0.010		0.024
(N)	8	8	8	8		8
5000 MG/KG	**	**		**		
MEAN	265.0	13.80	2.42	0.102		0.072
STD.DEV.	18.7	2.19	0.27	0.012		0.033
(N)	10	10	10	10		10

RUN 7

TABLE 8 - MEAN RELATIVE ORGAN WEIGHTS
(SEE KEYS B AND E FOR ABBREVIATIONS)

	LIVER/BW	KIDNY/BW	ADRNL/BW	TESTS/BW	OVAR/BW
MALE	K+J+	A+L+Q+	K+J+	K+J+	
0 MG/KG					
MEAN	0.028	0.0063	0.00010	0.0074	
STD.DEV.	0.001	0.0005	0.00001	0.0010	
(N)	8	8	7	8	
500 MG/KG		**			
MEAN	0.033	0.0080	0.00009	0.0067	
STD.DEV.	0.001	0.0011	0.00001	0.0008	
(N)	10	10	10	10	
2500 MG/KG	**	**			
MEAN	0.045	0.0100	0.00014	0.0078	
STD.DEV.	0.004	0.0007	0.00001	0.0017	
(N)	10	10	10	10	
5000 MG/KG	**	**	**	*	
MEAN	0.044	0.0102	0.00019	0.0087	
STD.DEV.	0.004	0.0015	0.00003	0.0004	
(N)	10	10	10	10	
FEMALE	K+J+	A+L+Q+	A+L+		A-L-
0 MG/KG					
MEAN	0.028	0.0072	0.00022		0.00027
STD.DEV.	0.002	0.0007	0.00006		0.00007
(N)	9	9	9		8
500 MG/KG		**			
MEAN	0.036	0.0084	0.00026		0.00029
STD.DEV.	0.002	0.0006	0.00004		0.00012
(N)	10	10	10		10
2500 MG/KG	**	**	**		
MEAN	0.056	0.0089	0.00036		0.00025
STD.DEV.	0.005	0.0007	0.00004		0.00008
(N)	8	8	8		8
5000 MG/KG	**	**	**		
MEAN	0.052	0.0091	0.00039		0.00027
STD.DEV.	0.008	0.0008	0.00006		0.00012
(N)	10	10	10		10

RUN 2

TABLE 9 - MEAN QUANTITATIVE HEMATOLOGY SATELLITE (DAY 96/97 VS. 125)
(SEE KEYS B AND C FOR ABBREVIATIONS AND UNITS)

	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS>>>>>	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
MALE	T	T	T-	T-	T-	T-	T+	T+
SATELLITE (DAY 96)								
MEAN	8.82	10.5	44.5	15.3	1044.	51.	17.4	34.5
STD.DEV.	0.31	2.4	1.7	0.6	92.	2.	0.6	1.0
(N)	8	8	8	8	8	8	8	8
SATELLITE (DAY 125)								
MEAN	8.48	7.7	43.0	15.6	1050.	51.	18.4	36.2
STD.DEV.	0.29	1.7	1.3	0.5	96.	1.	0.5	0.7
(N)	8	8	8	8	8	8	8	8
FEMALE	T-	T-	T-	T-	T-	T-	T-	T
SATELLITE (DAY 96)								
MEAN	7.76	7.6	41.0	14.3	991.	53.	18.4	35.0
STD.DEV.	0.30	1.8	2.3	0.7	241.	1.	0.5	0.5
(N)	3	3	3	3	3	3	3	3
SATELLITE (DAY 125)								
MEAN	8.16	5.1	42.8	15.4	1052.	53.	18.9	36.0
STD.DEV.	0.12	1.9	0.9	0.3	154.	2.	0.4	0.3
(N)	3	3	3	3	3	3	3	3

TABLE 10 - MEAN SERUM CHEMISTRY SATELLITE (DAY 96/97 VS. DAY 125)
(SEE KEYS B AND D FOR ABBREVIATIONS)

	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST
UNITS>>>>>	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L
MALE	T-	T+	T-	T	T+	T+	T+	T-	T-	T-	T+	T-
SATELLITE (DAY 96)												
MEAN	4.0	0.60	16.4	0.7	4.38	88.9	11.0	7.4	148.5	5.04	107.1	101.8
STD.DEV.	0.2	0.09	2.9	0.1	1.60	17.4	0.3	0.7	1.7	0.34	1.4	12.9
(N)	8	8	8	8	8	8	8	8	8	8	8	8
SATELLITE (DAY 125)												
MEAN	3.9	0.48	18.8	0.5	0.88	117.5	10.1	7.1	148.7	5.22	111.4	119.4
STD.DEV.	0.2	0.07	2.5	0.1	0.83	13.8	0.3	0.3	1.0	0.09	1.7	19.7
(N)	8	8	8	8	8	8	8	8	8	8	8	8
FEMALE	T-	NT	T	T-	T-	T-	T-	T-	T-	T-	T	T-
SATELLITE (DAY 96)												
MEAN	4.4	0.60	14.3	0.6	2.00	92.7	10.5	6.1	144.5	5.05	105.4	109.3
STD.DEV.	0.2	0	1.2	0.1	1.00	2.5	0.3	1.3	3.1	0.22	4.2	23.3
(N)	3	3	3	3	3	3	3	3	3	3	3	3
SATELLITE (DAY 125)												
MEAN	4.3	0.50	17.7	0.6	2.33	118.0	10.5	5.7	149.2	4.82	112.4	88.7
STD.DEV.	0.1	0.10	0.6	0.1	1.15	18.7	0.3	1.1	1.5	0.36	0.5	23.7
(N)	3	3	3	3	3	3	3	3	3	3	3	3

TABLE 10 - MEAN SERUM CHEMISTRY SATELLITE (DAY 96/97 VS. DAY 125)CON'T
(SEE KEYS B AND D FOR ABBREVIATIONS)

	ALT	TP	CHOL	TRIG
UNITS>>>>>	IU/L	g/dL	mg/dL	mg/dL
MALE	T+	T-	T+	T-
SATELLITE (DAY 96)				
MEAN	79.4	7.0	63.6	92.
STD.DEV.	21.0	0.3	13.9	16.
(N)	8	8	8	8
SATELLITE (DAY 125)				
MEAN	31.8	6.9	35.5	95.
STD.DEV.	6.2	0.2	4.4	11.
(N)	8	8	8	8
FEMALE	T+	T-	T-	T+
SATELLITE (DAY 96)				
MEAN	61.0	7.5	74.7	101.
STD.DEV.	7.0	0.5	16.5	7.
(N)	3	3	3	3
SATELLITE (DAY 125)				
MEAN	26.7	7.9	66.3	71.
STD.DEV.	5.5	0.1	17.2	9.
(N)	3	3	3	3

TABLE 11 - MEAN RELATIVE ORGAN WEIGHTS CONTROL VS. SATELLITE

	LIVER/BW	KIDNY/BW	ADRNL/BW	TESTS/BW	OVAR/BW
MALE	T-	T+	T	T-	
0 MG/KG					
MEAN	0.028	0.0063	0.00010	0.0074	
STD.DEV.	0.001	0.0005	0.00001	0.0010	
(N)	8	8	7	8	
SATELLITE					
MEAN	0.027	0.0078	0.00012	0.0084	
STD.DEV.	0.001	0.0006	0.00002	0.0011	
(N)	8	8	8	8	
FEMALE	T-	T-	T-		T-
0 MG/KG					
MEAN	0.028	0.0072	0.00022		0.00027
STD.DEV.	0.002	0.0007	0.00006		0.00007
(N)	9	9	9		8
SATELLITE					
MEAN	0.029	0.0080	0.00025		0.00026
STD.DEV.	0.001	0.0002	0.00004		0.00009
(N)	3	3	3		3

RUN 3

0 MG/KG

ICJ870M

INCISORS: Maloccluded.

ICJ878M

MESENTERIC LYMPH NODES: Reddened.
THORACIC CAVITY: Moderate amount of tan caseous material present, partially adhered to diaphragm and lungs.

ICJ882M - Spontaneous death on Day 4

LUNGS: Mottled pink/dark red.
STOMACH: Thin yellow material and gas.
THORACIC AORTA: Hole approximately 0.1 cm in diameter near the bifurcation of the trachea.
THORACIC CAVITY: Filled with dark red liquid.
TERMINAL BODY WEIGHT: 270.1 grams

ICJ885M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ861M

LIVER (All lobes): Pale.

ICJ886M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ848M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ845M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ898M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ904M - Spontaneous death on Day 60

LUNGS (All lobes, all surfaces): Dark red/black, tissue appears consolidated.
SKIN/FUR (Snout): Extreme amount of dry red material.
TERMINAL BODY WEIGHT: 583.0 grams

ICJ918F

LUNGS (Apical lobe): Tan area 0.4 cm in diameter.
THORACIC CAVITY: Contains moderate amount of frothy oily liquid.

ICJ957F

HEART: Surrounded by extreme amount of hard tan material.

ICJ948F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ962F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ951F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ968F

CERVICAL LYMPH NODES: Dark red.
EYE (Right): Damaged by eyebleeding.

ICJ908F - Spontaneous death on Day 56

GENERAL CONDITION: Extremely emaciated.
HEART: Surface roughened.
LUNGS (All lobes, all surfaces): Mottled red and dark red with tan caseous material adhering to surfaces.
SKIN/FUR (Ano-genital area): Extreme yellow/brown staining; (Head): Scabs; Dried red nasal discharge and unthrifty coat.
THORACIC CAVITY: Contains moderate amount of thin clear fluid and moderate amount of tan caseous material.
TERMINAL BODY WEIGHT: 186.7 grams

ICJ911F

HEART/PERICARDIUM: Extreme amount of tan/yellow caseous material surrounding heart.

ICJ916F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ942F

ALL TISSUES AND ORGANS: No observable abnormalities.

500 MG/KG

ICJ877M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ884M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ873M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ875M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ892M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ855M

SKIN/FUR (Ano-genital area): Slight yellow staining.

ICJ887M

INCISORS: Maloccluded.

ICJ900M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ859M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ872M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ959F

SKIN/FUR (Both forelegs): Alopecia.

ICJ956F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ943F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ960F

UTERUS: Moderately distended.

ICJ917F

CECUM: Slightly distended, ingesta thinner than normal.

ICJ927F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ925F

HEART: Surrounded by slight amount of tan caseous material.
OVARY (Left): Slightly larger than normal, appears ruptured.
THORACIC CAVITY: Moderate amount of tan liquid.

ICJ930F

LIVER (Medial lobe, right cleft on the visceral surface): Tan area 0.3 cm in diameter.

ICJ954F

CERVICAL LYMPH NODES: Red.
TEETH (Right upper incisor): Broken.

ICJ921F

ALL TISSUES AND ORGANS: No observable abnormalities.

2500 MG/KG

ICJ846M

CECUM: Slightly distended with gas.
SKIN/FUR (Ano-genital area): Brown staining.

ICJ896M

GENERAL: Slightly emaciated.
SKIN/FUR (Ano-genital area): Slight yellow staining.

ICJ893M

CECUM: Slightly larger than normal.
SKIN/FUR (Ano-genital area): Slight yellow staining.

ICJ881M

SKIN/FUR (Ano-genital area): Moderate yellow staining;
(Forepaws): Slight alopecia.

ICJ889M

GENERAL CONDITION: Slightly emaciated.
LUNGS (All lobes, all surfaces): Mottled pink/dark red.
SKIN/FUR: Unthrifty coat.

ICJ890M

TESTES (Both): Slightly smaller than normal, flaccid.

ICJ905M

ILEUM: Filled with thickened black material.

ICJ850M

SKIN/FUR (Ano-genital area): Slight yellow staining.

ICJ847M

SKIN/FUR (Ano-genital area): Moderate yellow-brown staining.

ICJ883M

CECUM: Ingesta thinner than normal.
JEJUNUM: Moderately distended with yellow liquid.
SKIN/FUR (Ano-genital area): Moderate yellow staining.

ICJ955F

COLON: Extremely distended with gas.

ICJ961F

OVARY (Right): Two black foci less than 0.1 cm embedded in ovary.
SKIN/FUR (Ano-genital area): Slight yellow staining.

ICJ964F - Spontaneous death on Day 77

HEART/PERICARDIUM: Surrounded by extreme amount of thickened dark red material.
LUNGS (All lobes, all surfaces): Mottled red/dark red, tissue

appears consolidated.
SKIN/FUR (Snout): Moderate amount of clear oral discharge.
THORACIC CAVITY: Filled with extreme amount of thin red liquid.
TERMINAL BODY WEIGHT: 295.3 grams

ICJ949F

SKIN/FUR (Ano-genital area): Slight staining;
(Right forepaw): Slight alopecia.

ICJ940F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ933F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ966F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ938F - Spontaneous death on Day 61

CECUM: Moderately distended with gas.
JEJUNUM: Filled with moderate amount of thickened black material.
LUNGS (All lobes, all surfaces): Mottled red/dark red.
SKIN/FUR (Ano-genital area): Moderate amount of yellow staining; (Snout): Extreme amount of dry dark red material.
STOMACH: Extremely distended, mucosa extremely red, contains a moderate amount of thickened black material.
TRACHEA: Moderately reddened.
TERMINAL BODY WEIGHT: 232.2 grams
NOTE: Slight postmortem changes in all tissues and organs.

ICJ941F

JEJUNUM: Slightly distended with yellow liquid.

ICJ934F

ALL TISSUES AND ORGANS: No observable abnormalities.

5000 MG/KG

ICJ874M

ANUS: Slightly swollen.
CECUM: Ingesta thinner than normal.
GENERAL CONDITION: Slightly emaciated.

ICJ867M

ADRENALS (Both): Pale.
ANUS: Slightly swollen.
CECUM: Slightly enlarged, moderately vascularized.
GENERAL: Slightly emaciated.

ICJ902M

ANUS: Moderately swollen.

ICJ869M

CECUM: Slightly distended with green liquid material.
SKIN/FUR (Trunk): Alopecia, posterior ventral.

ICJ891M

ANUS: Slightly swollen.
GENERAL CONDITION: Slightly emaciated.

ICJ871M

ANUS: Swollen
SKIN/FUR (Ano-genital area): Slight amount of yellow staining.

ICJ907M

ANUS: Slightly swollen.

ICJ899M

ANUS: Moderately swollen.
ILEUM/JEJUNUM: Slightly distended, filled with thin yellow liquid.
SKIN/FUR (Ano-genital area): Slight yellow staining.
STOMACH: Glandular and non-glandular portions slightly thickened.

ICJ851M

ANUS: Slightly swollen.
CECUM: Extremely larger than normal and moderately vascularized.
CERVICAL LYMPH NODES: Moderately reddened.
GENERAL CONDITION: Slightly emaciated.
LARGE INTESTINES: Distended with gas.
SKIN/FUR (Ano-genital area): Slight yellow staining.

ICJ868M

ANUS: Moderately swollen with scabs.
CECUM: Moderately distended, filled with thinner than normal ingesta.
SKIN/FUR (Ano-genital area): Moderate yellow staining.
STOMACH: Slightly thickened.

ICJ932F

ANUS: Slightly swollen.

ICJ950F - Spontaneous death on Day 50

ANUS: Swollen.
ESOPHAGUS: 0.8 cm hole approximately 2.5 cm from the base of the tongue.
EYE (Left): Slight clear discharge.
LUNGS (All lobes and surfaces): Dark red.
SKIN/FUR (Left lateral and left ventral abdomen): Alopecia.
SMALL INTESTINES: Moderate amount of amber liquid.
STOMACH: Moderate amount of yellow viscous liquid.
THORACIC CAVITY: Extreme amount of clear oil-like material with the lungs surrounded by tan fibrous material.
TERMINAL BODY WEIGHT: 265.6 grams
NOTE: Moderate postmortem changes in all tissues and organs.

ICJ922F

ANUS: Slightly swollen.
CECUM: Moderately distended with ingesta.
COLON: Moderately distended with feces.

ICJ909F

ANUS: Slightly swollen.
CECUM: Slightly distended, ingesta thinner than normal.

ICJ923F

ANUS: Slightly swollen.
CECUM: Slightly larger than normal.
COLON: Extremely distended with gas.

ICJ939F

ANUS: Slightly swollen.
EYE (Right): Damaged by eyebleeding.
LUNGS (All lobes and surfaces): Mottled pink/dark red.

ICJ935F - Spontaneous death on Day 55

ANUS: Swollen.
DUODENUM/JEJUNUM: Moderate amount of yellow ingesta.
GENERAL CONDITION: Moderately emaciated.
HEART AND LUNGS: Surrounded by an extreme amount of tan material.
LUNGS (Left lobe): Hole in the bronchi.
SKIN/FUR (Ano-genital area): Moderate yellow staining.
THORACIC CAVITY: Extreme amount of clear liquid.
TERMINAL BODY WEIGHT: Not taken.
NOTE: Moderate postmortem changes in all tissues and organs.

ICJ910F - Spontaneous death on Day 54

ANUS: Swollen.
CECUM: Moderate amount of hardened ingesta.
LUNGS (All lobes and surfaces): Slightly encased with fibrous adhesions.
SKIN/FUR (Posterior dorsal): Thin hair coat.
STOMACH: Moderate amount of yellow ingesta.
THORACIC CAVITY: Extreme amount of oily pale red liquid.
TERMINAL BODY WEIGHT: 234.7 grams

ICJ912F

ANUS: Moderately swollen.
CECUM: Slightly enlarged.
CERVICAL LYMPH NODES: Red.

ICJ914F - Spontaneous death on Day 67

ANUS: Slightly swollen.
LUNGS (All lobes and surfaces): Dark red, tissue appears consolidated.
SKIN/FUR (Snout): Moderate amount of clear oral discharge.
STOMACH: Slightly distended with a slight amount of gas and ingesta.
THORACIC CAVITY: Moderate amount of thin clear liquid.
TERMINAL BODY WEIGHT: 259.1 grams

ICJ944F

ANUS: Moderately swollen.

ICJ969F

ANUS: Swollen.
GENERAL CONDITION: Slightly emaciated.
INCISOR (Right upper): Missing.
SKIN/FUR (Ano-genital area): Slight yellow staining; (Both forepaws): Alopecia; (Around left eye): Dried red discharge.

ICJ924F

ANUS: Slightly swollen.
SKIN/FUR (Left flank): Alopecia.

ICJ958F

ANUS: Moderately swollen.
CECUM: Two times normal size, ingesta thinner than normal.
CERVICAL LYMPH NODES: Red.
JEJUNUM: Moderately distended with yellow liquid.

5000 MG/KG (SATELLITE)

ICJ856M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ853M

ILEUM: Moderately distended with gas.

ICJ852M - Spontaneous death on Day 52

ANUS: Swollen.
LUNGS (All lobes and surfaces): Mottled red.
SKIN/FUR (Ano-genital area): Extreme staining.
STOMACH: Moderately distended.
TERMINAL BODY WEIGHT: 267.4 grams

ICJ864M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ857M - Spontaneous death on Day 95

ANUS: Moderately swollen.
ESOPHAGUS: Hole 0.3 cm in diameter, 0.4 cm above the lungs.
HEART: Surrounded by tan material.
LUNGS (Diaphragmatic surfaces): Surrounded by tan material.
MESENTERIC LYMPH NODES: Dark red.

SKIN/FUR (Ano-genital area): Moderate amount of amber staining; (Around mouth): Moderate amount of amber staining.
SMALL INTESTINE: Moderately distended with amber liquid.
STOMACH: Distended two times normal with gas.
THORACIC CAVITY: Contains a moderate amount of red oily liquid.
TERMINAL BODY WEIGHT: 360.9 grams
NOTE: Moderate postmortem changes in all tissues and organs.

ICJ866M

CECUM: Moderately distended with gas.

ICJ895M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ862M

LIVER (Medial lobe, parietal surface): Cleft on the right portion of the lobe.

ICJ894M

CECUM: Moderately distended with gas.

ICJ879M

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ953F

UTERUS: Moderately distended.

ICJ931F - Spontaneous death on Day 53

ANUS: Slightly swollen.
LUNGS: Mottled dark red and red.
SKIN/FUR (Dorsal and ventral head and dorsal cervical area): Clear discharge.
TERMINAL BODY WEIGHT: Not taken

ICJ919F

ALL TISSUES AND ORGANS: No observable abnormalities.

ICJ928F - Spontaneous death on Day 9

SKIN/FUR (Ano-genital area): Slight yellow staining.
TERMINAL BODY WEIGHT: 207.1 grams
NOTE: Moderate postmortem changes in all tissues and organs.

ICJ945F

CECUM: Moderately distended with gas.
UTERUS: Slightly distended.

ICJ952F - Spontaneous death on Day 8

CECUM: Ingesta more compact than normal.
GENERAL CONDITION: Moderately emaciated.
HEART/THYMUS: Surrounded by tan caseous material, adhered to lungs.
LUNGS (All lobes and surfaces): Dark red and surrounded by tan/white caseous material.
SKIN/FUR (Ano-genital area): Slight urine stains; (Snout): Slight amount of dry material.
SMALL INTESTINES: Distended with gas and a slight amount of amber liquid.
THORACIC CAVITY: Filled with extreme amount of clear liquid.
TERMINAL BODY WEIGHT: 183.4 grams
NOTE: Moderate postmortem changes in all tissues and organs.

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ870M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ878M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ882M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DEAD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	DYSPNEA	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	PALE EXTREMITIES	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	HYPOACTIVITY	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
ICJ885M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ861M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ886M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ848M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ845M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ898M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ904M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ918F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ957F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ948F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ962F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ951F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ968F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ908F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ911F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ916F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ942F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ870M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	MALOCCLUDED INCISORS	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+	+
ICJ878M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ885M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ861M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ886M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ848M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ845M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ898M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ904M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ918F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ957F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ948F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ962F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ951F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ968F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ908F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DRY RALES	+	+	+	+	+	-	-	-	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-
ICJ911F		-	-	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ916F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ942F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ870M																		
	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ878M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ885M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ861M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ886M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ848M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ845M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ898M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ904M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ918F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ957F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ948F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ962F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ951F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DRIED RED NASAL DISCHARGE	+	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ968F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ908F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DYSPNEA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-
	DRIED RED NASAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	URINE STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
ICJ911F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ916F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ942F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ870M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ878M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ885M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	-	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-
ICJ861M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	SCABS SNOUT	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+	+
ICJ886M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ848M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ845M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ898M																		
	WITHIN NORMAL LIMITS	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ904M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	DEAD	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
ICJ918F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ957F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-	-	-	-	-	+	+	+	+	+	+
	DYSPNEA	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
	EMACIATED SLIGHT	-	-	-	-	-	-	+	+	+	+	+	-	-	-	-	-	-
ICJ948F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ962F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ951F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ968F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-	-	-	+	+	+	+	+	+	+	+
	MALOCCLUDED INCISORS	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-	-
	DRIED RED OCULAR DISCHARGE LEFT EYE	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ908F																		
	DEAD	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	DYSPNEA	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	DRIED RED NASAL DISCHARGE	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	URINE STAINING SLIGHT	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	URINE STAINING EXTREME	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING EXTREME	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	HYPOTHERMIA	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	SCABS HEAD	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	EMACIATED SLIGHT	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	EMACIATED MODERATE	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	EMACIATED EXTREME	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	POOR CONDITION SLIGHT	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	POOR CONDITION MODERATE	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	LITTLE SIGN OF STOOL	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	LITTLE SIGN OF FOOD CONSUMPTION	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	HYPOACTIVITY	-	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
ICJ911F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ916F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ942F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ870M																		
	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ878M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ885M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	-	-	+	+	+	-	+	-	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	+	-	-	-	-
	BROKEN LEFT UPPER INCISOR	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-
ICJ861M																		
	WITHIN NORMAL LIMITS	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SCABS SNOUT	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ886M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ848M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ845M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ898M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ918F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ957F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ948F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+
	SCABS VENTRAL CERVICAL	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
ICJ962F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ951F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ968F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ911F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ916F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ942F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - CONTROL

ANIMAL NUMBER	OBSERVATION		DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97
ICJ870M															
	MALOCCLUDED INCISORS		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ878M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ885M															
	WITHIN NORMAL LIMITS		+	+	+	+	-	+	+	+	+	+	+	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	+	-	-	-	-	-	-	-	-
ICJ861M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ886M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ848M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ845M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ898M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ918F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ957F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ948F															
	WITHIN NORMAL LIMITS		-	-	-	-	-	-	-	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	-	-	-	-	-	-
ICJ962F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ951F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ968F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ911F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ916F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ942F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ877M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ884M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ873M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ875M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ892M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ855M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ887M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ900M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ859M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ872M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ959F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ956F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ943F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ960F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ917F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ927F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ925F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ930F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ954F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ921F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ877M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ884M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ873M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ875M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ892M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ855M																		
	WITHIN NORMAL LIMITS	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
	URINE STAINING SLIGHT	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
ICJ887M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ900M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ859M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ872M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ959F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ956F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ943F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ960F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ917F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ927F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ925F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ930F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ954F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ921F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ877M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ884M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ873M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ875M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ892M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ855M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	+	-	-	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	+	+	-	-	-	-
ICJ887M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	-	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-	-	-
ICJ900M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ859M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+
ICJ872M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	+	+	+	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	+	+
ICJ959F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ956F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ943F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ960F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ917F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ927F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ925F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ930F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ954F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
ICJ921F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ877M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ884M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ873M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ875M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	-	-	-	-	+	+	-	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	+	+	+	-	-	+	-	-	-	-	-
ICJ892M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ855M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	-	+	-	-	-	-	-	-	-	-	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	+	+	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	+	-	-	+	+	+	+	+	-	-	-	-
ICJ887M																		
	DRIED RED NASAL DISCHARGE	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ900M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
ICJ859M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	-	+	-	+	+	+	+	+	+	-	-	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	-	+	-	-	-	-	-	-	+	+	-
ICJ872M																		
	WITHIN NORMAL LIMITS	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ959F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ956F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ943F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ960F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ917F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ927F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-
ICJ925F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ930F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	-	-	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
ICJ954F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	-	-	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SCABS MOUTH		-	-	-	-	-	-	-	-	-	+	+	+	+	+	-	-	-
ICJ921F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ877M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ884M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ873M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ875M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-
ICJ892M							+	-	-	-	-	-	-	-	-	-	-	-
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ855M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SWOLLEN ANUS	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
ICJ887M							+	-	-	-	-	-	-	-	-	-	-	-
	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-
ICJ900M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ859M																		
	WITHIN NORMAL LIMITS	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ872M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
ICJ959F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ956F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ943F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ960F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ917F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ927F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	URINE STAINING SLIGHT	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ925F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ930F																			
	WITHIN NORMAL LIMITS		+	+	+	-	+	+	+	-	-	+	-	+	+	-	+	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	+	-	-	-	+	+	-	+	-	-	+	-	+	+
ICJ954F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ921F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97
ICJ877M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ884M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ873M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ875M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ892M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ855M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ887M	WITHIN NORMAL LIMITS	+	+	-	+	-	-	-	-	+	-	+	-	-
	URINE STAINING SLIGHT	-	-	-	-	+	-	-	+	-	-	-	+	-
	URINE STAINING MODERATE	-	-	-	-	-	+	+	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	+	-	+	-	-	+	-	+	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	+	+	-	-	-	-	-	-
ICJ900M	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ859M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ872M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ959F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ956F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	+	+	+	+	+	+
ICJ943F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ960F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ917F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ927F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ925F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	-	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97
ICJ930F														
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	-	-	+	+	+	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	+	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	-	-	+
ICJ954F														
	WITHIN NORMAL LIMITS	+	+	+	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	+	+	-	-	-	-	-	-	-
	BROKEN RIGHT UPPER INCISOR	-	-	-	-	+	+	+	+	+	+	+	+	+
ICJ921F														
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ846M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ896M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ893M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ881M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ889M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ890M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ905M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ850M	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
ICJ847M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ883M	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ955F	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
ICJ961F	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ964F	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ949F	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ940F	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ933F	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ966F	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ938F	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ941F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ934F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ846M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ896M																		
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ893M																		
	WITHIN NORMAL LIMITS	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ881M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	-	-	-	-	-	-	-	+	+	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	+	+	+	+	+	+	-	-	+
ICJ889M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ890M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	-	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	-	-	+	-	-	-	-	-	-
ICJ905M																		
	WITHIN NORMAL LIMITS	-	+	+	+	+	+	+	+	+	-	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
ICJ850M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
ICJ847M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ883M																		
	WITHIN NORMAL LIMITS	-	+	+	+	+	+	+	-	-	-	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	+	+	+	+	-	-	-	-	-	-
ICJ955F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	EMACIATED SLIGHT	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-
ICJ961F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-
	SCABS MOUTH	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
ICJ964F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ949F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ940F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ933F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ966F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ938F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ941F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ934F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ846M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	-	-	-	+	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
ICJ896M																			
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ893M																			
	WITHIN NORMAL LIMITS		+	-	-	-	-	+	+	-	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	ALOPECIA HEAD		-	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
ICJ881M																			
	WITHIN NORMAL LIMITS		-	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	+	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
ICJ889M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-	+
	UNTHRIFTY COAT		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
ICJ890M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ905M																			
	WITHIN NORMAL LIMITS		+	-	+	+	+	+	+	+	+	-	+	+	-	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	+	-	-	-	-	-	-	-	+	-	-	+	-	-	-	-
ICJ850M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
ICJ847M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-	-	-
	ALOPECIA EXTREMITIES		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	-
ICJ883M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ955F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ961F																			
	WITHIN NORMAL LIMITS		+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ964F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ949F																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ940F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-
	URINE STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ933F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ966F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ938F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
ICJ941F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ934F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ846M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	-	-	+	+	-	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	+	+	-	-	-	+	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
ICJ896M																			
	ANOGENITAL STAINING	SLIGHT	+	-	-	-	-	-	-	-	+	+	+	+	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
	RED MATERIAL SEEN MOUTH		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ893M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	-	-	-	-	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	+	+	+	+	+	+	+	-	-	-	-	-
ICJ881M																			
	CLEAR ORAL DISCHARGE		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	+	+	+	+	+	-	+	+	+	+	+	-	+	+	+	+	+
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-	-
	SCABS MOUTH		-	-	-	+	-	+	+	+	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-	-
ICJ889M																			
	WITHIN NORMAL LIMITS		-	-	+	+	+	-	-	-	-	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	+	+	-	-	-	+	+	+	+	-	+	+	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
ICJ890M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
ICJ905M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	-	+	-	-	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	+	-	+	+	-	+	+	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
ICJ850M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	+	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
ICJ847M																			
	WITHIN NORMAL LIMITS		-	-	+	+	+	-	+	-	-	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	+	-	+	+	-	+	+	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES		+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ883M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ955F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	-	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
ICJ961F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
ICJ964F																			
	WITHIN NORMAL LIMITS		+	-	+	+	+	+	+	-	+	-	+	+	+	+	+	+	+
	CLEAR ORAL DISCHARGE		-	+	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
ICJ949F																			
	WITHIN NORMAL LIMITS		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+
ICJ940F																			
	WITHIN NORMAL LIMITS		-	-	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT		+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	EMACIATED SLIGHT		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ933F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-
ICJ966F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	EMACIATED SLIGHT		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	EMACIATED MODERATE		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
ICJ938F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-
	DEAD		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	WET RALES		-	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
	SOFT STOOL		-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
	HYPOTHERMIA		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	EMACIATED SLIGHT		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	EMACIATED MODERATE		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	POOR CONDITION SLIGHT		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	RED MATERIAL SEEN MOUTH		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	DRIED RED OCULAR DISCHARGE LEFT EYE		-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
	HYPOACTIVITY		-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ941F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ934F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ846M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	WET RALES	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	URINE STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-	-
	BROKEN LEFT UPPER INCISOR	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
ICJ896M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ893M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
ICJ881M																		
	URINE STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	ANOGENITAL STAINING SLIGHT	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	+	-	+	+	+	+	+	+
ICJ889M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
ICJ890M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-	+	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	+	-	-	-	-	-	-
ICJ905M																		
	WITHIN NORMAL LIMITS	+	+	-	-	+	+	-	+	+	+	-	+	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	+	+	-	-	+	-	-	-	+	-	+	+	+	+	+
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
ICJ850M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
ICJ847M																		
	WITHIN NORMAL LIMITS	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	-	+
	ANOGENITAL STAINING SLIGHT	-	-	+	-	-	-	+	-	-	-	+	-	-	-	+	+	-
ICJ883M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	+	+	-	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	-
ICJ955F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ961F																		
	WITHIN NORMAL LIMITS	+	+	+	-	-	-	+	+	+	+	+	-	-	+	+	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	+	+
	BROKEN LEFT UPPER INCISOR	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-
ICJ964F																		
	WITHIN NORMAL LIMITS	+	+	+	-	+	+	+	+	+	+	-	-	-	-	-	-	-
	DEAD	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ949F																		
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ940F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+
ICJ933F																		
	WITHIN NORMAL LIMITS	+	+	+	-	-	+	+	+	+	+	+	+	+	+	+	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
ICJ966F																		
	WITHIN NORMAL LIMITS	+	+	+	-	-	+	+	+	+	+	-	+	+	+	+	+	+
	URINE STAINING SLIGHT	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
ICJ941F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ934F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+
	SCABS MOUTH	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97
ICJ846M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ896M															
	WITHIN NORMAL LIMITS		-	-	-	-	-	-	-	-	-	-	+	-	-
	ANOGENITAL STAINING	SLIGHT	+	-	-	-	-	-	-	+	+	-	-	+	-
	UNTHRIFTY COAT		-	-	-	-	-	-	+	+	-	-	-	-	-
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	-	-	-
ICJ893M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ881M															
	ANOGENITAL STAINING	SLIGHT	+	+	+	+	+	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	+	-
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ889M															
	WITHIN NORMAL LIMITS		-	+	+	+	+	+	+	+	-	+	+	-	-
	UNTHRIFTY COAT		+	-	-	-	-	-	-	-	+	-	-	+	-
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ890M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ905M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	+	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-
ICJ850M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ847M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ883M															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	+	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ955F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ961F															
	WITHIN NORMAL LIMITS		+	+	-	+	+	+	+	-	+	+	+	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	+	-	-	-	-	+	-	-	-	-	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 2500 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97
ICJ949F															
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ940F															
	WITHIN NORMAL LIMITS		-	-	-	-	+	+	+	+	+	+	+	+	+
	UNTHRIFTY COAT		+	+	+	+	-	-	-	-	-	-	-	-	-
ICJ933F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	-	+	+	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-
ICJ966F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	-	-	-	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	+	+	-	-	-
ICJ941F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ934F															
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ874M																		
	WITHIN NORMAL LIMITS	+	-	+	+	+	+	+	+	+	+	-	-	+	+	-	-	-
	SOFT STOOL	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	-	-	+	+	+
ICJ867M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	+	+	+	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	+	+
ICJ902M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ869M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	-	-	+	+	+
	ALOPECIA ENTIRE BODY	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+
ICJ891M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	RED MATERIAL SEEN MOUTH	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ871M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ907M																		
	WITHIN NORMAL LIMITS	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	CLEAR ORAL DISCHARGE	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+	+
ICJ899M																		
	WITHIN NORMAL LIMITS	+	+	-	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	+	-	-	-	-	-	-	-	+	-	-	-	-	-	+
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ851M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	-	+	-	-	-
	URINE STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	-	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ868M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	RED DISCHARGE ANUS		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
ICJ932F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ950F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
	ANOGENITAL STAINING	EXTREME	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	ALOPECIA EXTREMITIES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	ALOPECIA TRUNK		-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
ICJ922F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	+	+	-	-	-	-	-	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-
ICJ909F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	URINE STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ923F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	-	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ939F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
ICJ935F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ910F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ912F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ914F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
ICJ944F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	+	+	+	+	+	-	-	-
	CLEAR ORAL DISCHARGE		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
ICJ969F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ924F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+
ICJ958F																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ874M																		
	WITHIN NORMAL LIMITS	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	-	-	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
ICJ867M																		
	WITHIN NORMAL LIMITS	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	+	+	+	+	-	-	-	-	-	-	-
ICJ902M																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ869M																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ891M																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ871M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ907M																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
	SCABS ANUS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+
ICJ899M																		
	DRIED RED NASAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-
	ANOGENITAL STAINING SLIGHT	+	+	-	-	-	-	-	-	-	-	-	-	+	+	-	-	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+
ICJ851M																		
	WET RALES	-	-	-	-	+	-	+	+	-	-	-	-	-	-	-	-	-
	URINE STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING EXTREME	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	SCABS POSTERIOR VENTRAL	-	-	-	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-
	POOR CONDITION SLIGHT	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ868M																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ932F																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ950F																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	+	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK		-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ922F																			
	WITHIN NORMAL LIMITS		-	-	-	-	-	-	-	+	+	+	+	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	-	-	-	-	+	+	+	+	+	+
ICJ909F																			
	WITHIN NORMAL LIMITS		-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+
ICJ923F																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ939F																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ935F																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ910F																			
	ANOGENITAL STAINING	SLIGHT	+	+	+	-	-	-	+	-	-	+	+	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ912F																			
	DRIED RED NASAL DISCHARGE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	ANOGENITAL STAINING	SLIGHT	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SCABS ANUS		-	-	-	-	-	-	+	+	+	+	+	+	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-
ICJ914F																			
	WITHIN NORMAL LIMITS		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS		-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	+	+	+	+	-	-	-	-	-	-
ICJ944F																			
	DRIED RED NASAL DISCHARGE		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	CLEAR ORAL DISCHARGE		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ969F																		
	DRIED RED NASAL DISCHARGE	-	-	-	+	+	-	+	-	-	-	-	-	-	-	-	-	-
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	+	-	-	+	+	+	-	-	+	+	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	SCABS ANUS	-	-	-	-	-	-	+	+	+	+	+	+	+	+	-	-	-
	SCABS BOTH FORE PAWS	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	+	+	+	+	+	+	+	+	-	-	-
	EMACIATED MODERATE	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
	POOR CONDITION SLIGHT	-	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-
	SORES PALATE	-	-	-	-	-	+	+	+	+	+	-	+	+	+	-	-	-
	MALOCCLUDED INCISORS	-	-	-	+	-	-	+	+	+	+	+	-	-	-	-	-	-
	MISSING RIGHT UPPER INCISOR	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	-	-	-	-	-	+	-	-	-	-	+	-	-	-	-	-	-
	DRIED RED OCULAR DISCHARGE BOTH EYES	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
ICJ924F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ958F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	+	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ874M																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ867M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	+	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ902M																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ869M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	+	+	+	-	-	-	+	+	+	+	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ891M																			
	ANOGENITAL STAINING	SLIGHT	-	+	+	-	-	+	+	+	+	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-
ICJ871M																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ907M																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	+	-	-	-	+	+	+	-	-	-	-	+	+	-	-	-
	ANOGENITAL STAINING	MODERATE	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SCABS ANUS		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	+	+	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	SORES ANUS		-	-	-	-	-	+	+	-	-	-	-	+	+	+	+	+	-
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	-	-	+	+	+	+	+	+	+	+	+	+
ICJ899M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	+	+	+	+	+	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ851M																			
	WET RALES		-	-	-	-	+	+	-	-	-	-	-	+	+	+	+	-	-
	CLEAR ORAL DISCHARGE		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
	ALOPECIA EXTREMITIES		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ868M																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ932F																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
ICJ950F																		
	DEAD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	DYSPNEA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	CLEAR ORAL DISCHARGE	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	ALOPECIA TRUNK	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+	+	-
	CLEAR OCULAR DISCHARGE BOTH EYES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ922F																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	+	+	+	+	-	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	-	-	-	-	+	-	+	+	+	+	+
ICJ909F																		
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-	-
ICJ923F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ939F																		
	DRY RALES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
	ANOGENITAL STAINING EXTREME	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SCABS ANUS	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-
	EMACIATED MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	POOR CONDITION SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SORES LEFT HINDLEG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	SORES ANUS	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	LITTLE SIGN OF STOOL	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	DRIED RED OCULAR DISCHARGE RIGHT EYE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-
	DRIED RED OCULAR DISCHARGE BOTH EYES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ935F																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ910F																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	+	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ912F																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ914F																			
	WITHIN NORMAL LIMITS		-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	-	-	-	+	+	+	+	+
ICJ944F																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	+	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ969F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	MISSING RIGHT UPPER INCISOR	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	-	-	-	-	+	+	+	+	-	+	+	+	-	-	-	-	+
	DRIED RED OCULAR DISCHARGE RIGHT EYE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ924F																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ958F																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ874M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	+	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	-	-	+	+	+
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
ICJ867M																		
	ANOGENITAL STAINING SLIGHT	-	-	+	-	+	+	-	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	+	-	+	-	-	-	-	+	+	+	+	+	-	-	-	-
	UNTHRIFTY COAT	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
ICJ902M																		
	CLEAR ORAL DISCHARGE	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	+	-	-	+	+	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
ICJ869M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ891M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ871M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING EXTREME	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	RED MATERIAL SEEN MOUTH	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
ICJ907M																		
	CLEAR ORAL DISCHARGE	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING EXTREME	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-
	SORES ANUS	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ899M																		
	ANOGENITAL STAINING SLIGHT	+	+	-	-	-	-	-	+	+	+	-	+	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
ICJ851M																		
	DRY RALES	+	+	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	-	-	+	+	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	ALOPECIA TRUNK	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	+
ICJ868M																		
	ANOGENITAL STAINING SLIGHT	+	+	-	-	-	+	-	-	-	-	-	-	-	-	+	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ932F																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-
	CLEAR ORAL DISCHARGE	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING EXTREME	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	-	-	+	+	+	+	+	+	+	+	+	+
	SORES ANUS	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
ICJ922F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ909F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
ICJ923F																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+
ICJ939F																		
	DRY RALES	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	DRIED RED NASAL DISCHARGE	+	+	-	+	-	-	-	+	+	-	+	+	+	+	+	-	-
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	+	+	+	+	+	-	+	+	+	+	+	-	-	-	-	-
	UNTHRIFTY COAT	-	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	+	-	-	-	-	+	+	+	+	-	-	-	-	-	-
	EMACIATED MODERATE	+	+	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-
	POOR CONDITION	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	POOR CONDITION SLIGHT	-	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-
	PALE EXTREMITIES	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	+	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ935F																		
	DEAD	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	DYSPNEA	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	HYPOTHERMIA	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	EMACIATED SLIGHT	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	POOR CONDITION SLIGHT	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	LITTLE SIGN OF STOOL	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	LITTLE SIGN OF FOOD CONSUMPTION	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	CLEAR OCULAR DISCHARGE RIGHT EYE	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ910F																		
	DEAD	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	DYSPNEA	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	HYPOTHERMIA	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	POOR CONDITION SLIGHT	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	LITTLE SIGN OF FOOD CONSUMPTION	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	CLEAR OCULAR DISCHARGE RIGHT EYE	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	HYPOACTIVITY	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ912F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	BROKEN RIGHT UPPER INCISOR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
ICJ914F																		
	DEAD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	DRY RALES	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ944F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	LITTLE SIGN OF STOOL	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	LITTLE SIGN OF FOOD CONSUMPTION	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ969F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	+	-	-	-	-	-	+	+	-	-	-	-	-	+
	ANOGENITAL STAINING MODERATE	-	+	+	-	-	-	-	-	-	-	-	-	-	-	+	+	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+
	MALOCCLUDED INCISORS	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+
	MISSING RIGHT UPPER INCISOR	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	RED OCULAR DISCHARGE LEFT EYE	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	RED OCULAR DISCHARGE RIGHT EYE	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	CLEAR OCULAR DISCHARGE LEFT EYE	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	+	+	-	-	+	+	+	+	+	-	+	-	-	-	+	+	-
	DRIED RED OCULAR DISCHARGE RIGHT EYE	-	-	+	-	-	-	-	-	-	+	-	-	-	+	-	-	-
ICJ924F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-
ICJ958F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	+	+	-	-	+	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION		DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ874M																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	-	+	+	-	-
ICJ867M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SWOLLEN TRUNK		-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK		+	+	+	+	-	+	+	-	+	-	-	-	-	-	-	-	-
ICJ902M																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
ICJ869M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	+	+	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
ICJ891M																			
	ANOGENITAL STAINING	SLIGHT	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ871M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES		+	-	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
	ALOPECIA TRUNK		-	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
ICJ907M																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ899M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ851M																			
	WET RALES		-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-
	DRY RALES		-	-	-	-	-	-	-	-	-	-	-	+	-	-	+	+	+
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+
	ANOGENITAL STAINING	MODERATE	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK		+	+	-	+	+	+	+	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ868M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ932F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ922F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-
ICJ909F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ923F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ939F																		
	WET RALES	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	DRY RALES	-	-	-	-	-	-	-	+	+	+	+	-	-	-	-	-	-
	URINE STAINING MODERATE	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	+	-	-	-	-	-	+
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
ICJ912F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	BROKEN RIGHT UPPER INCISOR	+	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ944F																		
	WITHIN NORMAL LIMITS	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ969F																		
	ANOGENITAL STAINING SLIGHT	+	+	+	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	+	+	+	+	+	+	-	-	-	-	+	+	+	+	+	+	+
	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	MISSING RIGHT UPPER INCISOR	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	DRIED RED OCULAR DISCHARGE LEFT EYE	+	-	-	+	+	+	+	+	+	+	+	+	-	+	+	+	+
	DRIED RED OCULAR DISCHARGE RIGHT EYE	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
ICJ924F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
ICJ958F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97
ICJ874M														
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ867M														
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ902M														
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ869M														
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ891M														
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ871M														
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	-	-	-	+	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ907M														
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
	RED MATERIAL SEEN PENIS	-	-	-	-	-	-	-	-	-	+	-	-	-
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	+	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	-	-	-	-	-	-	-	-
ICJ899M														
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ851M														
	DRY RALES	+	+	+	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-
ICJ868M														
	ANOGENITAL STAINING SLIGHT	-	+	-	-	-	-	-	+	-	-	-	+	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	+	-	-	-	-
	SCABS ANUS	-	-	-	-	-	-	-	+	+	+	-	+	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-
ICJ932F														
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	-	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG

ANIMAL NUMBER	OBSERVATION	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
ICJ922F																		
	WITHIN NORMAL LIMITS	-	-	-	+	-	-	-	-	-	-	-	-	-				
	SWOLLEN ANUS	+	+	+	-	+	+	+	+	+	+	+	+	+				
ICJ909F																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	+	-				
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	-	+				
ICJ923F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+				
	ALOPECIA TRUNK	+	+	+	-	-	-	-	-	-	-	-	-	-				
ICJ939F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+				
	ALOPECIA TRUNK	+	+	+	-	+	+	+	+	+	+	+	+	-				
ICJ912F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+				
ICJ944F																		
	SCABS MOUTH	+	+	+	-	-	-	-	-	-	-	-	-	-				
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+				
ICJ969F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+				
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+				
	EMACIATED SLIGHT	+	+	+	+	+	+	+	+	+	+	+	+	+				
	MALOCCLUDED INCISORS	+	+	+	+	+	+	+	+	+	+	+	+	-				
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	-	-	-	+				
	MISSING RIGHT UPPER INCISOR	+	+	+	+	+	+	+	+	+	+	+	+	+				
	DRIED RED OCULAR DISCHARGE LEFT EYE	+	-	-	-	-	-	-	+	+	+	+	+	+				
ICJ924F																		
	UNTHRIFTY COAT	-	+	+	-	-	-	-	-	-	-	-	-	-				
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+				
	EMACIATED SLIGHT	-	+	+	+	-	+	-	-	-	-	-	-	-				
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	+	+	+	+				
ICJ958F																		
	DRY RALES	-	-	-	-	-	-	-	-	+	-	-	-	-				
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-				
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+				

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION		DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ856M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ853M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-
ICJ852M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ864M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ857M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	-	-	-	-	-	-	-	-	+	-	+	+	+	+
	ALOPECIA EXTREMITIES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
ICJ866M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ895M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ862M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+
	ALOPECIA EXTREMITIES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
ICJ894M																			
	WITHIN NORMAL LIMITS		+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	+	+	+
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-	-	-
	SWOLLEN ANUS		-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 0	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	DAY 16
ICJ879M																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ953F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+
ICJ931F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+
ICJ919F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ928F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-
	DEAD	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
ICJ945F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+
ICJ952F																		
	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-
	DEAD	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
	DYSPNEA	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	URINE STAINING SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	HYPOACTIVITY	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ856M																		
	DRIED RED NASAL DISCHARGE	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
ICJ853M																		
	ANOGENITAL STAINING SLIGHT	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ852M																		
	ANOGENITAL STAINING SLIGHT	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
	ALOPECIA TRUNK	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ864M																		
	ANOGENITAL STAINING SLIGHT	-	+	-	-	-	-	-	-	-	-	+	-	+	-	-	+	+
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	+	+	-	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ857M																		
	ANOGENITAL STAINING MODERATE	-	-	-	+	-	-	-	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ866M																		
	DRIED RED NASAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+
	PROTRUDING ANUS	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	-	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ895M																		
	SCABS ANUS	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ862M																		
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+	-
	ANOGENITAL STAINING MODERATE	-	+	-	+	-	-	-	-	+	-	+	+	+	+	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-
	SCABS ANUS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	+	+	-	+	+	+	+	-	-	-	-	-	-	-
	SORES ANUS	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION		DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ894M																			
	ANOGENITAL STAINING	SLIGHT	+	+	-	+	+	-	+	+	+	+	-	-	+	+	-	+	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	+	+	+	+	+	-	-	-	-	-	-
	SORES ANUS		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ879M																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
ICJ953F																			
	ANOGENITAL STAINING	SLIGHT	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		+	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ931F																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ919F																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	DAY 29	DAY 30	DAY 31	DAY 32	DAY 33
ICJ945F																		
	CLEAR ORAL DISCHARGE	-	+	-	-	-	-	-	-	-	-	+	-	-	-	-	+	-
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ856M																		
	SCABS ANUS	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	+	+	-	-	-	-	-	+	+	+	+	+	+	-	+
	SORES ANUS	-	-	-	-	+	-	-	-	-	-	+	+	-	-	-	-	-
	ALOPECIA TRUNK	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ853M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	+	-	-	+	+	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ852M																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	+	+	-	-	+	+	+	-	-	+	-
	ANOGENITAL STAINING EXTREME	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	EMACIATED MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	RED MATERIAL SEEN MOUTH	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	-	-	-	-	-	+	+	+	+	+	-
ICJ864M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-
ICJ857M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ866M																		
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ895M																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ862M																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ894M																		
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION		DAY 34	DAY 35	DAY 36	DAY 37	DAY 38	DAY 39	DAY 40	DAY 41	DAY 42	DAY 43	DAY 44	DAY 45	DAY 46	DAY 47	DAY 48	DAY 49	DAY 50
ICJ879M																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	+	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
ICJ953F																			
	SOFT STOOL		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SCABS ANUS		-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+
	SWOLLEN ANUS		+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	-	-	-	+	-	-	-	+	-	-	-	-	-	-
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ931F																			
	WITHIN NORMAL LIMITS		-	-	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	-	-	-	+	+	+	+	+
ICJ919F																			
	CLEAR ORAL DISCHARGE		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	+	+	-	-	+
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ945F																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION		DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ856M																			
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	+	+	-	+	+	-	-	-	-	-
	ANOGENITAL STAINING	EXTREME	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	+	+	-	-	-	-	-	+	+	+	-	-	+	+	+	+	+
	EMACIATED	MODERATE	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	SORES ANUS		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ853M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ852M																			
	DEAD		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	EXTREME	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	UNTHRIFTY COAT		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	EMACIATED	MODERATE	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ864M																			
	ANOGENITAL STAINING	SLIGHT	-	+	-	-	-	-	+	+	+	+	+	-	-	-	+	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ857M																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ866M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	+	-	-	-	-	-	-	+	+	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SORES ANUS		-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+
	ALOPECIA EXTREMITIES		+	+	+	-	-	-	-	-	-	-	-	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+
ICJ895M																			
	ANOGENITAL STAINING	SLIGHT	-	+	-	-	-	-	+	+	-	+	+	+	+	-	+	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	+	-	-	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ862M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	+	-	+	+	+	+	+	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	+	-	-	-	+	-	-	-	-	-	-	-
	UNTHRIFTY COAT		-	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	BROKEN UPPER INCISOR(S)		-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-
	BROKEN RIGHT UPPER INCISOR		-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-
	ALOPECIA EXTREMITIES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 51	DAY 52	DAY 53	DAY 54	DAY 55	DAY 56	DAY 57	DAY 58	DAY 59	DAY 60	DAY 61	DAY 62	DAY 63	DAY 64	DAY 65	DAY 66	DAY 67
ICJ894M																		
	ANOGENITAL STAINING SLIGHT	+	+	-	-	-	-	-	+	-	+	+	+	+	+	+	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ879M																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	+	+	+	+	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ953F																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SCABS ANUS	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ931F																		
	DEAD	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ919F																		
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	MISSING RIGHT UPPER INCISOR	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
ICJ945F																		
	CLEAR ORAL DISCHARGE	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	+	-	-
	SWOLLEN ABDOMEN	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ856M																		
	DRIED RED NASAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	EMACIATED MODERATE	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	ALOPECIA TRUNK	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-
ICJ853M																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ864M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	+	-	+	+	-	+	-	-	+	+	+	+
	ANOGENITAL STAINING MODERATE	-	-	-	+	-	-	-	-	-	-	-	+	+	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ857M																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ866M																		
	URINE STAINING SLIGHT	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	+	+	-	+	-	-	-	-	-	-	-	-	-	-	-
	SORES ANUS	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	ALOPECIA EXTREMITIES	+	+	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+
ICJ895M																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ862M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	+	+
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA EXTREMITIES	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ894M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-	-	-
ICJ879M																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ953F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 68	DAY 69	DAY 70	DAY 71	DAY 72	DAY 73	DAY 74	DAY 75	DAY 76	DAY 77	DAY 78	DAY 79	DAY 80	DAY 81	DAY 82	DAY 83	DAY 84
ICJ919F																		
	URINE STAINING SLIGHT	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	BROKEN RIGHT UPPER INCISOR	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	MISSING RIGHT UPPER INCISOR	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICJ945F																		
	ANOGENITAL STAINING SLIGHT	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA HEAD	-	-	-	-	-	-	-	+	+	+	+	+	-	+	+	-	-
	ALOPECIA EXTREMITIES	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
ICJ856M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-
	EMACIATED MODERATE	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
ICJ853M																		
	DYSPNEA	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-
	DRY RALES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	DRIED RED NASAL DISCHARGE	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-
	SOFT STOOL	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SCABS SNOUT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	SCABS ANUS	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+
	SWOLLEN ABDOMEN	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
	POOR CONDITION MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
	LITTLE SIGN OF STOOL	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-
	RED OCULAR DISCHARGE RIGHT EYE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
	DRIED RED OCULAR DISCHARGE RIGHT EYE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
	DRIED RED OCULAR DISCHARGE BOTH EYES	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-
	HYPOACTIVITY	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-
ICJ864M																		
	ANOGENITAL STAINING SLIGHT	+	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	ANOGENITAL STAINING MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ857M																		
	DEAD	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
	WET RALES	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	CLEAR ORAL DISCHARGE	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
	RED OCULAR DISCHARGE BOTH EYES	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
ICJ866M																		
	ANOGENITAL STAINING SLIGHT	-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	-
	UNTHRIFTY COAT	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
	SCABS ANUS	+	+	+	+	-	+	+	+	+	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-
	SORES ANUS	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
	ALOPECIA EXTREMITIES	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION		DAY 85	DAY 86	DAY 87	DAY 88	DAY 89	DAY 90	DAY 91	DAY 92	DAY 93	DAY 94	DAY 95	DAY 96	DAY 97	DAY 98	DAY 99	DAY 100	DAY 101
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ895M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	+	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	-
ICJ862M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	-
ICJ894M																			
	DRY RALES		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
ICJ879M																			
	ANOGENITAL STAINING	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ953F																			
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	ALOPECIA TRUNK		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ919F																			
	WITHIN NORMAL LIMITS		-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ945F																			
	WET RALES		-	+	-	-	-	-	-	-	-	-	-	-	-	-	+	+	-
	DRY RALES		+	-	-	-	-	-	-	-	+	+	-	+	+	+	-	-	+
	ANOGENITAL STAINING	SLIGHT	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ANOGENITAL STAINING	MODERATE	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	EMACIATED	SLIGHT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	ALOPECIA TRUNK		-	-	-	-	+	+	+	+	+	+	-	-	-	-	-	+	+
	EYE DAMAGED FROM EYEBLEEDING RIGHT EYE		-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+
	DRIED RED OCULAR DISCHARGE RIGHT EYE		-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 102	DAY 103	DAY 104	DAY 105	DAY 106	DAY 107	DAY 108	DAY 109	DAY 110	DAY 111	DAY 112	DAY 113	DAY 114	DAY 115	DAY 116	DAY 117	DAY 118
ICJ856M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
ICJ853M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-
	DRY RALES	+	-	-	-	-	-	-	-	+	+	+	-	-	-	-	-	-
	SCABS SNOUT	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SCABS ANUS	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	SWOLLEN ANUS	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
	EMACIATED SLIGHT	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	POOR CONDITION SLIGHT	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	MALOCCLUDED INCISORS	-	-	-	-	-	-	-	-	-	+	+	-	-	-	+	+	-
	CLEAR OCULAR DISCHARGE RIGHT EYE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
	DRIED RED OCULAR DISCHARGE RIGHT EYE	+	+	+	+	+	+	+	+	+	+	+	+	+	-	+	-	+
ICJ864M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-
ICJ866M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-
ICJ895M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
ICJ862M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-
ICJ894M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-
ICJ879M																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-
ICJ953F																		
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
ICJ919F																		
	WITHIN NORMAL LIMITS	-	-	-	-	-	-	-	+	+	+	+	+	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 102	DAY 103	DAY 104	DAY 105	DAY 106	DAY 107	DAY 108	DAY 109	DAY 110	DAY 111	DAY 112	DAY 113	DAY 114	DAY 115	DAY 116	DAY 117	DAY 118
ICJ945F																		
	DRY RALES	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	SWOLLEN ANUS	+	+	+	+	+	+	+	+	+	+	+	+	+	-	-	-	-
	ALOPECIA TRUNK	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-
	EYE DAMAGED FROM EYEBLEEDING RIGHT EYE	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

APPENDIX A - INDIVIDUAL INLIFE OBSERVATIONS CONT.

DOSE GROUP - 5000 MG/KG SATELLITE

ANIMAL NUMBER	OBSERVATION	DAY 119	DAY 120	DAY 121	DAY 122	DAY 123	DAY 124	DAY 125
ICJ856M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+
ICJ853M	RED OCULAR DISCHARGE RIGHT EYE	+	-	+	-	-	-	+
	DRIED RED OCULAR DISCHARGE RIGHT EYE	-	+	-	+	+	+	-
ICJ864M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+
ICJ866M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	-
	DRIED RED NASAL DISCHARGE	-	-	-	-	-	-	+
ICJ895M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+
ICJ862M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+
ICJ894M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+
ICJ879M	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+
ICJ953F	WITHIN NORMAL LIMITS	-	-	-	-	-	+	+
	ALOPECIA TRUNK	+	+	+	+	+	-	-
ICJ919F	WITHIN NORMAL LIMITS	+	+	+	+	+	+	+
ICJ945F	DRY RALES	+	+	+	+	+	+	+
	EYE DAMAGED FROM EYEBLEEDING RIGHT EYE	+	+	+	+	+	-	-

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS)
DOSE: 0MG/KG

TIME=	PRE TEST	0 DAYS	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS
ICJ870M	244.4	249.3	253.8	269.3	288.8	302.7	321.8	334.8	354.7	362.6	363.5	381.7	394.3
ICJ878M	248.7	258.5	279.8	306.1	330.4	361.1	332.9	367.5	399.2	426.3	448.6	466.8	477.7
ICJ882M	251.8	257.0	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ885M	256.6	268.0	290.9	313.3	320.5	348.9	361.0	375.5	404.0	424.3	435.9	452.6	466.8
ICJ861M	259.3	273.4	317.2	360.0	394.9	431.4	469.0	496.6	527.5	549.6	575.0	588.3	610.3
ICJ886M	263.8	268.7	285.9	310.6	331.0	361.7	386.1	406.6	430.2	458.7	467.7	477.8	491.5
ICJ848M	267.0	280.0	329.2	374.0	412.8	445.8	481.2	513.9	546.9	580.5	592.9	614.7	634.8
ICJ845M	274.9	288.4	316.7	346.9	366.9	403.1	414.1	435.5	455.6	467.8	468.7	482.6	493.2
ICJ898M	278.6	291.3	315.6	335.8	354.4	386.9	410.5	434.5	454.2	474.2	490.4	507.3	518.3
ICJ904M	280.4	293.0	339.0	384.1	413.2	450.2	481.1	520.2	547.1	578.8	$X	$X	$X
MEAN	262.6	272.8	303.1	333.3	357.0	388.0	406.4	431.7	457.7	480.3	480.3	496.5	510.9
STD.DEV.	12.6	15.2	27.2	36.9	43.6	49.4	61.4	67.2	69.4	75.1	74.3	74.7	78.0
N	10	10	9	9	9	9	9	9	9	9	8	8	8
ICJ918F	212.8	223.1	233.9	246.6	256.1	267.3	277.0	285.1	295.4	301.3	305.5	306.5	312.7
ICJ957F	199.3	211.3	227.8	234.1	251.5	260.9	277.0	281.8	271.1	262.2	265.1	280.6	290.7
ICJ948F	209.5	214.1	217.5	231.7	242.3	251.0	271.7	271.6	286.9	288.5	285.8	284.7	277.4
ICJ962F	206.4	216.3	224.2	241.3	253.6	266.5	270.3	277.4	290.9	297.0	307.1	315.1	316.1
ICJ951F	195.6	202.9	208.7	221.2	234.7	259.1	246.9	258.9	258.5	259.5	261.0	259.9	265.4
ICJ968F	192.1	203.0	222.4	241.4	236.0	266.0	279.9	294.6	302.7	311.2	306.7	317.8	318.1
ICJ908F	187.4	193.4	198.0	214.5	215.2	224.8	231.5	232.7	226.5	$X	$X	$X	$X
ICJ911F	204.9	213.8	210.2	238.3	245.6	255.8	265.2	261.1	279.4	283.6	273.1	299.8	306.5
ICJ916F	220.0	226.4	237.5	255.6	270.9	280.6	305.5	312.1	323.3	332.0	322.5	334.6	333.2
ICJ942F	190.4	194.8	214.6	224.3	241.3	254.2	266.9	274.9	295.4	300.6	300.6	306.1	313.2
MEAN	201.8	209.9	219.5	234.9	244.7	258.6	269.2	275.0	283.0	292.9	291.9	300.6	303.7
STD.DEV.	10.6	11.2	12.1	12.4	14.9	14.6	19.7	21.5	26.6	22.8	21.5	22.5	21.6
N	10	10	10	10	10	10	10	10	10	9	9	9	9

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: 0MG/KG (CONT.)

TIME=	84 DAYS	91 DAYS	95 DAYS
ICJ870M	408.6	408.6	414.6
ICJ878M	496.4	481.9	485.0
ICJ882M	$X	$X	$X
ICJ885M	481.7	490.8	497.7
ICJ861M	628.2	646.6	657.0
ICJ886M	509.5	525.8	534.0
ICJ848M	653.2	670.1	677.0
ICJ845M	510.7	523.8	525.0
ICJ898M	537.7	550.3	550.0
ICJ904M	$X	$X	$X
MEAN	528.3	537.2	542.5
STD.DEV.	79.1	86.1	87.3
N	8	8	8
ICJ918F	319.1	326.0	325.0
ICJ957F	291.6	309.3	312.0
ICJ948F	278.9	280.4	274.0
ICJ962F	328.7	335.1	332.4
ICJ951F	263.9	277.7	270.6
ICJ968F	327.3	343.1	348.0
ICJ908F	$X	$X	$X
ICJ911F	308.4	306.1	310.0
ICJ916F	339.3	348.1	344.6
ICJ942F	322.8	326.4	327.0
MEAN	308.9	316.9	316.0
STD.DEV.	25.4	25.5	27.8
N	9	9	9

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: 500MG/KG

TIME=	PRE TEST	0 DAYS	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS
ICJ877M	237.3	252.2	280.1	318.1	347.3	374.5	395.3	412.2	434.5	437.8	443.8	461.5	458.8
ICJ884M	247.8	254.0	262.8	275.3	287.0	312.1	335.7	363.2	391.0	413.4	419.4	437.6	448.3
ICJ873M	251.4	259.1	284.8	318.2	350.6	380.1	413.5	439.4	464.4	481.2	494.2	513.0	514.3
ICJ875M	256.8	271.8	315.0	354.2	389.5	422.5	454.1	480.7	508.7	529.9	551.0	565.0	575.3
ICJ892M	260.9	266.6	312.7	337.3	363.5	399.3	431.5	458.2	482.6	506.5	528.2	546.9	559.2
ICJ855M	261.8	275.5	327.2	367.9	399.6	442.7	484.4	519.9	551.6	578.2	588.1	609.7	613.9
ICJ887M	265.5	275.6	290.8	310.0	322.2	335.9	361.3	374.0	393.7	401.0	411.6	426.4	430.6
ICJ900M	270.5	278.6	330.0	375.5	407.9	449.8	483.2	505.1	536.0	548.1	560.3	588.0	604.9
ICJ859M	279.8	287.8	341.7	384.3	422.6	455.8	490.5	520.5	549.6	576.3	592.0	609.6	630.3
ICJ872M	286.7	294.4	309.6	329.4	360.0	388.9	416.2	441.6	457.0	483.5	491.7	513.4	525.2
MEAN	261.9	271.6	305.5	337.0	365.0	396.2	426.6	451.5	476.9	495.6	508.0	527.1	536.1
STD.DEV.	14.8	13.9	25.1	33.8	41.4	48.1	52.9	56.6	59.7	63.9	66.8	68.3	72.4
N	10	10	10	10	10	10	10	10	10	10	10	10	10
ICJ959F	214.0	217.1	225.8	256.9	263.2	271.1	287.3	285.1	300.5	304.0	309.5	318.4	319.6
ICJ956F	199.8	204.9	220.9	221.9	229.3	238.3	244.2	247.0	257.7	272.0	262.3	266.5	273.9
ICJ943F	210.2	210.6	218.9	247.0	256.3	262.8	273.7	284.9	288.4	294.9	296.9	303.9	298.1
ICJ960F	207.2	213.4	230.1	240.0	257.1	269.9	271.1	279.7	283.7	289.7	290.5	298.9	301.6
ICJ917F	198.5	205.3	216.4	244.5	252.1	261.0	268.6	276.8	291.2	288.9	289.8	292.6	297.4
ICJ927F	192.8	202.1	211.4	217.9	229.2	240.7	249.0	257.1	264.9	275.6	274.2	271.7	271.7
ICJ925F	182.2	189.5	212.5	222.3	234.5	243.7	247.7	252.7	255.3	269.2	273.3	269.8	280.5
ICJ930F	204.9	213.8	221.6	243.2	249.1	261.9	273.7	285.5	294.7	298.2	302.7	305.2	308.6
ICJ954F	219.9	230.0	247.2	250.0	271.7	282.2	291.4	302.4	301.8	315.7	314.1	303.0	303.7
ICJ921F	189.3	195.6	194.9	216.6	222.3	226.9	235.0	240.9	259.2	261.0	259.0	265.5	268.0
MEAN	201.9	208.2	220.0	236.0	246.5	255.9	264.2	271.2	279.7	286.9	287.2	289.6	292.3
STD.DEV.	11.7	11.5	13.6	14.8	16.6	17.5	19.1	20.3	18.5	17.2	19.3	19.4	17.6
N	10	10	10	10	10	10	10	10	10	10	10	10	10

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: 500MG/KG (CONT.)

TIME=	84 DAYS	91 DAYS	95 DAYS
ICJ877M	476.0	480.8	477.0
ICJ884M	470.1	477.8	487.0
ICJ873M	534.5	546.1	551.0
ICJ875M	600.2	617.8	625.0
ICJ892M	589.6	604.5	608.4
ICJ855M	658.6	658.1	672.0
ICJ887M	448.8	456.9	463.7
ICJ900M	627.4	647.3	647.0
ICJ859M	649.9	655.2	651.0
ICJ872M	549.8	561.3	571.0
MEAN	560.5	570.6	575.3
STD.DEV.	76.8	77.7	77.7
N	10	10	10
ICJ959F	321.0	323.3	331.5
ICJ956F	273.5	269.9	273.1
ICJ943F	302.2	310.7	301.0
ICJ960F	299.3	304.5	303.0
ICJ917F	298.3	298.3	300.2
ICJ927F	280.3	289.4	288.2
ICJ925F	275.0	281.0	281.0
ICJ930F	320.9	328.0	324.0
ICJ954F	312.5	316.8	311.4
ICJ921F	273.2	277.7	277.0
MEAN	295.6	300.0	299.0
STD.DEV.	19.1	20.1	19.6
N	10	10	10

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: 2500MG/KG

TIME=	PRE TEST	0 DAYS	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS
ICJ846M	242.9	250.4	261.7	289.8	310.3	326.7	338.0	351.9	365.7	375.4	369.4	388.8	398.3
ICJ896M	245.8	256.1	284.9	307.7	319.5	348.5	367.7	378.7	399.2	409.4	412.8	424.7	425.5
ICJ893M	253.6	266.3	308.0	324.4	349.2	375.1	394.6	404.1	426.2	436.7	436.1	456.3	456.8
ICJ881M	256.7	266.8	288.3	315.4	338.9	362.7	379.6	399.1	404.9	412.1	425.0	441.1	442.8
ICJ889M	261.5	269.5	291.9	308.2	315.0	339.7	353.4	370.2	378.3	385.6	395.0	398.8	400.8
ICJ890M	262.2	273.4	297.7	321.8	335.0	353.4	374.9	376.6	388.3	401.3	399.6	415.9	423.1
ICJ905M	268.0	280.9	295.9	307.3	321.3	353.6	372.9	391.9	397.3	414.2	416.6	428.8	428.2
ICJ850M	268.9	277.3	298.9	320.6	335.8	358.2	367.2	380.5	383.7	395.3	396.1	413.3	417.7
ICJ847M	279.6	291.0	325.8	354.8	373.9	408.5	443.2	456.5	467.8	478.8	484.0	495.8	497.5
ICJ883M	281.9	293.2	331.0	334.1	363.0	392.5	422.9	442.5	446.3	446.7	468.7	478.5	480.1
MEAN	262.1	272.5	298.4	318.4	336.2	361.9	381.4	395.2	405.8	415.6	420.3	434.2	437.1
STD.DEV.	13.0	13.8	20.0	17.6	20.9	24.4	31.4	32.4	31.9	30.9	34.9	34.2	32.5
N	10	10	10	10	10	10	10	10	10	10	10	10	10
ICJ955F	213.7	221.3	233.5	230.1	248.9	262.5	266.9	259.1	261.2	276.4	278.9	279.9	276.9
ICJ961F	201.7	204.8	221.0	226.4	250.9	266.7	272.6	276.9	279.1	287.7	297.4	302.0	296.4
ICJ964F	211.1	229.3	235.7	240.4	264.6	271.1	277.3	289.9	283.7	290.0	299.1	293.6	291.1
ICJ949F	208.4	212.7	219.2	234.9	243.1	249.6	253.0	255.5	260.9	267.4	269.3	265.7	269.9
ICJ940F	198.1	206.8	214.5	219.1	240.7	242.8	252.0	252.5	249.5	271.9	273.0	280.2	287.1
ICJ933F	193.9	207.1	218.0	222.3	243.7	252.7	265.8	271.1	272.9	276.8	297.1	286.3	285.3
ICJ966F	186.1	189.7	197.2	210.0	230.2	239.0	240.6	250.2	240.9	254.2	258.3	262.1	261.3
ICJ938F	205.2	214.0	213.5	248.2	269.1	280.5	294.2	295.5	301.2	307.8	$X	$X	$X
ICJ941F	219.5	222.1	245.8	252.6	271.2	284.1	284.2	309.7	289.4	291.8	300.5	312.2	299.9
ICJ934F	190.5	199.0	206.4	222.2	235.8	245.7	259.0	257.3	254.1	263.6	266.8	273.0	273.7
MEAN	202.8	210.7	220.5	230.6	249.8	259.5	266.6	271.8	269.3	278.8	282.3	283.9	282.4
STD.DEV.	10.7	11.8	14.4	13.4	14.1	15.9	16.2	20.6	19.2	15.8	16.4	16.5	12.8
N	10	10	10	10	10	10	10	10	10	10	9	9	9

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: 2500MG/KG (CONT.)

TIME=	84 DAYS	91 DAYS	95 DAYS
ICJ846M	400.0	412.2	416.0
ICJ896M	444.9	442.1	439.0
ICJ893M	471.3	481.7	482.6
ICJ881M	461.1	466.1	464.6
ICJ889M	411.3	413.7	414.0
ICJ890M	438.9	459.2	460.4
ICJ905M	443.9	457.7	458.1
ICJ850M	428.2	435.4	432.0
ICJ847M	524.7	538.1	536.9
ICJ883M	501.6	511.6	496.5
MEAN	452.6	461.8	460.0
STD.DEV.	38.6	40.3	38.1
N	10	10	10
ICJ955F	279.3	282.3	283.0
ICJ961F	307.0	304.6	298.0
ICJ964F	$X	$X	$X
ICJ949F	267.7	271.6	271.0
ICJ940F	291.9	281.7	278.0
ICJ933F	291.0	289.4	277.0
ICJ966F	261.1	259.0	259.0
ICJ938F	$X	$X	$X
ICJ941F	310.8	304.8	309.3
ICJ934F	273.4	275.0	275.0
MEAN	285.3	283.6	281.3
STD.DEV.	18.0	15.8	15.8
N	8	8	8

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: 5000MG/KG

TIME=	PRE TEST	0 DAYS	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS
ICJ874M	245.6	261.2	289.8	295.1	330.7	357.8	381.2	382.4	378.9	400.7	365.2	397.5	411.6
ICJ867M	247.7	253.9	263.2	283.1	304.4	323.8	343.6	357.9	363.2	360.0	355.5	373.8	383.0
ICJ902M	251.6	261.4	293.2	309.2	321.7	346.6	363.4	371.2	390.4	389.5	372.0	390.0	410.1
ICJ869M	253.8	267.4	295.6	313.4	332.2	360.4	387.4	387.5	408.8	422.1	438.6	454.4	454.8
ICJ891M	257.8	268.0	284.4	297.2	286.6	328.4	309.4	336.9	348.4	358.6	365.3	355.8	379.3
ICJ871M	262.8	273.1	298.0	318.7	334.9	349.8	361.1	375.3	382.7	407.9	394.1	425.8	432.2
ICJ907M	264.9	272.7	287.7	305.6	325.8	330.7	316.5	349.5	350.0	380.3	354.6	388.3	403.0
ICJ899M	271.2	282.3	301.0	333.0	342.1	381.8	392.8	401.9	414.2	436.0	436.3	455.3	464.9
ICJ851M	275.6	285.7	298.3	308.9	276.7	323.1	342.9	343.4	373.0	382.7	382.4	389.9	397.9
ICJ868M	281.5	294.6	315.8	334.1	362.8	388.1	391.8	413.9	427.6	434.6	450.3	451.5	458.6
MEAN	261.3	272.0	292.7	309.8	321.8	349.1	359.0	372.0	383.7	397.2	391.4	408.2	419.5
STD.DEV.	12.1	12.5	13.5	16.1	25.9	23.3	30.4	25.3	26.8	28.0	36.8	36.0	31.3
N	10	10	10	10	10	10	10	10	10	10	10	10	10
ICJ932F	212.7	214.3	231.0	244.5	262.0	281.9	288.7	293.1	313.4	322.0	308.6	346.5	325.9
ICJ950F	201.7	209.5	227.3	235.3	272.9	258.5	278.8	294.0	271.4	$X	$X	$X	$X
ICJ922F	208.7	216.8	218.3	244.1	252.9	264.6	283.1	274.9	286.6	285.9	293.0	295.7	289.5
ICJ909F	206.9	213.8	232.7	237.5	241.4	249.1	251.9	250.1	254.6	267.2	268.7	263.0	271.1
ICJ923F	196.8	205.6	213.5	224.0	233.1	241.8	249.0	249.5	260.2	261.2	257.9	264.4	263.3
ICJ939F	194.4	196.6	212.8	218.1	232.6	238.7	261.5	267.8	218.1	240.0	272.7	271.1	270.3
ICJ935F	183.3	188.1	200.3	216.7	233.8	241.6	250.1	243.5	246.3	$X	$X	$X	$X
ICJ910F	204.7	208.8	224.2	239.9	243.1	257.9	261.6	260.5	255.4	$X	$X	$X	$X
ICJ912F	218.6	236.3	245.8	267.4	269.9	268.6	280.5	283.9	282.8	297.4	300.2	316.1	306.7
ICJ914F	187.5	186.7	201.0	213.7	228.1	240.2	253.2	253.7	251.3	262.2	264.7	$X	$X
ICJ944F	209.8	212.2	217.8	231.7	228.2	249.6	259.7	248.4	253.3	258.4	263.8	271.2	265.9
ICJ969F	206.2	207.5	214.2	234.8	208.3	228.4	239.3	253.4	261.6	271.0	240.0	267.0	257.0
ICJ924F	185.2	180.3	207.4	224.2	228.1	247.0	252.3	263.9	251.2	257.2	250.0	263.9	264.1
ICJ958F	205.1	214.1	216.9	233.4	247.4	263.8	269.6	270.9	282.7	287.4	290.7	296.1	287.5
MEAN	201.5	206.5	218.8	233.2	241.6	252.3	262.8	264.8	263.5	273.6	273.7	285.5	280.1
STD.DEV.	10.7	14.5	12.6	14.0	18.0	14.3	15.0	16.7	22.8	22.8	21.8	28.0	22.1
N	14	14	14	14	14	14	14	14	14	11	11	10	10

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: 5000MG/KG (CONT.)

TIME=	84 DAYS	91 DAYS	95 DAYS
ICJ874M	421.5	425.2	420.6
ICJ867M	404.2	374.9	392.3
ICJ902M	425.2	416.7	416.1
ICJ869M	480.1	479.9	481.7
ICJ891M	384.5	380.4	385.6
ICJ871M	442.8	438.7	441.9
ICJ907M	426.0	411.5	421.9
ICJ899M	480.3	474.2	476.8
ICJ851M	405.5	411.6	419.7
ICJ868M	476.1	475.1	467.5
MEAN	434.6	428.8	432.4
STD.DEV.	34.3	37.9	33.7
N	10	10	10
ICJ932F	327.8	330.2	327.9
ICJ950F	$X	$X	$X
ICJ922F	291.1	296.3	286.3
ICJ909F	281.9	283.6	273.3
ICJ923F	265.5	267.7	270.1
ICJ939F	277.9	280.6	282.4
ICJ935F	$X	$X	$X
ICJ910F	$X	$X	$X
ICJ912F	308.0	310.6	308.2
ICJ914F	$X	$X	$X
ICJ944F	277.8	282.1	277.2
ICJ969F	276.0	277.6	276.8
ICJ924F	276.4	274.1	276.6
ICJ958F	298.5	297.3	300.0
MEAN	288.1	290.0	287.9
STD.DEV.	18.7	18.9	18.5
N	10	10	10

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: SATELLITE

TIME=	PRE TEST	0 DAYS	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS
ICJ856M	237.0	238.1	263.9	258.4	264.0	283.0	291.8	276.4	291.1	318.7	295.2	306.1	325.3
ICJ853M	249.1	258.9	290.8	315.3	308.7	341.7	362.6	372.0	360.2	404.5	407.9	422.8	442.0
ICJ852M	249.8	262.2	283.4	309.9	307.2	343.0	363.6	367.0	315.8	$X	$X	$X	$X
ICJ864M	255.3	264.8	297.6	326.6	342.7	367.7	389.3	395.1	401.1	413.1	428.3	411.3	431.5
ICJ857M	259.7	270.7	297.4	296.3	313.4	337.8	364.7	344.6	377.3	363.9	390.0	395.9	401.3
ICJ866M	264.4	275.2	278.2	302.0	317.7	346.7	353.0	369.4	369.6	366.6	359.6	340.6	380.4
ICJ895M	264.4	273.0	295.6	310.6	324.2	354.9	364.5	365.7	396.2	414.3	393.7	383.9	402.7
ICJ862M	269.3	282.1	309.3	315.4	335.8	346.3	383.1	397.3	409.3	405.9	406.5	415.6	434.5
ICJ894M	275.4	281.5	296.5	303.3	314.8	333.0	354.7	360.9	370.2	376.7	392.8	395.2	403.6
ICJ879M	283.2	293.9	316.8	338.8	354.3	370.3	371.8	398.8	412.7	431.4	438.7	449.4	451.1
MEAN	260.8	270.0	293.0	307.7	318.3	342.4	359.9	364.7	370.4	388.3	390.3	391.2	408.0
STD.DEV.	13.6	15.3	15.1	21.3	24.6	24.1	26.5	35.7	39.9	34.9	42.4	43.7	38.7
N	10	10	10	10	10	10	10	10	10	9	9	9	9
ICJ953F	215.1	208.8	234.6	250.1	259.4	270.3	285.6	285.0	286.4	299.5	309.7	307.7	312.6
ICJ931F	198.7	205.4	232.3	242.6	235.3	274.3	270.0	272.4	274.3	$X	$X	$X	$X
ICJ919F	194.5	203.4	221.1	235.6	247.5	261.4	261.4	275.8	278.8	283.9	289.8	288.0	287.4
ICJ928F	191.8	189.9	212.6	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ945F	220.2	228.1	242.2	262.2	278.0	286.8	302.9	311.8	321.6	352.2	331.1	346.8	345.5
ICJ952F	191.6	194.0	187.6	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	202.0	204.9	221.7	247.6	255.1	273.2	280.0	286.3	290.3	311.9	310.2	314.2	315.2
STD.DEV.	12.5	13.4	19.7	11.4	18.2	10.5	18.3	17.8	21.5	35.8	20.7	29.9	29.1
N	6	6	6	4	4	4	4	4	4	3	3	3	3

APPENDIX B - INDIVIDUAL BODY WEIGHTS (GRAMS) (CONT.)
DOSE: SATELLITE (CONT.)

TIME=	84 DAYS	91 DAYS	95 DAYS	104 DAYS	111 DAYS	118 DAYS	124 DAYS
ICJ856M	328.0	323.2	333.5	346.0	366.1	382.4	393.8
ICJ853M	460.7	459.8	450.9	408.6	417.9	458.5	474.7
ICJ852M	$X	$X	$X	$X	$X	$X	$X
ICJ864M	444.0	446.2	448.8	462.7	487.6	509.1	525.6
ICJ857M	408.3	417.0	$X	$X	$X	$X	$X
ICJ866M	377.3	384.0	361.9	380.2	395.4	418.0	428.7
ICJ895M	408.1	407.6	409.2	429.4	461.8	488.7	500.1
ICJ862M	452.7	456.0	451.5	461.7	486.6	519.7	542.6
ICJ894M	419.5	434.8	425.5	431.4	454.8	479.3	494.0
ICJ879M	454.9	463.9	476.0	479.9	506.4	540.7	555.0
MEAN	417.1	421.4	419.7	425.0	447.1	474.6	489.3
STD.DEV.	43.3	45.4	49.2	45.3	49.4	53.2	55.6
N	9	9	8	8	8	8	8
ICJ953F	316.9	318.8	311.7	305.5	308.2	311.5	314.2
ICJ931F	$X	$X	$X	$X	$X	$X	$X
ICJ919F	286.1	286.4	285.8	285.4	295.6	315.0	311.9
ICJ928F	$X	$X	$X	$X	$X	$X	$X
ICJ945F	307.0	338.6	337.3	325.0	350.1	352.9	360.3
ICJ952F	$X	$X	$X	$X	$X	$X	$X
MEAN	303.3	314.6	311.6	305.3	318.0	326.5	328.8
STD.DEV.	15.7	26.4	25.8	19.8	28.5	23.0	27.3
N	3	3	3	3	3	3	3

NOTE: $ - VALUE EXCLUDED FROM CALCULATIONS
X - ANIMAL DEAD

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS)
DOSE: 0MG/KG

TIME=	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS	84 DAYS	91 DAYS
ICJ870M	118.6	107.6	114.2	113.2	107.7	96.0	115.5	99.1	87.5	125.7	112.1	99.8	95.2
ICJ878M	135.3	120.0	114.0	126.6	85.6	96.8	137.9	121.6	112.0	121.8	143.0	104.6	76.7
ICJ882M	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ885M	138.4	114.3	96.8	116.4	108.7	100.8	120.7	117.1	108.8	123.8	117.2	108.1	145.7
ICJ861M	170.0	157.5	141.8	144.3	140.7	130.8	134.7	131.3	135.2	117.9	124.5	126.5	124.1
ICJ886M	131.5	117.0	117.0	124.9	133.3	115.5	131.7	133.6	103.6	125.7	119.4	114.3	114.8
ICJ848M	178.1	157.6	161.5	146.8	146.1	137.3	146.7	148.1	111.2	131.7	132.6	130.9	115.5
ICJ845M	156.7	133.8	118.6	133.3	127.4	114.7	116.6	115.5	89.0	103.5	111.6	106.2	103.6
ICJ898M	139.8	112.9	99.2	116.2	112.7	107.6	111.6	109.5	101.5	106.4	103.5	108.5	95.9
ICJ904M	161.8	156.9	147.5	$S	$S	144.1	141.4	142.3	$X	$X	$X	$X	$X
MEAN	147.8	130.8	123.4	127.7	120.3	116.0	128.5	124.2	106.1	119.6	120.5	112.4	108.9
STD.DEV.	19.7	21.1	22.1	12.8	20.2	17.8	12.7	15.9	15.0	9.9	12.6	10.9	21.0
N	9	9	9	8	8	9	9	9	8	8	8	8	8
ICJ918F	$S	102.7	104.4	108.8	114.6	105.4	113.8	129.3	102.5	124.4	113.8	110.8	113.6
ICJ957F	119.7	$S	$S	108.3	102.5	96.1	90.6	$S	35.2	89.0	103.0	86.4	101.6
ICJ948F	$S	100.9	108.2	$S	$S	99.5	97.8	96.0	73.2	83.3	82.6	76.5	79.7
ICJ962F	$S	$S	$S	137.4	100.1	96.7	106.9	109.3	103.3	111.7	104.0	95.8	98.4
ICJ951F	90.1	89.0	81.2	107.0	73.7	71.5	$S	69.0	67.5	68.7	84.0	68.7	74.1
ICJ968F	117.3	109.4	91.3	116.3	108.2	102.9	95.8	98.0	72.0	98.3	91.8	102.3	108.7
ICJ908F	101.7	91.9	$S	$S	86.4	70.4	68.8	$X	$X	$X	$X	$X	$X
ICJ911F	105.7	109.0	96.2	100.0	98.4	78.7	102.3	100.5	67.8	98.0	$S	79.3	86.3
ICJ916F	130.3	126.0	$S	122.6	123.8	113.1	91.8	98.3	78.6	96.6	96.3	83.1	83.3
ICJ942F	114.5	102.0	104.3	99.7	101.3	87.6	103.5	106.6	79.8	93.8	95.5	86.2	77.4
MEAN	111.3	103.9	97.6	112.5	101.0	92.2	96.8	100.9	75.5	96.0	96.4	87.7	91.5
STD.DEV.	13.2	11.5	10.1	12.6	14.7	14.6	12.8	16.8	20.3	15.9	10.5	13.2	14.4
N	7	8	6	8	9	10	9	8	9	9	8	9	9

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 0MG/KG (CON'T)

TIME= 9
5

	DAYS
ICJ870M	55.3
ICJ878M	49.1
ICJ882M	$X
ICJ885M	69.6
ICJ861M	71.2
ICJ886M	66.5
ICJ848M	70.2
ICJ845M	60.3
ICJ898M	52.6
ICJ904M	$X
MEAN	61.9
STD.DEV.	8.7
N	8
ICJ918F	67.8
ICJ957F	61.5
ICJ948F	45.1
ICJ962F	55.6
ICJ951F	41.6
ICJ968F	52.6
ICJ908F	$X
ICJ911F	50.4
ICJ916F	52.3
ICJ942F	52.1
MEAN	53.2
STD.DEV.	7.9
N	9

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 500MG/KG

TIME=	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS	84 DAYS	91 DAYS
ICJ877M	137.1	132.3	127.4	126.1	$S	105.3	118.2	105.5	86.6	109.7	108.6	101.0	98.7
ICJ884M	122.1	95.0	92.2	107.4	114.4	110.2	121.3	121.2	90.9	120.0	125.1	133.5	106.2
ICJ873M	141.5	118.9	119.2	134.5	126.2	118.7	124.6	122.2	105.3	122.0	105.1	104.6	101.2
ICJ875M	172.5	159.0	154.3	165.1	154.4	153.3	$S	$S	$S	146.9	152.0	155.3	140.6
ICJ892M	170.1	136.0	129.7	147.8	145.8	141.9	137.8	139.9	$S	136.3	151.8	137.3	125.8
ICJ855M	174.6	162.5	146.1	157.0	166.5	155.7	166.5	159.4	$S	$S	$S	147.9	126.5
ICJ887M	139.9	115.2	96.9	108.6	106.2	94.0	106.0	101.1	83.1	105.3	96.7	98.4	103.7
ICJ900M	158.7	147.0	143.1	166.4	153.4	135.8	151.7	145.6	$S	140.2	135.8	129.1	126.3
ICJ859M	176.5	163.2	$S	151.7	149.7	141.1	143.6	149.9	134.6	139.9	138.4	113.0	108.0
ICJ872M	148.8	119.5	125.4	138.7	143.0	127.9	138.2	140.5	127.0	138.4	140.2	126.0	126.6
MEAN	154.2	134.9	126.0	140.3	140.0	128.4	134.2	131.7	104.6	128.7	128.2	124.6	116.4
STD.DEV.	19.0	23.0	21.1	21.3	20.0	20.8	18.6	20.2	21.8	14.9	20.5	19.8	14.4
N	10	10	9	10	9	10	9	9	6	9	9	10	10
ICJ959F	107.4	113.0	97.4	95.7	107.0	87.5	$S	103.4	83.7	141.0	90.6	$S	104.5
ICJ956F	117.6	102.3	$S	103.0	118.6	94.8	108.9	107.2	78.8	107.5	98.7	95.8	94.4
ICJ943F	107.8	112.4	92.0	$S	103.5	100.8	100.8	102.7	88.2	101.1	90.6	88.3	91.3
ICJ960F	118.2	101.0	105.9	98.8	$S	87.1	87.4	$S	76.3	106.4	85.6	80.4	89.2
ICJ917F	116.7	105.7	$S	$S	98.5	84.8	96.5	$S	$S	122.3	83.0	82.9	$S
ICJ927F	96.0	82.5	86.2	$S	90.1	$S	$S	$N	70.6	82.8	77.6	91.9	$S
ICJ925F	113.5	95.6	91.5	101.6	93.7	83.1	93.9	102.1	76.7	98.2	98.0	86.7	91.4
ICJ930F	106.7	102.2	92.4	102.2	102.0	88.8	91.8	97.6	75.8	99.5	89.0	97.4	92.5
ICJ954F	127.2	106.5	106.4	113.9	103.4	104.0	93.9	100.5	89.3	86.3	$S	132.5	$S
ICJ921F	94.1	100.8	$S	$S	88.7	85.5	96.6	$S	$S	92.0	90.2	88.1	96.8
MEAN	110.5	102.2	96.0	102.5	100.6	90.7	96.2	102.3	79.9	103.7	89.3	93.8	94.3
STD.DEV.	10.3	8.7	7.7	6.2	9.3	7.4	6.4	3.2	6.5	17.3	6.7	15.5	5.1
N	10	10	7	6	9	9	8	6	8	10	9	9	7

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 500MG/KG (CON'T)

TIME= 9
5

	DAYS
ICJ877M	55.7
ICJ884M	71.8
ICJ873M	61.1
ICJ875M	85.6
ICJ892M	74.0
ICJ855M	75.3
ICJ887M	62.2
ICJ900M	71.9
ICJ859M	63.2
ICJ872M	80.1
MEAN	70.1
STD.DEV.	9.4
N	10
ICJ959F	63.0
ICJ956F	56.1
ICJ943F	45.9
ICJ960F	49.9
ICJ917F	$S
ICJ927F	52.8
ICJ925F	59.7
ICJ930F	52.1
ICJ954F	48.6
ICJ921F	51.9
MEAN	53.3
STD.DEV.	5.4
N	9

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 2500MG/KG

TIME=	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS	84 DAYS	91 DAYS
ICJ846M	106.9	$S	138.9	134.2	122.5	103.6	129.8	125.4	84.6	136.2	146.3	109.5	136.8
ICJ896M	149.3	134.1	$S	$S	$S	120.4	$S	$S	99.6	147.2	133.6	131.6	128.6
ICJ893M	170.8	129.9	138.1	141.9	143.2	124.4	$S	$S	114.5	$S	145.8	137.4	$S
ICJ881M	137.2	131.9	129.7	141.7	136.3	126.2	133.0	141.9	128.6	147.4	138.4	147.0	136.2
ICJ889M	143.3	124.7	108.3	132.0	140.6	128.7	129.9	128.9	119.5	137.8	130.3	125.5	120.1
ICJ890M	142.3	133.0	125.0	129.1	133.8	106.3	140.3	129.3	102.1	147.5	$S	$S	150.0
ICJ905M	150.5	116.2	122.1	142.4	139.0	135.2	137.1	140.1	106.4	141.2	131.1	$S	142.4
ICJ850M	136.7	$S	130.1	$S	$S	113.8	128.1	125.1	103.5	$S	136.9	129.8	$S
ICJ847M	155.0	150.5	$S	167.5	179.7	152.8	153.4	$S	136.8	$S	167.0	165.6	161.8
ICJ883M	179.0	158.4	$S	$S	166.3	137.8	$S	134.2	134.5	156.9	152.0	151.1	150.9
MEAN	147.1	134.8	127.5	141.3	145.2	124.9	135.9	132.1	113.0	144.9	142.4	137.2	140.9
STD.DEV.	19.8	13.6	10.5	12.7	18.6	14.9	8.8	6.8	16.8	7.1	11.8	17.3	13.3
N	10	8	7	7	8	10	7	7	10	7	9	8	8
ICJ955F	104.5	$S	$S	117.1	105.9	$S	98.4	$S	160.2	$S	98.0	$S	110.2
ICJ961F	117.7	106.4	120.9	121.4	129.6	92.1	115.7	118.3	107.4	124.2	117.1	116.1	121.7
ICJ964F	107.2	103.7	$S	$S	116.9	$S	$S	$S	100.5	$S	$S	$X	$X
ICJ949F	99.2	92.5	88.7	94.9	102.3	92.7	99.8	101.7	84.3	103.3	91.7	103.4	94.9
ICJ940F	103.6	94.3	105.9	110.6	104.0	95.0	106.0	124.7	113.3	123.9	122.0	118.6	109.1
ICJ933F	115.8	$S	$S	$S	$S	$S	$S	114.1	$S	121.8	$S	102.3	108.7
ICJ966F	98.5	100.2	100.7	103.5	$S	101.3	87.8	111.0	87.0	106.3	96.0	95.3	94.5
ICJ938F	94.9	134.0	133.4	$S	$S	111.5	$S	$S	$X	$X	$X	$X	$X
ICJ941F	110.4	103.4	94.5	130.0	101.0	123.0	91.8	105.5	93.5	123.7	100.8	105.3	99.1
ICJ934F	97.6	112.4	105.5	$S	$S	96.1	$S	103.1	106.9	106.5	105.1	100.9	107.9
MEAN	104.9	105.9	107.1	112.9	110.0	101.7	99.9	111.2	106.6	115.7	104.4	106.0	105.8
STD.DEV.	7.8	13.0	15.4	12.6	11.2	11.5	10.0	8.5	23.9	9.7	11.2	8.4	9.2
N	10	8	7	6	6	7	6	7	8	7	7	7	8

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 2500MG/KG (CON'T)

TIME= 95 DAYS

ICJ846M	83.0
ICJ896M	64.3
ICJ893M	86.0
ICJ881M	77.5
ICJ889M	72.8
ICJ890M	89.2
ICJ905M	78.7
ICJ850M	73.8
ICJ847M	97.1
ICJ883M	80.1
MEAN	80.3
STD.DEV.	9.2
N	10
ICJ955F	67.1
ICJ961F	64.9
ICJ964F	$X
ICJ949F	60.9
ICJ940F	65.2
ICJ933F	61.6
ICJ966F	54.4
ICJ938F	$X
ICJ941F	60.4
ICJ934F	65.4
MEAN	62.5
STD.DEV.	4.1
N	8

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 5000MG/KG

TIME=	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS	84 DAYS	91 DAYS
ICJ874M	139.6	116.8	$S	158.0	159.4	130.7	137.8	156.6	$F	$S	179.9	139.1	146.7
ICJ867M	116.9	146.4	$S	$S	156.4	156.0	160.7	129.5	120.9	187.0	172.4	161.1	129.2
ICJ902M	152.8	134.6	$S	165.0	151.8	142.5	162.2	155.6	$S	163.4	$S	$S	146.1
ICJ869M	144.0	147.3	155.6	181.8	173.9	148.9	176.0	177.1	150.7	190.4	167.3	174.9	164.1
ICJ891M	136.6	147.8	114.0	$S	$S	131.6	159.7	$N	139.1	143.5	173.4	141.9	134.5
ICJ871M	145.6	143.3	147.9	150.7	143.6	154.9	173.2	168.1	107.6	$S	167.9	150.5	142.1
ICJ907M	138.0	147.5	$S	$S	$S	131.5	$S	$S	86.6	$S	179.8	166.6	122.5
ICJ899M	137.9	156.7	132.9	$S	146.7	165.4	167.3	166.7	114.3	$S	185.6	159.8	$S
ICJ851M	121.5	131.9	$S	170.0	134.1	116.0	$F	$S	$S	$U	$S	147.0	147.8
ICJ868M	144.2	146.7	165.1	169.0	138.0	$S	162.1	153.6	$S	$S	164.1	157.6	164.5
MEAN	137.7	141.9	143.1	165.8	150.5	141.9	162.4	158.2	119.9	171.1	173.8	155.4	144.2
STD.DEV.	10.9	11.3	20.1	10.7	12.8	15.7	11.6	15.2	22.8	22.0	7.4	11.8	14.3
N	10	10	5	6	8	9	8	7	6	4	8	9	9
ICJ932F	$S	129.1	141.1	144.7	$S	120.5	$S	160.8	78.8	$S	137.6	141.4	138.6
ICJ950F	113.8	105.2	$S	$S	$S	163.3	114.1	$X	$X	$X	$X	$X	$X
ICJ922F	110.9	129.7	124.0	$S	$S	$S	$S	149.0	112.7	216.7	125.6	142.9	137.8
ICJ909F	100.8	$S	$S	$S	$S	102.6	142.2	127.3	91.1	$S	$S	$S	123.6
ICJ923F	105.0	108.7	$S	116.9	$S	264.8	135.3	108.0	99.7	114.0	$S	108.9	96.9
ICJ939F	111.8	106.9	126.8	110.8	$S	132.2	42.5	$S	127.9	153.4	123.7	136.1	$S
ICJ935F	89.1	101.2	119.3	113.4	$S	118.8	117.4	$X	$X	$X	$X	$X	$X
ICJ910F	93.6	118.5	110.3	$S	$S	$S	127.2	$X	$X	$X	$X	$X	$X
ICJ912F	$S	$S	$S	$S	$S	132.2	140.0	$S	111.3	165.1	$S	122.6	137.9
ICJ914F	$S	125.5	$S	$S	$S	$S	$S	$S	249.7	$X	$X	$X	$X
ICJ944F	90.5	118.1	102.1	$S	$S	110.7	$S	99.6	130.4	156.3	130.7	$S	142.3
ICJ969F	84.0	108.9	109.2	96.0	$S	$S	107.4	$S	$S	$S	109.4	109.1	$S
ICJ924F	103.0	97.4	116.2	128.3	$S	130.5	$S	$S	102.6	$S	$S	$S	$S
ICJ958F	106.3	$S	119.9	134.1	$S	130.9	137.7	$S	121.1	147.1	$S	133.7	$S
MEAN	100.8	113.6	118.8	120.6		140.7	118.2	128.9	122.5	158.8	125.4	127.8	129.5
STD.DEV.	10.1	11.2	11.4	16.3	N/A	46.5	31.0	26.1	47.5	33.4	10.4	14.4	17.2
N	11	11	9	7		10	9	5	10	6	5	7	6

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 5000MG/KG (CON'T)

TIME= 9
5

	DAYS
ICJ874M	81.1
ICJ867M	83.0
ICJ902M	92.2
ICJ869M	103.2
ICJ891M	88.9
ICJ871M	88.6
ICJ907M	99.7
ICJ899M	$S
ICJ851M	88.7
ICJ868M	92.0
MEAN	90.8
STD.DEV.	7.1
N	9
ICJ932F	87.7
ICJ950F	$X
ICJ922F	77.2
ICJ909F	69.3
ICJ923F	67.2
ICJ939F	83.8
ICJ935F	$X
ICJ910F	$X
ICJ912F	$S
ICJ914F	$X
ICJ944F	77.3
ICJ969F	76.7
ICJ924F	73.8
ICJ958F	74.7
MEAN	76.4
STD.DEV.	6.4
N	9

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 5000 MG/KG (SATELLITE)

TIME=	7 DAYS	14 DAYS	21 DAYS	28 DAYS	35 DAYS	42 DAYS	49 DAYS	56 DAYS	63 DAYS	70 DAYS	77 DAYS	84 DAYS	91 DAYS
ICJ856M	150.4	106.8	114.6	144.5	137.2	98.9	141.8	169.8	65.7	$S	154.3	119.9	134.0
ICJ853M	153.8	146.7	115.1	$S	154.3	134.5	167.5	180.9	140.7	191.3	190.3	175.5	172.6
ICJ852M	140.5	140.8	102.2	$S	170.4	137.1	115.5	$X	$X	$X	$X	$X	$X
ICJ864M	147.9	156.0	144.4	166.5	159.0	143.1	154.0	156.8	136.6	139.1	165.6	144.6	129.1
ICJ857M	161.6	132.4	$S	178.2	$S	117.0	$S	135.2	$S	170.1	166.1	151.9	178.8
ICJ866M	120.6	140.4	140.9	153.2	137.3	142.8	137.6	122.0	102.2	158.4	153.0	104.1	144.9
ICJ895M	139.5	140.1	$S	160.3	139.0	127.5	$S	164.6	102.6	132.8	165.3	131.5	140.1
ICJ862M	161.4	125.7	174.1	$S	181.0	$S	$S	$S	171.6	209.6	191.4	$S	169.5
ICJ894M	147.6	125.8	149.4	$S	147.1	158.4	150.5	151.7	150.5	168.7	178.3	$S	177.3
ICJ879M	148.3	$S	$S	$S	182.8	$S	$S	207.5	$S	188.2	163.3	151.5	183.6
MEAN	147.2	135.0	134.4	160.5	156.5	132.4	144.5	161.1	124.3	169.8	169.7	139.9	158.9
STD.DEV.	11.9	14.3	25.0	12.8	18.1	18.2	17.6	26.6	35.9	26.3	14.0	23.5	21.5
N	10	9	7	5	9	8	6	8	7	8	9	7	9
ICJ953F	112.2	$S	$N	$S	$S	$S	$S	$S	$S	$S	$S	$S	$S
ICJ931F	109.8	$S	140.6	$S	$S	$S	130.4	$X	$X	$X	$X	$X	$X
ICJ919F	126.8	121.4	$S	$S	$S	152.0	147.3	156.1	$S	151.2	158.7	137.8	137.3
ICJ928F	106.1	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ945F	114.3	141.1	138.5	150.5	$S	$S	$S	184.7	147.4	144.1	172.0	113.9	173.2
ICJ952F	89.2	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	109.7	131.3	139.6	150.5		152.0	138.9	170.4	147.4	147.7	165.4	125.9	155.3
STD.DEV.	12.3	13.9	1.5	N/A	N/A	N/A	12.0	20.2	N/A	5.0	9.4	16.9	25.4
N	6	2	2	1		1	2	2	1	2	2	2	2

APPENDIX C - INDIVIDUAL FOOD CONSUMPTION (GRAMS) (CON'T)
DOSE: 5000MG/KG (SATELLITE) (CON'T)

TIME=	95 DAYS	104 DAYS	111 DAYS	118 DAYS	124 DAYS
ICJ856M	90.5	199.5	185.2	180.6	144.9
ICJ853M	85.3	134.2	188.2	203.9	162.5
ICJ852M	$X	$X	$X	$X	$X
ICJ864M	102.2	213.5	208.0	206.2	174.7
ICJ857M	$X	$X	$X	$X	$X
ICJ866M	49.9	201.3	177.7	182.8	144.2
ICJ895M	89.9	227.2	226.0	219.7	169.0
ICJ862M	103.7	220.9	222.7	229.7	193.6
ICJ894M	80.3	221.8	234.7	225.4	185.2
ICJ879M	100.3	220.5	226.7	226.9	180.8
MEAN	87.8	204.9	208.7	209.4	169.4
STD.DEV.	17.4	30.2	22.1	19.5	18.0
N	8	8	8	8	8
ICJ953F	$S	$N	$S	$S	$S
ICJ931F	$X	$X	$X	$X	$X
ICJ919F	81.1	157.4	170.4	$S	136.1
ICJ928F	$X	$X	$X	$X	$X
ICJ945F	97.9	180.5	197.3	175.3	156.6
ICJ952F	$X	$X	$X	$X	$X
MEAN	89.5	169.0	183.9	175.3	146.4
STD.DEV.	11.9	16.3	19.0	N/A	14.5
N	2	2	2	1	2

NOTE: $ - VALUE EXCLUDED
S - EXCESSIVE SPILLAGE
U - URINE IN FEEDER
F - FECES IN FEEDER
N - NM DESCRIPTION
X - ANIMAL DEAD

APPENDIX D - INDIVIDUAL QUANTITATIVE HEMATOLOGY
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 0MG/KG

PARAMETERS=	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS=	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
ICJ870M	8.94	7.9	46.0	16.0	771	52	17.9	34.8
ICJ878M	8.98	5.6	45.6	16.0	724	51	17.8	35.0
ICJ882M	$X	$X	$X	$X	$X	$X	$X	$X
ICJ885M	9.05	6.5	44.3	15.6	826	49	17.2	35.1
ICJ861M	8.39	9.1	44.7	15.6	729	53	18.6	34.9
ICJ886M	8.46	5.8	42.3	14.3	821	50	16.9	33.8
ICJ848M	$C	$C	$C	$C	$C	$C	$C	$C
ICJ845M	8.56	5.5	46.1	16.0	761	54	18.7	34.6
ICJ898M	8.63	12.8	45.7	15.7	756	53	18.2	34.4
ICJ904M	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	8.72	7.6	45.0	15.6	770	52	17.9	34.7
STD.DEV.	0.27	2.7	1.3	0.6	40	2	0.7	0.4
N	7	7	7	7	7	7	7	7
ICJ918F	7.50	5.6	39.2	13.8	954	52	18.3	35.1
ICJ957F	$C	$C	$C	$C	$C	$C	$C	$C
ICJ948F	7.00	2.4	38.3	13.6	904	55	19.5	35.6
ICJ962F	7.06	2.9	37.9	13.3	742	54	18.9	35.2
ICJ951F	7.90	7.1	41.7	14.9	610	53	18.9	35.7
ICJ968F	7.64	5.8	41.4	14.6	846	54	19.2	35.3
ICJ908F	$X	$X	$X	$X	$X	$X	$X	$X
ICJ911F	7.67	10.1	39.3	14.0	835	51	18.2	35.5
ICJ916F	7.49	3.9	41.0	14.8	673	55	19.7	36.0
ICJ942F	7.17	5.0	38.1	13.7	771	53	19.1	36.0
MEAN	7.43	5.4	39.6	14.1	792	53	19.0	35.6
STD.DEV.	0.32	2.5	1.5	0.6	116	1	0.5	0.3
N	8	8	8	8	8	8	8	8

APPENDIX D - INDIVIDUAL QUANTITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 500MG/KG

PARAMETERS=	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS=	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
ICJ877M	8.60	14.2	44.6	15.4	905	52	17.8	34.4
ICJ884M	8.97	7.8	44.0	15.4	863	49	17.1	34.9
ICJ873M	8.43	9.9	42.8	14.7	901	51	17.5	34.4
ICJ875M	8.59	8.6	45.2	15.3	889	53	17.8	33.8
ICJ892M	7.87	8.5	41.4	14.5	834	53	18.4	34.9
ICJ855M	8.88	9.4	45.1	15.8	844	51	17.7	35.0
ICJ887M	9.23	5.6	44.7	15.4	884	48	16.7	34.5
ICJ900M	8.72	7.7	42.8	14.9	967	49	17.1	34.8
ICJ859M	8.66	10.9	45.3	15.4	801	52	17.8	33.9
ICJ872M	8.68	9.6	44.1	15.4	882	51	17.7	35.0
MEAN	8.66	9.2	44.0	15.2	877	51	17.6	34.6
STD.DEV.	0.36	2.3	1.3	0.4	45	2	0.5	0.4
N	10	10	10	10	10	10	10	10
ICJ959F	7.24	5.0	40.0	14.1	1012	55	19.5	35.2
ICJ956F	8.11	4.9	42.7	14.8	869	53	18.2	34.6
ICJ943F	7.50	5.3	39.6	13.9	916	53	18.6	35.1
ICJ960F	7.53	3.7	41.0	14.3	726	55	19.0	34.9
ICJ917F	7.03	3.7	38.5	13.7	902	55	19.5	35.5
ICJ927F	7.29	4.2	39.2	13.6	814	54	18.7	34.8
ICJ925F	7.12	5.1	39.1	14.1	809	55	19.7	35.9
ICJ930F	7.15	3.0	39.4	13.8	782	55	19.3	35.0
ICJ954F	7.34	5.8	40.0	14.0	804	54	19.1	35.1
ICJ921F	7.23	3.2	40.1	14.5	827	55	20.0	36.1
MEAN	7.35	4.4	40.0	14.1	846	54	19.2	35.2
STD.DEV.	0.31	1.0	1.2	0.4	81	1	0.6	0.5
N	10	10	10	10	10	10	10	10

APPENDIX D - INDIVIDUAL QUANTITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 2500MG/KG

PARAMETERS=	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS=	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
ICJ846M	8.72	8.2	44.3	15.4	873	51	17.7	34.9
ICJ896M	8.61	8.4	43.9	15.1	1038	51	17.6	34.4
ICJ893M	8.28	12.9	39.6	14.0	1036	48	16.9	35.3
ICJ881M	8.30	13.2	41.4	14.7	1071	50	17.7	35.5
ICJ889M	8.65	5.5	43.5	15.0	953	50	17.4	34.6
ICJ890M	8.15	10.2	39.9	13.9	1105	49	17.1	34.8
ICJ905M	8.92	10.2	42.8	14.7	985	48	16.5	34.4
ICJ850M	8.72	9.4	42.3	14.7	926	49	16.9	34.8
ICJ847M	8.99	10.6	41.9	14.8	1074	47	16.4	35.2
ICJ883M	7.98	15.0	39.3	13.7	1023	49	17.2	34.9
MEAN	8.53	10.4	41.9	14.6	1008	49	17.1	34.9
STD.DEV.	0.34	2.8	1.8	0.6	73	1	0.5	0.4
N	10	10	10	10	10	10	10	10
ICJ955F	8.27	4.5	43.3	15.4	999	52	18.6	35.5
ICJ961F	7.48	3.1	41.0	14.4	806	55	19.2	35.1
ICJ964F	$X	$X	$X	$X	$X	$X	$X	$X
ICJ949F	6.53	3.9	34.1	12.2	893	52	18.7	35.9
ICJ940F	7.21	3.8	39.2	13.8	904	54	19.1	35.2
ICJ933F	6.78	4.8	33.8	12.0	988	50	17.7	35.6
ICJ966F	7.44	4.2	39.7	14.1	943	53	18.9	35.4
ICJ938F	$X	$X	$X	$X	$X	$X	$X	$X
ICJ941F	7.36	5.6	36.9	13.0	738	50	17.7	35.2
ICJ934F	6.63	3.9	36.2	13.0	866	55	19.6	35.8
MEAN	7.21	4.2	38.0	13.5	892	53	18.7	35.5
STD.DEV.	0.57	0.8	3.4	1.2	89	2	0.7	0.3
N	8	8	8	8	8	8	8	8

APPENDIX D - INDIVIDUAL QUANTITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 5000MG/KG

PARAMETERS=	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS=	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
ICJ874M	8.96	10.4	46.7	16.2	780	52	18.1	34.7
ICJ867M	8.62	8.1	45.0	15.4	1081	52	17.8	34.1
ICJ902M	8.50	11.4	43.2	15.2	926	51	17.9	35.1
ICJ869M	8.44	12.3	42.0	14.8	925	50	17.5	35.2
ICJ891M	8.98	7.0	43.9	15.2	897	49	17.0	34.7
ICJ871M	8.80	9.5	41.4	14.3	1086	47	16.3	34.7
ICJ907M	9.03	10.3	45.1	15.3	1116	50	17.0	34.0
ICJ899M	8.71	11.1	42.4	14.7	1130	49	16.9	34.7
ICJ851M	8.99	13.7	45.0	15.7	911	50	17.4	34.8
ICJ868M	8.73	14.2	45.3	15.4	989	52	17.7	34.1
MEAN	8.78	10.8	44.0	15.2	984	50	17.4	34.6
STD.DEV.	0.21	2.3	1.7	0.5	115	2	0.6	0.4
N	10	10	10	10	10	10	10	10
ICJ932F	7.87	7.1	40.4	14.6	922	51	18.6	36.2
ICJ922F	7.47	5.6	39.9	14.1	912	53	18.8	35.3
ICJ909F	8.34	5.9	43.3	15.5	945	52	18.6	35.9
ICJ923F	7.62	5.4	40.3	14.2	1053	53	18.7	35.3
ICJ939F	7.84	9.1	42.2	15.0	1039	54	19.2	35.6
ICJ912F	7.25	8.5	40.5	14.1	1111	56	19.5	34.9
ICJ944F	7.24	6.8	38.3	13.8	889	53	19.1	36.0
ICJ969F	7.68	5.6	41.0	14.7	1246	53	19.2	35.9
ICJ924F	8.54	9.0	44.0	15.5	1077	52	18.2	35.3
ICJ958F	7.38	4.8	38.3	13.5	1035	52	18.3	35.2
MEAN	7.72	6.8	40.8	14.5	1023	53	18.8	35.6
STD.DEV.	0.44	1.6	1.9	0.7	110	1	0.4	0.4
N	10	10	10	10	10	10	10	10

APPENDIX D - INDIVIDUAL QUANTITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 96)

PARAMETERS=	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS=	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
ICJ856M	8.69	6.1	46.3	16.3	951	53	18.8	35.3
ICJ853M	8.55	13.4	45.3	14.6	1041	53	17.1	32.3
ICJ852M	$X	$X	$X	$X	$X	$X	$X	$X
ICJ864M	8.62	9.6	42.5	14.8	971	49	17.1	34.8
ICJ857M	$X	$X	$X	$X	$X	$X	$X	$X
ICJ866M	8.91	10.4	43.9	15.2	972	49	17.0	34.6
ICJ895M	9.32	8.9	45.2	15.7	1173	49	16.8	34.7
ICJ862M	8.83	10.4	44.8	15.6	1193	51	17.7	34.9
ICJ894M	9.19	11.9	46.4	15.7	1049	51	17.1	33.9
ICJ879M	8.44	13.2	41.6	14.6	1005	49	17.3	35.2
MEAN	8.82	10.5	44.5	15.3	1044	51	17.4	34.5
STD.DEV.	0.31	2.4	1.7	0.6	92	2	0.6	1.0
N	8	8	8	8	8	8	8	8
ICJ953F	8.05	8.9	43.6	15.1	717	54	18.8	34.7
ICJ931F	$X	$X	$X	$X	$X	$X	$X	$X
ICJ919F	7.78	5.6	40.2	13.9	1083	52	17.9	34.7
ICJ928F	$X	$X	$X	$X	$X	$X	$X	$X
ICJ945F	7.46	8.3	39.1	13.9	1172	52	18.6	35.5
ICJ952F	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	7.76	7.6	41.0	14.3	991	53	18.4	35.0
STD.DEV.	0.30	1.8	2.3	0.7	241	1	0.5	0.5
N	3	3	3	3	3	3	3	3

APPENDIX D - INDIVIDUAL QUANTITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 125)

PARAMETERS=	RBC	WBC	HCT	HGB	PLT	MCV	MCH	MCHC
UNITS=	x10E6	x10E3	%	g/dL	x10E3	fL	pg	g/dL
ICJ856M	8.35	6.1	44.4	16.2	916	53	19.4	36.5
ICJ853M	7.94	7.6	41.4	14.7	1128	52	18.6	35.6
ICJ852M	$X	$X	$X	$X	$X	$X	$X	$X
ICJ864M	8.50	7.5	42.6	15.8	939	50	18.6	37.2
ICJ857M	$X	$X	$X	$X	$X	$X	$X	$X
ICJ866M	8.66	11.1	42.5	15.5	1028	49	17.9	36.5
ICJ895M	8.84	6.2	44.4	15.8	1115	50	17.9	35.6
ICJ862M	8.38	7.6	42.5	15.7	1134	51	18.7	36.9
ICJ894M	8.78	6.5	44.7	15.9	980	51	18.1	35.5
ICJ879M	8.35	9.0	41.7	14.9	1160	50	17.9	35.8
MEAN	8.48	7.7	43.0	15.6	1050	51	18.4	36.2
STD.DEV.	0.29	1.7	1.3	0.5	96	1	0.5	0.7
N	8	8	8	8	8	8	8	8
ICJ953F	8.16	5.3	43.7	15.7	901	54	19.2	35.9
ICJ931F	$X	$X	$X	$X	$X	$X	$X	$X
ICJ919F	8.28	3.1	41.9	15.2	1209	51	18.4	36.3
ICJ928F	$X	$X	$X	$X	$X	$X	$X	$X
ICJ945F	8.04	6.8	42.8	15.3	1046	53	19.0	35.7
ICJ952F	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	8.16	5.1	42.8	15.4	1052	53	18.9	36.0
STD.DEV.	0.12	1.9	0.9	0.3	154	2	0.4	0.3
N	3	3	3	3	3	3	3	3

NOTE: $ - VALUE EXCLUDED FROM CALCULATION
C - CLOTTED SAMPLE
X - ANIMAL DEAD

APPENDIX E - INDIVIDUAL QUALITATIVE HEMATOLOGY
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 0MG/KG

PARAMETERS=	SEG	LYMPH	MONO	EOSIN	BASO	LUC
UNITS=	%	%	%	%	%	%
ICJ870M	20.3	70.4	3.5	0.8	0.4	4.6
ICJ878M	25.6	65.2	3.9	0.8	0.4	4.1
ICJ882M	$X	$X	$X	$X	$X	$X
ICJ885M	18.5	71.5	2.8	1.5	0.2	5.4
ICJ861M	15.3	78.4	1.5	1.5	0.4	2.9
ICJ886M	23.4	66.1	4.6	1.1	0.3	4.5
ICJ848M	$C	$C	$C	$C	$C	$C
ICJ845M	17.1	73.4	2.3	1.4	0.3	5.5
ICJ898M	18.1	72.4	3.6	0.6	0.4	4.9
ICJ904M	$X	$X	$X	$X	$X	$X
MEAN	19.8	71.1	3.2	1.1	0.3	4.6
STD.DEV.	3.6	4.5	1.0	0.4	0.1	0.9
N	7	7	7	7	7	7
ICJ918F	15.9	72.0	3.3	1.5	0.3	7.0
ICJ957F	$C	$C	$C	$C	$C	$C
ICJ948F	16.3	70.6	4.5	1.9	0.3	6.5
ICJ962F	22.8	64.0	5.4	0.9	0.1	6.9
ICJ951F	7.0	82.9	3.3	0.9	0.4	5.4
ICJ968F	16.9	73.9	3.3	0.8	0.2	4.9
ICJ908F	$X	$X	$X	$X	$X	$X
ICJ911F	33.6	54.9	4.9	0.5	0.3	5.9
ICJ916F	17.5	69.0	6.5	0.8	0.1	6.1
ICJ942F	19.0	71.5	3.9	0.8	0.3	4.5
MEAN	18.6	69.9	4.4	1.0	0.3	5.9
STD.DEV.	7.5	8.0	1.2	0.5	0.1	0.9
N	8	8	8	8	8	8

APPENDIX E - INDIVIDUAL QUALITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 500MG/KG

PARAMETERS=	SEG	LYMPH	MONO	EOSIN	BASO	LUC
UNITS=	%	%	%	%	%	%
ICJ877M	16.8	76.0	2.1	0.8	0.6	3.7
ICJ884M	25.8	64.1	3.7	0.8	0.3	5.3
ICJ873M	19.7	69.8	3.6	0.6	0.3	6.0
ICJ875M	20.5	70.7	2.3	0.5	0.3	5.7
ICJ892M	15.4	75.0	3.1	0.9	0.4	5.2
ICJ855M	13.6	75.9	3.3	0.9	0.3	5.9
ICJ887M	19.1	73.5	2.4	0.6	0.4	3.9
ICJ900M	21.4	69.8	2.1	0.9	0.4	5.6
ICJ859M	18.1	72.2	2.6	1.1	0.5	5.5
ICJ872M	16.1	72.1	4.9	0.5	0.3	6.2
MEAN	18.7	71.9	3.0	0.8	0.4	5.3
STD.DEV.	3.5	3.6	0.9	0.2	0.1	0.8
N	10	10	10	10	10	10
ICJ959F	9.0	83.1	2.0	1.4	0.2	4.4
ICJ956F	17.5	74.3	2.5	2.1	0.3	3.3
ICJ943F	16.1	76.1	2.4	1.3	0.3	3.7
ICJ960F	16.3	77.3	2.1	1.8	0.2	2.4
ICJ917F	12.6	77.1	3.5	1.6	0.4	4.9
ICJ927F	14.8	74.5	3.2	3.4	0.2	4.0
ICJ925F	16.6	74.1	2.4	2.6	0.4	4.0
ICJ930F	20.5	72.2	2.8	0.8	0.2	3.4
ICJ954F	8.4	84.7	2.2	0.8	0.3	3.6
ICJ921F	18.4	71.0	2.7	2.9	0.2	4.8
MEAN	15.0	76.4	2.6	1.9	0.3	3.9
STD.DEV.	3.9	4.4	0.5	0.9	0.1	0.7
N	10	10	10	10	10	10

APPENDIX E - INDIVIDUAL QUALITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 2500MG/KG

PARAMETERS=	SEG	LYMPH	MONO	EOSIN	BASO	LUC
UNITS=	%	%	%	%	%	%
ICJ846M	29.0	62.2	2.9	0.5	0.3	5.1
ICJ896M	21.4	66.8	3.9	1.2	0.3	6.4
ICJ893M	17.7	69.8	3.9	1.2	0.5	7.0
ICJ881M	18.3	70.7	3.8	0.7	0.5	6.1
ICJ889M	24.3	68.5	2.7	0.5	0.2	3.8
ICJ890M	25.9	63.6	3.6	0.5	0.3	6.1
ICJ905M	17.7	72.9	2.1	1.0	0.3	6.0
ICJ850M	25.1	64.2	3.1	1.6	0.3	5.7
ICJ847M	18.1	71.4	3.9	0.5	0.3	5.8
ICJ883M	28.6	49.9	4.6	0.9	0.4	15.6
MEAN	22.6	66.0	3.5	0.9	0.3	6.8
STD.DEV.	4.5	6.7	0.7	0.4	0.1	3.2
N	10	10	10	10	10	10
ICJ955F	19.8	69.3	4.7	2.0	0.1	4.1
ICJ961F	14.8	77.8	2.7	1.2	0.1	3.4
ICJ964F	$X	$X	$X	$X	$X	$X
ICJ949F	20.4	68.9	3.7	2.2	0.1	4.7
ICJ940F	14.4	78.0	2.8	0.7	0.1	4.0
ICJ933F	16.5	72.6	3.3	0.6	0.2	6.9
ICJ966F	18.8	71.0	3.8	1.7	0.2	4.6
ICJ938F	$X	$X	$X	$X	$X	$X
ICJ941F	9.8	83.2	2.3	0.6	0.3	3.8
ICJ934F	9.1	80.6	3.2	0.9	0.2	6.1
MEAN	15.5	75.2	3.3	1.2	0.2	4.7
STD.DEV.	4.3	5.4	0.8	0.6	0.1	1.2
N	8	8	8	8	8	8

APPENDIX E - INDIVIDUAL QUALITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: 5000MG/KG

PARAMETERS=	SEG	LYMPH	MONO	EOSIN	BASO	LUC
UNITS=	%	%	%	%	%	%
ICJ874M	32.2	53.0	4.4	2.6	0.3	7.4
ICJ867M	26.0	61.0	4.3	0.6	0.4	7.7
ICJ902M	24.8	69.1	2.1	0.3	0.4	3.4
ICJ869M	36.6	52.8	4.4	0.5	0.4	5.3
ICJ891M	20.7	70.1	2.8	0.6	0.3	5.6
ICJ871M	28.7	60.2	3.0	0.6	0.3	7.1
ICJ907M	18.5	64.3	4.7	1.0	0.5	11.0
ICJ899M	26.1	60.3	3.9	1.3	0.6	7.8
ICJ851M	34.1	58.2	2.3	1.2	0.6	3.6
ICJ868M	37.3	50.2	3.9	1.1	0.4	7.0
MEAN	28.5	59.9	3.6	1.0	0.4	6.6
STD.DEV.	6.5	6.7	0.9	0.7	0.1	2.2
N	10	10	10	10	10	10
ICJ932F	26.5	58.5	4.0	4.8	0.3	5.8
ICJ950F	$X	$X	$X	$X	$X	$X
ICJ922F	19.8	63.2	4.1	5.4	0.3	7.2
ICJ909F	40.1	46.0	6.3	1.7	0.2	5.8
ICJ923F	37.1	55.5	3.8	0.4	0.2	3.1
ICJ939F	34.1	58.8	2.6	1.1	0.3	3.2
ICJ935F	$X	$X	$X	$X	$X	$X
ICJ910F	$X	$X	$X	$X	$X	$X
ICJ912F	44.3	46.9	3.7	1.1	0.2	3.8
ICJ914F	$X	$X	$X	$X	$X	$X
ICJ944F	21.8	61.5	6.6	0.9	0.2	8.9
ICJ969F	30.4	57.3	5.4	0.9	0.2	5.9
ICJ924F	14.9	71.7	5.4	1.0	0.4	6.7
ICJ958F	14.1	75.8	4.4	0.8	0.2	4.8
MEAN	28.3	59.5	4.6	1.8	0.3	5.5
STD.DEV.	10.6	9.4	1.3	1.8	0.1	1.8
N	10	10	10	10	10	10

APPENDIX E - INDIVIDUAL QUALITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 96)

PARAMETERS=	SEG	LYMPH	MONO	EOSIN	BASO	LUC
UNITS=	%	%	%	%	%	%
ICJ856M	31.3	61.8	2.0	0.8	0.3	3.7
ICJ853M	72.3	19.0	3.1	0.1	0.2	5.4
ICJ852M	$X	$X	$X	$X	$X	$X
ICJ864M	39.5	51.4	3.7	0.7	0.2	4.4
ICJ857M	$X	$X	$X	$X	$X	$X
ICJ866M	17.9	73.6	2.1	1.1	0.4	4.9
ICJ895M	23.2	62.1	3.1	3.2	0.4	8.1
ICJ862M	21.1	63.4	4.8	0.7	0.4	9.7
ICJ894M	29.8	59.2	4.5	1.2	0.4	4.9
ICJ879M	30.9	61.9	2.5	0.4	0.5	3.9
MEAN	33.3	56.6	3.2	1.0	0.4	5.6
STD.DEV.	17.2	16.3	1.0	0.9	0.1	2.1
N	8	8	8	8	8	8
ICJ953F	41.2	48.1	4.6	1.1	0.3	4.7
ICJ931F	$X	$X	$X	$X	$X	$X
ICJ919F	30.4	57.4	5.2	1.6	0.2	5.1
ICJ928F	$X	$X	$X	$X	$X	$X
ICJ945F	34.4	54.0	5.1	0.8	0.2	5.5
ICJ952F	$X	$X	$X	$X	$X	$X
MEAN	35.3	53.2	5.0	1.2	0.2	5.1
STD.DEV.	5.5	4.7	0.3	0.4	0.1	0.4
N	3	3	3	3	3	3

APPENDIX E - INDIVIDUAL QUALITATIVE HEMATOLOGY (CONT.)
(SEE KEY C FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 125)

PARAMETERS=	SEG	LYMPH	MONO	EOSIN	BASO	LUC
UNITS=	%	%	%	%	%	%
ICJ856M	18.9	73.3	2.4	1.6	0.2	3.5
ICJ853M	30.1	59.9	3.4	0.5	0.2	5.9
ICJ852M	$X	$X	$X	$X	$X	$X
ICJ864M	17.3	73.9	3.3	1.2	0.2	4.1
ICJ857M	$X	$X	$X	$X	$X	$X
ICJ866M	10.4	83.1	1.8	1.2	0.2	3.3
ICJ895M	$X	$X	$X	$X	0.3	5.9
ICJ862M	10.8	76.5	3.8	1.4	0.3	7.2
ICJ894M	20.3	70.2	4.0	1.0	0.2	4.4
ICJ879M	11.6	78.4	3.2	0.5	0.3	5.0
MEAN	17.1	73.6	3.1	1.1	0.2	4.9
STD.DEV.	7.0	7.3	0.8	0.4	0.1	1.3
N	7	7	7	7	8	8
ICJ953F	9.8	79.9	4.4	0.8	0.2	5.0
ICJ931F	$X	$X	$X	$X	$X	$X
ICJ919F	13.7	75.7	3.9	2.1	0.1	4.4
ICJ928F	$X	$X	$X	$X	$X	$X
ICJ945F	15.6	74.3	4.0	1.0	0.2	5.0
ICJ952F	$X	$X	$X	$X	$X	$X
MEAN	13.0	76.6	4.1	1.3	0.2	4.8
STD.DEV.	3.0	2.9	0.3	0.7	0.1	0.3
N	3	3	3	3	3	3

NOTE: X - ANIMAL DEAD
$ - NOT USED IN CALCULATIONS
C - CLOTTED SAMPLE

APPENDIX F - METHODOLOGY AND REFERENCES FOR HEMATOLOGY

Parameter	Specimen	Method or Reference
Hemoglobin (HGB)	Whole Blood	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Hematocrit (HCT)	Whole Blood	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Erythrocytes (RBC)	Whole Blood	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Total Leukocytes (WBC)	Whole Blood	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Platelets (PLT)	Whole Blood	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Differential WBC and Erythrocyte Morphology	Whole Blood	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Mean Corpuscular Volume (MCV)	Calculated	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Mean Corpuscular Hemoglobin (MCH)	Calculated	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Mean Corpuscular Hemoglobin Concentration (MCHC)	Calculated	Technicon H-1 Hematology Analyzer, Technicon Instruments, Inc.
Prothrombin Time (PT)	Plasma	Fibrometer (BBL Inc.)
Activated Partial Thromboplastin Time (APTT)	Plasma	Fibrometer (BBL Inc.)

Note: This is an overall key, actual parameters evaluated for this study are listed under Experimental Evaluation.

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 0MG/KG

PARAMETERS=	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST	ALT
UNITS=	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L	IU/L
ICJ870M	4.0	0.50	8.0	0.4	2.00	124.0	9.9	7.1	150.5	4.82	111.2	83.0	34.0
ICJ878M	4.2	0.40	11.0	0.6	1.00	116.0	11.0	7.4	148.5	5.13	112.7	119.0	46.0
ICJ882M	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ885M	4.2	0.50	12.0	0.5	2.00	125.0	11.1	6.6	146.6	5.10	109.0	88.0	40.0
ICJ861M	4.1	0.50	9.0	0.6	2.00	128.0	11.3	7.2	148.3	4.85	106.0	74.0	35.0
ICJ886M	4.4	0.50	10.0	0.4	3.00	154.0	10.2	8.3	149.8	5.65	112.2	111.0	37.0
ICJ848M	4.1	0.50	11.0	0.6	1.00	125.0	10.7	7.6	148.0	5.89	109.8	118.0	37.0
ICJ845M	4.2	0.50	8.0	0.6	1.00	124.0	11.1	6.6	144.7	5.68	108.4	88.0	36.0
ICJ898M	4.0	0.50	9.0	0.4	3.00	133.0	11.1	6.9	147.9	4.98	110.6	77.0	35.0
ICJ904M	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	4.2	0.49	9.8	0.5	1.88	128.6	10.8	7.2	148.0	5.26	110.0	94.8	37.5
STD.DEV.	0.1	0.04	1.5	0.1	0.83	11.3	0.5	0.6	1.8	0.42	2.2	18.4	3.9
N	8	8	8	8	8	8	8	8	8	8	8	8	8
ICJ918F	5.0	0.60	11.0	0.6	0.00	110.0	10.9	4.7	144.8	3.97	105.7	60.0	32.0
ICJ957F	4.6	0.60	15.0	0.6	2.00	106.0	11.3	5.6	147.4	5.35	109.6	140.0	36.0
ICJ948F	5.0	0.60	11.0	0.6	1.00	109.0	11.0	5.2	144.5	4.45	110.0	60.0	34.0
ICJ962F	4.8	0.60	10.0	0.4	0.00	110.0	11.3	5.3	147.3	4.76	110.8	153.0	132.0
ICJ951F	4.4	0.40	16.0	0.6	1.00	99.0	11.2	5.4	149.4	5.09	115.0	95.0	32.0
ICJ968F	4.4	0.60	11.0	0.7	0.00	119.0	10.8	6.5	143.5	4.24	106.1	87.0	35.0
ICJ908F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ911F	4.0	0.50	17.0	0.7	2.00	108.0	10.8	5.7	145.5	4.77	109.6	92.0	33.0
ICJ916F	4.5	0.50	13.0	0.7	1.00	97.0	11.5	5.3	149.6	4.65	112.5	211.0	156.0
ICJ942F	4.8	0.50	11.0	0.5	2.00	107.0	11.7	5.5	147.4	4.80	109.4	127.0	56.0
MEAN	4.6	0.54	12.8	0.6	1.00	107.2	11.2	5.5	146.6	4.68	109.9	113.9	60.7
STD.DEV.	0.3	0.07	2.6	0.1	0.87	6.4	0.3	0.5	2.2	0.42	2.9	49.0	48.2
N	9	9	9	9	9	9	9	9	9	9	9	9	9

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 0MG/KG (CONT.)

PARAMETERS=	TP	CHOL	TRIG
UNITS=	g/dL	mg/dL	mg/dL
ICJ870M	7.1	43.0	96
ICJ878M	7.5	36.0	101
ICJ882M	$X	$X	$X
ICJ885M	7.3	42.0	95
ICJ861M	7.2	39.0	119
ICJ886M	7.5	37.0	100
ICJ848M	7.3	38.0	101
ICJ845M	7.1	34.0	87
ICJ898M	6.9	45.0	128
ICJ904M	$X	$X	$X
MEAN	7.2	39.3	103
STD.DEV.	0.2	3.8	13
N	8	8	8
ICJ918F	8.2	54.0	78
ICJ957F	8.0	60.0	104
ICJ948F	8.0	59.0	73
ICJ962F	7.6	48.0	113
ICJ951F	7.5	41.0	79
ICJ968F	7.4	42.0	78
ICJ908F	$X	$X	$X
ICJ911F	7.4	37.0	80
ICJ916F	7.2	42.0	111
ICJ942F	7.7	52.0	119
MEAN	7.7	48.3	93
STD.DEV.	0.3	8.4	18
N	9	9	9

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 500MG/KG

PARAMETERS=	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST	ALT
UNITS=	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L	IU/L
ICJ877M	4.1	0.50	10.0	0.6	2.00	104.0	11.2	7.3	148.4	5.52	108.4	108.0	51.0
ICJ884M	4.2	0.50	13.0	0.6	2.00	97.0	10.8	6.7	147.3	5.02	106.8	77.0	37.0
ICJ873M	4.1	0.50	10.0	0.5	3.00	119.0	11.5	7.5	148.9	4.91	109.8	74.0	41.0
ICJ875M	4.1	0.40	10.0	0.7	1.00	133.0	10.8	6.8	146.8	5.68	106.8	92.0	40.0
ICJ892M	4.1	0.40	10.0	0.6	1.00	123.0	11.3	7.7	147.6	5.01	109.0	77.0	32.0
ICJ855M	4.3	0.50	10.0	0.6	1.00	109.0	11.4	7.6	148.2	5.10	108.4	66.0	35.0
ICJ887M	4.1	0.40	11.0	0.5	1.00	111.0	11.1	7.5	148.4	5.46	111.4	102.0	43.0
ICJ900M	4.2	0.60	9.0	0.5	2.00	109.0	11.2	7.0	147.9	5.58	108.0	90.0	40.0
ICJ859M	4.2	0.50	9.0	0.6	0.00	111.0	11.4	7.2	149.0	5.62	108.0	111.0	59.0
ICJ872M	4.3	0.50	12.0	0.5	3.00	122.0	10.9	7.9	148.2	4.74	107.0	83.0	47.0
MEAN	4.2	0.48	10.4	0.6	1.60	113.8	11.2	7.3	148.1	5.26	108.4	88.0	42.5
STD.DEV.	0.1	0.06	1.3	0.1	0.97	10.5	0.3	0.4	0.7	0.34	1.4	15.2	8.0
N	10	10	10	10	10	10	10	10	10	10	10	10	10
ICJ959F	5.2	0.60	12.0	0.6	0.00	91.0	12.0	5.6	148.9	5.05	109.6	73.0	31.0
ICJ956F	4.7	0.70	12.0	0.7	0.00	100.0	10.8	5.5	150.6	4.99	109.2	85.0	29.0
ICJ943F	4.4	0.60	12.0	0.8	1.00	106.0	10.7	4.3	145.9	4.32	109.8	73.0	25.0
ICJ960F	4.6	0.60	15.0	0.7	1.00	110.0	11.5	5.0	150.2	4.72	110.8	91.0	22.0
ICJ917F	4.9	0.50	10.0	0.6	1.00	103.0	11.0	5.2	145.9	5.18	106.3	77.0	22.0
ICJ927F	5.0	0.70	10.0	0.7	1.00	86.0	11.7	5.5	149.6	4.95	109.2	87.0	30.0
ICJ925F	4.4	0.60	15.0	0.8	0.00	92.0	10.9	4.7	147.4	5.18	110.6	82.0	22.0
ICJ930F	5.1	0.50	12.0	0.7	2.00	115.0	11.2	5.0	140.0	5.16	101.9	200.0	150.0
ICJ954F	4.5	0.50	14.0	0.8	0.00	133.0	10.8	5.4	146.8	4.54	106.5	72.0	27.0
ICJ921F	5.1	0.50	10.0	0.7	0.00	104.0	10.9	4.1	145.0	4.17	105.3	96.0	22.0
MEAN	4.8	0.58	12.2	0.7	0.60	104.0	11.2	5.0	147.0	4.83	107.9	93.6	38.0
STD.DEV.	0.3	0.08	1.9	0.1	0.70	13.6	0.4	0.5	3.1	0.37	2.8	38.3	39.5
N	10	10	10	10	10	10	10	10	10	10	10	10	10

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 500MG/KG (CONT.)

PARAMETERS=	TP	CHOL	TRIG
UNITS=	g/dL	mg/dL	mg/dL
ICJ877M	7.3	48.0	110
ICJ884M	7.4	65.0	121
ICJ873M	7.2	43.0	128
ICJ875M	7.2	33.0	109
ICJ892M	7.2	47.0	120
ICJ855M	7.5	44.0	136
ICJ887M	7.3	57.0	132
ICJ900M	7.2	41.0	148
ICJ859M	7.5	45.0	141
ICJ872M	7.7	45.0	158
MEAN	7.4	46.8	130
STD.DEV.	0.2	8.8	16
N	10	10	10
ICJ959F	8.4	68.0	89
ICJ956F	7.9	73.0	83
ICJ943F	7.6	47.0	74
ICJ960F	7.5	59.0	82
ICJ917F	7.9	50.0	75
ICJ927F	8.4	70.0	77
ICJ925F	7.5	65.0	89
ICJ930F	8.2	78.0	100
ICJ954F	7.6	59.0	70
ICJ921F	8.5	67.0	87
MEAN	8.0	63.6	83
STD.DEV.	0.4	9.8	9
N	10	10	10

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 2500MG/KG

PARAMETERS=	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST	ALT
UNITS=	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L	IU/L
ICJ846M	4.2	0.50	15.0	0.5	4.00	78.0	11.3	6.6	148.1	5.11	105.3	85.0	57.0
ICJ896M	4.1	0.60	14.0	0.6	3.00	100.0	10.8	7.5	146.3	4.99	108.8	96.0	89.0
ICJ893M	4.2	0.50	12.0	0.8	3.00	110.0	11.4	7.3	148.8	5.08	108.8	89.0	84.0
ICJ881M	4.0	0.70	18.0	0.9	3.00	88.0	11.1	7.3	147.5	4.84	106.4	75.0	69.0
ICJ889M	4.3	0.50	10.0	0.5	2.00	96.0	10.1	7.6	152.0	5.78	113.7	118.0	46.0
ICJ890M	3.8	0.60	13.0	0.7	5.00	77.0	10.8	7.9	150.0	4.71	110.8	86.0	95.0
ICJ905M	4.5	0.60	10.0	0.5	2.00	111.0	11.1	7.8	147.0	5.40	106.8	84.0	68.0
ICJ850M	4.1	0.70	15.0	0.5	2.00	90.0	11.2	7.5	148.4	5.23	109.8	126.0	94.0
ICJ847M	4.1	1.00	8.0	0.5	2.00	109.0	10.7	8.9	146.6	5.29	106.4	93.0	93.0
ICJ883M	4.1	0.50	18.0	0.7	3.00	90.0	11.6	7.6	148.0	5.11	106.6	65.0	55.0
MEAN	4.1	0.62	13.3	0.6	2.90	94.9	11.0	7.6	148.3	5.15	108.3	91.7	75.0
STD.DEV.	0.2	0.15	3.4	0.1	0.99	12.5	0.4	0.6	1.7	0.30	2.6	18.3	18.3
N	10	10	10	10	10	10	10	10	10	10	10	10	10
ICJ955F	4.7	0.60	13.0	0.6	2.00	101.0	11.0	5.6	144.9	4.85	106.5	82.0	54.0
ICJ961F	5.1	0.80	12.0	0.5	1.00	96.0	11.0	4.3	142.9	4.86	105.5	91.0	40.0
ICJ964F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ949F	4.8	0.70	15.0	0.6	0.00	74.0	10.7	4.8	144.3	5.01	104.7	102.0	36.0
ICJ940F	4.8	0.60	12.0	0.6	2.00	87.0	10.9	5.4	147.9	4.83	109.0	120.0	34.0
ICJ933F	5.1	0.60	11.0	0.6	1.00	85.0	12.1	5.4	147.0	5.18	109.2	104.0	104.0
ICJ966F	5.2	0.60	9.0	0.7	1.00	80.0	11.3	6.6	147.0	5.60	106.5	108.0	51.0
ICJ938F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ941F	5.0	0.60	11.0	0.7	3.00	93.0	11.0	4.6	145.5	4.46	107.6	90.0	44.0
ICJ934F	5.0	0.60	10.0	0.6	1.00	100.0	10.9	4.6	144.3	4.22	104.5	81.0	49.0
MEAN	5.0	0.64	11.6	0.6	1.38	89.5	11.1	5.2	145.5	4.88	106.7	97.3	51.5
STD.DEV.	0.2	0.07	1.8	0.1	0.92	9.7	0.4	0.7	1.7	0.42	1.8	13.6	22.4
N	8	8	8	8	8	8	8	8	8	8	8	8	8

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 2500MG/KG (CONT.)

PARAMETERS=	T P	C H O L	T R I G
UNITS=	g/dL	mg/dL	mg/dL
ICJ846M	7.3	67.0	82
ICJ896M	6.8	62.0	122
ICJ893M	7.1	81.0	93
ICJ881M	6.8	46.0	119
ICJ889M	7.3	68.0	85
ICJ890M	6.6	55.0	96
ICJ905M	7.7	68.0	97
ICJ850M	6.9	50.0	109
ICJ847M	7.2	58.0	357
ICJ883M	7.7	95.0	144
MEAN	7.1	65.0	130
STD.DEV.	0.4	14.6	82
N	10	10	10
ICJ955F	7.9	102.0	182
ICJ961F	8.1	78.0	105
ICJ964F	$X	$X	$X
ICJ949F	7.8	92.0	166
ICJ940F	7.8	76.0	145
ICJ933F	8.2	127.0	89
ICJ966F	8.2	93.0	93
ICJ938F	$X	$X	$X
ICJ941F	8.3	79.0	86
ICJ934F	8.1	113.0	93
MEAN	8.1	95.0	120
STD.DEV.	0.2	18.2	39
N	8	8	8

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 5000MG/KG

PARAMETERS=	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST	ALT
UNITS=	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L	IU/L
ICJ874M	3.8	0.90	16.0	0.4	3.00	88.0	10.4	9.0	150.6	6.06	112.7	124.0	126.0
ICJ867M	4.1	0.60	20.0	0.7	6.00	88.0	10.9	7.4	148.2	4.99	107.2	113.0	77.0
ICJ902M	4.0	0.50	14.0	0.5	4.00	81.0	11.2	8.0	150.9	4.98	108.8	105.0	81.0
ICJ869M	4.2	0.60	13.0	0.6	2.00	108.0	11.1	8.0	148.4	5.29	106.4	89.0	93.0
ICJ891M	4.2	0.60	14.0	0.5	5.00	88.0	11.1	7.4	149.1	5.01	108.2	108.0	74.0
ICJ871M	4.0	0.50	16.0	0.5	5.00	88.0	10.3	6.5	146.8	5.89	106.6	117.0	61.0
ICJ907M	4.0	0.60	14.0	0.8	8.00	76.0	11.2	7.8	150.0	4.89	109.0	102.0	75.0
ICJ899M	4.3	0.50	14.0	0.8	3.00	104.0	11.2	7.0	147.3	5.00	102.9	98.0	142.0
ICJ851M	4.0	0.60	13.0	0.6	7.00	115.0	11.0	7.6	148.9	5.42	109.8	103.0	73.0
ICJ868M	4.2	0.70	11.0	0.7	6.00	102.0	11.6	8.2	147.5	5.38	106.8	101.0	105.0
MEAN	4.1	0.61	14.5	0.6	4.90	93.8	11.0	7.7	148.8	5.29	107.8	106.0	90.7
STD.DEV.	0.1	0.12	2.4	0.1	1.91	12.6	0.4	0.7	1.4	0.41	2.6	10.0	26.0
N	10	10	10	10	10	10	10	10	10	10	10	10	10
ICJ932F	4.7	0.50	13.0	0.7	0.00	84.0	11.4	5.8	147.6	5.17	106.8	101.0	56.0
ICJ950F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ922F	5.4	0.50	16.0	0.6	1.00	82.0	11.9	5.5	146.4	4.76	107.6	124.0	60.0
ICJ909F	4.3	1.00	10.0	0.6	1.00	79.0	11.1	7.4	147.4	5.02	110.0	143.0	79.0
ICJ923F	4.8	0.70	13.0	0.7	2.00	77.0	10.8	4.9	141.1	5.19	104.3	104.0	69.0
ICJ939F	4.7	0.70	11.0	0.6	0.00	83.0	10.7	6.3	145.9	5.18	107.2	124.0	36.0
ICJ935F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ910F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ912F	4.8	0.60	14.0	0.6	3.00	86.0	10.6	5.3	146.7	4.67	106.6	116.0	75.0
ICJ914F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ944F	5.4	0.80	13.0	0.6	1.00	97.0	11.3	6.5	143.1	4.83	104.3	105.0	76.0
ICJ969F	4.5	0.80	12.0	0.8	3.00	76.0	10.6	6.9	145.9	5.10	105.3	117.0	87.0
ICJ924F	4.3	0.60	15.0	0.6	5.00	75.0	10.7	5.1	144.4	5.24	108.2	99.0	65.0
ICJ958F	5.5	0.60	15.0	0.7	3.00	75.0	11.5	5.7	144.4	4.65	104.3	126.0	90.0
MEAN	4.8	0.68	13.2	0.7	1.90	81.4	11.1	5.9	145.3	4.98	106.5	115.9	69.3
STD.DEV.	0.4	0.15	1.9	0.1	1.60	6.8	0.5	0.8	2.0	0.23	1.9	13.9	16.0
N	10	10	10	10	10	10	10	10	10	10	10	10	10

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: 5000MG/KG (CONT.)

PARAMETERS=	TP	CHOL	TRIG
UNITS=	g/dL	mg/dL	mg/dL
ICJ874M	6.6	55.0	88
ICJ867M	7.3	85.0	121
ICJ902M	6.8	65.0	82
ICJ869M	7.3	64.0	92
ICJ891M	7.3	95.0	101
ICJ871M	6.7	56.0	88
ICJ907M	7.3	81.0	108
ICJ899M	7.5	59.0	113
ICJ851M	6.9	49.0	79
ICJ868M	7.5	59.0	133
MEAN	7.1	66.8	101
STD.DEV.	0.3	15.0	18
N	10	10	10
ICJ932F	7.6	67.0	70
ICJ950F	$X	$X	$X
ICJ922F	8.9	86.0	93
ICJ909F	7.1	77.0	495
ICJ923F	7.4	78.0	100
ICJ939F	8.3	70.0	90
ICJ935F	$X	$X	$X
ICJ910F	$X	$X	$X
ICJ912F	8.2	88.0	80
ICJ914F	$X	$X	$X
ICJ944F	9.1	122.0	370
ICJ969F	7.7	72.0	114
ICJ924F	7.6	71.0	98
ICJ958F	9.0	88.0	105
MEAN	8.1	81.9	162
STD.DEV.	0.7	16.1	146
N	10	10	10

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 96)

PARAMETERS=	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST	ALT
UNITS=	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L	IU/L
ICJ856M	4.1	0.40	13.0	0.5	3.00	85.0	10.7	6.9	147.8	4.75	106.4	112.0	51.0
ICJ853M	3.7	0.60	14.0	0.5	4.00	125.0	11.0	8.1	151.4	5.17	105.1	92.0	102.0
ICJ852M	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ864M	4.0	0.60	15.0	0.7	4.00	80.0	10.8	6.3	146.4	4.88	106.4	87.0	50.0
ICJ857M	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ866M	3.9	0.60	18.0	0.7	8.00	104.0	10.7	7.0	147.8	5.35	109.2	122.0	74.0
ICJ895M	4.4	0.70	19.0	0.6	4.00	78.0	10.9	8.2	147.0	5.61	108.4	100.0	97.0
ICJ862M	3.9	0.70	19.0	0.8	5.00	75.0	11.2	7.4	147.6	5.12	107.0	105.0	81.0
ICJ894M	4.3	0.60	13.0	0.7	3.00	89.0	11.3	7.8	150.0	4.55	106.2	110.0	77.0
ICJ879M	3.9	0.60	20.0	0.7	4.00	75.0	11.6	7.8	149.8	4.90	108.2	86.0	103.0
MEAN	4.0	0.60	16.4	0.7	4.38	88.9	11.0	7.4	148.5	5.04	107.1	101.8	79.4
STD.DEV.	0.2	0.09	2.9	0.1	1.60	17.4	0.3	0.7	1.7	0.34	1.4	12.9	21.0
N	8	8	8	8	8	8	8	8	8	8	8	8	8
ICJ953F	4.3	0.60	13.0	0.5	3.00	93.0	10.4	4.9	142.2	5.28	103.2	93.0	69.0
ICJ931F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ919F	4.3	0.60	15.0	0.6	2.00	95.0	10.3	6.0	148.0	5.03	110.2	136.0	58.0
ICJ928F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ945F	4.6	0.60	15.0	0.6	1.00	90.0	10.8	7.4	143.4	4.84	102.8	99.0	56.0
ICJ952F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	4.4	0.60	14.3	0.6	2.00	92.7	10.5	6.1	144.5	5.05	105.4	109.3	61.0
STD.DEV.	0.2	0.00	1.2	0.1	1.00	2.5	0.3	1.3	3.1	0.22	4.2	23.3	7.0
N	3	3	3	3	3	3	3	3	3	3	3	3	3

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 96) (CONT.)

PARAMETERS=	TP	CHOL	TRIG
UNITS=	g/dL	mg/dL	mg/dL
ICJ856M	7.0	46.0	104
ICJ853M	6.6	84.0	89
ICJ852M	$X	$X	$X
ICJ864M	7.0	61.0	86
ICJ857M	$X	$X	$X
ICJ866M	6.8	66.0	74
ICJ895M	7.5	82.0	126
ICJ862M	6.8	50.0	91
ICJ894M	7.2	66.0	86
ICJ879M	6.8	54.0	79
MEAN	7.0	63.6	92
STD.DEV.	0.3	13.9	16
N	8	8	8
ICJ953F	7.1	91.0	109
ICJ931F	$X	$X	$X
ICJ919F	7.4	75.0	96
ICJ928F	$X	$X	$X
ICJ945F	8.1	58.0	99
ICJ952F	$X	$X	$X
MEAN	7.5	74.7	101
STD.DEV.	0.5	16.5	7
N	3	3	3

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 125)

PARAMETERS=	ALB	TBIL	BUN	CREA	GGT	GLU	Ca	PHOS	Na+	K+	Cl-	AST	ALT
UNITS=	g/dL	mg/dL	mg/dL	mg/dL	IU/L	mg/dL	mg/dL	mg/dL	mmol/L	mmol/L	mmol/L	IU/L	IU/L
ICJ856M	4.0	0.40	20.0	0.4	2.00	107.0	9.8	7.4	149.7	5.21	112.7	122.0	34.0
ICJ853M	3.7	0.50	20.0	0.7	1.00	95.0	9.6	7.6	147.5	5.23	108.6	120.0	31.0
ICJ852M	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ864M	3.8	0.50	20.0	0.5	0.00	109.0	10.3	6.7	147.3	5.11	109.2	108.0	25.0
ICJ857M	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ866M	3.7	0.40	16.0	0.4	2.00	116.0	10.0	6.8	148.9	5.17	112.3	141.0	34.0
ICJ895M	4.1	0.40	14.0	0.5	1.00	119.0	10.4	7.0	148.3	5.35	112.9	116.0	45.0
ICJ862M	3.8	0.50	19.0	0.7	1.00	136.0	10.3	6.8	150.2	5.23	113.1	109.0	30.0
ICJ894M	3.8	0.60	22.0	0.4	0.00	133.0	10.0	7.2	149.0	5.35	111.5	151.0	27.0
ICJ879M	4.0	0.50	19.0	0.5	0.00	125.0	10.2	6.9	148.9	5.11	110.8	88.0	28.0
MEAN	3.9	0.48	18.8	0.5	0.88	117.5	10.1	7.1	148.7	5.22	111.4	119.4	31.8
STD.DEV.	0.2	0.07	2.5	0.1	0.83	13.8	0.3	0.3	1.0	0.09	1.7	19.7	6.2
N	8	8	8	8	8	8	8	8	8	8	8	8	8
ICJ953F	4.3	0.50	18.0	0.7	1.00	112.0	10.6	4.7	150.1	4.45	111.9	74.0	24.0
ICJ931F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ919F	4.4	0.60	17.0	0.6	3.00	103.0	10.2	5.7	147.5	5.17	112.9	116.0	23.0
ICJ928F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
ICJ945F	4.2	0.40	18.0	0.6	3.00	139.0	10.8	6.8	150.0	4.84	112.5	76.0	33.0
ICJ952F	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X	$X
MEAN	4.3	0.50	17.7	0.6	2.33	118.0	10.5	5.7	149.2	4.82	112.4	88.7	26.7
STD.DEV.	0.1	0.10	0.6	0.1	1.15	18.7	0.3	1.1	1.5	0.36	0.5	23.7	5.5
N	3	3	3	3	3	3	3	3	3	3	3	3	3

APPENDIX G - INDIVIDUAL SERUM CHEMISTRY (CONT.)
(SEE KEY D FOR ABBREVIATIONS AND UNITS)
DOSE: SATELLITE (DAY 125) (CONT.)

PARAMETERS=	TP	CHOL	TRIG
UNITS=	g/dL	mg/dL	mg/dL
ICJ856M	6.8	33.0	87
ICJ853M	6.8	40.0	81
ICJ852M	$X	$X	$X
ICJ864M	7.0	34.0	102
ICJ857M	$X	$X	$X
ICJ866M	6.7	27.0	94
ICJ895M	7.3	41.0	116
ICJ862M	6.9	37.0	96
ICJ894M	6.7	35.0	100
ICJ879M	7.2	37.0	86
MEAN	6.9	35.5	95
STD.DEV.	0.2	4.4	11
N	8	8	8
ICJ953F	7.8	82.0	77
ICJ931F	$X	$X	$X
ICJ919F	7.9	69.0	76
ICJ928F	$X	$X	$X
ICJ945F	7.9	48.0	61
ICJ952F	$X	$X	$X
MEAN	7.9	66.3	71
STD.DEV.	0.1	17.2	9
N	3	3	3

NOTE: $ - VALUE EXCLUDED
X - ANIMAL DEAD

APPENDIX H - METHODOLOGY AND REFERENCES FOR SERUM CHEMISTRY
Beckman Synchron CX5

Parameter	Specimen	Method or Reference
Aspartate Aminotransferase (AST)	Serum	Enzymatic Transamination with Concurrent Oxidation of NADH
Alanine Aminotransferase (ALT)	Serum	Enzymatic Transamination with Concurrent Oxidation of NADH
Alkaline Phosphatase (ALP)	Serum	Enzymatic Hydrolysis of P-nitrophenylphosphate
Gamma-Glutamyl Transferase	Serum	Enzymatic transfer of Gamma-Glutymal Group (Szasz)
Lactate Dehydrogenase	Serum	Oxidation of L-Lactate with Concurrent Reduction of NAD
Blood Urea Nitrogen (BUN)	Serum	Enzymatic Hydrolysis with Urease
Glucose (GLU)	Serum	Enzymatic Transfer with Hexokinase and concomitant reduction of NAD
Cholesterol (CHOL)	Serum	Enzymatic Hydrolysis and Reaction with 4-aminoantipyrine and Phenol
Triglycerides (TRIG)	Serum	Enzymatic Hydrolysis and Reaction with (INT)
Total Protein (TP)	Serum	Binding of Cupric Ions (Biuret)
Albumin (ALB)	Serum	Dye Binding, Bromcresol Green (BCG)
Globulin (GLOB)	Serum	Calculation (Total Protein - Albumin)
Creatinine (CREA)	Serum	Combination with Alkaline Picrate (Jaffe)
Total Bilirubin (TBIL)	Serum	Diazotization with Caffeine and Sodium Benzoate (Jendrassik-Grof)
Sodium (Na)	Serum	Ion-Selective Electrodes
Potassium (K)	Serum	Ion-Selective Electrodes
Chloride (Cl)	Serum	Ion-Selective Electrodes
Carbon Dioxide (CO2)	Serum	Ion-Selective Electrodes
Calcium (Ca)	Serum	Dye Binding with Arsenazo III
Inorganic Phosphorous (PHOS)	Serum	Reaction with Molybdate to form Phosphomolybdate Complex

Note: This is an overall key, actual parameters evaluated for this study are listed under Experimental evaluation.

APPENDIX I - INDIVIDUAL ORGAN WEIGHTS
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 0MG/KG

PARAMETERS=	TBW	LIVER	KIDNEY	ADRNL	TESTES	OVAR
UNITS=	(g)	(g)	(g)	(g)	(g)	(g)
ICJ870M	404.9	10.15	2.63	0.040	3.1961	
ICJ878M	472.5	12.66	2.98	0.042	3.8044	
ICJ882M	$X	$X	$X	$X	$X	
ICJ885M	482.7	12.98	3.27	0.041	4.1922	
ICJ861M	645.6	17.64	3.60	0.059	3.8109	
ICJ886M	521.5	15.01	3.20	0.046	3.6606	
ICJ848M	664.6	19.48	4.14	$N	4.0162	
ICJ845M	513.1	14.13	3.64	0.054	4.1813	
ICJ898M	538.7	15.45	3.11	0.057	3.9531	
ICJ904M	$X	$X	$X	$X	$X	
MEAN	530.5	14.69	3.32	0.048	3.8519	
STD.DEV.	87.1	2.93	0.46	0.008	0.3234	N/A
N	8	8	8	7	8	
ICJ918F	310.7	9.93	2.75	0.084		0.070
ICJ957F	295.4	8.26	2.07	0.065		0.104
ICJ948F	266.2	7.74	1.92	0.058		0.052
ICJ962F	323.1	8.63	2.22	0.094		0.024*$
ICJ951F	260.4	6.33	1.77	0.057		0.091
ICJ968F	336.8	9.15	2.28	0.032		0.080
ICJ908F	$X	$X	$X	$X		$X
ICJ911F	293.0	8.39	2.04	0.075		0.106
ICJ916F	337.5	8.75	2.29	0.083		0.085
ICJ942F	320.3	9.97	2.26	0.058		0.057
MEAN	304.8	8.57	2.18	0.067		0.081
STD.DEV.	28.3	1.12	0.28	0.019	N/A	0.020
N	9	9	9	9		8

APPENDIX I - INDIVIDUAL ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 500MG/KG

PARAMETERS=	TBW	LIVER	KIDNEY	ADRNL	TESTES	OVAR
UNITS=	(g)	(g)	(g)	(g)	(g)	(g)
ICJ877M	467.0	15.43	3.51	0.043	3.5899	
ICJ884M	468.2	15.40	3.96	0.038	3.2202	
ICJ873M	535.4	17.92	3.88	0.045	3.2581	
ICJ875M	608.1	21.11	5.10	0.061	3.9749	
ICJ892M	594.2	20.04	5.08	0.053	3.8490	
ICJ855M	656.0	20.46	4.44	0.059	4.2485	
ICJ887M	450.7	14.68	4.70	0.031	3.7384	
ICJ900M	632.4	20.50	4.36	0.055	4.1583	
ICJ859M	637.4	20.87	5.19	0.052	3.9033	
ICJ872M	553.0	18.63	4.06	0.047	3.2593	
MEAN	560.2	18.50	4.43	0.048	3.7200	
STD.DEV.	77.2	2.51	0.58	0.009	0.3770	N/A
N	10	10	10	10	10	
ICJ959F	316.6	12.28	2.66	0.073		0.071
ICJ956F	261.4	9.22	2.18	0.067		0.052
ICJ943F	288.2	10.13	2.32	0.067		0.108
ICJ960F	293.7	10.44	2.23	0.074		0.095
ICJ917F	287.6	10.14	2.49	0.061		0.071
ICJ927F	277.4	11.33	2.44	0.067		0.063
ICJ925F	266.6	10.17	2.40	0.084		0.162
ICJ930F	306.9	10.13	2.62	0.075		0.065
ICJ954F	293.8	10.05	2.16	0.095		0.071
ICJ921F	265.1	9.41	2.45	0.075		0.060
MEAN	285.7	10.33	2.40	0.074		0.082
STD.DEV.	18.2	0.89	0.17	0.010	N/A	0.033
N	10	10	10	10		10

APPENDIX I - INDIVIDUAL ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 2500MG/KG

PARAMETERS=	TBW	LIVER	KIDNEY	ADRNL	TESTES	OVAR
UNITS=	(g)	(g)	(g)	(g)	(g)	(g)
ICJ846M	394.1	16.98	4.00	0.050	3.3373	
ICJ896M	422.4	19.00	3.68	0.061	3.6840	
ICJ893M	461.2	22.83	4.74	0.063	3.7996	
ICJ881M	447.2	21.92	4.98	0.058	3.1040	
ICJ889M	393.3	16.16	3.95	0.050	3.4117	
ICJ890M	441.1	18.41	4.14	0.068	1.5419	
ICJ905M	434.6	17.60	3.97	0.060	4.1481	
ICJ850M	409.7	18.42	4.02	0.055	3.6531	
ICJ847M	514.1	25.47	5.22	0.067	3.6286	
ICJ883M	475.5	21.72	5.14	0.078	3.9237	
MEAN	439.3	19.85	4.38	0.061	3.4232	
STD.DEV.	37.7	2.98	0.57	0.009	0.7249	N/A
N	10	10	10	10	10	
ICJ955F	261.4	13.87	2.21	0.087		0.063
ICJ961F	278.8	13.96	2.38	0.100		0.110
ICJ964F	$X	$X	$X	$X		$X
ICJ949F	252.0	13.50	2.00	0.098		0.042
ICJ940F	262.7	13.19	2.43	0.113		0.080
ICJ933F	264.5	15.37	2.40	0.084		0.074
ICJ966F	241.4	14.56	2.33	0.088		0.056
ICJ938F	$X	$X	$X	$X		$X
ICJ941F	281.4	17.89	2.35	0.095		0.075
ICJ934F	258.1	15.33	2.61	0.084		0.035
MEAN	262.5	14.71	2.34	0.094		0.067
STD.DEV.	13.1	1.51	0.18	0.010	N/A	0.024
N	8	8	8	8		8

APPENDIX I - INDIVIDUAL ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 5000MG/KG

PARAMETERS=	TBW	LIVER	KIDNEY	ADRNL	TESTES	OVAR
UNITS=	(g)	(g)	(g)	(g)	(g)	(g)
ICJ874M	402.3	17.77	3.97	0.084	3.3536	
ICJ867M	363.7	13.78	4.43	0.051	2.8571	
ICJ902M	386.8	17.78	4.77	0.072	3.5914	
ICJ869M	458.0	23.03	4.53	0.104	4.1429	
ICJ891M	356.8	16.14	4.33	0.063	3.1865	
ICJ871M	415.5	17.08	3.67	0.097	3.4999	
ICJ907M	391.8	18.04	4.14	0.083	3.3400	
ICJ899M	448.3	22.57	3.96	0.073	3.7995	
ICJ851M	386.2	15.33	3.52	0.074	3.3971	
ICJ868M	448.1	18.60	3.79	0.082	3.9676	
MEAN	405.8	18.01	4.11	0.078	3.5136	
STD.DEV.	35.8	2.90	0.40	0.015	0.3797	N/A
N	10	10	10	10	10	
ICJ932F	307.4	13.75	2.77	0.089		0.107
ICJ950F	$X	$X	$X	$X		$X
ICJ922F	267.5	12.19	2.23	0.097		0.051
ICJ909F	251.5	13.09	2.50	0.113		0.043
ICJ923F	244.3	12.24	2.09	0.084		0.032
ICJ939F	260.8	11.94	2.33	0.104		0.099
ICJ935F	$X	$X	$X	$X		$X
ICJ910F	$X	$X	$X	$X		$X
ICJ912F	282.8	13.79	2.78	0.119		0.073
ICJ914F	$X	$X	$X	$X		$X
ICJ944F	256.7	15.50	2.70	0.097		0.041
ICJ969F	256.4	15.21	2.18	0.099		0.107
ICJ924F	250.2	11.55	2.08	0.122		0.119
ICJ958F	272.1	18.71	2.53	0.099		0.051
MEAN	265.0	13.80	2.42	0.102		0.072
STD.DEV.	18.7	2.19	0.27	0.012	N/A	0.033
N	10	10	10	10		10

APPENDIX I - INDIVIDUAL ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 5000 (SATELLITE)MG/KG

PARAMETERS=	TBW	LIVER	KIDNEY	ADRNL	TESTES	OVAR
UNITS=	(g)	(g)	(g)	(g)	(g)	(g)
ICJ856M	363.0	8.99	2.75	0.037	3.8873	
ICJ853M	437.9	11.96	3.63	0.070	3.4537	
ICJ852M	$X	$X	$X	$X	$X	
ICJ864M	490.6	12.96	3.67	0.055	4.2872	
ICJ857M	$X	$X	$X	$X	$X	
ICJ866M	392.4	11.21	3.46	0.052	3.6211	
ICJ895M	459.4	12.22	3.29	0.054	3.7084	
ICJ862M	504.2	13.29	3.63	0.061	3.8008	
ICJ894M	460.7	13.25	3.71	0.040	3.6707	
ICJ879M	504.4	13.57	3.66	0.073	3.7075	
MEAN	451.6	12.18	3.48	0.055	3.7671	
STD.DEV.	51.8	1.52	0.32	0.013	0.2455	N/A
N	8	8	8	8	8	
ICJ953F	293.6	8.47	2.28	0.077		0.052
ICJ931F	$X	$X	$X	$X		$X
ICJ919F	283.3	8.42	2.28	0.081		0.101
ICJ928F	$X	$X	$X	$X		$X
ICJ945F	328.3	9.67	2.68	0.068		0.077
ICJ952F	$X	$X	$X	$X		$X
MEAN	301.7	8.85	2.41	0.075		0.077
STD.DEV.	23.6	0.71	0.23	0.007	N/A	0.025
N	3	3	3	3		3

NOTE: $ - VALUE EXCLUDED FROM CALCULATIONS
N - NOT MEASURED
X - ANIMAL DEAD
* - ONE OVARY NOT PRESENT

APPENDIX J - INDIVIDUAL RELATIVE ORGAN WEIGHTS
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 0MG/KG

PARAMETERS=	LIVER/BW	KIDNY/BW	ADRNL/BW	TESTS/BW	OVAR/BW
UNITS=					
ICJ870M	0.025	0.0065	.00010	0.0079	
ICJ878M	0.027	0.0063	.00009	0.0081	
ICJ885M	0.027	0.0068	.00008	0.0087	
ICJ861M	0.027	0.0056	.00009	0.0059	
ICJ886M	0.029	0.0061	.00009	0.0070	
ICJ848M	0.029	0.0062	$N	0.0060	
ICJ845M	0.028	0.0071	.00011	0.0081	
ICJ898M	0.029	0.0058	.00011	0.0073	
MEAN	0.028	0.0063	.00010	0.0074	
STD.DEV.	0.001	0.0005	.00001	0.0010	N/A
N	8	8	7	8	
ICJ918F	0.032	0.0089	.00027		.00023
ICJ957F	0.028	0.0070	.00022		.00035
ICJ948F	0.029	0.0072	.00022		.00020
ICJ962F	0.027	0.0069	.00029		*$
ICJ951F	0.024	0.0068	.00022		.00035
ICJ968F	0.027	0.0068	.00010		.00024
ICJ911F	0.029	0.0070	.00026		.00036
ICJ916F	0.026	0.0068	.00025		.00025
ICJ942F	0.031	0.0071	.00018		.00018
MEAN	0.028	0.0072	.00022		.00027
STD.DEV.	0.002	0.0007	.00006	N/A	.00007
N	9	9	9		8

APPENDIX J - INDIVIDUAL RELATIVE ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 500MG/KG

PARAMETERS=	LIVER/BW	KIDNY/BW	ADRNL/BW	TESTS/BW	OVAR/BW
UNITS=					
ICJ877M	0.033	0.0075	.00009	0.0077	
ICJ884M	0.033	0.0085	.00008	0.0069	
ICJ873M	0.033	0.0072	.00008	0.0061	
ICJ875M	0.035	0.0084	.00010	0.0065	
ICJ892M	0.034	0.0085	.00009	0.0065	
ICJ855M	0.031	0.0068	.00009	0.0065	
ICJ887M	0.033	0.0104	.00007	0.0083	
ICJ900M	0.032	0.0069	.00009	0.0066	
ICJ859M	0.033	0.0081	.00008	0.0061	
ICJ872M	0.034	0.0073	.00009	0.0059	
MEAN	0.033	0.0080	.00009	0.0067	
STD.DEV.	0.001	0.0011	.00001	0.0008	N/A
N	10	10	10	10	
ICJ959F	0.039	0.0084	.00023		.00022
ICJ956F	0.035	0.0083	.00026		.00020
ICJ943F	0.035	0.0081	.00023		.00037
ICJ960F	0.036	0.0076	.00025		.00032
ICJ917F	0.035	0.0087	.00021		.00025
ICJ927F	0.041	0.0088	.00024		.00023
ICJ925F	0.038	0.0090	.00032		.00061
ICJ930F	0.033	0.0085	.00024		.00021
ICJ954F	0.034	0.0074	.00032		.00024
ICJ921F	0.035	0.0092	.00028		.00023
MEAN	0.036	0.0084	.00026		.00029
STD.DEV.	0.002	0.0006	.00004	N/A	.00012
N	10	10	10		10

APPENDIX J - INDIVIDUAL RELATIVE ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 2500MG/KG

PARAMETERS=	LIVER/BW	KIDNY/BW	ADRNL/BW	TESTS/BW	OVAR/BW
UNITS=					
ICJ846M	0.043	0.0101	.00013	0.0085	
ICJ896M	0.045	0.0087	.00014	0.0087	
ICJ893M	0.050	0.0103	.00014	0.0082	
ICJ881M	0.049	0.0111	.00013	0.0069	
ICJ889M	0.041	0.0100	.00013	0.0087	
ICJ890M	0.042	0.0094	.00015	0.0035	
ICJ905M	0.040	0.0091	.00014	0.0095	
ICJ850M	0.045	0.0098	.00013	0.0089	
ICJ847M	0.050	0.0102	.00013	0.0071	
ICJ883M	0.046	0.0108	.00016	0.0083	
MEAN	0.045	0.0100	.00014	0.0078	
STD.DEV.	0.004	0.0007	.00001	0.0017	N/A
N	10	10	10	10	
ICJ955F	0.053	0.0085	.00033		.00024
ICJ961F	0.050	0.0085	.00036		.00039
ICJ949F	0.054	0.0079	.00039		.00017
ICJ940F	0.050	0.0093	.00043		.00030
ICJ933F	0.058	0.0091	.00032		.00028
ICJ966F	0.060	0.0097	.00036		.00023
ICJ941F	0.064	0.0084	.00034		.00027
ICJ934F	0.059	0.0101	.00033		.00014
MEAN	0.056	0.0089	.00036		.00025
STD.DEV.	0.005	0.0007	.00004	N/A	.00008
N	8	8	8		8

APPENDIX J - INDIVIDUAL RELATIVE ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 5000MG/KG

PARAMETERS=	LIVER/BW	KIDNY/BW	ADRNL/BW	TESTS/BW	OVAR/BW
UNITS=					
ICJ874M	0.044	0.0099	.00021	0.0083	
ICJ867M	0.038	0.0122	.00014	0.0079	
ICJ902M	0.046	0.0123	.00019	0.0093	
ICJ869M	0.050	0.0099	.00023	0.0090	
ICJ891M	0.045	0.0121	.00018	0.0089	
ICJ871M	0.041	0.0088	.00023	0.0084	
ICJ907M	0.046	0.0106	.00021	0.0085	
ICJ899M	0.050	0.0088	.00016	0.0085	
ICJ851M	0.040	0.0091	.00019	0.0088	
ICJ868M	0.042	0.0085	.00018	0.0089	
MEAN	0.044	0.0102	.00019	0.0087	
STD.DEV.	0.004	0.0015	.00003	0.0004	N/A
N	10	10	10	10	
ICJ932F	0.045	0.0090	.00029		.00035
ICJ922F	0.046	0.0083	.00036		.00019
ICJ909F	0.052	0.0099	.00045		.00017
ICJ923F	0.050	0.0086	.00034		.00013
ICJ939F	0.046	0.0089	.00040		.00038
ICJ912F	0.049	0.0098	.00042		.00026
ICJ944F	0.060	0.0105	.00038		.00016
ICJ969F	0.059	0.0085	.00039		.00042
ICJ924F	0.046	0.0083	.00049		.00048
ICJ958F	0.069	0.0093	.00036		.00019
MEAN	0.052	0.0091	.00039		.00027
STD.DEV.	0.008	0.0008	.00006	N/A	.00012
N	10	10	10		10

APPENDIX J - INDIVIDUAL RELATIVE ORGAN WEIGHTS (CON'T)
(SEE KEY E FOR ABBREVIATIONS)
DOSE: 5000 (SATELLITE)MG/KG

PARAMETERS=	LIVER/BW	KIDNY/BW	ADRNL/BW	TESTS/BW	OVAR/BW
UNITS=					
ICJ856M	0.025	0.0076	.00010	0.0107	
ICJ853M	0.027	0.0083	.00016	0.0079	
ICJ864M	0.026	0.0075	.00011	0.0087	
ICJ866M	0.029	0.0088	.00013	0.0092	
ICJ895M	0.027	0.0072	.00012	0.0081	
ICJ862M	0.026	0.0072	.00012	0.0075	
ICJ894M	0.029	0.0081	.00009	0.0080	
ICJ879M	0.027	0.0073	.00014	0.0074	
MEAN	0.027	0.0078	.00012	0.0084	
STD.DEV.	0.001	0.0006	.00002	0.0011	N/A
N	8	8	8	8	
ICJ953F	0.029	0.0078	.00026		.00018
ICJ919F	0.030	0.0080	.00029		.00036
ICJ945F	0.029	0.0082	.00021		.00023
MEAN	0.029	0.0080	.00025		.00026
STD.DEV.	0.001	0.0002	.00004	N/A	.00009
N	3	3	3		3

NOTE: $ - VALUE EXCLUDED FROM CALCULATIONS
N - NOT MEASURED
* - ONE OVARY NOT PRESENT

APPENDIX K - TOTAL VOLUME OF INDIVIDUAL DOSES (ML)
DOSE: 0MG/KG

TIME=	WEEK 1 (a)	WEEK 1 (b)	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14 (c)	WEEK 14 (d)
ICJ870M	1.2	2.5	2.5	2.7	2.9	3.0	3.2	3.4	3.6	3.6	3.6	3.8	4.0	4.2	4.2	4.2
ICJ878M	1.3	2.6	2.8	3.2	3.4	3.6	3.4	3.8	4.0	4.4	4.6	4.8	4.8	5.0	4.8	5.0
ICJ882M	1.3	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
ICJ885M	1.3	2.7	2.9	3.2	3.2	3.6	3.6	3.8	4.0	4.2	4.4	4.6	4.8	4.8	5.0	5.0
ICJ861M	1.4	2.7	3.2	3.6	4.0	4.4	4.8	5.0	5.4	5.6	5.8	6.0	6.2	6.4	6.6	6.6
ICJ886M	1.3	2.7	2.9	3.2	3.4	3.6	4.0	4.2	4.4	4.6	4.8	4.8	5.0	5.2	5.4	5.4
ICJ848M	1.4	2.8	3.4	3.8	4.2	4.6	4.8	5.2	5.6	5.8	6.0	6.2	6.4	6.6	6.8	6.8
ICJ845M	1.4	2.9	3.2	3.6	3.8	4.0	4.2	4.4	4.6	4.8	4.8	4.8	5.0	5.2	5.2	5.4
ICJ898M	1.5	2.9	3.2	3.4	3.6	4.0	4.2	4.4	4.6	4.8	5.0	5.2	5.2	5.4	5.6	5.6
ICJ904M	1.5	2.9	3.4	3.8	4.2	4.6	4.8	5.2	5.6	5.8	X	X	X	X	X	X
ICJ918F	1.1	2.2	2.3	2.5	2.6	2.7	2.8	2.9	3.0	3.0	3.2	3.2	3.2	3.2	3.4	3.4
ICJ957F	1.1	2.1	2.3	2.3	2.5	2.6	2.8	2.8	2.7	2.6	2.7	2.8	2.9	2.9	3.2	3.2
ICJ948F	1.1	2.1	2.2	2.3	2.4	2.5	2.7	2.7	2.9	2.9	2.9	2.8	2.8	2.8	2.8	2.7
ICJ962F	1.1	2.2	2.2	2.4	2.5	2.7	2.7	2.8	2.9	3.0	3.2	3.2	3.2	3.4	3.4	3.4
ICJ951F	1.0	2.0	2.1	2.2	2.3	2.6	2.5	2.6	2.6	2.6	2.6	2.6	2.7	2.6	2.8	2.7
ICJ968F	1.0	2.0	2.2	2.4	2.4	2.7	2.8	2.9	3.0	3.2	3.2	3.2	3.2	3.4	3.4	3.6
ICJ908F	0.97	1.9	2.0	2.1	2.2	2.2	2.3	2.3	2.3	X	X	X	X	X	X	X
ICJ911F	1.1	2.1	2.1	2.4	2.5	2.6	2.7	2.6	2.8	2.8	2.7	3.0	3.2	3.2	3.2	3.2
ICJ916F	1.1	2.3	2.4	2.6	2.7	2.8	3.2	3.2	3.2	3.4	3.2	3.4	3.4	3.4	3.6	3.4
ICJ942F	0.97	1.9	2.1	2.2	2.4	2.5	2.7	2.7	3.0	3.0	3.0	3.2	3.2	3.2	3.4	3.4

X = ANIMAL DEAD
(a) - DAYS 0-4 (INCORRECT CONCENTRATION)
(b) - DAYS 5-6 (CORRECT CONCENTRATION)
(c) - BASED ON DAY 91 BODY WEIGHT
(d) - BASED ON DAY 95 BODY WEIGHT

APPENDIX K - TOTAL VOLUME OF INDIVIDUAL DOSES (ML) (CON'T)
DOSE: 500MG/KG

TIME=	WEEK 1 (a)	WEEK 1 (b)	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14 (c)	WEEK 14 (d)
ICJ877M	1.3	2.5	2.8	3.2	3.6	3.8	4.0	4.2	4.4	4.4	4.4	4.6	4.6	4.8	4.8	4.8
ICJ884M	1.3	2.5	2.6	2.8	2.9	3.2	3.4	3.6	4.0	4.2	4.2	4.4	4.6	4.8	4.8	5.0
ICJ873M	1.3	2.6	2.8	3.2	3.6	3.8	4.2	4.4	4.6	4.8	5.0	5.2	5.2	5.4	5.6	5.6
ICJ875M	1.4	2.7	3.2	3.6	4.0	4.2	4.6	4.8	5.2	5.4	5.6	5.6	5.8	6.0	6.2	6.4
ICJ892M	1.3	2.7	3.2	3.4	3.6	4.0	4.4	4.6	4.8	5.2	5.4	5.6	5.6	6.0	6.0	6.2
ICJ855M	1.4	2.8	3.4	3.8	4.0	4.4	4.8	5.2	5.6	5.8	6.0	6.2	6.2	6.6	6.6	6.8
ICJ887M	1.4	2.8	2.9	3.2	3.2	3.4	3.6	3.8	4.0	4.0	4.2	4.4	4.4	4.6	4.6	4.6
ICJ900M	1.4	2.8	3.4	3.8	4.2	4.6	4.8	5.2	5.4	5.6	5.6	6.0	6.0	6.4	6.6	6.6
ICJ859M	1.4	2.9	3.4	3.8	4.2	4.6	5.0	5.2	5.6	5.8	6.0	6.2	6.4	6.6	6.6	6.6
ICJ872M	1.5	2.9	3.2	3.4	3.6	4.0	4.2	4.4	4.6	4.8	5.0	5.2	5.4	5.6	5.6	5.8
ICJ959F	1.1	2.2	2.3	2.6	2.6	2.7	2.9	2.9	3.0	3.0	3.2	3.2	3.2	3.2	3.2	3.4
ICJ956F	1.0	2.0	2.2	2.2	2.3	2.4	2.4	2.5	2.6	2.7	2.6	2.7	2.7	2.7	2.7	2.7
ICJ943F	1.1	2.1	2.2	2.5	2.6	2.6	2.7	2.8	2.9	2.9	3.0	3.0	3.0	3.0	3.2	3.0
ICJ960F	1.1	2.1	2.3	2.4	2.6	2.7	2.7	2.8	2.8	2.9	2.9	3.0	3.0	3.0	3.0	3.0
ICJ917F	1.0	2.1	2.2	2.4	2.5	2.6	2.7	2.8	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0
ICJ927F	1.0	2.0	2.1	2.2	2.3	2.4	2.5	2.6	2.6	2.8	2.7	2.7	2.7	2.8	2.9	2.9
ICJ925F	0.95	1.9	2.1	2.2	2.3	2.4	2.5	2.5	2.6	2.7	2.7	2.7	2.8	2.7	2.8	2.8
ICJ930F	1.1	2.1	2.2	2.4	2.5	2.6	2.7	2.9	2.9	3.0	3.0	3.2	3.2	3.2	3.4	3.2
ICJ954F	1.2	2.3	2.5	2.5	2.7	2.8	2.9	3.0	3.0	3.2	3.2	3.0	3.0	3.2	3.2	3.2
ICJ921F	0.98	2.0	1.9	2.2	2.2	2.3	2.3	2.4	2.6	2.6	2.6	2.7	2.7	2.7	2.8	2.8

X = ANIMAL DEAD
(a) - DAYS 0-4 (INCORRECT CONCENTRATION)
(b) - DAYS 5-6 (CORRECT CONCENTRATION)
(c) - BASED ON DAY 91 BODY WEIGHT
(d) - BASED ON DAY 95 BODY WEIGHT

APPENDIX K - TOTAL VOLUME OF INDIVIDUAL DOSES (ML) (CON'T)
DOSE: 2500MG/KG

TIME=	WEEK 1 (a)	WEEK 1 (b)	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14 (c)	WEEK 14 (d)
ICJ846M	1.3	2.5	2.6	2.9	3.2	3.4	3.4	3.6	3.8	3.8	3.8	4.0	4.0	4.0	4.2	4.2
ICJ896M	1.3	2.6	2.8	3.2	3.2	3.6	3.8	3.8	4.0	4.2	4.2	4.2	4.4	4.4	4.4	4.4
ICJ893M	1.3	2.7	3.2	3.2	3.6	3.8	4.0	4.0	4.4	4.4	4.4	4.6	4.6	4.8	4.8	4.8
ICJ881M	1.3	2.7	2.9	3.2	3.4	3.6	3.8	4.0	4.0	4.2	4.2	4.4	4.4	4.6	4.8	4.6
ICJ889M	1.3	2.7	2.9	3.2	3.2	3.4	3.6	3.8	3.8	4.0	4.0	4.0	4.0	4.2	4.2	4.2
ICJ890M	1.4	2.7	3.0	3.2	3.4	3.6	3.8	3.8	4.0	4.2	4.0	4.2	4.2	4.4	4.6	4.6
ICJ905M	1.4	2.8	3.0	3.2	3.2	3.6	3.8	4.0	4.0	4.2	4.2	4.4	4.4	4.4	4.6	4.6
ICJ850M	1.4	2.8	3.0	3.2	3.4	3.6	3.8	3.8	3.8	4.0	4.0	4.2	4.2	4.4	4.4	4.4
ICJ847M	1.5	2.9	3.4	3.6	3.8	4.2	4.4	4.6	4.8	4.8	4.8	5.0	5.0	5.2	5.4	5.4
ICJ883M	1.5	2.9	3.4	3.4	3.6	4.0	4.2	4.4	4.6	4.6	4.8	4.8	4.8	5.0	5.2	5.0
ICJ955F	1.1	2.2	2.3	2.3	2.5	2.6	2.7	2.6	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8
ICJ961F	1.0	2.0	2.2	2.3	2.5	2.7	2.7	2.8	2.8	2.9	3.0	3.0	3.0	3.2	3.0	3.0
ICJ964F	1.2	2.3	2.4	2.4	2.6	2.7	2.8	2.9	2.8	2.9	3.0	2.9	2.9	X	X	X
ICJ949F	1.1	2.1	2.2	2.3	2.4	2.5	2.5	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
ICJ940F	1.0	2.1	2.1	2.2	2.4	2.4	2.5	2.5	2.5	2.7	2.7	2.8	2.9	2.9	2.8	2.8
ICJ933F	1.0	2.1	2.2	2.2	2.4	2.5	2.7	2.7	2.7	2.8	3.0	2.9	2.9	2.9	2.9	2.8
ICJ966F	0.95	1.9	2.0	2.1	2.3	2.4	2.4	2.5	2.4	2.5	2.6	2.6	2.6	2.6	2.6	2.6
ICJ938F	1.1	2.1	2.1	2.5	2.7	2.8	2.9	3.0	3.0	3.2	X	X	X	X	X	X
ICJ941F	1.1	2.2	2.5	2.5	2.7	2.8	2.8	3.2	2.9	2.9	3.0	3.2	3.0	3.2	3.0	3.2
ICJ934F	1.0	2.0	2.1	2.2	2.4	2.5	2.6	2.6	2.5	2.6	2.7	2.7	2.7	2.7	2.7	2.8

X = ANIMAL DEAD
(a) - DAYS 0-4 (INCORRECT CONCENTRATION)
(b) - DAYS 5-6 (CORRECT CONCENTRATION)
(c) - BASED ON DAY 91 BODY WEIGHT
(d) - BASED ON DAY 95 BODY WEIGHT

APPENDIX K - TOTAL VOLUME OF INDIVIDUAL DOSES (ML) (CON'T)
DOSE: 5000MG/KG

TIME=	WEEK 1 (a)	WEEK 1 (b)	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14 (c)	WEEK 14 (d)
ICJ874M	1.3	2.6	2.9	3.0	3.4	3.6	3.8	3.8	3.8	4.0	3.8	4.0	4.2	4.2	4.4	4.2
ICJ867M	1.3	2.5	2.6	2.8	3.0	3.2	3.4	3.6	3.6	3.6	3.6	3.8	3.8	4.0	3.8	4.0
ICJ902M	1.3	2.6	2.9	3.2	3.2	3.6	3.6	3.8	4.0	4.0	3.8	4.0	4.2	4.4	4.2	4.2
ICJ869M	1.3	2.7	3.0	3.2	3.4	3.6	4.0	4.0	4.2	4.2	4.4	4.6	4.6	4.8	4.8	4.8
ICJ891M	1.3	2.7	2.8	3.0	2.9	3.4	3.2	3.4	3.6	3.6	3.8	3.6	3.8	3.8	3.8	4.0
ICJ871M	1.4	2.7	3.0	3.2	3.4	3.6	3.6	3.8	3.8	4.2	4.0	4.4	4.4	4.4	4.4	4.4
ICJ907M	1.4	2.7	2.9	3.2	3.4	3.4	3.2	3.6	3.6	3.8	3.6	4.0	4.0	4.4	4.2	4.2
ICJ899M	1.4	2.8	3.0	3.4	3.4	3.8	4.0	4.0	4.2	4.4	4.4	4.6	4.6	4.8	4.8	4.8
ICJ851M	1.4	2.9	3.0	3.2	2.8	3.2	3.4	3.4	3.8	3.8	3.8	4.0	4.0	4.2	4.2	4.2
ICJ868M	1.5	2.9	3.2	3.4	3.6	4.0	4.0	4.2	4.4	4.4	4.6	4.6	4.6	4.8	4.8	4.8
ICJ932F	1.1	2.1	2.3	2.4	2.6	2.8	2.9	2.9	3.2	3.2	3.2	3.6	3.4	3.4	3.4	3.4
ICJ950F	1.1	2.1	2.3	2.4	2.7	2.6	2.8	2.9	2.7	X	X	X	X	X	X	X
ICJ922F	1.1	2.2	2.2	2.4	2.5	2.6	2.8	2.7	2.9	2.9	2.9	3.0	2.9	2.9	3.0	2.9
ICJ909F	1.1	2.1	2.3	2.4	2.4	2.5	2.5	2.5	2.5	2.7	2.7	2.6	2.7	2.8	2.8	2.7
ICJ923F	1.0	2.1	2.1	2.2	2.3	2.4	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7
ICJ939F	0.98	2.0	2.1	2.2	2.3	2.4	2.6	2.7	2.2	2.4	2.7	2.7	2.7	2.8	2.8	2.8
ICJ935F	0.94	1.9	2.0	2.2	2.3	2.4	2.5	2.4	2.5	X	X	X	X	X	X	X
ICJ910F	1.0	2.1	2.2	2.4	2.4	2.6	2.6	2.6	2.6	X	X	X	X	X	X	X
ICJ912F	1.2	2.4	2.5	2.7	2.7	2.7	2.8	2.8	2.8	3.0	3.0	3.2	3.2	3.2	3.2	3.2
ICJ914F	0.93	1.9	2.0	2.1	2.3	2.4	2.5	2.5	2.5	2.6	2.6	X	X	X	X	X
ICJ944F	1.1	2.1	2.2	2.3	2.3	2.5	2.6	2.5	2.5	2.6	2.6	2.7	2.7	2.8	2.8	2.8
ICJ969F	1.0	2.1	2.1	2.3	2.1	2.3	2.4	2.5	2.6	2.7	2.4	2.7	2.6	2.8	2.8	2.8
ICJ924F	0.90	1.8	2.1	2.2	2.3	2.5	2.5	2.6	2.5	2.6	2.5	2.6	2.6	2.8	2.7	2.8
ICJ958F	1.1	2.1	2.2	2.3	2.5	2.6	2.7	2.7	2.8	2.9	2.9	3.0	2.9	3.0	3.0	3.0

X = ANIMAL DEAD
(a) - DAYS 0-4 (INCORRECT CONCENTRATION)
(b) - DAYS 5-6 (CORRECT CONCENTRATION)
(c) - BASED ON DAY 91 BODY WEIGHT
(d) - BASED ON DAY 95 BODY WEIGHT

APPENDIX K - TOTAL VOLUME OF INDIVIDUAL DOSES (ML) (CON'T)
DOSE: 5000 MG/KG (SATELLITE)

TIME=	WEEK 1 (a)	WEEK 1 (b)	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14 (c)	WEEK 14 (d)
ICJ856M	1.2	2.4	2.6	2.6	2.6	2.8	2.9	2.8	2.9	3.2	3.0	3.2	3.4	3.4	3.2	3.4
ICJ853M	1.3	2.6	2.9	3.2	3.2	3.4	3.6	3.8	3.6	4.0	4.2	4.2	4.4	4.6	4.6	4.6
ICJ852M	1.3	2.6	2.8	3.2	3.2	3.4	3.6	3.8	3.2	X	X	X	X	X	X	X
ICJ864M	1.3	2.6	3.0	3.4	3.4	3.8	4.0	4.0	4.0	4.2	4.4	4.2	4.4	4.4	4.6	4.6
ICJ857M	1.4	2.7	3.0	3.0	3.2	3.4	3.6	3.4	3.8	3.6	4.0	4.0	4.0	4.2	4.2	X
ICJ866M	1.4	2.8	2.8	3.0	3.2	3.6	3.6	3.8	3.8	3.8	3.6	3.4	3.8	3.8	3.8	3.6
ICJ895M	1.4	2.7	3.0	3.2	3.2	3.6	3.6	3.8	4.0	4.2	4.0	3.8	4.0	4.2	4.2	4.2
ICJ862M	1.4	2.8	3.2	3.2	3.4	3.6	3.8	4.0	4.2	4.2	4.2	4.2	4.4	4.6	4.6	4.6
ICJ894M	1.4	2.8	3.0	3.0	3.2	3.4	3.6	3.6	3.8	3.8	4.0	4.0	4.0	4.2	4.4	4.4
ICJ879M	1.5	2.9	3.2	3.4	3.6	3.8	3.8	4.0	4.2	4.4	4.4	4.6	4.6	4.6	4.6	4.8
ICJ953F	1.0	2.1	2.3	2.5	2.6	2.7	2.9	2.9	2.9	3.0	3.2	3.2	3.2	3.2	3.2	3.2
ICJ931F	1.0	2.1	2.3	2.4	2.4	2.7	2.7	2.7	2.7	X	X	X	X	X	X	X
ICJ919F	1.1	2.0	2.2	2.4	2.5	2.6	2.6	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9
ICJ928F	0.95	1.9	2.1	X	X	X	X	X	X	X	X	X	X	X	X	X
ICJ945F	1.1	2.3	2.4	2.6	2.8	2.9	3.0	3.2	3.2	3.6	3.4	3.6	3.6	3.2	3.4	3.4
ICJ952F	0.97	1.9	1.9	X	X	X	X	X	X	X	X	X	X	X	X	X

X = ANIMAL DEAD
(a) - DAYS 0-4 (INCORRECT CONCENTRATION)
(b) - DAYS 5-6 (CORRECT CONCENTRATION)
(c) - BASED ON DAY 91 BODY WEIGHT
(d) - BASED ON DAY 95 BODY WEIGHT

APPENDIX L - DOSING TIMES IN RELATION TO PHOTOPERIOD
(Dosing Time 11:00 plus-or-minus 2.0 Hours; Deviations denoted by *)

TEST DAY	DOSING START TIME	APPROXIMATE HOURS AFTER LIGHTS ON
WEEK 1		
Day 0	14:18*	7.5
Day 1	09:38	2.5
Day 2	10:05	3.0
Day 3	13:17*	6.5
Day 4	10:19	3.5
Day 5	10:10	3.0
Day 6	10:07	3.0
WEEK 2		
Day 7	10:07	3.0
Day 8	09:25	2.5
Day 9	13:35*	6.5
Day 10	12:34	5.5
Day 11	10:03	3.0
Day 12	09:56	3.0
Day 13	12:53	6.0
WEEK 3		
Day 14	10:51	4.0
Day 15	09:57	3.0
Day 16	12:10	5.0
Day 17	12:14	5.0
Day 18	11:16	4.5
Day 19	11:02	4.0
Day 20	11:05	4.0
WEEK 4		
Day 21	12:58	6.0
Day 22	09:07	2.0
Day 23	10:00	3.0
Day 24	12:02	5.0
Day 25	10:10	3.0
Day 26	10:20	3.5
Day 27	10:30	3.5
WEEK 5		
Day 28	10:38	3.5
Day 29	09:10	2.0
Day 30	09:07	2.0
Day 31	09:19	2.5
Day 32	09:42	2.5
Day 33	10:42	3.5
Day 34	09:53	3.0
WEEK 6		
Day 35	09:38	2.5
Day 36	08:18*	1.5
Day 37	08:47*	2.0
Day 38	10:46	4.0
Day 39	11:10	4.0
Day 40	10:58	4.0
Day 41	10:55	4.0
WEEK 7		
Day 42	11:12	4.0
Day 43	09:11	2.0
Day 44	12:27	5.5
Day 45	10:50	4.0
Day 46	09:45	3.0
Day 47	09:04	2.0
Day 48	15:36*	8.5

TEST DAY	DOSING START TIME	APPROXIMATE HOURS AFTER LIGHTS ON
WEEK 8		
Day 49	10:13	3.0
Day 50	09:37	2.5
Day 51	11:48	5.0
Day 52	11:36	4.5
Day 53	10:43	3.5
Day 54	12:43	5.5
Day 55	12:52	6.0
WEEK 9		
Day 56	10:45	4.0
Day 57	09:18	2.5
Day 58	10:47	4.0
Day 59	09:00	2.0
Day 60	12:23	5.5
Day 61	10:53	4.0
Day 62	08:42*	1.5
WEEK 10		
Day 63	10:55	4.0
Day 64	09:27	2.5
Day 65	12:08	5.0
Day 66	12:47	6.0
Day 67	10:52	4.0
Day 68	09:33	2.5
Day 69	12:30	5.5
WEEK 11		
Day 70	10:50	4.0
Day 71	09:22	2.5
Day 72	12:42	6.0
Day 73	13:19*	6.5
Day 74	10:31	3.5
Day 75	10:13	3.0
Day 76	11:56	5.0
WEEK 12		
Day 77	14:35*	7.5
Day 78	08:52*	2.0
Day 79	09:55	3.0
Day 80	09:11	2.0
Day 81	08:55*	2.0
Day 82	10:55	4.0
Day 83	10:08	3.0
WEEK 13		
Day 84	10:09	3.0
Day 85	08:43*	1.5
Day 86	11:22	4.5
Day 87	10:59	4.0
Day 88	09:50	3.0
Day 89	10:08	3.0
Day 90	10:51	4.0
WEEK 14		
Day 91	10:16	3.5
Day 92	09:17	2.5
Day 93	12:02	5.0
Day 94	13:17*	6.5
Day 95	14:44*	8.0
Day 96	09:40	2.5

APPENDIX M - OPHTHALMOSCOPIC EXAMINATION SUMMARY
(Pretest Examination)

DIPLOMATE: AMERICAN COLLEGE
OF VETERINARY OPHTHALMOLOGISTS

JAMES M. CLINTON, V. M. D.
ANIMAL EYE CLINIC AT SOUTH JERSEY ANIMAL HOSPITAL
ROUTE 541 ABOVE CHURCH ROAD -- P. O. BOX 115
MEDFORD, NEW JERSEY 08055

TELEPHONE (609) 654-0304

EXXON
Study: 158270
G. Trimmer, Study Director

Examination Date:
16 October 1990

Pre-test Ophthalmoscopic Examination Summary

Both eyes of all of the rats assigned to the study were examined by focal illumination and indirect ophthalmoscopy. Mydriasis was produced with 1% atropine and the eyes examined in subdued light. Lesions were identified in the following rats:

Rat No.	Observations
ICJ858	Right Eye: Focal retinopathy.
ICJ901	Right Eye: Pre-retinal hemorrhage.
ICJ906	Left Eye: Focal retinopathy.

Comments

Ideally, the three rats listed above should not be used in the forthcoming study. The remaining rats are ophthalmoscopically normal.

James M. Clinton

James M. Clinton, V.M.D.

APPENDIX M - OPHTHALMOSCOPIC EXAMINATION SUMMARY
(Terminal Examination)

DIPLOMATE: AMERICAN COLLEGE
OF VETERINARY OPHTHALMOLOGISTS

JAMES M. CLINTON, V. M. D.
ANIMAL EYE CLINIC AT SOUTH JERSEY ANIMAL HOSPITAL
ROUTE 541 ABOVE CHURCH ROAD -- P. O. BOX 115
MEDFORD, NEW JERSEY 08055

TELEPHONE (609) 654-0304

EXXON
Study: 158270
Gary Trimmer

Examination Date:
17 January 1991

Ophthalmoscopic Examination Summary

Both eyes of all of the HSD:CD rats were examined by focal illumination and indirect ophthalmoscopy. Mydriasis was produced with 1% atropine and the eyes examined in subdued light. The dose levels and group identifications were not disclosed to me until after my examinations.

A unilateral lesion was identified in the following rat:

Rat No.	Sex	Observation
ICJ909	Female	Left Eye: Focal retinopathy.

Comments

The lesion noted is probably a sequela to a prior viral infection.

James M. Clinton

James M. Clinton, V.M.D.

APPENDIX N - ANALYTICAL REPORT

Analysis of MRD-89-582 in Corn Oil

Summary

Samples of MRD-89-582 in corn oil were received from the Compound Preparation Department by Analytical Chemistry and analyzed by Gas Chromatography (see Table N-4 for conditions). Concentration verification analyses showed values to be within 5.6% of the target levels (Table N-1).

Analytical Procedure

Aliquots of samples were diluted with toluene to a final analytical concentration of approximately 0.4 mg/ml. Standardization and quantitation was achieved using a one-point calibration of the neat material diluted in toluene to a concentration comparable to that of the samples. Reported concentrations are means of duplicate injections.

Stability

Samples of the 5 % and 50 % nominal concentration levels were kept in conditions of room temperature and refrigeration. Aliquots of these samples were analyzed on Day 0, Day 5, and Day 8. Stability was demonstrated for up to 8 days under conditions of both refrigeration and room temperature. See Table N-2 for analytical results.

Uniformity

Triplicate aliquots of the 5 % and 50 % nominal concentration levels were and analyzed for uniformity. Uniformity was demonstrated at both dose levels. See Table N-3 for results of uniformity analysis.

APPENDIX N - ANALYTICAL REPORT (CONT.)

Table N-1

Concentration Verification

Sample	Analyzed Concentration Analysis Date		
	(19 Oct 90)	(16 Nov 90)	(20 Dec 90)
5 %	5.25 *	5.22	5.05
25 %	26.4	25.7	24.7
50 %	52.5 *	52.1	49.6

* average results from uniformity testing.

APPENDIX N - ANALYTICAL REPORT (CONT.)

Table N-2

Stability Analysis

Sample	Day 0 (11 Oct 90)	Day 5 (16 Oct 90)	Day 8 (19 Oct 90)
Refrigerated		5.06 %	4.90 %
5 %	4.94 %		
Room Temperature		5.05 %	5.06 %
Refrigerated		49.6 %	46.5 %
50 %	49.2 %		
Room Temperature		49.5 %	50.7 %

APPENDIX N - ANALYTICAL REPORT (CONT.)

Table N-3

Uniformity Analysis

(October 19, 1990) Sample		Results
5 %		5.15 % 5.19 % 5.40 %
	x +/- SD	5.25 +/- 0.13
50 %		52.6 % 52.9 % 51.9 %
	x +/- SD	52.5 +/- 0.51

APPENDIX N - ANALYTICAL REPORT (CONT.)

Table N-4

Gas Chromatography Conditions

Gas Chromatograph	Hewlett-Packard 5890A
Integrator	Hewlett-Packard 3396A
Column	DB-1 15 m x 0.53 mm id Megabore capillary column 1.5 um film thickness (J & W Scientific)
Detector	Flame Ionization
Injection Volume	1 microliter
Chart Speed	0.5 cm/minute
Attenuation	2^4
Flow Rate (ml/minute)	Hydrogen - 15 Air - 400 Carrier Gas - 5
Temperature Profile	Injector - 300 Detector - 300 Oven - 70 C initial 110 C final Ramp - 2 C/minute

APPENDIX O - NOTES AND PROTOCOL/ENVIRONMENTAL DEVIATIONS

AGE AND WEIGHT AT INITIATION OF DOSING:

The animals were approximately 2 weeks outside the age range specified in the protocol. The male animals were slightly heavier than the weight range specified in the protocol. These deviations did not adversely affect the study results.

EXPERIMENTAL GROUPS:

Four Group 5 animals were transferred to Group 4 at study termination. The raw data for these animals prior to necropsy can be found in the Group 5 data. In this report, data for these animals is listed under Group 4.

DOSING TIMES:

The protocol specified that the animals would be dosed at approximately the same time each day plus-or-minus 2.0 hours. This did not occur on fourteen occasions. These deviations which did not adversely affect the study results are identified in Appendix L.

BODY WEIGHT AND FOOD CONSUMPTION ON DAY 91:

The protocol initially stated that body weights and food consumption would be measured on Day 91. However protocol revision 1 changed this to be Day 90. When the study was extended five days, the protocol should have been amended to again read Day 91, which was not done until Day 98, after the measurements were made. This deviation did not adversely affect the study results.

TERMINAL BODY WEIGHTS:

Due to a technician oversight, terminal body weights of animals ICJ935 and ICJ931 (spontaneous deaths) were not recorded at the time of necropsy. These deviations did not adversely affect the study results.

CONCENTRATION VERIFICATION:

The fourth and final concentration verification was not performed due to a communication error. The effect of this error on the study is unknown but in the opinion of the study director it is felt to be minor since the earlier concentration verification results showed that the test material mixtures were being prepared properly.

HISTOPATHOLOGY:

A small number of tissues were noted as not available for evaluation by the pathologist and are noted in Appendix P. The thymus was one of the more frequently noted missing tissues and may not have been present in animals of this age. Due to the lack of treatment related findings in these tissues of other animals these deviations did not adversely affect the study results.

APPENDIX P - HISTOPATHOLOGY REPORT

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

SUBMITTED TO:

G. W. Trimmer
Exxon Biomedical Sciences, Inc.
Mettler's Road CN 2350
East Millstone, NJ 08875-2350

SUBMITTED BY:

W. Ray Brown, D.V.M., Ph.D.
Veterinary Pathologist

RESEARCH PATHOLOGY SERVICES, INC.
438 East Butler Avenue
New Britain, PA 18901
(215) 345-7070

July 3, 1991

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

TABLE OF CONTENTS

REPORT

Page

METHOD. 1

RESULTS 3

SUMMARY. 8

QUALITY ASSURANCE UNIT STATEMENT 11

TABLES

1. INCIDENCE AND DEGREE OF SEVERITY OF TREATMENT-RELATED HISTOMORPHOLOGIC LESIONS. 12

2. INCIDENCE OF HISTOMORPHOLOGIC OBSERVATIONS - ALL RATS OF ALL GROUPS. 14

APPENDICES

I. HISTOMORPHOLOGIC OBSERVATIONS. . . . . .I-1 TO I-25

KEY TO HISTOMORPHOLOGIC OBSERVATIONS I-1

I-1. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 1 MALE RATS I-2

I-2. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 2 MALE RATS. I-4

I-3. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 3 MALE RATS. I-5

I-4. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 4 MALE RATS I-6

I-5. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 5A MALE RATS I-9

I-6. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 5B MALE RATS. . . .I-11

I-7. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 1 FEMALE RATS . . .I-13

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

TABLE OF CONTENTS (Continued)

I-8. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 2 FEMALE RATS. . . I-16

I-9. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 3 FEMALE RATS. . . I-17

I-10. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 4 FEMALE RATS. . . I-19

I-11. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 5A FEMALE RATS. . .I-22

I-12. HISTOMORPHOLOGIC OBSERVATIONS - GROUP 5B FEMALE RATS. . .I-24

II. INDIVIDUAL ANIMAL GROSS AND HISTOMORPHOLOGY DATA. . .II-1 TO II-102

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

METHOD

Microscopic examination was made of the specified tissues from 100 male and female Sprague-Dawley (HSD:CD) rats equally divided by sex at initiation of the study into five treatment groups used in a 90-day oral toxicity study of MRD-89-582.

The dose group identification, dosage levels, and number of rats in each group are shown below.

Dose Group	Dose Level* (mg/kg)	Number of Rats per Group
1 (Control)	0	10M,10F
2	500	10M,10F
3	2500	10M,10F
4	5000	10M,14F
5A (Satellite)**	5000	2M,3F
5B (Satellite)***	5000	8M,3F

* mg test material/kg body weight
** Satellite group rats (Group 5A) that died prior to the 13 week necropsy.
*** The surviving satellite group rats (Group 5B) were dosed at the high dose level seven days a week for approximately 13 weeks and were then observed for reversibility, persistence or delayed occurrence of toxic effects for at least 28 days post-treatment.

All of the surviving rats from Groups 1, 2, 3 and 4 were necropsied after at least 90 days of dosing. In order to provide 10 surviving rats of each sex in the high dose group (Group 4), four of the remaining female rats from the satellite group also were necropsied at the same in-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

METHOD (Continued)

terval. The remaining surviving rats from Group 5 were necropsied after at least 28 days post-treatment for reversibility studies (Group 5B).

The in-life observations, gross necropsy observations, tissue processing and microscopic slide preparation (hematoxylin- and eosin-stained sections) were performed by Exxon Biomedical Sciences, Inc.

The following tissues were examined microscopically from all Groups 1, 4 and 5 male and female rats designated for the terminal necropsy and any non-surviving rats from Groups 2 and 3: adrenal glands, aorta, bone (femur and sternum) and bone marrow (sternum), brain, cecum, cervix, colon, duodenum, epididymides, esophagus, eyes, heart, ileum, jejunum, kidneys, exorbital lacrimal gland, liver, lung, lymph nodes (cervical and mesenteric), mammary gland (females only), femoris muscle, sciatic nerve, ovaries, pancreas, parathyroid, pituitary, prostate, rectum, salivary glands, seminal vesicles, spinal cord (cervical, midthoracic and lumbar), spleen, stomach, testes, thymus, thyroid, trachea, urinary bladder, uterus, and tissues with gross changes. Microscopic evaluation of the surviving rats of the Groups 2 and 3 (low and mid dosage groups) was limited sections of the kidneys, liver, lung, stomach, and tissues with gross changes.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

RESULTS

The incidence and degree of severity of treatment-related lesions is presented in Table 1. The type and incidence of microscopic changes in all rats of all groups are summarized in Table 2. The microscopic observations in each rat of the various dosage groups are presented in tabular form in Appendix I (Tables I-1 to I-12). The gross necropsy observations, detailed descriptions of the microscopic observations and any correlation of the microscopic findings with the gross changes in these rats are contained in Appendix II.

Treatment-related microscopic changes were observed in the kidneys of male rats at all dosage levels of MRD-89-582, the liver of male and female rats at all dosage levels, and the stomach and/or anus of male and female rats at 2500 and 5000 mg/kg of MRD-89-582.

The treatment-related effect in the liver consisted of hepatocellular hypertrophy, predominantly in centrilobular areas (Table 1). The incidence and intensity of this centrilobular hepatocellular hypertrophy generally occurred in a dose-related manner.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

RESULTS (Continued)

Microscopic examination of the liver of the satellite group rats (Group 5B) necropsied after the 28-day recovery period showed no evidence of hepatocellular hypertrophy indicating that the change was reversible.

Microscopic examination of the kidneys of male rats showed changes typical of those which have been reported for male rats exposed to certain light hydrocarbon compounds. These renal changes consisted of accumulations of hyaline droplets in the cytoplasm of the proximal convoluted tubules, dilatation and granular cast formations in the medullary tubules and increased basophilia of cortical tubules. These affected basophilic cortical tubules showed changes consistent with both degeneration and regeneration. The renal changes were observed only in male rats with essentially no difference in the incidence and/or severity of the lesions among the groups (Table 1).

Microscopic examination of the kidneys in the remaining satellite group male rats necropsied after the 28-day reversibility period showed no evidence of hyaline droplets in the cortical tubules, but there were

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

RESULTS (Continued)

dilated tubules with granular casts in the medulla of four of the eight male rats necropsied at this interval. Also, focal chronic nephritis was seen in three of the eight surviving rats of this group. There was no difference in the incidence of cortical basophilic tubules between the control and satel-lite group male rats. This also indicates that the renal changes are reversible with discontinuation of the exposure to the test compound.

Microscopic examination of the stomach revealed a thickening of the nonglandular mucosa due to hyperplasia and hyperkeratosis of the squamous epithelium. Other associated gastric changes seen at a low incidence in a few of the affected rats included edema and inflammatory cell infiltrations in the submucosa and focal necrosis of the superficial glandular mucosa. The incidence and severity of the hyperplasia and hyperkeratosis occurred in a dose-related manner (Table 1). The stomach of the rats necropsied after the 28-day reversibility period (Satellite Group 5B) showed no residual changes in any of the three female rats, but three of the eight male rats necropsied at this interval still had a minimal to slight hyperplasia and hyperkeratosis of the mucosa of the nonglandular area of the stomach. Although there were still residual effects seen in the stomach of a few of the surviving satellite group rats, the incidence

RESULTS (Continued)

and intensity was decreased indicating that the effect also is reversible.

At necropsy, the anus of most rats of the 5000 mg/kg dosage group was described as being swollen. Microscopically, the skin and mucosa around the anus of these rats was thickened due to hyperplasia and hyperkeratosis. Also, there were areas of necrosis, neutrophilic inflammatory cell infiltrations and pustular formations in the superficial mucosa and epidermis of the anus and skin around the anus. Similar gross changes were not observed in the anus of rats necropsied after the reversibility period.

Fourteen rats died during the 90-day treatment period (one female and two male control rats, two 2500 mg/kg female rats, four 5000 mg/kg female rats and two male and three female rats in the 5000 mg/kg satellite group). Thirteen of these rats had lesions involving the trachea, esophagus, thoracic cavity or lungs consistent with intubation or dosing accidents. These lesions included acute hemorrhage, congestion and/or edema in the lungs, fibrinopurulent pericarditis or pleuritis. Several of these rats also had variable amounts of a pale yellow foreign

RESULTS (Continued)

material within pulmonary alveoli which is most likely the result of inadvertent intratracheal intubation or aspiration.

All other microscopic changes were considered to have occurred spontaneously and to be unrelated to treatment or they were judged to have been secondary in the non-surviving rats. The type and incidence of these changes are listed and summarized in Table 2.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

SUMMARY

Microscopic examination was made of the specified tissues from four treatment groups of male and female rats given 0 (Control), 500, 2500, or 5000 mg/kg of MRD-89-582, orally by gavage, seven days a week, for up to thirteen weeks. A satellite group of rats also was given 5000 mg/kg of the test article for up to thirteen weeks. The surviving satellite group rats were maintained for an additional 28 days without treatment for reversibility, persistence or delayed occurrence of toxic effects.

Treatment-related microscopic changes were observed in the kidneys of male rats at all dosage levels of MRD-89-582, the liver of male and female rats at all dosage levels and the stomach and anus of male and female rats of the 2500 and 5000 mg/kg dosage groups.

The treatment-related findings in the kidneys of the male rats consisted of hyaline droplets in the proximal convoluted tubules, dilatation and granular cast formations in medullary tubules and increased basophilia of cortical tubules representing areas of degeneration and regeneration of cortical tubular epithelium.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

SUMMARY (Continued)

The major treatment-related effect in the gastrointestinal tract of the mid and high dose rats included hyperplasia and hyperkeratosis of the squamous mucosa. Also, the anus of several of these rats was grossly swollen due to hyperplasia and hyperkeratosis of the epidermis, focal necrosis, and neutrophilic infiltrations with pustule formations.

The treatment-related microscopic effect in the liver consisted of a dose-related increased incidence and/or intensity of centrilobular hepatocellular hypertrophy in rats at all dosage levels of MRD-89-582.

Microscopic examination of the surviving rats necropsied after the 28-day reversibility period showed no evidence of hepatocellular hypertrophy indicating complete reversibility of the hepatic change. There were still residual changes in the kidneys of male rats consisting of dilated medullary tubules with cast formations and foci of chronic nephritis. However, the hyaline droplets were not evident after the reversibility period. Minimal to slight hyperplasia and hyperkeratosis of the squamous mucosa of the stomach was still evident in a few male rats and none of the female rats necropsied after the reversibility period. However, the incidence and severity of this change in the male rats was decreased indicating that this gastric change also is reversible.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

SUMMARY (Continued)

All other microscopic changes were considered to have occurred spontaneously and to be unrelated to treatment or to have been secondary in the rats that did not survive to termination of the study.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

QUALITY ASSURANCE UNIT STATEMENT

All aspects of the histopathologic evaluation and report preparation for the histopathology segment of the study listed above have been performed according to the Standard Operating Procedures of Research Pathology Services, Inc. and were audited in accordance with the procedures established by the Quality Assurance Unit of Research Pathology Services, Inc. in compliance with the "Good Laboratory Practice Standards" (40 CFR 160).

Quality Assurance inspections were performed and findings reported to management on 05/02/91, 05/06/91, 05/20/91, 05/28/91, 06/18/91, 06/20/91, 07/02/91 and 07/03/91.

Karen W. Harkins

Karen W. Harkins
Quality Assurance Unit

07-03-91
Date

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 1

Incidence and Degree of Severity of Treatment-Related Histomorphologic Lesions

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
ANUS:												
NO. EXAMINED	0	0	0	8	2	0	0	0	0	14	1	0
NO. NORMAL	0	0	0	0	0	0	0	0	0	0	0	0
-hyperplasia/hyperkeratosis	[0]	[0]	[0]	[5]	[2]	[0]	[0]	[0]	[0]	[14]	[1]	[0]
slight	0	0	0	1	0	0	0	0	0	2	0	0
moderate	0	0	0	4	2	0	0	0	0	12	1	0
-infiltration, neutrophilic/pustule(s)	[0]	[0]	[0]	[8]	[2]	[0]	[0]	[0]	[0]	[14]	[1]	[0]
minimal	0	0	0	2	1	0	0	0	0	2	0	0
slight	0	0	0	2	1	0	0	0	0	9	1	0
moderate	0	0	0	3	0	0	0	0	0	3	0	0
marked	0	0	0	1	0	0	0	0	0	0	0	0
-necrosis, mucosa	[0]	[0]	[0]	[3]	[1]	[0]	[0]	[0]	[0]	[0]	[1]	[0]
slight	0	0	0	1	1	0	0	0	0	0	1	0
moderate	0	0	0	1	0	0	0	0	0	0	0	0
marked	0	0	0	1	0	0	0	0	0	0	0	0
KIDNEYS:												
NO. EXAMINED	10	10	10	10	2	8	10	10	10	14	3	3
NO. NORMAL	8	0	0	0	0	2	8	10	9	13	2	3
-basophilia, cortical tubules, multifocal	[1]	[6]	[8]	[10]	[1]	[2]	[0]	[0]	[0]	[1]	[0]	[0]
minimal	1	3	3	2	1	2	0	0	0	1	0	0
slight	0	2	3	6	0	0	0	0	0	0	0	0
moderate	0	1	2	2	0	0	0	0	0	0	0	0
-dilated tubule(s)/granular cast(s), medulla	[0]	[3]	[7]	[8]	[2]	[4]	[0]	[0]	[0]	[0]	[0]	[0]
minimal	0	0	3	1	0	4	0	0	0	0	0	0
slight	0	0	1	4	1	0	0	0	0	0	0	0
moderate	0	3	3	3	1	0	0	0	0	0	0	0
-hyaline droplets, cortical tubules	0	10	10	10	2	0	0	0	0	0	0	0
LIVER:												
NO. EXAMINED	10	10	10	10	2	8	10	10	10	14	3	3
NO. NORMAL	3	4	4	2	0	2	4	4	1	2	2	1
-hypertrophy, hepatocellular, centrilobular	[0]	[3]	[5]	[4]	[1]	[0]	[0]	[3]	[9]	[10]	[1]	[0]
minimal	0	3	4	1	0	0	0	3	5	6	1	0
slight	0	0	1	3	1	0	0	0	4	4	0	0
STOMACH:												
NO. EXAMINED	10	10	10	10	2	8	10	10	10	14	3	3
NO. NORMAL	10	9	3	1	1	5	10	9	2	3	1	2
-edema/inflammation, submucosa	[0]	[0]	[2]	[1]	[0]	[0]	[0]	[0]	[1]	[0]	[0]	[0]
slight	0	0	1	0	0	0	0	0	0	0	0	0
moderate	0	0	1	1	0	0	0	0	1	0	0	0

[ ] = Total incidence of specified lesion, all grades.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 1 (Continued)

Incidence and Degree of Severity of Treatment-Related Histomorphologic Lesions

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
STOMACH (Continued):												
-hyperplasia/hyperkeratosis, nonglandular mucosa	[0]	[0]	[7]	[9]	[1]	[3]	[0]	[0]	[8]	[11]	[1]	[0]
minimal	0	0	4	0	0	2	0	0	6	0	0	0
slight	0	0	1	3	1	1	0	0	2	2	1	0
moderate	0	0	1	6	0	0	0	0	0	9	0	0
marked	0	0	1	0	0	0	0	0	0	0	0	0
-necrosis, glandular mucosa, focal	[0]	[0]	[0]	[1]	[0]	[0]	[0]	[0]	[0]	[0]	[0]	[0]
slight	0	0	0	1	0	0	0	0	0	0	0	0

[ ] = Total incidence of specified lesion, all grades.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 2

Incidence of Histomorphologic Observations - All Rats of All Groups

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
ADRENAL GLANDS:												
NO. EXAMINED	10	0	0	9	2	8	10	0	2	14	3	3
NO. NORMAL	6	0	0	4	2	5	9	0	2	13	2	3
-accessory adrenocortical tissue	1	0	0	0	0	0	0	0	0	0	0	0
-congestion	0	0	0	0	0	0	0	0	0	0	1	0
-hypertrophy, zona glomerulosa	4	0	0	5	0	3	1	0	0	1	0	0
-vacuolation, cortex	0	0	0	1	0	0	0	0	0	0	0	0
-vacuolation, cortex, diffuse	1	0	0	0	0	0	0	0	0	0	0	0
ANUS:												
NO. EXAMINED	0	0	0	8	2	0	0	0	0	14	1	0
NO. NORMAL	0	0	0	0	0	0	0	0	0	0	0	0
-hyperplasia/hyperkeratosis	0	0	0	5	2	0	0	0	0	14	1	0
-infiltration, neutrophilic/pustule(s)	0	0	0	8	2	0	0	0	0	14	1	0
-necrosis, mucosa	0	0	0	3	1	0	0	0	0	0	1	0
AORTA:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	13	3	3
NO. NORMAL	10	0	0	10	2	8	9	0	2	11	2	3
-inflammation, fibrinopurulent	0	0	0	0	0	0	1	0	0	2	1	0
BONE (FEMUR):												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	2
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	2
BONE (STERNUM):												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	3
BONE MARROW (STERNUM):												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	8	10	0	2	13	3	3
-atrophy	0	0	0	0	0	0	0	0	0	1	0	0
BRAIN:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	3
CECUM:												
NO. EXAMINED	10	0	3	10	2	8	10	1	2	14	3	3
NO. NORMAL	10	0	3	10	2	8	10	1	2	14	2	3
-Advanced autolysis precludes evaluation	0	0	0	0	0	0	0	0	0	0	1	0
CERVIX:												
NO. EXAMINED							10	0	2	14	3	3
NO. NORMAL							10	0	2	14	3	3
COLON:												
NO. EXAMINED	10	0	0	10	2	8	10	0	3	14	3	3
NO. NORMAL	10	0	0	9	2	8	9	0	2	14	2	3
-Advanced autolysis precludes evaluation	0	0	0	0	0	0	0	0	0	0	1	0
-distention	0	0	0	1	0	0	1	0	1	0	0	0

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 2 (Continued)

Incidence of Histomorphologic Observations - All Rats of All Groups

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
DUODENUM:												
NO. EXAMINED	10	0	0	10	2	8	10	0	1	14	3	3
NO. NORMAL	9	0	0	10	2	8	10	0	1	14	2	3
-Advanced autolysis precludes evaluation	0	0	0	0	0	0	0	0	0	0	1	0
-ectopic pancreatic tissue	1	0	0	0	0	0	0	0	0	0	0	0
EPIDIDYMIDES:												
NO. EXAMINED	10	0	0	10	2	8						
NO. NORMAL	10	0	0	10	2	8						
ESOPHAGUS:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	9	0	0	10	1	8	10	0	2	11	3	3
-inflammation, fibrinopurulent	0	0	0	0	1	0	0	0	0	1	0	0
-inflammation, tunica muscularis, chronic	1	0	0	0	0	0	0	0	0	0	0	0
-necrosis, muscular wall, focal	0	0	0	0	0	0	0	0	0	1	0	0
-perforation	0	0	0	0	1	0	0	0	0	1	0	0
EYES:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	6	0	0	6	2	6	6	0	2	10	2	3
-cataract, bilateral	0	0	0	0	0	0	0	0	0	0	1	0
-cataract, unilateral	0	0	0	0	0	0	0	0	0	1	0	0
-hemorrhage, periorbital, bilateral	0	0	0	0	0	0	1	0	0	0	0	0
-hemorrhage, periorbital, unilateral	4	0	0	4	0	2	3	0	0	3	0	0
HEART:												
NO. EXAMINED	10	0	0	10	2	8	10	1	2	14	3	3
NO. NORMAL	10	0	0	9	1	5	7	0	1	11	2	3
-abscess	0	0	0	0	0	0	2	0	0	0	0	0
-dilatation, atrial	0	0	0	0	0	0	0	0	1	0	0	0
-myocarditis, chronic, focal	0	0	0	1	0	2	0	0	0	0	0	0
-periarteritis	0	0	0	0	0	1	0	0	0	0	0	0
-pericarditis, chronic	0	0	0	0	0	0	1	1	0	0	0	0
-pericarditis, fibrinopurulent	0	0	0	0	1	0	2	0	0	3	1	0
ILEUM:												
NO. EXAMINED	9	0	1	10	2	8	10	0	2	14	3	3
NO. NORMAL	9	0	0	9	2	7	10	0	2	14	3	3
-distention	0	0	1	1	0	1	0	0	0	0	0	0
JEJUNUM:												
NO. EXAMINED	10	0	1	10	2	8	8	0	3	14	3	3
NO. NORMAL	10	0	1	9	2	8	8	0	3	11	2	3
-Advanced autolysis precludes evaluation	0	0	0	0	0	0	0	0	0	1	1	0
-distention	0	0	0	1	0	0	0	0	0	2	0	0
KIDNEYS:												
NO. EXAMINED	10	10	10	10	2	8	10	10	10	14	3	3
NO. NORMAL	8	0	0	0	0	2	8	10	9	13	2	3
-basophilia, cortical tubules, multifocal	1	6	8	10	1	2	0	0	0	1	0	0
-dilatation, pelvis	1	0	0	0	0	0	0	0	0	0	0	0

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 2 (Continued)

Incidence of Histomorphologic Observations - All Rats of All Groups

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
KIDNEYS (Continued):												
-dilated tubule(s)/granular cast(s), medulla	0	3	7	8	2	4	0	0	0	0	0	0
-hyaline droplets, cortical tubules	0	10	10	10	2	0	0	0	0	0	0	0
-mineralization, multifocal	0	1	0	0	0	0	1	0	1	0	1	0
-mineralization, pelvic	0	0	0	0	0	0	1	0	0	0	0	0
-nephritis, chronic, multifocal	0	0	0	0	0	3	0	0	0	0	0	0
LACRIMAL GLAND:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	9	0	0	10	2	8	10	0	2	14	3	3
-infiltration, lymphocytic	1	0	0	0	0	0	0	0	0	0	0	0
LIVER:												
NO. EXAMINED	10	10	10	10	2	8	10	10	10	14	3	3
NO. NORMAL	3	4	4	2	0	2	4	4	1	2	2	1
-congestion	0	0	0	0	0	0	1	0	0	1	0	0
-hemosiderosis, focal	0	0	0	0	0	0	0	0	1	0	0	0
-hypertrophy, hepatocellular, centrilobular	0	3	5	4	1	0	0	3	9	10	1	0
-infiltration, mononuclear-cell, multifocal	5	4	2	3	0	6	2	2	1	2	0	2
-lipidosis, tension, focal	0	0	0	1	0	0	0	0	0	0	0	0
-necrosis, anoxic, centrilobular	0	0	0	0	1	0	0	0	0	0	0	0
-necrosis, focal	0	0	0	0	0	0	1	1	0	0	0	0
-vacuolation, hepatocellular, centrilobular	1	0	0	0	0	0	0	0	0	0	0	0
-vacuolation, hepatocellular, midzonal	1	0	0	0	0	0	0	0	0	0	0	0
-vacuolation, hepatocellular, multifocal	0	0	0	0	0	0	0	0	1	0	0	0
-vacuolation, hepatocellular, periportal	2	0	0	0	0	0	2	1	0	0	0	0
LUNG:												
NO. EXAMINED	10	10	10	10	2	8	10	10	10	14	3	3
NO. NORMAL	6	10	7	4	0	6	6	6	4	3	0	3
-congestion	1	0	0	0	1	0	1	0	2	4	2	0
-cyst(s)	0	0	0	0	0	0	1	0	0	0	0	0
-edema	1	0	0	0	0	0	0	0	1	1	0	0
-foreign material, intra-alveolar	0	0	1	0	0	0	1	2	4	3	3	0
-hemorrhage, acute, focal	1	0	0	0	0	0	0	0	0	0	0	0
-hemorrhage, focal	1	0	1	0	0	0	0	0	0	1	1	0
-inflammation, granulomatous	0	0	0	0	0	0	1	0	0	0	0	0
-inflammation, interstitial, focal	1	0	0	2	0	0	2	2	3	5	0	0
-macrophages, alveoli, focal	1	0	2	4	0	1	3	2	2	2	0	0
-mineralization, vascular	0	0	0	0	0	1	0	0	0	0	0	0
-pleuritis, fibrinopurulent	0	0	0	0	1	0	1	0	0	3	1	0
-pneumonia, acute	0	0	0	0	0	0	0	0	0	1	0	0
-thrombus	0	0	0	1	0	0	0	0	0	0	0	0
LYMPH NODE, CERVICAL:												
NO. EXAMINED	10	0	0	10	2	8	9	1	1	14	3	3
NO. NORMAL	7	0	0	6	2	7	2	0	0	8	2	3
-congestion	1	0	0	1	0	0	3	0	0	3	1	0
-hyperplasia, lymphoid	3	0	0	4	0	1	6	1	1	4	0	0

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 2 (Continued)

Incidence of Histomorphologic Observations - All Rats of All Groups

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
LYMPH NODE, MESENTERIC:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	9	0	0	10	1	8	10	0	2	13	2	3
-congestion	1	0	0	0	1	0	0	0	0	1	0	0
-hyperplasia, lymphoid	0	0	0	0	0	0	0	0	0	0	1	0
MAMMARY GLAND:												
NO. EXAMINED							9	0	2	14	3	3
NO. NORMAL							9	0	2	14	2	3
-Advanced autolysis precludes evaluation							0	0	0	0	1	0
MUSCLE, FEMORIS:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	2
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	2
NERVE, SCIATIC:												
NO. EXAMINED	10	0	0	10	1	8	10	0	2	14	3	2
NO. NORMAL	10	0	0	10	1	8	10	0	2	14	3	2
OVARIES:												
NO. EXAMINED							10	1	3	14	3	3
NO. NORMAL							10	0	2	14	3	3
-cyst(s), intraovarian							0	0	1	0	0	0
-cyst(s), paraovarian							0	1	0	0	0	0
PANCREAS:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	7	0	0	10	2	8	10	0	2	14	3	3
-hyperplasia, islet-cell, focal	1	0	0	0	0	0	0	0	0	0	0	0
-infiltration, mononuclear-cell, multifocal	2	0	0	0	0	0	0	0	0	0	0	0
PARATHYROID:												
NO. EXAMINED	9	0	0	9	1	8	9	0	2	13	3	3
NO. NORMAL	9	0	0	9	1	8	9	0	2	13	3	3
PITUITARY:												
NO. EXAMINED	10	0	0	9	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	9	2	7	10	0	2	14	3	3
-cyst(s), pars distalis	0	0	0	0	0	1	0	0	0	0	0	0
PROSTATE:												
NO. EXAMINED	10	0	0	10	2	8						
NO. NORMAL	10	0	0	10	2	8						
RECTUM:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	9	2	8	10	0	2	14	3	3
-distention	0	0	0	1	0	0	0	0	0	0	0	0
SALIVARY GLANDS:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	3

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 2 (Continued)

Incidence of Histomorphologic Observations - All Rats of All Groups

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
SEMINAL VESICLES:												
NO. EXAMINED	10	0	0	10	2	8						
NO. NORMAL	10	0	0	10	2	8						
SKIN (GROSS LESION):												
NO. EXAMINED	0	0	0	0	0	0	0	1	0	0	0	0
NO. NORMAL	0	0	0	0	0	0	0	0	0	0	0	0
-atrophy, hair follicle(s)	0	0	0	0	0	0	0	1	0	0	0	0
SPINAL CORD, CERVICAL:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	3
SPINAL CORD, MIDTHORACIC:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	3
SPINAL CORD, LUMBAR:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	8	10	0	2	14	3	3
SPLEEN:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	0	8	9	0	1	11	3	3
-atrophy	0	0	0	0	2	0	0	0	1	3	0	0
-hyperplasia, red pulp	0	0	0	0	0	0	1	0	0	0	0	0
STOMACH:												
NO. EXAMINED	10	10	10	10	2	8	10	10	10	14	3	3
NO. NORMAL	10	9	3	1	1	5	10	9	2	3	1	2
-Advanced autolysis precludes evaluation	0	0	0	0	0	0	0	0	0	0	1	0
-dilatation, mucosal glands	0	1	0	1	0	1	0	1	0	0	0	1
-edema/inflammation, submucosa	0	0	2	1	0	0	0	0	1	0	0	0
-hyperplasia/hyperkeratosis, nonglandular mucosa	0	0	7	9	1	3	0	0	8	11	1	0
-necrosis, glandular mucosa, focal	0	0	0	1	0	0	0	0	0	0	0	0
TESTES:												
NO. EXAMINED	10	0	1	10	2	8						
NO. NORMAL	10	0	0	10	2	8						
-atrophy, diffuse, bilateral	0	0	1	0	0	0						
THYMUS:												
NO. EXAMINED	9	0	0	10	1	8	7	0	2	13	3	3
NO. NORMAL	9	0	0	10	0	8	6	0	1	11	2	2
-atrophy	0	0	0	0	1	0	0	0	0	2	0	0
-cyst(s)	0	0	0	0	0	0	0	0	0	0	0	1
-hemorrhage	0	0	0	0	0	0	0	0	1	0	0	0
-inflammation, fibrinopurulent	0	0	0	0	0	0	0	0	0	2	1	0
-inflammation, granulomatous	0	0	0	0	0	0	1	0	0	0	0	0
THYROID:												
NO. EXAMINED	9	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	9	0	0	10	2	8	10	0	2	13	2	3
-Advanced autolysis precludes evaluation	0	0	0	0	0	0	0	0	0	0	1	0

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE 2 (Continued)

Incidence of Histomorphologic Observations - All Rats of All Groups

Dose Group:	1	2	3	4	5A	5B	1	2	3	4	5A	5B
Sex:	M	M	M	M	M	M	F	F	F	F	F	F
Number of Animals/Group:	10	10	10	10	2	8	10	10	10	14	3	3
THYROID (Continued):												
-hypertrophy/hyperplasia, follicular epithelium	0	0	0	0	0	0	0	0	0	1	0	0
TRACHEA:												
NO. EXAMINED	10	0	0	10	2	8	10	0	2	14	3	3
NO. NORMAL	10	0	0	10	2	7	10	0	2	14	3	3
-cystic tracheal glands	0	0	0	0	0	1	0	0	0	0	0	0
URINARY BLADDER:												
NO. EXAMINED	10	0	0	10	2	8	9	0	2	14	3	3
NO. NORMAL	8	0	0	10	2	7	9	0	2	14	3	3
-cást, eosinophilic	2	0	0	0	0	1	0	0	0	0	0	0
UTERUS:												
NO. EXAMINED							10	1	2	14	3	3
NO. NORMAL							8	0	1	14	1	0
-cystic endometrial gland(s)							1	0	1	0	0	0
-distention, lumen							1	1	0	0	2	3

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

APPENDIX I

HISTOMORPHOLOGIC OBSERVATIONS

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

KEY TO HISTOMORPHOLOGIC OBSERVATIONS

- = No change (not remarkable, within normal histologic limits or indicated change not present).

* = Tissue not available (specified tissue missing, insufficient tissue in plane of section, artifact precludes evaluation, or specified tissue not present in section).

A = Advanced autolysis precludes evaluation.

< > = Microscopic finding(s) in tissue(s) with gross observation(s).

<-> = Within normal limits [no microscopic change(s) to correlate with the gross observation(s)].

( ) = Only one of a pair of organs available.

P = Indicated change or lesion present.

1 = Minimal degree or amount of indicated change or lesion.

2 = Slight degree or amount of indicated change or lesion.

3 = Moderate degree or amount of indicated change or lesion.

4 = Marked degree or amount of indicated change or lesion.

SS = Scheduled Sacrifice

SD = Spontaneous Death

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-1

Histomorphologic Observations

Dose Group:	1	1	1	1	1	1	1	1	1	1
Animal Number (ICJ):	845	848	861	870	878	882	885	886	898	904
Sex:	M	M	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SD	SS	SS	SS	SD
ADRENAL GLANDS:										
-accessory adrenocortical tissue	-	(-)	-	-	-	-	-	-	P	-
-hypertrophy, zona glomerulosa	-	(-)	-	2	-	-	2	2	3	-
-vacuolation, cortex, diffuse	-	(-)	-	-	-	-	2	-	-	-
AORTA:	-	-	-	-	-	<->	-	-	-	-
BONE (FEMUR):	-	-	-	-	-	-	-	-	-	-
BONE (STERNUM):	-	-	-	-	-	-	-	-	-	-
BONE MARROW (STERNUM):	-	-	-	-	-	-	-	-	-	-
BRAIN:	-	-	-	-	-	-	-	-	-	-
CECUM:	-	-	-	-	-	-	-	-	-	-
COLON:	-	-	-	-	-	-	-	-	-	-
DUODENUM:										
-ectopic pancreatic tissue	-	-	-	-	-	-	P	-	-	-
EPIDIDYMIDES:	-	-	-	-	-	-	-	-	-	-
ESOPHAGUS:										
-inflammation, tunica muscularis, chronic	-	-	-	-	1	-	-	-	-	-
EYES:										
-hemorrhage, periorbital, unilateral	3	3	-	-	2	-	1	-	-	(-)
HEART:	-	-	-	-	-	-	-	-	-	-
ILEUM:	-	*	-	-	-	-	-	-	-	-
JEJUNUM:	-	-	-	-	-	-	-	-	-	-
KIDNEYS:										
-basophilia, cortical tubules, multifocal	-	-	1	-	-	-	-	-	-	-
-dilatation, pelvis	-	-	-	1	-	-	-	-	-	-
LACRIMAL GLAND:										
-infiltration, lymphocytic	-	-	2	-	-	-	-	-	-	-
LIVER:										
-infiltration, mononuclear-cell, multifocal	1	-	<1>	1	1	-	-	-	1	-
-vacuolation, hepatocellular, centrilobular	-	-	-	-	-	-	-	2	-	-
-vacuolation, hepatocellular, midzonal	-	-	<2>	-	-	-	-	-	-	-
-vacuolation, hepatocellular, periportal	-	2	-	-	2	-	-	-	-	-
LUNG:										
-congestion	-	-	-	-	-	-	-	-	-	<4>
-edema	-	-	-	-	-	-	-	-	-	<4>
-hemorrhage, acute, focal	-	-	-	-	-	<3>	-	-	-	-
-hemorrhage, focal	-	-	-	-	-	-	-	-	-	<3>

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-1 (Continued)

Histomorphologic Observations

Dose Group:	1	1	1	1	1	1	1	1	1	1
Animal Number (ICJ):	845	848	861	870	878	882	885	886	898	904
Sex:	M	M	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SD	SS	SS	SS	SD
LUNG (Continued):										
-inflammation, interstitial, focal	-	-	-	-	-	-	-	1	-	-
-macrophages, alveoli, focal	-	-	-	-	-	-	1	-	-	-
LYMPH NODE, CERVICAL:										
-congestion	-	1	-	-	-	-	-	-	-	-
-hyperplasia, lymphoid	-	2	-	-	2	2	-	-	-	-
LYMPH NODE, MESENTERIC:										
-congestion	-	-	-	-	<1>	-	-	-	-	-
MUSCLE, FEMORIS:	-	-	-	-	-	-	-	-	-	-
NERVE, SCIATIC:	-	-	-	-	-	-	-	-	-	-
PANCREAS:										
-hyperplasia, islet-cell, focal	1	-	-	-	-	-	-	-	-	-
-infiltration, mononuclear-cell, multifocal	-	-	-	-	-	-	1	-	-	1
PARATHYROID:	-	-	-	-	-	-	-	-	-	*
PITUITARY:	-	-	-	-	-	-	-	-	-	-
PROSTATE:	-	-	-	-	-	-	-	-	-	-
RECTUM:	-	-	-	-	-	-	-	-	-	-
SALIVARY GLANDS:	-	-	-	-	-	-	-	-	-	-
SEMINAL VESICLES:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, CERVICAL:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, MIDTHORACIC:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, LUMBAR:	-	-	-	-	-	-	-	-	-	-
SPLEEN:	-	-	-	-	-	-	-	-	-	-
STOMACH:	-	-	-	-	-	<->	-	-	-	-
TESTES:	-	-	-	-	-	-	-	-	-	-
THYMUS:	-	-	-	-	-	-	-	-	-	*
THYROID:	-	-	-	-	-	-	-	-	-	*
TRACHEA:	-	-	-	-	-	-	-	-	-	-
URINARY BLADDER:										
-cast, eosinophilic	-	-	-	P	P	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-2

Histomorphologic Observations

Dose Group:	2	2	2	2	2	2	2	2	2	2
Animal Number (ICJ):	855	859	872	873	875	877	884	887	892	900
Sex:	M	M	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS	SS	SS
KIDNEYS:										
-basophilia, cortical tubules, multifocal	-	-	1	1	1	-	2	3	2	-
-dilated tubule(s)/granular cast(s), medulla	-	-	-	-	-	-	3	3	3	-
-hyaline droplets, cortical tubules	P	P	P	P	P	P	P	P	P	P
-mineralization, multifocal	-	-	-	-	2	-	-	-	-	-
LIVER:										
-hypertrophy, hepatocellular, centrilobular	-	-	1	-	-	-	-	-	1	1
-infiltration, mononuclear-cell, multifocal	-	-	1	1	1	1	-	-	-	-
LUNG:	-	-	-	-	-	-	-	-	-	-
STOMACH:										
-dilatation, mucosal glands	-	-	-	-	-	1	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-3

Histomorphologic Observations

Dose Group:	3	3	3	3	3	3	3	3	3	3
Animal Number (ICJ):	846	847	850	881	883	889	890	893	896	905
Sex:	M	M	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS	SS	SS
CECUM:	<->				<->			<->		
ILEUM:										
-distention										<1>
JEJUNUM:					<->					
KIDNEYS:										
-basophilia, cortical tubules, multifocal	2	2	-	1	1	3	2	3	1	-
-dilated tubule(s)/granular cast(s), medulla	2	-	1	3	3	-	1	3	-	1
-hyaline droplets, cortical tubules	P	P	P	P	P	P	P	P	P	P
LIVER:										
-hypertrophy, hepatocellular, centrilobular	-	-	1	1	-	-	2	1	1	-
-infiltration, mononuclear-cell, multifocal	-	-	-	-	-	1	1	-	-	-
LUNG:										
-foreign material, intra-alveolar	-	-	-	-	-	<P>	-	-	-	-
-hemorrhage, focal	-	-	-	-	-	<3>	-	-	-	-
-macrophages, alveoli, focal	-	-	-	-	-	-	-	1	-	1
STOMACH:										
-edema/inflammation, submucosa	2	-	-	-	-	-	-	3	-	-
-hyperplasia/hyperkeratosis, nonglandular mucosa	3	1	1	1	-	-	2	4	-	1
TESTES:										
-atrophy, diffuse, bilateral							<4>			

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-4

Histomorphologic Observations

Dose Group:	4	4	4	4	4	4	4	4	4	4
Animal Number (ICJ):	851	867	868	869	871	874	891	899	902	907
Sex:	M	M	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS	SS	SS
ADRENAL GLANDS:										
-hypertrophy, zona glomerulosa	2	<->	2	-	1	-	*	1	-	2
-vacuolation, cortex	-	<->	-	-	-	-	*	3	-	-
ANUS:										
-hyperplasia/hyperkeratosis	-	<*>	-		<3>	-	<3>	<3>	<2>	<3>
-infiltration, neutrophilic/pustule(s)	<1>	<*>	<4>		<3>	<3>	<2>	<3>	<1>	<2>
-necrosis, mucosa	-	<*>	<4>		<3>	<2>	-	-	-	-
AORTA:	-	-	-	-	-	-	-	-	-	-
BONE (FEMUR):	-	-	-	-	-	-	-	-	-	-
BONE (STERNUM):	-	-	-	-	-	-	-	-	-	-
BONE MARROW (STERNUM):	-	-	-	-	-	-	-	-	-	-
BRAIN:	-	-	-	-	-	-	-	-	-	-
CECUM:	<->	<->	<->	<->	-	<->	-	-	-	-
COLON:										
-distention	<2>	-	-	-	-	-	-	-	-	-
DUODENUM:	-	-	-	-	-	-	-	-	-	-
EPIDIDYMIDES:	-	-	-	-	-	-	-	-	-	-
ESOPHAGUS:	-	-	-	-	-	-	-	-	-	-
EYES:										
-hemorrhage, periorbital, unilateral	2	-	-	-	-	3	(-)	-	3	1
HEART:										
-myocarditis, chronic, focal	-	-	-	-	1	-	-	-	-	-
ILEUM:										
-distention	-	-	-	-	-	-	-	<1>	-	-
JEJUNUM:										
-distention	-	-	-	-	-	-	-	<1>	-	-
KIDNEYS:										
-basophilia, cortical tubules, multifocal	2	3	2	2	2	1	3	2	1	2
-dilated tubule(s)/granular cast(s), medulla	2	3	-	2	-	1	3	2	3	2
-hyaline droplets, cortical tubules	P	P	P	P	P	P	P	P	P	P
LACRIMAL GLAND:	-	-	-	-	-	-	-	-	-	-
LIVER:										
-hypertrophy, hepatocellular, centrilobular	-	-	-	-	-	1	-	2	2	2

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-4 (Continued)

Histomorphologic Observations

Dose Group:	4	4	4	4	4	4	4	4	4	4
Animal Number (ICJ):	851	867	868	869	871	874	891	899	902	907
Sex:	M	M	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS	SS	SS
LIVER (Continued):										
-infiltration, mononuclear-cell, multifocal	-	-	1	1	-	-	1	-	-	-
-lipidosis, tension, focal	-	-	-	-	1	-	-	-	-	-
LUNG:										
-inflammation, interstitial, focal	-	-	-	1	-	1	-	-	-	-
-macrophages, alveoli, focal	-	-	-	-	-	1	1	-	1	1
-thrombus	P	-	-	-	-	-	-	-	-	-
LYMPH NODE, CERVICAL:										
-congestion	<1>	-	-	-	-	-	-	-	-	-
-hyperplasia, lymphoid	<3>	-	2	-	-	3	-	-	2	-
LYMPH NODE, MESENTERIC:	-	-	-	-	-	-	-	-	-	-
MUSCLE, FEMORIS:	-	-	-	-	-	-	-	-	-	-
NERVE, SCIATIC:	-	-	-	-	-	-	-	-	-	-
PANCREAS:	-	-	-	-	-	-	-	-	-	-
PARATHYROID:	-	-	*	-	-	-	-	-	-	-
PITUITARY:	-	*	-	-	-	-	-	-	-	-
PROSTATE:	-	-	-	-	-	-	-	-	-	-
RECTUM:										
-distention	<2>	-	-	-	-	-	-	-	-	-
SALIVARY GLANDS:	-	-	-	-	-	-	-	-	-	-
SEMINAL VESICLES:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, CERVICAL:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, MIDTHORACIC:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, LUMBAR:	-	-	-	-	-	-	-	-	-	-
SPLEEN:	-	-	-	-	-	-	-	-	-	-
STOMACH:										
-dilatation, mucosal glands	-	-	-	-	-	1	-	-	-	-
-edema/inflammation, submucosa	-	-	-	-	3	-	-	-	-	-
-hyperplasia/hyperkeratosis, nonglandular mucosa	-	3	<3>	2	2	3	3	<3>	2	3
-necrosis, glandular mucosa, focal	-	-	-	-	2	-	-	-	-	-
TESTES:	-	-	-	-	-	-	-	-	-	-
THYMUS:	-	-	-	-	-	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-4 (Continued)

Histomorphologic Observations

Dose Group:	4	4	4	4	4	4	4	4	4	4
Animal Number (ICJ):	851	867	868	869	871	874	891	899	902	907
Sex:	M	M	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS	SS	SS
THYROID:	-	-	-	-	-	-	-	-	-	-
TRACHEA:	-	-	-	-	-	-	-	-	-	-
URINARY BLADDER:	-	-	-	-	-	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-5

Histomorphologic Observations

Dose Group:	5A	5A
Animal Number (ICJ):	852	857
Sex:	M	M
Death Type:	SD	SD
ADRENAL GLANDS:	-	-
ANUS:		
-hyperplasia/hyperkeratosis	<3>	<3>
-infiltration, neutrophilic/pustule(s)	<2>	<1>
-necrosis, mucosa	<2>	-
AORTA:	-	-
BONE (FEMUR):	-	-
BONE (STERNUM):	-	-
BONE MARROW (STERNUM):	-	-
BRAIN:	-	-
CECUM:	-	-
COLON:	-	-
DUODENUM:	-	-
EPIDIDYMIDES:	-	-
ESOPHAGUS:		
-inflammation, fibrinopurulent	-	<3>
-perforation	-	<P>
EYES:	-	-
HEART:		
-pericarditis, fibrinopurulent	-	<4>
ILEUM:	-	<->
JEJUNUM:	-	<->
KIDNEYS:		
-basophilia, cortical tubules, multifocal	-	1
-dilated tubule(s)/granular cast(s), medulla	3	2
-hyaline droplets, cortical tubules	P	P
LACRIMAL GLAND:	-	-
LIVER:		
-hypertrophy, hepatocellular, centrilobular	2	-
-necrosis, anoxic, centrilobular	-	3
LUNG:		
-congestion	<2>	-
-pleuritis, fibrinopurulent	-	<2>
LYMPH NODE, CERVICAL:	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-5 (Continued)

Histomorphologic Observations

Dose Group:	5A	5A
Animal Number (ICJ):	852	857
Sex:	M	M
Death Type:	SD	SD
LYMPH NODE, MESENTERIC:		
-congestion	-	<2>
MUSCLE, FEMORIS:	-	-
NERVE, SCIATIC:	*	-
PANCREAS:	-	-
PARATHYROID:	-	*
PITUITARY:	-	-
PROSTATE:	-	-
RECTUM:	-	-
SALIVARY GLANDS:	-	-
SEMINAL VESICLES:	-	-
SPINAL CORD, CERVICAL:	-	-
SPINAL CORD, MIDTHORACIC:	-	-
SPINAL CORD, LUMBAR:	-	-
SPLEEN:		
-atrophy	2	3
STOMACH:		
-hyperplasia/hyperkeratosis, nonglandular mucosa	<->	<2>
TESTES:	-	-
THYMUS:		
-atrophy	2	*
THYROID:	-	-
TRACHEA:	-	-
URINARY BLADDER:	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-6

Histomorphologic Observations

Dose Group:	5B	5B	5B	5B	5B	5B	5B	5B
Animal Number (ICJ):	853	856	862	864	866	879	894	895
Sex:	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS
ADRENAL GLANDS:								
-hypertrophy, zona glomerulosa	-	2	2	-	-	1	-	-
AORTA:	-	-	-	-	-	-	-	-
BONE (FEMUR):	-	-	-	-	-	-	-	-
BONE (STERNUM):	-	-	-	-	-	-	-	-
BONE MARROW (STERNUM):	-	-	-	-	-	-	-	-
BRAIN:	-	-	-	-	-	-	-	-
CECUM:	-	-	-	-	<->	-	<->	-
COLON:	-	-	-	-	-	-	-	-
DUODENUM:	-	-	-	-	-	-	-	-
EPIDIDYMIDES:	-	-	-	-	-	-	-	-
ESOPHAGUS:	-	-	-	-	-	-	-	-
EYES:								
-hemorrhage, periorbital, unilateral	3	-	-	-	1	-	-	-
HEART:								
-myocarditis, chronic, focal	-	-	1	-	-	-	1	-
-periarteritis	-	-	-	-	2	-	-	-
ILEUM:								
-distention	<2>	-	-	-	-	-	-	-
JEJUNUM:	-	-	-	-	-	-	-	-
KIDNEYS:								
-basophilia, cortical tubules, multifocal	-	1	1	-	-	-	-	-
-dilated tubule(s)/granular cast(s), medulla	-	1	1	-	-	-	1	1
-nephritis, chronic, multifocal	2	-	-	-	1	-	1	-
LACRIMAL GLAND:	-	-	-	-	-	-	-	-
LIVER:								
-infiltration, mononuclear-cell, multifocal	1	1	<1>	1	1	-	1	-
LUNG:								
-macrophages, alveoli, focal	-	-	1	-	-	-	-	-
-mineralization, vascular	-	1	-	-	-	-	-	-
LYMPH NODE, CERVICAL:								
-hyperplasia, lymphoid	-	-	3	-	-	-	-	-
LYMPH NODE, MESENTERIC:	-	-	-	-	-	-	-	-
MUSCLE, FEMORIS:	-	-	-	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-6 (Continued)

Histomorphologic Observations

Dose Group:	5B	5B	5B	5B	5B	5B	5B	5B
Animal Number (ICJ):	853	856	862	864	866	879	894	895
Sex:	M	M	M	M	M	M	M	M
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS
NERVE, SCIATIC:	-	-	-	-	-	-	-	-
PANCREAS:	-	-	-	-	-	-	-	-
PARATHYROID:	-	-	-	-	-	-	-	-
PITUITARY:								
-cyst(s), pars distalis	-	-	P	-	-	-	-	-
PROSTATE:	-	-	-	-	-	-	-	-
RECTUM:	-	-	-	-	-	-	-	-
SALIVARY GLANDS:	-	-	-	-	-	-	-	-
SEMINAL VESICLES:	-	-	-	-	-	-	-	-
SPINAL CORD, CERVICAL:	-	-	-	-	-	-	-	-
SPINAL CORD, MIDTHORACIC:	-	-	-	-	-	-	-	-
SPINAL CORD, LUMBAR:	-	-	-	-	-	-	-	-
SPLEEN:	-	-	-	-	-	-	-	-
STOMACH:								
-dilatation, mucosal glands	-	-	1	-	-	-	-	-
-hyperplasia/hyperkeratosis, nonglandular mucosa	2	-	1	-	1	-	-	-
TESTES:	-	-	-	-	-	-	-	-
THYMUS:	-	-	-	-	-	-	-	-
THYROID:	-	-	-	-	-	-	-	-
TRACHEA:								
-cystic tracheal glands	P	-	-	-	-	-	-	-
URINARY BLADDER:								
-cast, eosinophilic	-	-	P	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-7

Histomorphologic Observations

Dose Group:	1	1	1	1	1	1	1	1	1	1
Animal Number (ICJ):	908	911	916	918	942	948	951	957	962	968
Sex:	F	F	F	F	F	F	F	F	F	F
Death Type:	SD	SS	SS	SS	SS	SS	SS	SS	SS	SS
ADRENAL GLANDS:										
-hypertrophy, zona glomerulosa	-	-	-	-	-	-	3	-	-	-
AORTA:										
-inflammation, fibrinopurulent	3	-	-	-	-	-	-	-	-	-
BONE (FEMUR):	-	-	-	-	-	-	-	-	-	-
BONE (STERNUM):	-	-	-	-	-	-	-	-	-	-
BONE MARROW (STERNUM):	-	-	-	-	-	-	-	-	-	-
BRAIN:	-	-	-	-	-	-	-	-	-	-
CECUM:	-	-	-	-	-	-	-	-	-	-
CERVIX:	-	-	-	-	-	-	-	-	-	-
COLON:										
-distention	-	-	-	2	-	-	-	-	-	-
DUODENUM:	-	-	-	-	-	-	-	-	-	-
ESOPHAGUS:	-	-	-	-	-	-	-	-	-	-
EYES:										
-hemorrhage, periorbital, bilateral	-	-	-	-	-	-	3	-	-	-
-hemorrhage, periorbital, unilateral	-	1	-	-	-	-	-	2	-	4
HEART:										
-abscess	-	<P>	-	-	-	-	-	<P>	-	-
-pericarditis, chronic	-	<3>	-	-	-	-	-	-	-	-
-pericarditis, fibrinopurulent	<4>	-	-	-	-	-	-	<4>	-	-
ILEUM:	-	-	-	-	-	-	-	-	-	-
JEJUNUM:	-	-	-	-	-	*	-	-	*	-
KIDNEYS:										
-mineralization, multifocal	-	-	-	-	-	-	-	-	1	-
-mineralization, pelvic	-	-	-	-	-	-	-	-	-	1
LACRIMAL GLAND:	-	-	-	-	-	-	-	-	-	-
LIVER:										
-congestion	3	-	-	-	-	-	-	-	-	-
-infiltration, mononuclear-cell, multifocal	-	2	-	-	-	-	-	-	1	-
-necrosis, focal	-	-	-	-	1	-	-	-	-	-
-vacuolation, hepatocellular, periportal	-	-	1	-	-	-	-	-	-	2
LUNG:										
-congestion	<2>	-	-	-	-	-	-	-	-	-
-cyst(s)	-	-	-	<P>	-	-	-	-	-	-
-foreign material, intra-alveolar	<P>	-	-	-	-	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-7 (Continued)

Histomorphologic Observations

Dose Group:	1	1	1	1	1	1	1	1	1	1
Animal Number (ICJ):	908	911	916	918	942	948	951	957	962	968
Sex:	F	F	F	F	F	F	F	F	F	F
Death Type:	SD	SS	SS	SS	SS	SS	SS	SS	SS	SS
LUNG (Continued):										
-inflammation, granulomatous	-	-	-	<2>	-	-	-	-	-	-
-inflammation, interstitial, focal	-	-	1	<2>	-	-	-	-	-	-
-macrophages, alveoli, focal	-	-	1	<1>	-	1	-	-	-	-
-pleuritis, fibrinopurulent	<3>	-	-	-	-	-	-	-	-	-
LYMPH NODE, CERVICAL:										
-congestion	*	-	-	-	1	-	2	-	-	<2>
-hyperplasia, lymphoid	*	1	-	2	2	2	-	2	-	<3>
LYMPH NODE, MESENTERIC:	-	-	-	-	-	-	-	-	-	-
MAMMARY GLAND:	*	-	-	-	-	-	-	-	-	-
MUSCLE, FEMORIS:	-	-	-	-	-	-	-	-	-	-
NERVE, SCIATIC:	-	-	-	-	-	-	-	-	-	-
OVARIES:	-	-	-	-	-	-	-	-	(-)	-
PANCREAS:	-	-	-	-	-	-	-	-	-	-
PARATHYROID:	-	-	-	-	-	*	-	-	-	-
PITUITARY:	-	-	-	-	-	-	-	-	-	-
RECTUM:	-	-	-	-	-	-	-	-	-	-
SALIVARY GLANDS:	-	-	-	-	-	-	-	-	-	-
SKIN (GROSS LESION):	<*>									
SPINAL CORD, CERVICAL:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, MIDTHORACIC:	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, LUMBAR:	-	-	-	-	-	-	-	-	-	-
SPLEEN:										
-hyperplasia, red pulp	3	-	-	-	-	-	-	-	-	-
STOMACH:	-	-	-	-	-	-	-	-	-	-
THYMUS:										
-inflammation, granulomatous	*	-	*	*	-	-	-	2	-	-
THYROID:	-	-	-	-	-	-	-	-	-	-
TRACHEA:	-	-	-	-	-	-	-	-	-	-
URINARY BLADDER:	-	-	-	-	-	-	-	-	*	-
UTERUS:										
-cystic endometrial gland(s)	-	-	-	P	-	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-7 (Continued)

Histomorphologic Observations

Dose Group:	1	1	1	1	1	1	1	1	1	1
Animal Number (ICJ):	908	911	916	918	942	948	951	957	962	968
Sex:	F	F	F	F	F	F	F	F	F	F
Death Type:	SD	SS	SS	SS	SS	SS	SS	SS	SS	SS
UTERUS (Continued):										
-distention, lumen	-	-	-	-	-	-	-	1	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-8

Histomorphologic Observations

Dose Group:	2	2	2	2	2	2	2	2	2	2
Animal Number (ICJ):	917	921	925	927	930	943	954	956	959	960
Sex:	F	F	F	F	F	F	F	F	F	F
Death Type:	SS	SS	SS	SS	SS	SS	SS	SS	SS	SS
CECUM:	<->									
HEART:										
-pericarditis, chronic			<2>							
KIDNEYS:	-	-	-	-	-	-	-	-	-	-
LIVER:										
-hypertrophy, hepatocellular, centrilobular	-	1	1	-	<->	-	-	-	1	-
-infiltration, mononuclear-cell, multifocal	-	-	-	-	<->	1	-	1	-	-
-necrosis, focal	-	-	-	-	<->	1	-	-	-	-
-vacuolation, hepatocellular, periportal	-	-	-	-	<->	-	2	-	-	-
LUNG:										
-foreign material, intra-alveolar	-	-	-	-	P	-	-	-	-	P
-inflammation, interstitial, focal	-	-	-	-	1	-	-	-	-	2
-macrophages, alveoli, focal	1	-	-	-	-	1	-	-	-	-
LYMPH NODE, CERVICAL:										
-hyperplasia, lymphoid							<3>			
OVARIES:										
-cyst(s), paraovarian			<P>							
SKIN (GROSS LESION):										
-atrophy, hair follicle(s)									<1>	
STOMACH:										
-dilatation, mucosal glands	-	-	1	-	-	-	-	-	-	-
UTERUS:										
-distention, lumen										<3>

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-9

Histomorphologic Observations

Dose Group:	3	3	3	3	3	3	3	3	3	3
Animal Number (ICJ):	933	934	938	940	941	949	955	961	964	966
Sex:	F	F	F	F	F	F	F	F	F	F
Death Type:	SS	SS	SD	SS	SS	SS	SS	SS	SD	SS
ADRENAL GLANDS:			-						-	
AORTA:			-						-	
BONE (FEMUR):			-						-	
BONE (STERNUM):			-						-	
BONE MARROW (STERNUM):			-						-	
BRAIN:			-						-	
CECUM:			<->						-	
CERVIX:			-						-	
COLON:										
-distention			-				<2>		-	
DUODENUM:			*						-	
ESOPHAGUS:			-						-	
EYES:			-						-	
HEART:										
-dilatation, atrial			3						<->	
ILEUM:			-						-	
JEJUNUM:			<->		<->				-	
KIDNEYS:										
-mineralization, multifocal	-	-	-	-	-	-	-	2	-	-
LACRIMAL GLAND:			-						-	
LIVER:										
-hemosiderosis, focal	-	-	-	-	-	-	-	-	-	1
-hypertrophy, hepatocellular, centrilobular	1	2	2	1	1	2	-	2	1	1
-infiltration, mononuclear-cell, multifocal	-	-	-	-	1	-	-	-	-	-
-vacuolation, hepatocellular, multifocal	-	-	-	-	-	-	-	1	-	-
LUNG:										
-congestion	-	-	<2>	-	-	-	-	-	<2>	-
-edema	-	-	<2>	-	-	-	-	-	-	-
-foreign material, intra-alveolar	-	-	-	-	P	-	P	-	<P>	P
-inflammation, interstitial, focal	-	-	-	-	2	-	1	-	-	1
-macrophages, alveoli, focal	-	-	-	1	-	-	-	-	<1>	-
LYMPH NODE, CERVICAL:										
-hyperplasia, lymphoid			*						3	
LYMPH NODE, MESENTERIC:			-						-	

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-9 (Continued)

Histomorphologic Observations

Dose Group:	3	3	3	3	3	3	3	3	3	3
Animal Number (ICJ):	933	934	938	940	941	949	955	961	964	966
Sex:	F	F	F	F	F	F	F	F	F	F
Death Type:	SS	SS	SD	SS	SS	SS	SS	SS	SD	SS
MAMMARY GLAND:			-						-	
MUSCLE, FEMORIS:			-						-	
NERVE, SCIATIC:			-						-	
OVARIES:										
-cyst(s), intraovarian			-					<P>	-	
PANCREAS:			-						-	
PARATHYROID:			-						-	
PITUITARY:			-						-	
RECTUM:			-						-	
SALIVARY GLANDS:			-						-	
SPINAL CORD, CERVICAL:			-						-	
SPINAL CORD, MIDTHORACIC:			-						-	
SPINAL CORD, LUMBAR:			-						-	
SPLEEN:										
-atrophy			3						-	
STOMACH:										
-edema/inflammation, submucosa	-	-	<->	-	-	-	-	-	-	3
-hyperplasia/hyperkeratosis, nonglandular mucosa	1	1	<->	-	2	1	1	1	2	1
THYMUS:										
-hemorrhage			3						-	
THYROID:			-						-	
TRACHEA:			<->						-	
URINARY BLADDER:			-						-	
UTERUS:										
-cystic endometrial gland(s)			-						P	

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-10

Histomorphologic Observations

Dose Group:	4	4	4	4	4	4	4	4	4	4	4	4	4	4
Animal Number (ICJ):	909	910	912	914	922	923	924	932	935	939	944	950	958	969
Sex:	F	F	F	F	F	F	F	F	F	F	F	F	F	F
Death Type:	SS	SD	SS	SD	SS	SS	SS	SS	SD	SS	SS	SD	SS	SS
ADRENAL GLANDS:														
-hypertrophy, zona glomerulosa	-	-	-	-	-	-	-	-	2	-	-	-	-	-
ANUS:														
-hyperplasia/hyperkeratosis	<3>	<3>	<3>	<3>	<2>	<3>	<3>	<3>	<2>	<3>	<3>	<3>	<3>	<3>
-infiltration, neutrophilic/pustule(s)	<2>	<2>	<2>	<1>	<1>	<3>	<2>	<3>	<2>	<3>	<2>	<2>	<2>	<2>
AORTA:														
-inflammation, fibrinopurulent	-	3	-	-	-	-	-	-	*	-	-	3	-	-
BONE (FEMUR):	-	-	-	-	-	-	-	-	-	-	-	-	-	-
BONE (STERNUM):	-	-	-	-	-	-	-	-	-	-	-	-	-	-
BONE MARROW (STERNUM):														
-atrophy	-	-	-	-	-	-	-	-	2	-	-	-	-	-
BRAIN:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CECUM:	<->>	<->>	<->>	-	<->>	<->>	-	-	-	-	-	-	<->>	-
CERVIX:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
COLON:	-	-	-	-	<->>	<->>	-	-	-	-	-	-	-	-
DUODENUM:	-	-	-	-	-	-	-	-	<->>	-	-	<->>	-	-
ESOPHAGUS:														
-inflammation, fibrinopurulent	-	-	-	-	-	-	-	-	3	-	-	-	-	-
-necrosis, muscular wall, focal	-	-	-	-	-	-	-	-	-	-	-	-	1	-
-perforation	-	-	-	-	-	-	-	-	-	-	-	<P>	-	-
EYES:														
-cataract, unilateral	-	-	-	-	-	(-)	-	-	P	-	-	<->>	-	-
-hemorrhage, periorbital, unilateral	-	-	-	-	-	(-)	2	2	-	3	-	<->>	-	-
HEART:														
-pericarditis, fibrinopurulent	-	4	-	-	-	-	-	-	<4>	-	-	2	-	-
ILEUM:	-	-	-	-	-	-	-	-	-	-	-	<->>	-	-
JEJUNUM:														
-distention	-	-	-	-	-	-	-	-	<A>	-	-	<2>	<2>	-
KIDNEYS:														
-basophilia, cortical tubules, multifocal	-	-	-	-	-	-	-	-	-	-	-	-	1	-
LACRIMAL GLAND:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LIVER:														
-congestion	-	2	-	-	-	-	-	-	-	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-10 (Continued)

Histomorphologic Observations

Dose Group:	4	4	4	4	4	4	4	4	4	4	4	4	4	4
Animal Number (ICJ):	909	910	912	914	922	923	924	932	935	939	944	950	958	969
Sex:	F	F	F	F	F	F	F	F	F	F	F	F	F	F
Death Type:	SS	SD	SS	SD	SS	SS	SS	SS	SD	SS	SS	SD	SS	SS
LIVER (Continued):														
-hypertrophy, hepatocellular, centrilobular	1	-	1	2	2	1	-	2	-	1	1	-	2	1
-infiltration, mononuclear-cell, multifocal	-	-	-	-	1	-	1	-	-	-	-	-	-	-
LUNG:														
-congestion	-	<3>	-	<1>	-	-	-	-	<3>	-	-	<3>	-	-
-edema	-	-	-	-	-	-	-	-	<3>	-	-	-	-	-
-foreign material, intra-alveolar	-	-	-	<P>	-	-	-	-	-	<P>	-	<P>	-	-
-hemorrhage, focal	-	-	-	-	-	-	-	-	-	<3>	-	-	-	-
-inflammation, interstitial, focal	-	-	1	-	1	-	1	1	-	-	-	-	-	1
-macrophages, alveoli, focal	-	-	-	-	1	-	-	-	-	-	-	-	1	-
-pleuritis, fibrinopurulent	-	<3>	-	-	-	-	-	-	<3>	-	-	<3>	-	-
-pneumonia, acute	-	-	-	-	-	-	-	-	-	<2>	-	-	-	-
LYMPH NODE, CERVICAL:														
-congestion	-	-	<1>	-	-	-	-	-	-	2	-	-	<1>	-
-hyperplasia, lymphoid	2	-	<2>	-	-	-	2	-	-	-	3	-	-	-
LYMPH NODE, MESENTERIC:														
-congestion	-	-	-	-	-	3	-	-	-	-	-	-	-	-
MAMMARY GLAND:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MUSCLE, FEMORIS:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NERVE, SCIATIC:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
OVARIES:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
PANCREAS:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
PARATHYROID:	-	-	-	-	-	-	-	-	-	-	*	-	-	-
PITUITARY:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
RECTUM:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SALIVARY GLANDS:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, CERVICAL:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, MIDTHORACIC:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SPINAL CORD, LUMBAR:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SPLEEN:														
-atrophy	-	3	-	-	-	-	-	-	3	-	-	2	-	-
STOMACH:														
-hyperplasia/hyperkeratosis, nonglandular mucosa	3	<->	3	<2>	3	3	3	3	-	3	3	<->	3	2

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-10 (Continued)

Histomorphologic Observations

Dose Group:	4	4	4	4	4	4	4	4	4	4	4	4	4	4
Animal Number (ICJ):	909	910	912	914	922	923	924	932	935	939	944	950	958	969
Sex:	F	F	F	F	F	F	F	F	F	F	F	F	F	F
Death Type:	SS	SD	SS	SD	SS	SS	SS	SS	SD	SS	SS	SD	SS	SS
THYMUS:														
-atrophy	-	*	-	-	-	-	-	-	3	-	-	3	-	-
-inflammation, fibrinopurulent	-	*	-	-	-	-	-	-	4	-	-	4	-	-
THYROID:														
-hypertrophy/hyperplasia, follicular epithelium	-	-	-	-	3	-	-	-	-	-	-	-	-	-
TRACHEA:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
URINARY BLADDER:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
UTERUS:	-	-	-	-	-	-	-	-	-	-	-	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-11

Histomorphologic Observations

Dose Group:	5A	5A	5A
Animal Number (ICJ):	928	931	952
Sex:	F	F	F
Death Type:	SD	SD	SD
ADRENAL GLANDS:			
-congestion	-	3	-
ANUS:			
-hyperplasia/hyperkeratosis		<3>	
-infiltration, neutrophilic/pustule(s)		<2>	
-necrosis, mucosa		<2>	
AORTA:			
-inflammation, fibrinopurulent	-	-	3
BONE (FEMUR):	-	-	-
BONE (STERNUM):	-	-	-
BONE MARROW (STERNUM):	-	-	-
BRAIN:	-	-	-
CECUM:	A	-	<->
CERVIX:	-	-	-
COLON:	A	-	-
DUODENUM:	A	-	<->
ESOPHAGUS:	-	-	-
EYES:			
-cataract, bilateral	P	-	-
HEART:			
-pericarditis, fibrinopurulent	-	-	<4>
ILEUM:	-	-	<->
JEJUNUM:	A	-	<->
KIDNEYS:			
-mineralization, multifocal	-	-	1
LACRIMAL GLAND:	-	-	-
LIVER:			
-hypertrophy, hepatocellular, centrilobular	-	1	-
LUNG:			
-congestion	-	<3>	<3>
-foreign material, intra-alveolar	P	<P>	<P>
-hemorrhage, focal	2	-	-
-pleuritis, fibrinopurulent	-	-	<3>
LYMPH NODE, CERVICAL:			
-congestion	-	-	2

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-11 (Continued)

Histomorphologic Observations

Dose Group:	5A	5A	5A
Animal Number (ICJ):	928	931	952
Sex:	F	F	F
Death Type:	SD	SD	SD
LYMPH NODE, MESENTERIC:			
-hyperplasia, lymphoid	3	-	-
MAMMARY GLAND:	A	-	-
MUSCLE, FEMORIS:	-	-	-
NERVE, SCIATIC:	-	-	-
OVARIES:	-	-	-
PANCREAS:	-	-	-
PARATHYROID:	-	-	-
PITUITARY:	-	-	-
RECTUM:	-	-	-
SALIVARY GLANDS:	-	-	-
SPINAL CORD, CERVICAL:	-	-	-
SPINAL CORD, MIDTHORACIC:	-	-	-
SPINAL CORD, LUMBAR:	-	-	-
SPLEEN:	-	-	-
STOMACH:			
-hyperplasia/hyperkeratosis, nonglandular mucosa	A	2	-
THYMUS:			
-inflammation, fibrinopurulent	-	-	<4>
THYROID:	A	-	-
TRACHEA:	-	-	-
URINARY BLADDER:	-	-	-
UTERUS:			
-distention, lumen	2	3	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-12

Histomorphologic Observations

Dose Group:	5B	5B	5B
Animal Number (ICJ):	919	945	953
Sex:	F	F	F
Death Type:	SS	SS	SS
ADRENAL GLANDS:	-	-	-
AORTA:	-	-	-
BONE (FEMUR):	-	*	-
BONE (STERNUM):	-	-	-
BONE MARROW (STERNUM):	-	-	-
BRAIN:	-	-	-
CECUM:	-	<->	-
CERVIX:	-	-	-
COLON:	-	-	-
DUODENUM:	-	-	-
ESOPHAGUS:	-	-	-
EYES:	-	-	-
HEART:	-	-	-
ILEUM:	-	-	-
JEJUNUM:	-	-	-
KIDNEYS:	-	-	-
LACRIMAL GLAND:	-	-	-
LIVER:			
-infiltration, mononuclear-cell, multifocal	1	1	-
LUNG:	-	-	-
LYMPH NODE, CERVICAL:	-	-	-
LYMPH NODE, MESENTERIC:	-	-	-
MAMMARY GLAND:	-	-	-
MUSCLE, FEMORIS:	-	*	-
NERVE, SCIATIC:	-	*	-
OVARIES:	-	-	-
PANCREAS:	-	-	-
PARATHYROID:	-	-	-

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

TABLE I-12 (Continued)

Histomorphologic Observations

Dose Group:			
Animal Number (ICJ):	5B 919	5B 945	5B 953
Sex:	F	F	F
Death Type:	SS	SS	SS
PITUITARY:	-	-	-
RECTUM:	-	-	-
SALIVARY GLANDS:	-	-	-
SPINAL CORD, CERVICAL:	-	-	-
SPINAL CORD, MIDTHORACIC:	-	-	-
SPINAL CORD, LUMBAR:	-	-	-
SPLEEN:	-	-	-
STOMACH:			
-dilatation, mucosal glands	-	1	-
THYMUS:			
-cyst(s)	-	P	-
THYROID:	-	-	-
TRACHEA:	-	-	-
URINARY BLADDER:	-	-	-
UTERUS:			
-distention, lumen	2	<2>	<3>

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

HISTOPATHOLOGY

APPENDIX II

INDIVIDUAL ANIMAL GROSS AND HISTOMORPHOLOGY DATA

KEY TO CORRELATION OF HISTOMORPHOLOGIC OBSERVATIONS

Not applicable = Microscopic evaluation/correlation not appropriate or not required by protocol.

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ845
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

EYES:	hemorrhage, periorbital, unilateral (moderate)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
PANCREAS:	hyperplasia, islet-cell, focal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS
NERVE, SCIATIC	PARATHYROID	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
TESTES	THYMUS	THYROID	TRACHEA
URINARY BLADDER			

End of Record- ICJ845

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ848
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

EYES:	hemorrhage, periorbital, unilateral (moderate)
LIVER:	vacuolation, hepatocellular, periportal (slight)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (slight) congestion (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS (1)	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	HEART
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LUNG
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS
PARATHYROID	PITUITARY	PROSTATE	RECTUM
SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH	TESTES
THYMUS	THYROID	TRACHEA	URINARY BLADDER

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

ILEUM
ADRENAL GLANDS (1)

End of Record- ICJ848

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ861
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

LIVER: All lobes, pale.

RELATED HISTOPATHOLOGY:

infiltration, mononuclear-cell, multifocal
vacuolation, hepatocellular, midzonal

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:	basophilia, cortical tubules, multifocal (minimal)
LACRIMAL GLAND:	infiltration, lymphocytic (slight)
LIVER:	vacuolation, hepatocellular, midzonal (slight)
	infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	LUNG
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC
PANCREAS	PARATHYROID	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
TESTES	THYMUS	THYROID	TRACHEA
URINARY BLADDER			

End of Record- ICJ861

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ870
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Incisors, maloccluded (not taken).

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
KIDNEYS:	dilatation, pelvis (minimal)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
URINARY BLADDER:	cast, eosinophilic

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	LACRIMAL GLAND	LUNG
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC
PANCREAS	PARATHYROID	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
TESTES	THYMUS	THYROID	TRACHEA

COMMENTS:

RECTUM	The section submitted is from the anorectal junction (not remarkable).

End of Record- ICJ870

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ878
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Thoracic cavity, moderate amount of tan caseous material, present partially adhered to diaphragm and lungs.
LYMPH NODE: Mesenteric, reddened.

RELATED HISTOPATHOLOGY:

Not applicable

congestion, LYMPH NODE, MESENTERIC

HISTOMORPHOLOGIC OBSERVATIONS:

ESOPHAGUS:	inflammation, tunica muscularis, chronic (minimal)
EYES:	hemorrhage, periorbital, unilateral (slight)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
	vacuolation, hepatocellular, periportal (slight)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (slight)
LYMPH NODE, MESENTERIC:	congestion (minimal)
URINARY BLADDER:	cast, eosinophilic

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	HEART	ILEUM
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LUNG
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	STOMACH	TESTES	THYMUS
THYROID	TRACHEA		

End of Record- ICJ878

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ882
SEX: M

DOSE GROUP: 1
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
AORTA: Thoracic aorta, hole, approximately 0.1cm diameter, near bifurcation of trachea.	No microscopic change to correlate
GENERAL: Thoracic cavity, filled with dark red liquid.	Not applicable
LUNG: Mottled pink/dark red.	hemorrhage, acute, focal
STOMACH: Thin yellow material, gas.	No microscopic change to correlate

HISTOMORPHOLOGIC OBSERVATIONS:

AORTA:	No microscopic change to correlate
LUNG:	hemorrhage, acute, focal (moderate)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (slight)
STOMACH:	No microscopic change to correlate

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LIVER	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS
NERVE, SCIATIC	PANCREAS	PARATHYROID	PITUITARY
PROSTATE	RECTUM	SALIVARY GLANDS	SEMINAL VESICLES
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
STOMACH	TESTES	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

End of Record- ICJ882

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ885
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	vacuolation, cortex, diffuse (slight)
DUODENUM:	hypertrophy, zona glomerulosa (slight)
EYES:	ectopic pancreatic tissue
LUNG:	hemorrhage, periorbital, unilateral (minimal)
PANCREAS:	macrophages, alveoli, focal (minimal)
	infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	EPIDIDYMIDES
ESOPHAGUS	HEART	ILEUM	JEJUNUM
KIDNEYS	LACRIMAL GLAND	LIVER	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	STOMACH	TESTES	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ885

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ886
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
LIVER:	vacuolation, hepatocellular, centrilobular (slight)
LUNG:	inflammation, interstitial, focal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC
PANCREAS	PARATHYROID	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
TESTES	THYMUS	THYROID	TRACHEA
URINARY BLADDER			

End of Record- ICJ886

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ898
SEX: M

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS: accessory adrenocortical tissue

LIVER: hypertrophy, zona glomerulosa (moderate)
infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS
NERVE, SCIATIC	PANCREAS	PARATHYROID	PITUITARY
PROSTATE	RECTUM	SALIVARY GLANDS	SEMINAL VESICLES
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
STOMACH	TESTES	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

End of Record- ICJ898

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ904
SEX: M

DOSE GROUP: 1
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):

GENERAL: Skin/fur, snout, extreme amount of dry red material.
LUNG: All lobes and surfaces, dark red/black, tissue appears consolidated.

RELATED HISTOPATHOLOGY:

Not applicable

hemorrhage, focal
congestion
edema

HISTOMORPHOLOGIC OBSERVATIONS:

LUNG: hemorrhage, focal (moderate)
congestion (marked)
edema (marked)

PANCREAS: infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES (1)
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LIVER	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
TESTES	TRACHEA	URINARY BLADDER	

COMMENTS:

EYES/OPTIC NERVE: Some postmortem decomposition, but no lesions are observed (not remarkable).

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

EYES (1)
PARATHYROID
THYMUS
THYROID

End of Record- ICJ904

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ855
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Skin/fur, anogenital area, slight yellow staining (not taken).

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LIVER LUNG STOMACH

End of Record- ICJ855

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ859
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LIVER LUNG STOMACH

End of Record- ICJ859

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ872
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules

LIVER: basophilia, cortical tubules, multifocal (minimal)
infiltration, mononuclear-cell, multifocal (minimal)
hypertrophy, hepatocellular, centrilobular (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG STOMACH

End of Record- ICJ872

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ873
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules

LIVER: basophilia, cortical tubules, multifocal (minimal)
infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG STOMACH

End of Record- ICJ873

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ875
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: mineralization, multifocal (slight)
hyaline droplets, cortical tubules

LIVER: basophilia, cortical tubules, multifocal (minimal)
infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG STOMACH

End of Record- ICJ875

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ877
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:	hyaline droplets, cortical tubules
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
STOMACH:	dilatation, mucosal glands (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG

End of Record- ICJ877

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ884
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:

hyaline droplets, cortical tubules
basophilia, cortical tubules, multifocal (slight)
dilated tubule(s)/granular cast(s), medulla (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LIVER LUNG STOMACH

End of Record- ICJ884

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ887
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Incisors, maloccluded (not taken).

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules
basophilia, cortical tubules, multifocal (moderate)
dilated tubule(s)/granular cast(s), medulla (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LIVER LUNG STOMACH

End of Record- ICJ887

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ892
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules
basophilia, cortical tubules, multifocal (slight)
dilated tubule(s)/granular cast(s), medulla (moderate)

LIVER: hypertrophy, hepatocellular, centrilobular (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG STOMACH

End of Record- ICJ892

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ900
SEX: M

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules
LIVER: hypertrophy, hepatocellular, centrilobular (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG STOMACH

End of Record- ICJ900

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ846
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
GASTROINTESTINAL TRACT: Cecum, distended with gas, slight.	No microscopic change to correlate, CECUM
GENERAL: Skin/fur, anogenital area, brown staining.	Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
KIDNEYS:	hyaline droplets, cortical tubules basophilia, cortical tubules, multifocal (slight) dilated tubule(s)/granular cast(s), medulla (slight)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate) edema/inflammation, submucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

CECUM LIVER LUNG

End of Record- ICJ846

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ847
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Skin/fur, moderate yellow-brown staining, anogenital area (not taken).

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules

STOMACH: basophilia, cortical tubules, multifocal (slight)
hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LIVER LUNG

End of Record- ICJ847

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ850
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Skin/fur, anogenital area, slight yellow staining (not taken).

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:	hyaline droplets, cortical tubules
LIVER:	dilated tubule(s)/granular cast(s), medulla (minimal)
STOMACH:	hypertrophy, hepatocellular, centrilobular (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG

End of Record- ICJ850

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ881
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Skin/fur, anogenital area, moderate yellow staining (not taken); slight alopecia forepaws.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:	hyaline droplets, cortical tubules
-	basophilia, cortical tubules, multifocal (minimal)
LIVER:	dilated tubule(s)/granular cast(s), medulla (moderate)
STOMACH:	hypertrophy, hepatocellular, centrilobular (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG

End of Record- ICJ881

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ883
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Cecum, ingesta thinner than normal; jejunum, distended with yellow liquid, moderate.
GENERAL: Skin/fur, anogenital area, moderate yellow staining (not taken).

RELATED HISTOPATHOLOGY:

No microscopic change to correlate, JEJUNUM
No microscopic change to correlate, CECUM

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
JEJUNUM:	No microscopic change to correlate
KIDNEYS:	hyaline droplets, cortical tubules basophilia, cortical tubules, multifocal (minimal) dilated tubule(s)/granular cast(s), medulla (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

CECUM
STOMACH
JEJUNUM
LIVER
LUNG

End of Record- ICJ883

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ889
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: General condition, emaciated, slight; skin/fur, unthrifty coat (not taken).
LUNG: All lobes and surfaces, mottled pink/dark red.

RELATED HISTOPATHOLOGY:

Not applicable

foreign material, intra-alveolar hemorrhage, focal

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:	hyaline droplets, cortical tubules
LIVER:	basophilia, cortical tubules, multifocal (moderate)
LUNG:	infiltration, mononuclear-cell, multifocal (minimal)
	foreign material, intra-alveolar hemorrhage, focal (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

STOMACH

End of Record- ICJ889

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ890
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

TESTES: Both, smaller than normal, slight, flaccid.

RELATED HISTOPATHOLOGY:

atrophy, diffuse, bilateral

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:	hyaline droplets, cortical tubules
	basophilia, cortical tubules, multifocal (slight)
LIVER:	dilated tubule(s)/granular cast(s), medulla (minimal)
	infiltration, mononuclear-cell, multifocal (minimal)
STOMACH:	hypertrophy, hepatocellular, centrilobular (slight)
TESTES:	hyperplasia/hyperkeratosis, nonglandular mucosa (slight)
	atrophy, diffuse, bilateral (marked)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG

End of Record- ICJ890

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ893
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
GASTROINTESTINAL TRACT: Cecum, larger than normal, slight.	No microscopic change to correlate, CECUM
GENERAL: Skin/fur, slight yellow staining, anogenital area (not taken).	Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
KIDNEYS:	hyaline droplets, cortical tubules basophilia, cortical tubules, multifocal (moderate)
LIVER:	dilated tubule(s)/granular cast(s), medulla (moderate)
LUNG:	hypertrophy, hepatocellular, centrilobular (minimal)
STOMACH:	macrophages, alveoli, focal (minimal) edema/inflammation, submucosa (moderate) hyperplasia/hyperkeratosis, nonglandular mucosa (marked)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

CECUM

End of Record- ICJ893

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ896
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Skin/fur, slight yellow staining, anogenital area (not taken); general, emaciated, slight.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: hyaline droplets, cortical tubules

LIVER: basophilia, cortical tubules, multifocal (minimal)
hypertrophy, hepatocellular, centrilobular (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG STOMACH

End of Record- ICJ896

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ905
SEX: M

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Ileum, filled with thickened black material.

RELATED HISTOPATHOLOGY:

distention, ILEUM

HISTOMORPHOLOGIC OBSERVATIONS:

ILEUM:	distention (minimal)
KIDNEYS:	hyaline droplets, cortical tubules
	dilated tubule(s)/granular cast(s), medulla (minimal)
LUNG:	macrophages, alveoli, focal (minimal)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LIVER

End of Record- ICJ905

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ851
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen, slight.	infiltration, neutrophilic/pustule(s)
GASTROINTESTINAL TRACT: Cecum, larger than normal, extreme, vascularized, moderate; large intestine, distended with gas.	distention, COLON No microscopic change to correlate, CECUM distention, RECTUM
GENERAL: Skin/fur, anogenital area, slight yellow staining (not taken); general, emaciated, slight.	Not applicable
LYMPH NODE: Cervical, reddened, moderate.	congestion, LYMPH NODE, CERVICAL hyperplasia, lymphoid, LYMPH NODE, CERVICAL

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
ANUS:	infiltration, neutrophilic/pustule(s) (minimal)
CECUM:	No microscopic change to correlate
COLON:	distention (slight)
EYES:	hemorrhage, periorbital, unilateral (slight)
KIDNEYS:	hyaline droplets, cortical tubules basophilia, cortical tubules, multifocal (slight)
LUNG:	dilated tubule(s)/granular cast(s), medulla (slight)
LYMPH NODE, CERVICAL:	thrombus hyperplasia, lymphoid (moderate)
RECTUM:	congestion (minimal) distention (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	DUODENUM	EPIDIDYMIDES
ESOPHAGUS	HEART	ILEUM	JEJUNUM
LACRIMAL GLAND	LIVER	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS
NERVE, SCIATIC	PANCREAS	PARATHYROID	PITUITARY
PROSTATE	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
TESTES	THYMUS	THYROID	TRACHEA
URINARY BLADDER			

End of Record- ICJ851

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ867
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ADRENAL GLANDS: Both, pale.	No microscopic change to correlate
ANUS: Swollen, slight.	Tissue not available
GASTROINTESTINAL TRACT: Cecum, enlarged, slight, vascularized, moderate.	Tissue not available
GENERAL: Emaciated, slight.	No microscopic change to correlate, CECUM
	Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	No microscopic change to correlate
CECUM:	No microscopic change to correlate
KIDNEYS:	basophilia, cortical tubules, multifocal (moderate) hyaline droplets, cortical tubules dilated tubule(s)/granular cast(s), medulla (moderate)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	LACRIMAL GLAND
LIVER	LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PROSTATE	RECTUM	SALIVARY GLANDS	SEMINAL VESICLES
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
TESTES	THYMUS	THYROID	TRACHEA
URINARY BLADDER			

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

ANUS
ANUS
PITUITARY

End of Record- ICJ867

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ868
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen with scabs, moderate.	necrosis, mucosa infiltration, neutrophilic/pustule(s)
GASTROINTESTINAL TRACT: Cecum, distended, moderate, filled with thinner than normal ingesta.	No microscopic change to correlate, CECUM
GENERAL: Skin/fur, moderate yellow staining, anogenital area (not taken).	Not applicable
STOMACH: Thickened, slight.	hyperplasia/hyperkeratosis, nonglandular mucosa

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
ANUS:	necrosis, mucosa (marked) infiltration, neutrophilic/pustule(s) (marked)
CECUM:	No microscopic change to correlate
KIDNEYS:	basophilia, cortical tubules, multifocal (slight) hyaline droplets, cortical tubules
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (slight)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	LACRIMAL GLAND	LUNG
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	TESTES	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

PARATHYROID

End of Record- ICJ868

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ869
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Cecum, distended with green liquid material, slight.
GENERAL: Skin/fur, alopecia on trunk, posterior ventral (not taken).

RELATED HISTOPATHOLOGY:

No microscopic change to correlate. CECUM

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
KIDNEYS:	basophilia, cortical tubules, multifocal (slight) hyaline droplets, cortical tubules
LIVER:	dilated tubule(s)/granular cast(s), medulla (slight)
LUNG:	infiltration, mononuclear-cell, multifocal (minimal)
STOMACH:	inflammation, interstitial, focal (minimal) hyperplasia/hyperkeratosis, nonglandular mucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	LACRIMAL GLAND
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC
PANCREAS	PARATHYROID	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	TESTES
THYMUS	THYROID	TRACHEA	URINARY BLADDER

End of Record- ICJ869

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ871
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen.

GENERAL: Skin/fur, anogenital area, slight amount of yellow staining (not taken).

RELATED HISTOPATHOLOGY:

necrosis, mucosa
hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)
Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (minimal)
ANUS:	necrosis, mucosa (moderate)
	hyperplasia/hyperkeratosis (moderate)
	infiltration, neutrophilic/pustule(s) (moderate)
HEART:	myocarditis, chronic, focal (minimal)
KIDNEYS:	basophilia, cortical tubules, multifocal (slight)
	hyaline droplets, cortical tubules
LIVER:	lipidosis, tension, focal (minimal)
STOMACH:	edema/inflammation, submucosa (moderate)
	necrosis, glandular mucosa, focal (slight)
	hyperplasia/hyperkeratosis, nonglandular mucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	ILEUM
JEJUNUM	LACRIMAL GLAND	LUNG	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS
PARATHYROID	PITUITARY	PROSTATE	RECTUM
SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	TESTES	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

COMMENTS:

EYES/OPTIC NERVE — The lens is missing in both eyes, but all other ocular structures are not remarkable.

End of Record- ICJ871

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ874
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen, slight.	necrosis, mucosa
GASTROINTESTINAL TRACT: Cecum, ingesta thinner than normal.	infiltration, neutrophilic/pustule(s) No microscopic change to correlate, CECUM
GENERAL: General condition, emaciation, slight.	Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	necrosis, mucosa (slight)
CECUM:	infiltration, neutrophilic/pustule(s) (moderate)
EYES:	No microscopic change to correlate
KIDNEYS:	hemorrhage, periorbital, unilateral (moderate) dilated tubule(s)/granular cast(s), medulla (minimal) hyaline droplets, cortical tubules
LIVER:	basophilia, cortical tubules, multifocal (minimal)
LUNG:	hypertrophy, hepatocellular, centrilobular (minimal) macrophages, alveoli, focal (minimal)
LYMPH NODE, CERVICAL:	inflammation, interstitial, focal (minimal)
STOMACH:	hyperplasia, lymphoid (moderate) dilatation, mucosal glands (minimal) hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	HEART
ILEUM	JEJUNUM	LACRIMAL GLAND	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	TESTES	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

End of Record- ICJ874

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ891
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

GENERAL: General condition, emaciated, slight.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)
Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
KIDNEYS:	infiltration, neutrophilic/pustule(s) (slight)
	hyaline droplets, cortical tubules
	basophilia, cortical tubules, multifocal (moderate)
LIVER:	dilated tubule(s)/granular cast(s), medulla (moderate)
LUNG:	infiltration, mononuclear-cell, multifocal (minimal)
STOMACH:	macrophages, alveoli, focal (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES (1)	HEART
ILEUM	JEJUNUM	LACRIMAL GLAND	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS
PARATHYROID	PITUITARY	PROSTATE	RECTUM
SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	TESTES	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

ADRENAL GLANDS
EYES (1)

End of Record- ICJ891

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ899
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen, moderate.	infiltration, neutrophilic/pustule(s)
GASTROINTESTINAL TRACT: Ileum/jejunum, distended, slight, filled with thin yellow liquid.	hyperplasia/hyperkeratosis distention, JEJUNUM distention, ILEUM
GENERAL: Skin/fur, slight yellow staining, anogenital area (not taken).	Not applicable
STOMACH: Glandular and nonglandular portions thickened, slight.	hyperplasia/hyperkeratosis, nonglandular mucosa

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	vacuolation, cortex (moderate)
ANUS:	hypertrophy, zona glomerulosa (minimal) hyperplasia/hyperkeratosis (moderate)
ILEUM:	infiltration, neutrophilic/pustule(s) (moderate)
JEJUNUM:	distention (minimal)
KIDNEYS:	distention (minimal) hyaline droplets, cortical tubules basophilia, cortical tubules, multifocal (slight)
LIVER:	dilated tubule(s)/granular cast(s), medulla (slight)
STOMACH:	hypertrophy, hepatocellular, centrilobular (slight) hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	HEART
LACRIMAL GLAND	LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	TESTES	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

End of Record- ICJ899

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ902
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, moderate.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (slight)
EYES:	infiltration, neutrophilic/pustule(s) (minimal)
KIDNEYS:	hemorrhage, periorbital, unilateral (moderate)
	hyaline droplets, cortical tubules
	basophilia, cortical tubules, multifocal (minimal)
LIVER:	dilated tubule(s)/granular cast(s), medulla (moderate)
LUNG:	hypertrophy, hepatocellular, centrilobular (slight)
LYMPH NODE, CERVICAL:	macrophages, alveoli, focal (minimal)
STOMACH:	hyperplasia, lymphoid (slight)
	hyperplasia/hyperkeratosis, nonglandular mucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	HEART
ILEUM	JEJUNUM	LACRIMAL GLAND	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	TESTES	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

End of Record- ICJ902

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ907
SEX: M

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
ANUS:	hyperplasia/hyperkeratosis (moderate)
EYES:	infiltration, neutrophilic/pustule(s) (slight)
KIDNEYS:	hemorrhage, periorbital, unilateral (minimal)
	hyaline droplets, cortical tubules
	basophilia, cortical tubules, multifocal (slight)
LIVER:	dilated tubule(s)/granular cast(s), medulla (slight)
LUNG:	hypertrophy, hepatocellular, centrilobular (slight)
STOMACH:	macrophages, alveoli, focal (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	HEART	ILEUM
JEJUNUM	LACRIMAL GLAND	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	TESTES	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

End of Record- ICJ907

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ852
SEX: M

DOSE GROUP: 5A
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):

ANUS: Swollen.

GENERAL: Skin/fur, anogenital staining, extreme.
LUNG: All lobes and surfaces, mottled red.
STOMACH: Distended, moderate.

RELATED HISTOPATHOLOGY:

infiltration, neutrophilic/pustule(s)
necrosis, mucosa
hyperplasia/hyperkeratosis
Not applicable
congestion
No microscopic change to correlate

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	necrosis, mucosa (slight)
	hyperplasia/hyperkeratosis (moderate)
KIDNEYS:	infiltration, neutrophilic/pustule(s) (slight)
	hyaline droplets, cortical tubules
LIVER:	dilated tubule(s)/granular cast(s), medulla (moderate)
LUNG:	hypertrophy, hepatocellular, centrilobular (slight)
SPLEEN:	congestion (slight)
STOMACH:	atrophy (slight)
THYMUS:	No microscopic change to correlate
	atrophy (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	LACRIMAL GLAND
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	PANCREAS
PARATHYROID	PITUITARY	PROSTATE	RECTUM
SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	STOMACH	TESTES	THYROID
TRACHEA	URINARY BLADDER		

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

NERVE, SCIATIC

End of Record- ICJ852

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ857
SEX: M

DOSE GROUP: 5A
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen, moderate.	hyperplasia/hyperkeratosis
ESOPHAGUS: Hole, 0.3cm in diameter, 0.4cm above the lungs.	infiltration, neutrophilic/pustule(s) perforation
GASTROINTESTINAL TRACT: Small intestine, distended with amber liquid, moderate.	inflammation, fibrinopurulent
GENERAL: Skin/fur, anogenital area, moderate amount of amber staining around mouth; moderate amount of amber staining; thoracic cavity, contains moderate amount of red oily liquid.	No microscopic change to correlate, JEJUNUM No microscopic change to correlate, ILEUM Not applicable
HEART: Surrounded by tan material.	pericarditis, fibrinopurulent
LUNG: Diaphragmatic surfaces surrounded by tan material.	pleuritis, fibrinopurulent
LYMPH NODE: Mesenteric, dark red.	congestion, LYMPH NODE, MESENTERIC
STOMACH: Distended with gas, 2 times normal.	hyperplasia/hyperkeratosis, nonglandular mucosa

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
ESOPHAGUS:	infiltration, neutrophilic/pustule(s) (minimal) perforation
HEART:	inflammation, fibrinopurulent (moderate)
ILEUM:	pericarditis, fibrinopurulent (marked)
JEJUNUM:	No microscopic change to correlate
KIDNEYS:	No microscopic change to correlate hyaline droplets, cortical tubules basophilia, cortical tubules, multifocal (minimal)
LIVER:	dilated tubule(s)/granular cast(s), medulla (slight)
LUNG:	necrosis, anoxic, centrilobular (moderate)
LYMPH NODE, MESENTERIC:	pleuritis, fibrinopurulent (slight)
SPLEEN:	congestion (slight)
STOMACH:	atrophy (moderate) hyperplasia/hyperkeratosis, nonglandular mucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	EYES	ILEUM
JEJUNUM	LACRIMAL GLAND	LYMPH NODE, CERVICAL	MUSCLE, FEMORIS
NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	TESTES	THYROID
TRACHEA	URINARY BLADDER		

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

PARATHYROID
THYMUS

End of Record- ICJ857

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ853
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Ileum, distended with gas, moderate.

RELATED HISTOPATHOLOGY:

distention, ILEUM

HISTOMORPHOLOGIC OBSERVATIONS:

EYES:	hemorrhage, periorbital, unilateral (moderate)
ILEUM:	distention (slight)
KIDNEYS:	nephritis, chronic, multifocal (slight)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (slight)
TRACHEA:	cystic tracheal glands

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	HEART
JEJUNUM	LACRIMAL GLAND	LUNG	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS
PARATHYROID	PITUITARY	PROSTATE	RECTUM
SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	TESTES	THYMUS
THYROID	URINARY BLADDER		

End of Record- ICJ853

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ856
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
KIDNEYS:	basophilia, cortical tubules, multifocal (minimal)
	dilated tubule(s)/granular cast(s), medulla (minimal)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
LUNG:	mineralization, vascular (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	LACRIMAL GLAND	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS
PARATHYROID	PITUITARY	PROSTATE	RECTUM
SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH	TESTES
THYMUS	THYROID	TRACHEA	URINARY BLADDER

End of Record- ICJ856

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ862
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

LIVER: Medial lobe, parietal surface, cleft on the right portion of the lobe.

RELATED HISTOPATHOLOGY:

infiltration, mononuclear-cell, multifocal

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
HEART:	myocarditis, chronic, focal (minimal)
KIDNEYS:	basophilia, cortical tubules, multifocal (minimal)
	dilated tubule(s)/granular cast(s), medulla (minimal)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
LUNG:	macrophages, alveoli, focal (minimal)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (moderate)
PITUITARY:	cyst(s), pars distalis
STOMACH:	dilatation, mucosal glands (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)
URINARY BLADDER:	cast, eosinophilic

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	ILEUM
JEJUNUM	LACRIMAL GLAND	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS
NERVE, SCIATIC	PANCREAS	PARATHYROID	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	TESTES
THYMUS	THYROID	TRACHEA	

End of Record- ICJ862

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ864
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	STOMACH	TESTES	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ864

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ866
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Cecum, distended with gas, moderate.

RELATED HISTOPATHOLOGY:

No microscopic change to correlate, CECUM

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
EYES:	hemorrhage, periorbital, unilateral (minimal)
HEART:	periarteritis (slight)
KIDNEYS:	nephritis, chronic, multifocal (minimal)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	ILEUM
JEJUNUM	LACRIMAL GLAND	LUNG	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS
PARATHYROID	PITUITARY	PROSTATE	RECTUM
SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	TESTES	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ866

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ879
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS: hypertrophy, zona glomerulosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	COLON	DUODENUM
EPIDIDYMIDES	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LIVER	LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	STOMACH	TESTES	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ879

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ894
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Cecum, distended with gas, moderate.

RELATED HISTOPATHOLOGY:

No microscopic change to correlate, CECUM

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
HEART:	myocarditis, chronic, focal (minimal)
KIDNEYS:	dilated tubule(s)/granular cast(s), medulla (minimal) nephritis, chronic, multifocal (minimal)
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
ILEUM	JEJUNUM	LACRIMAL GLAND	LUNG
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MUSCLE, FEMORIS	NERVE, SCIATIC
PANCREAS	PARATHYROID	PITUITARY	PROSTATE
RECTUM	SALIVARY GLANDS	SEMINAL VESICLES	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
TESTES	THYMUS	THYROID	TRACHEA
URINARY BLADDER			

End of Record- ICJ894

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ895
SEX: M

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: dilated tubule(s)/granular cast(s), medulla (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	COLON
DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	LACRIMAL GLAND
LIVER	LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	PANCREAS	PARATHYROID
PITUITARY	PROSTATE	RECTUM	SALIVARY GLANDS
SEMINAL VESICLES	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	STOMACH	TESTES	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ895

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ908
SEX: F

DOSE GROUP: 1
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):

GENERAL: Skin/fur, extreme yellow brown staining, anogenital area; dried red nasal discharge; unthrifty; general condition, emaciated, extreme; thoracic cavity contains moderate amount of thin clear fluid and moderate amount of tan caseous material.
HEART: Roughened surface.
LUNG: Mottled red/dark red with tan caseous material adhering to all lobes and surfaces.

SKIN: Scabs on head.

RELATED HISTOPATHOLOGY:

Not applicable

pericarditis, fibrinopurulent
pleuritis, fibrinopurulent
congestion
foreign material, intra-alveolar
Tissue not available, SKIN (GROSS LESION)

HISTOMORPHOLOGIC OBSERVATIONS:

AORTA:	
HEART:	inflammation, fibrinopurulent (moderate)
LIVER:	pericarditis, fibrinopurulent (marked)
LUNG:	congestion (moderate)
	congestion (slight)
	pleuritis, fibrinopurulent (moderate)
SPLEEN:	foreign material, intra-alveolar
	hyperplasia, red pulp (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	CERVIX	COLON
DUODENUM	ESOPHAGUS	EYES	ILEUM
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LYMPH NODE, MESENTERIC
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	STOMACH
THYROID	TRACHEA	URINARY BLADDER	UTERUS

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

LYMPH NODE, CERVICAL
MAMMARY GLAND
SKIN (GROSS LESION)
THYMUS

End of Record- ICJ908

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ911
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

HEART: Heart/pericardium, extreme amount of tan/yellow caseous material surrounding heart.

RELATED HISTOPATHOLOGY:

pericarditis, chronic
abscess

HISTOMORPHOLOGIC OBSERVATIONS:

EYES:	hemorrhage, periorbital, unilateral (minimal)
HEART:	pericarditis, chronic (moderate)
	abscess
LIVER:	infiltration, mononuclear-cell, multifocal (slight)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	ILEUM
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LUNG
LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH	THYMUS
THYROID	TRACHEA	URINARY BLADDER	UTERUS

End of Record- ICJ911

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ916
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: vacuolation, hepatocellular, periportal (minimal)
LUNG: macrophages, alveoli, focal (minimal)
inflammation, interstitial, focal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
STOMACH	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

THYMUS

End of Record- ICJ916

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ918
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Thoracic cavity, contains moderate amount of frothy oily liquid.
LUNG: Apical lobe, tan area, 0.4cm in diameter.

RELATED HISTOPATHOLOGY:

Not applicable

cyst(s)
inflammation, interstitial, focal
macrophages, alveoli, focal
inflammation, granulomatous

HISTOMORPHOLOGIC OBSERVATIONS:

COLON:	distention (slight)
LUNG:	cyst(s) inflammation, granulomatous (slight) macrophages, alveoli, focal (minimal)
LYMPH NODE, CERVICAL:	inflammation, interstitial, focal (slight)
UTERUS:	hyperplasia, lymphoid (slight) cystic endometrial gland(s)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
DUODENUM	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LIVER	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
THYROID	TRACHEA	URINARY BLADDER	

COMMENTS:

EYES/OPTIC NERVE	There is no lens in one eye, but all other ocular structures are normal (not remarkable).

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

THYMUS

End of Record- ICJ918

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ942
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER:	necrosis, focal (minimal)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (slight) congestion (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LUNG	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
STOMACH	THYMUS	THYROID	TRACHEA
URINARY BLADDER	UTERUS		

End of Record- ICJ942

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ948
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LUNG:	macrophages, alveoli, focal (minimal)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	KIDNEYS	LACRIMAL GLAND
LIVER	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH	THYMUS
THYROID	TRACHEA	URINARY BLADDER	UTERUS

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

JEJUNUM
PARATHYROID

End of Record- ICJ948

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ951
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (moderate)
EYES:	hemorrhage, periorbital, bilateral (moderate)
LYMPH NODE, CERVICAL:	congestion (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	CERVIX	COLON
DUODENUM	ESOPHAGUS	HEART	ILEUM
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LIVER
LUNG	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
THYMUS	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

End of Record- ICJ951

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ957
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

HEART: Surrounded by extreme amount hard tan material.

RELATED HISTOPATHOLOGY:

pericarditis, fibrinopurulent
abscess

HISTOMORPHOLOGIC OBSERVATIONS:

EYES:	hemorrhage, periorbital, unilateral (slight)
HEART:	pericarditis, fibrinopurulent (marked) abscess
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (slight)
THYMUS:	inflammation, granulomatous (slight)
UTERUS:	distention, lumen (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	ILEUM
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LIVER
LUNG	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
THYROID	TRACHEA	URINARY BLADDER	

COMMENTS:

THYMUS	The inflammation is in the connective tissues and on the capsule around the thymus.
THYMUS	Slight granulomatous inflammation in the connective tissues and capsule around the thymus.

End of Record- ICJ957

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ962
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS: mineralization, multifocal (minimal)
LIVER: infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	LACRIMAL GLAND	LUNG
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES (1)	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH
THYMUS	THYROID	TRACHEA	UTERUS

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

JEJUNUM
OVARIES (1)
URINARY BLADDER

End of Record- ICJ962

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ968
SEX: F

DOSE GROUP: 1
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

LYMPH NODE: Cervical, dark red.

RELATED HISTOPATHOLOGY:

congestion, LYMPH NODE, CERVICAL
hyperplasia, lymphoid, LYMPH NODE, CERVICAL

HISTOMORPHOLOGIC OBSERVATIONS:

EYES:	hemorrhage, periorbital, unilateral (marked)
KIDNEYS:	mineralization, pelvic (minimal)
LIVER:	vacuolation, hepatocellular, periportal (slight)
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (moderate)
	congestion (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	HEART
ILEUM	JEJUNUM	LACRIMAL GLAND	LUNG
LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH	THYMUS
THYROID	TRACHEA	URINARY BLADDER	UTERUS

COMMENTS:

NERVE, SCIATIC — Present on the muscle section (not remarkable).

End of Record- ICJ968

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ917
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Cecum, distended, slight, ingesta thinner than normal.

RELATED HISTOPATHOLOGY:

No microscopic change to correlate, CECUM

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:
LUNG: No microscopic change to correlate
macrophages, alveoli, focal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

CECUM KIDNEYS LIVER STOMACH

End of Record- ICJ917

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ921
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: hypertrophy, hepatocellular, centrilobular (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG STOMACH

End of Record- ICJ921

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ925
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
GENERAL: Thoracic cavity, moderate amount thin tan liquid.	Not applicable
HEART: Surrounded by slight amount caseous tan material.	pericarditis, chronic
OVARIES: Left, larger than normal, slight, appears ruptured.	cyst(s), paraovarian

HISTOMORPHOLOGIC OBSERVATIONS:

HEART:	pericarditis, chronic (slight)
LIVER:	hypertrophy, hepatocellular, centrilobular (minimal)
OVARIES:	cyst(s), paraovarian
STOMACH:	dilatation, mucosal glands (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG

End of Record- ICJ925

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ927
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LIVER LUNG STOMACH

End of Record- ICJ927

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ930
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

LIVER: Median lobe, right cleft, visceral surface, tan area. 0.3cm in diameter.

RELATED HISTOPATHOLOGY:

No microscopic change to correlate

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: No microscopic change to correlate
LUNG: inflammation, interstitial, focal (minimal)
foreign material, intra-alveolar

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LIVER STOMACH

End of Record- ICJ930

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ943
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: infiltration, mononuclear-cell, multifocal (minimal)

LUNG: necrosis, focal (minimal)
macrophages, alveoli, focal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS STOMACH

End of Record- ICJ943

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ954
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Teeth, right upper incisor broken (not taken).
LYMPH NODE: Cervical, red.

RELATED HISTOPATHOLOGY:

Not applicable

hyperplasia, lymphoid, LYMPH NODE, CERVICAL

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: vacuolation, hepatocellular, periportal (slight)
LYMPH NODE, CERVICAL: hyperplasia, lymphoid (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG STOMACH

End of Record- ICJ954

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ956
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: infiltration, mononuclear-cell, multifocal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG STOMACH

End of Record- ICJ956

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ959
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

SKIN: Skin/fur, alopecia, both forelegs.

RELATED HISTOPATHOLOGY:

atrophy, hair follicle(s), SKIN (GROSS LESION)

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: hypertrophy, hepatocellular, centrilobular (minimal)
SKIN (GROSS LESION): atrophy, hair follicle(s) (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG STOMACH

End of Record- ICJ959

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ960
SEX: F

DOSE GROUP: 2
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

UTERUS: Distended, moderate.

RELATED HISTOPATHOLOGY:

distention, lumen

HISTOMORPHOLOGIC OBSERVATIONS:

LUNG: inflammation, interstitial, focal (slight)
foreign material, intra-alveolar

UTERUS: distention, lumen (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LIVER STOMACH

End of Record- ICJ960

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ933
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: hypertrophy, hepatocellular, centrilobular (minimal)
STOMACH: hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG

End of Record- ICJ933

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ934
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: hypertrophy, hepatocellular, centrilobular (slight)
STOMACH: hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG

End of Record- ICJ934

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ938
SEX: F

DOSE GROUP: 3
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
GASTROINTESTINAL TRACT: Cecum, distended with gas, moderate; jejunum, filled with moderate amount thickened black material.	No microscopic change to correlate, JEJUNUM No microscopic change to correlate, CECUM
GENERAL: Skin/fur, anogenital area, moderate amount yellow staining; snout, extreme amount dry dark red material.	Not applicable
LUNG: All lobes and surfaces, mottled red/dark red, moderate.	congestion edema
STOMACH: Distended, extreme; moderate amount thickened black material, mucosa red, extreme.	No microscopic change to correlate
TRACHEA: Reddened, moderate.	No microscopic change to correlate

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
HEART:	dilatation, atrial (moderate)
JEJUNUM:	No microscopic change to correlate
LIVER:	hypertrophy, hepatocellular, centrilobular (slight)
LUNG:	congestion (slight) edema (slight)
SPLEEN:	atrophy (moderate)
STOMACH:	No microscopic change to correlate
THYMUS:	hemorrhage (moderate)
TRACHEA:	No microscopic change to correlate

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	ESOPHAGUS	EYES	ILEUM
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LYMPH NODE, MESENTERIC
MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES
PANCREAS	PARATHYROID	PITUITARY	RECTUM
SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
STOMACH	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

DUODENUM
LYMPH NODE, CERVICAL

End of Record- ICJ938

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ940
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: hypertrophy, hepatocellular, centrilobular (minimal)
LUNG: macrophages, alveoli, focal (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS STOMACH

End of Record- ICJ940

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ941
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Jejunum, distended with yellow liquid, slight.

RELATED HISTOPATHOLOGY:

No microscopic change to correlate, JEJUNUM

HISTOMORPHOLOGIC OBSERVATIONS:

JEJUNUM:	No microscopic change to correlate
LIVER:	infiltration, mononuclear-cell, multifocal (minimal) hypertrophy, hepatocellular, centrilobular (minimal)
LUNG:	inflammation, interstitial, focal (slight) foreign material, intra-alveolar
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

JEJUNUM KIDNEYS

End of Record- ICJ941

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ949
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: Skin/fur, slight staining in anogenital area (not taken); skin/fur, right forepaw, slight alopecia.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER:	hypertrophy, hepatocellular, centrilobular (slight)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LUNG

End of Record- ICJ949

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ955
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
GASTROINTESTINAL TRACT: Colon, distended with gas, extreme.	distention, COLON

HISTOMORPHOLOGIC OBSERVATIONS:

COLON:	distention (slight)
LUNG:	inflammation, interstitial, focal (minimal) foreign material, intra-alveolar
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS LIVER

End of Record- ICJ955

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ961
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
GENERAL: Skin/fur, slight yellow anogenital staining (not taken).	Not applicable
OVARIES: Right, two black foci, <0.1cm diameter, embedded in ovary.	cyst(s), intraovarian

HISTOMORPHOLOGIC OBSERVATIONS:

KIDNEYS:	mineralization, multifocal (slight)
LIVER:	vacuolation, hepatocellular, multifocal (minimal)
	hypertrophy, hepatocellular, centrilobular (slight)
OVARIES:	cyst(s), intraovarian
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

LUNG

COMMENTS:

KIDNEYS	Small amount of multifocal mineralization at the corticomedullary junction.
OVARIES	The cyst is filled with blood.

End of Record- ICJ961

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ964
SEX: F

DOSE GROUP: 3
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
GENERAL: Skin/fur, snout, moderate amount of clear oral discharge (not taken); thoracic cavity, filled with extreme amount of thin red liquid.	Not applicable
HEART: Heart/pericardium, surrounded by extreme amount of thickened dark red material.	No microscopic change to correlate
LUNG: All lobes and surfaces, tissue appears consolidated, mottled red/dark red.	foreign material, intra-alveolar congestion macrophages, alveoli, focal

HISTOMORPHOLOGIC OBSERVATIONS:

HEART:	No microscopic change to correlate
LIVER:	hypertrophy, hepatocellular, centrilobular (minimal)
LUNG:	macrophages, alveoli, focal (minimal) congestion (slight) foreign material, intra-alveolar
LYMPH NODE, CERVICAL:	hyperplasia, lymphoid (moderate)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (slight)
UTERUS:	cystic endometrial gland(s)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ964

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ966
SEX: F

DOSE GROUP: 3
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER:	hemosiderosis, focal (minimal)
LUNG:	hypertrophy, hepatocellular, centrilobular (minimal) inflammation, interstitial, focal (minimal) foreign material, intra-alveolar
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (minimal) edema/inflammation, submucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

KIDNEYS

End of Record- ICJ966

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ909
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

GASTROINTESTINAL TRACT: Cecum, ingesta thinner than normal, distended, slight.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)
No microscopic change to correlate, CECUM

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
CECUM:	infiltration, neutrophilic/pustule(s) (slight)
LIVER:	No microscopic change to correlate
LYMPH NODE, CERVICAL:	hypertrophy, hepatocellular, centrilobular (minimal)
STOMACH:	hyperplasia, lymphoid (slight)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LUNG	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
THYMUS	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

COMMENTS:

LIVER — The hypertrophy is predominantly in centrilobular areas.

End of Record- ICJ909

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ910
SEX: F

DOSE GROUP: 4
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen.	hyperplasia/hyperkeratosis infiltration, neutrophilic/pustule(s)
GASTROINTESTINAL TRACT: Cecum, contains moderate amount of hardened ingesta.	No microscopic change to correlate, CECUM
GENERAL: Thoracic cavity, contains extreme amount of oily pale red liquid; skin/fur, posterior dorsal, thin hair coat.	Not applicable
LUNG: All lobes and surfaces, encased with fibrous adhesions, slight.	pleuritis, fibrinopurulent congestion
STOMACH: Contains moderate amount of yellow ingesta.	No microscopic change to correlate

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
AORTA:	infiltration, neutrophilic/pustule(s) (slight)
CECUM:	inflammation, fibrinopurulent (moderate)
HEART:	No microscopic change to correlate
LIVER:	pericarditis, fibrinopurulent (marked)
LUNG:	congestion (slight) congestion (moderate)
SPLEEN:	pleuritis, fibrinopurulent (moderate)
STOMACH:	atrophy (moderate) No microscopic change to correlate

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	CERVIX	COLON
DUODENUM	ESOPHAGUS	EYES	ILEUM
JEJUNUM	KIDNEYS	LACRIMAL GLAND	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	STOMACH	THYROID	TRACHEA
URINARY BLADDER	UTERUS		

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

THYMUS

End of Record- ICJ910

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ912
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, moderate.

GASTROINTESTINAL TRACT: Cecum, enlarged, slight.
LYMPH NODE: Cervical, red.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)
No microscopic change to correlate, CECUM
hyperplasia, lymphoid, LYMPH NODE, CERVICAL
congestion, LYMPH NODE, CERVICAL

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
CECUM:	infiltration, neutrophilic/pustule(s) (slight)
LIVER:	No microscopic change to correlate
LUNG:	hypertrophy, hepatocellular, centrilobular (minimal)
LYMPH NODE, CERVICAL:	inflammation, interstitial, focal (minimal)
	hyperplasia, lymphoid (slight)
STOMACH:	congestion (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS
THYROID	TRACHEA	URINARY BLADDER	UTERUS

COMMENTS:

LIVER — The hypertrophy is predominantly in centrilobular areas.

End of Record- ICJ912

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ914
SEX: F

DOSE GROUP: 4
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen, slight.	hyperplasia/hyperkeratosis
GENERAL: Skin/fur, snout, moderate amount clear oral discharge; thoracic cavity, moderate amount of thin clear liquid.	infiltration, neutrophilic/pustule(s) Not applicable
LUNG: All lobes and surfaces, dark red; tissue appears consolidated.	foreign material, intra-alveolar congestion
STOMACH: Distended, slight; slight amount of gas and ingesta.	hyperplasia/hyperkeratosis, nonglandular mucosa

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
LIVER:	infiltration, neutrophilic/pustule(s) (minimal)
LUNG:	hypertrophy, hepatocellular, centrilobular (slight) congestion (minimal)
STOMACH:	foreign material, intra-alveolar hyperplasia/hyperkeratosis, nonglandular mucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
THYMUS	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

COMMENTS:

LIVER	The hypertrophy is predominantly in centrilobular areas.

End of Record- ICJ914

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ922
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

GASTROINTESTINAL TRACT: Cecum, distended with ingesta, moderate; colon, distended with feces, moderate.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)
No microscopic change to correlate, COLON
No microscopic change to correlate, CECUM

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (slight)
CECUM:	infiltration, neutrophilic/pustule(s) (minimal)
COLON:	No microscopic change to correlate
LIVER:	No microscopic change to correlate
	infiltration, mononuclear-cell, multifocal (minimal)
LUNG:	hypertrophy, hepatocellular, centrilobular (slight)
	macrophages, alveoli, focal (minimal)
STOMACH:	inflammation, interstitial, focal (minimal)
THYROID:	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)
	hypertrophy/hyperplasia, follicular epithelium (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
THYMUS	TRACHEA	URINARY BLADDER	UTERUS

COMMENTS:

LIVER — The hypertrophy is predominantly in centrilobular areas.

End of Record- ICJ922

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ923
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

GASTROINTESTINAL TRACT: Colon, distended with gas, extreme; cecum, larger than normal, slight.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)
No microscopic change to correlate, COLON
No microscopic change to correlate, CECUM

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
	infiltration, neutrophilic/pustule(s) (moderate)
CECUM:	No microscopic change to correlate
COLON:	No microscopic change to correlate
LIVER:	hypertrophy, hepatocellular, centrilobular (minimal)
LYMPH NODE, MESENTERIC:	congestion (moderate)
STOMACH:	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES (1)
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LUNG	LYMPH NODE, CERVICAL	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
THYMUS	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

COMMENTS:

EYES/OPTIC NERVE	The lens is not present in the eye section, but all other ocular structures are normal (not remarkable).
LIVER	The hypertrophy is predominantly in centrilobular areas.

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

EYES (1)

End of Record- ICJ923

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ924
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

GENERAL: Skin/fur, alopecia, left flank (not taken).

RELATED HISTOPATHOLOGY:

infiltration, neutrophilic/pustule(s)
hyperplasia/hyperkeratosis
Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
EYES:	infiltration, neutrophilic/pustule(s) (slight)
LIVER:	hemorrhage, periorbital, unilateral (slight)
LUNG:	infiltration, mononuclear-cell, multifocal (minimal)
LYMPH NODE, CERVICAL:	inflammation, interstitial, focal (minimal)
STOMACH:	hyperplasia, lymphoid (slight)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS	THYROID
TRACHEA	URINARY BLADDER	UTERUS	

End of Record- ICJ924

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ932
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
EYES:	infiltration, neutrophilic/pustule(s) (moderate)
LIVER:	hemorrhage, periorbital, unilateral (slight)
LUNG:	hypertrophy, hepatocellular, centrilobular (slight)
STOMACH:	inflammation, interstitial, focal (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS
THYROID	TRACHEA	URINARY BLADDER	UTERUS

COMMENTS:

LIVER — The hypertrophy is predominantly in centrilobular areas.

End of Record- ICJ932

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ935
SEX: F

DOSE GROUP: 4
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen.	hyperplasia/hyperkeratosis infiltration, neutrophilic/pustule(s)
GASTROINTESTINAL TRACT: Duodenum/jejunum, contains moderate amount of yellow ingesta.	No microscopic change to correlate, DUODENUM Advanced autolysis precludes evaluation, JEJUNUM
GENERAL: Skin/fur, anogenital area, moderate yellow staining; general condition, emaciated, moderate; thoracic cavity, contains extreme amount of clear liquid.	Not applicable
HEART: Surrounded by extreme amount of tan material.	pericarditis, fibrinopurulent
LUNG: Surrounded by extreme amount of tan material; left lobe, hole in the bronchi.	edema congestion pleuritis, fibrinopurulent

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	hypertrophy, zona glomerulosa (slight)
ANUS:	hyperplasia/hyperkeratosis (slight) infiltration, neutrophilic/pustule(s) (slight)
BONE MARROW (STERNUM):	atrophy (slight)
DUODENUM:	No microscopic change to correlate
ESOPHAGUS:	inflammation, fibrinopurulent (moderate)
EYES:	cataract, unilateral
HEART:	pericarditis, fibrinopurulent (marked)
JEJUNUM:	Advanced autolysis precludes evaluation
LUNG:	congestion (moderate) edema (moderate)
SPLEEN:	pleuritis, fibrinopurulent (moderate)
THYMUS:	atrophy (moderate) inflammation, fibrinopurulent (marked) atrophy (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

BONE (FEMUR)	BONE (STERNUM)	BRAIN	CECUM
CERVIX	COLON	DUODENUM	ILEUM
KIDNEYS	LACRIMAL GLAND	LIVER	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	STOMACH	THYROID	TRACHEA
URINARY BLADDER	UTERUS		

COMMENTS:

ESOPHAGUS	Present on the heart section (moderate fibrinopurulent inflammation around the periphery).

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

AORTA

CONTINUED- ICJ935

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ935
SEX: F

DOSE GROUP: 4
DEATH TYPE: Spontaneous Death

AUTOLYSIS PRECLUDES EVALUATION:

JEJUNUM

End of Record- ICJ935

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ939
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, slight.

LUNG: All lobes and surfaces, mottled pink/dark red.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutropnilic/pustule(s)
pneumonia, acute
hemorrhage, focal
foreign material, intra-alveolar

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
EYES:	infiltration, neutropnilic/pustule(s) (moderate)
LIVER:	hemorrhage, periorbital, unilateral (moderate)
LUNG:	hypertrophy, hepatocellular, centrilobular (minimal)
	pneumonia, acute (slight)
	hemorrhage, focal (moderate)
LYMPH NODE, CERVICAL:	foreign material, intra-alveolar
STOMACH:	congestion (slight)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS	THYROID
TRACHEA	URINARY BLADDER	UTERUS	

COMMENTS:

LIVER — The hypertrophy is predominantly in centrilobular areas.

End of Record- ICJ939

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ944
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, moderate.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
LIVER:	infiltration, neutrophilic/pustule(s) (slight)
LYMPH-NODE, CERVICAL:	hypertrophy, hepatocellular, centrilobular (minimal)
STOMACH:	hyperplasia, lymphoid (moderate)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LUNG	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS
THYROID	TRACHEA	URINARY BLADDER	UTERUS

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

PARATHYROID

End of Record- ICJ944

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ950
SEX: F

DOSE GROUP: 4
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):

	RELATED HISTOPATHOLOGY:
ANUS: Swollen.	hyperplasia/hyperkeratosis
ESOPHAGUS: Hole, 0.8cm, approximately 2.5cm from the base of the tongue.	infiltration, neutrophilic/pustule(s) perforation
EYES: Left- clear discharge.	No microscopic change to correlate
GASTROINTESTINAL TRACT: Small intestine, contains moderate amount of amber liquid.	No microscopic change to correlate, DUODENUM distention, JEJUNUM No microscopic change to correlate, ILEUM
GENERAL: Skin/fur, alopecia, left lateral abdomen and left ventral abdomen;thoracic cavity contains extremeamount of clear oil like material; lungs surrounded by tan fibrous material.	Not applicable
LUNG: Surrounded by tan fibrous material; all lobes and surfaces, dark red.	congestion pleuritis, fibrinopurulent foreign material, intra-alveolar
STOMACH: Contains moderate amount of yellow viscous liquid.	No microscopic change to correlate

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
AORTA:	infiltration, neutrophilic/pustule(s) (slight)
DUODENUM:	inflammation, fibrinopurulent (moderate)
ESOPHAGUS:	No microscopic change to correlate
EYES:	perforation
HEART:	No microscopic change to correlate
ILEUM:	pericarditis, fibrinopurulent (slight)
JEJUNUM:	No microscopic change to correlate
LUNG:	distention (slight) congestion (moderate) pleuritis, fibrinopurulent (moderate) foreign material, intra-alveolar
SPLEEN:	atrophy (slight)
STOMACH:	No microscopic change to correlate
THYMUS:	atrophy (moderate) inflammation, fibrinopurulent (marked)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	CERVIX	COLON
DUODENUM	EYES	ILEUM	KIDNEYS
LACRIMAL GLAND	LIVER	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES
PANCREAS	PARATHYROID	PITUITARY	RECTUM
SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
STOMACH	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

COMMENTS:

AORTA — Moderate fibrinopurulent inflammation around the periphery.

CONTINUED- ICJ950

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ950
SEX: F

DOSE GROUP: 4
DEATH TYPE: Spontaneous Death

COMMENTS:

ESOPHAGUS

There is a perforation in the esophagus to correlate with the "hole" described grossly.

End of Record- ICJ950

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ958
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen, moderate.

GASTROINTESTINAL TRACT: Cecum, Two times normal size, ingesta thinner than normal; jejunum, distended with yellow liquid, moderate.
LYMPH NODE: Cervical, red.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutropnilic/pustule(s)
distention, JEJUNUM
No microscopic change to correlate, CECUM

congestion, LYMPH NODE, CERVICAL

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
CECUM:	infiltration, neutrophilic/pustule(s) (slight)
ESOPHAGUS:	No microscopic change to correlate
JEJUNUM:	necrosis, muscular wall, focal (minimal)
KIDNEYS:	distention (slight)
LIVER:	basophilia, cortical tubules, multifocal (minimal)
LUNG:	hypertrophy, hepatocellular, centrilobular (slight)
LYMPH NODE, CERVICAL:	macrophages, alveoli, focal (minimal)
STOMACH:	congestion (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	EYES	HEART
ILEUM	LACRIMAL GLAND	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
THYMUS	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

COMMENTS:

JEJUNUM

The lumen is slightly distended, but there are no lesions in the mucosa.

End of Record- ICJ958

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ969
SEX: F

DOSE GROUP: 4
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

ANUS: Swollen.

GENERAL: General condition, emaciated, slight; skin/fur, alopecia, both forepaws, slight yellow anogenital staining (not taken); dried red discharge around left eye; incisors, right upper, missing.

RELATED HISTOPATHOLOGY:

hyperplasia/hyperkeratosis
infiltration, neutrophilic/pustule(s)
Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

ANUS:	hyperplasia/hyperkeratosis (moderate)
LIVER:	infiltration, neutrophilic/pustule(s) (slight)
LUNG:	hypertrophy, hepatocellular, centrilobular (minimal)
STOMACH:	inflammation, interstitial, focal (minimal)
	hyperplasia/hyperkeratosis, nonglandular mucosa (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND
MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES	PANCREAS
PARATHYROID	PITUITARY	RECTUM	SALIVARY GLANDS
SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN
THYMUS	THYROID	TRACHEA	URINARY BLADDER
UTERUS			

End of Record- ICJ969

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ928
SEX: F

DOSE GROUP: 5A
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):

GENERAL: Skin/fur, anogenital area, slight yellow staining.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

EYES:	cataract, bilateral
LUNG:	hemorrhage, focal (slight) foreign material, intra-alveolar
LYMPH NODE, MESENTERIC:	hyperplasia, lymphoid (moderate)
UTERUS:	distention, lumen (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CERVIX	ESOPHAGUS
HEART	ILEUM	KIDNEYS	LACRIMAL GLAND
LIVER	LYMPH NODE, CERVICAL	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS	TRACHEA
URINARY BLADDER			

COMMENTS:

EYES/OPTIC NERVE	There is some postmortem decomposition, but there is evidence of nuclear debris within the lens of both eyes consistent with terminal cataracts.
KIDNEYS	There is some postmortem decomposition evident, but no lesions are observed (not remarkable).

AUTOLYSIS PRECLUDES EVALUATION:

CECUM	COLON	DUODENUM	JEJUNUM
MAMMARY GLAND	STOMACH	THYROID	

End of Record- ICJ928

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ931
SEX: F

DOSE GROUP: 5A
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):	RELATED HISTOPATHOLOGY:
ANUS: Swollen, slight.	hyperplasia/hyperkeratosis necrosis, mucosa infiltration, neutrophilic/pustule(s)
GENERAL: Skin/fur, clear discharge on ventral and dorsal surfaces of entire head and dorsal cervical area.	Not applicable
LUNG: Mottled dark red/red.	foreign material, intra-alveolar congestion

HISTOMORPHOLOGIC OBSERVATIONS:

ADRENAL GLANDS:	congestion (moderate)
ANUS:	necrosis, mucosa (slight) hyperplasia/hyperkeratosis (moderate)
LIVER:	infiltration, neutrophilic/pustule(s) (slight)
LUNG:	hypertrophy, hepatocellular, centrilobular (minimal) congestion (moderate)
STOMACH:	foreign material, intra-alveolar
UTERUS:	hyperplasia/hyperkeratosis, nonglandular mucosa (slight) distention, lumen (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

AORTA	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	CERVIX	COLON
DUODENUM	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS
NERVE, SCIATIC	OVARIES	PANCREAS	PARATHYROID
PITUITARY	RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL
SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC	SPLEEN	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ931

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ952
SEX: F

DOSE GROUP: 5A
DEATH TYPE: Spontaneous Death

GROSS OBSERVATION(S):

	RELATED HISTOPATHOLOGY:
GASTROINTESTINAL TRACT: Cecum, ingesta more compact than normal; small intestine, distended with gas and slight amount of amber liquid.	No microscopic change to correlate, DUODENUM No microscopic change to correlate, JEJUNUM No microscopic change to correlate, ILEUM No microscopic change to correlate, CECUM
GENERAL: Skin/fur, snout, slight amount of dry material; anogenital area, slight urine stains; thoracic cavity, filled with extreme amount of clear liquid; general condition, emaciation, moderate.	Not applicable
HEART: Surrounded by tan caseous material, adhered to lungs.	pericarditis, fibrinopurulent
LUNG: All lobes and surfaces, dark red, surrounded by tan/white caseous material.	foreign material, intra-alveolar congestion pleuritis, fibrinopurulent
THYMUS: Surrounded by tan caseous material, adhered to lungs.	inflammation, fibrinopurulent

HISTOMORPHOLOGIC OBSERVATIONS:

AORTA:	inflammation, fibrinopurulent (moderate)
CECUM:	No microscopic change to correlate
DUODENUM:	No microscopic change to correlate
HEART:	pericarditis, fibrinopurulent (marked)
ILEUM:	No microscopic change to correlate
JEJUNUM:	No microscopic change to correlate
KIDNEYS:	mineralization, multifocal (minimal)
LUNG:	congestion (moderate) pleuritis, fibrinopurulent (moderate)
LYMPH NODE, CERVICAL:	foreign material, intra-alveolar congestion (slight)
THYMUS:	inflammation, fibrinopurulent (marked)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	BONE (FEMUR)	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	CERVIX	COLON
DUODENUM	ESOPHAGUS	EYES	ILEUM
JEJUNUM	LACRIMAL GLAND	LIVER	LYMPH NODE, MESENTERIC
MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES
PANCREAS	PARATHYROID	PITUITARY	RECTUM
SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	STOMACH	THYROID	TRACHEA
URINARY BLADDER	UTERUS		

COMMENTS:

AORTA
Moderate fibrinopurulent inflammation around the periphery.

End of Record- ICJ952

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ919
SEX: F

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GENERAL: No gross changes.

RELATED HISTOPATHOLOGY:

Not applicable

HISTOMORPHOLOGIC OBSERVATIONS:

LIVER: infiltration, mononuclear-cell, multifocal (minimal)
UTERUS: distention, lumen (slight)

THE-FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC
MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC	OVARIES
PANCREAS	PARATHYROID	PITUITARY	RECTUM
SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR	SPINAL CORD, MIDTHORACIC
SPLEEN	STOMACH	THYMUS	THYROID
TRACHEA	URINARY BLADDER		

End of Record- ICJ919

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ945
SEX: F

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

GASTROINTESTINAL TRACT: Distended with gas, moderate.
UTERUS: Distended, slight.

RELATED HISTOPATHOLOGY:

No microscopic change to correlate, CECUM distention, lumen

HISTOMORPHOLOGIC OBSERVATIONS:

CECUM:	No microscopic change to correlate
LIVER:	infiltration, mononuclear-cell, multifocal (minimal)
STOMACH:	dilatation, mucosal glands (minimal)
THYMUS:	cyst(s)
UTERUS:	distention, lumen (slight)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (STERNUM)	BONE MARROW (STERNUM)
BRAIN	CECUM	CERVIX	COLON
DUODENUM	ESOPHAGUS	EYES	HEART
ILEUM	JEJUNUM	KIDNEYS	LACRIMAL GLAND
LUNG	LYMPH NODE, CERVICAL	LYMPH NODE, MESENTERIC	MAMMARY GLAND
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	THYROID	TRACHEA
URINARY BLADDER			

TISSUE(S) NOT AVAILABLE FOR EVALUATION:

BONE (FEMUR)
MUSCLE, FEMORIS
NERVE, SCIATIC

End of Record- ICJ945

90-DAY ORAL TOXICITY STUDY IN THE RAT
STUDY NUMBER 158270 - TEST MATERIAL MRD-89-582

ANIMAL NUMBER: ICJ953
SEX: F

DOSE GROUP: 5B
DEATH TYPE: Scheduled Sacrifice

GROSS OBSERVATION(S):

UTERUS: Distended, moderate.

RELATED HISTOPATHOLOGY:

distention, lumen

HISTOMORPHOLOGIC OBSERVATIONS:

UTERUS:

distention, lumen (moderate)

THE FOLLOWING TISSUE(S) WERE WITHIN NORMAL LIMITS:

ADRENAL GLANDS	AORTA	BONE (FEMUR)	BONE (STERNUM)
BONE MARROW (STERNUM)	BRAIN	CECUM	CERVIX
COLON	DUODENUM	ESOPHAGUS	EYES
HEART	ILEUM	JEJUNUM	KIDNEYS
LACRIMAL GLAND	LIVER	LUNG	LYMPH NODE, CERVICAL
LYMPH NODE, MESENTERIC	MAMMARY GLAND	MUSCLE, FEMORIS	NERVE, SCIATIC
OVARIES	PANCREAS	PARATHYROID	PITUITARY
RECTUM	SALIVARY GLANDS	SPINAL CORD, CERVICAL	SPINAL CORD, LUMBAR
SPINAL CORD, MIDTHORACIC	SPLEEN	STOMACH	THYMUS
THYROID	TRACHEA	URINARY BLADDER	

End of Record- ICJ953